AD-A205 024

Comparative Inhalation Toxicology of Selected Materials

Final Report for Phase III Studies

M. B. Snipes, Ph.D.

D. E. Bice, Ph.D.

D. G. Burt, D.V.M.

E. G. Damon, Ph.D.

A. F. Eidson, Ph.D.

F. F. Hahn, D.V.M., Ph.D.

J. R. Harkema, D.V.M., Ph.D.

R. F. Henderson, Ph.D.
J. L. Mauderly, D.V.M.
J. A. Pickrell, D.V.M., Ph.D.

F. A. Seiler, Ph.D.

H. C. Yeh, Ph.D.

June, 1988

Supported by

U.S. Army Medical Research and Development Command Fort Detrick, Frederick, MD 21701-5012

Project Order 85PP5805

H

Inhalation Toxicology Research Institute Lovelace Biomedical and Environmental Research Institute P.O. Box 5890 Albuquerque, NM 87185

Approved for public release; distribution unlimited.

The findings in this report are not to be construed as an official Department of the Army position unless so designated by other authorized documents.

2 24

SECULI	Y CLASSI	FICATION	OF THIS	PAGE

REPORT DOCUMENTATION PAGE Form Approved OMB No. 0224 0128						
				OMB No 0704-0188		
1a. REPORT SECURITY CLASSIFICATION UNCLASSIFIED		15 RESTRICTIVE	MARKINGS			
28. SECURITY CLASSIFICATION AUTHORITY			AVAILABILITY OF			
2b. DECLASSIFICATION/DOWNGRADING SCHEDULE			on unlimited			
4. PERFORMING ORGANIZATION REPORT NUMBER	(\$)	5 MONITORING	ORGANIZATION RI	PORT NU	MBER(S)	
6. NAME OF PERFORMING ORGANIZATION Inhal. Toxicol. Res. Institute Lovelace Bio. & Environ. Res. Institute	6b. OFFICE SYMBOL (If applicable)	U.S. Army	DNITORING ORGAI Biomedical t Laborator	Researc	th and	
6c. ADDRESS (City, State, and ZIP Code)		76. ADDRESS (Cit	y, State, and ZIP (ode)		
P. O. Box 5890 Albuquerque, NM 87185		Fort Detri Frederick,	ck MD 21701-5	010		
8. NAME OF FUNDING / SPONSORING ORGANIZATION	Bb OFFICE SYMBOL (If applicable)	9 PROCUREMENT	INSTRUMENT IDE	NTIFICATI	ON NUMBER	
U.S. Army Med. R & D Command		85 PP 5 805				
Bc. ADDRESS (City, State, and ZIP Code)		10 SOURCE OF F				
Fort Detrick Frederick, MD 21701-5012		PROGRAM ELEMENT NO.	PROJECT NO.	TASK NO.	WORK UNIT ACCESSION NO.	
11. TITLE (Include Security Classification)			<u> </u>			
COMPARATIVE INHALATION TOXICOLOG						
12 PERSONAL AUTHOR(S) M.B. Snipes, D. J.R. Harkema, R.F. Henderson, J.	E. Bice, D.G. B	Burt, E.G. Da	mon, A.F. E	idson,	F.F.Hahn,	
13a. TYPE OF REPORT 13b. TIME COV	vered 6 to 10/87	14. DATE OF REPO 1988, June	RT (Year, Month, I	Day) 15.	PAGE COUNT 185	
16. SUPPLEMENTARY NOTATION				** ***		
17. COSATI CODES	18. SUBJECT TERMS (C	ontinue on reverse	e if necessary and	identify b	by block number)	
FIELD GROUP SUB-GROUP	Rats, inhal toxicity.	ation, subch	ronic, copp	er, zir	nc, alloy, .	
19. ABSTRACT (Continue on reverse if necessary as A subchronic inhalation study of	nd identify by block nu	imber)		cted w	4+h E344/N	
rats. Exposures were 1.5 hours/d	lay, 4 days/wee	k to 0, 0.32	, 1.0, 3.2,	or 10	mg Cu-Zn/m³ for	
13 weeks, followed by a 4-week re	covery period.	Rats were	exposed nose	-only	to aerosols	
with average mass median aerodyna 2.7). The Cu-Zn alloy did not ac	imic glameters (cumulate in lu	ot I.I µm (go nas. indicat	eometric sta ing that it	noaro cleare	deviation d rapidly and	
reached equilibrium concentration	is in tissues o	f the respira	atory tract	after	a few days of	
exposure. The 13-week exposures tract. Focal atrophy (mild seven	produced adver	se biologica	l changes of	ily in	the respiratory	
rats exposed to 1.0 or 3.2 mg Cu-	-Zn/m ³ , and in	68 percent o	f rats expos	ed to	10 mg	
Cu-Zn/m ³ . This lesion resolved o	during the reco	very period	in rats expo	sed to	1.0 mg	
Cu-Zn/m ³ , but was still present in 2 percent and 32 percent, respectively, of the rats exposed to 3.2 or 10 mg Cu-Zn/m ³ . A mild alveolar macrophage hyperplasia occurred in 50						
percent of the rats exposed to 3.2 mg Cu-Zn/m³, and a mild to moderate macrophage hyperplasia occurred in 82 percent of the rats exposed to 10 mg Cu-Zn/m³. After the recovery						
20. DISTRIBUTION / AVAILABILITY OF ABSTRACT		21. ABSTRACT SEC	CURITY CLASSIFICA			
Ø UNCLASSIFIED/UNLIMITED ☐ SAME AS RP	T. DTIC USERS	226 TELEPHONE (nclude Area Code			
Mrs. Virginia Miller DO Form 1473, JUN 86	Mrs. Virginia Miller (301) 663-7325 SGRD-RMI-S					

19. ABSTRACT (Cont.) period, macrophage hyperplasia (mild severity) persisted in 23 percent of the rats exposed to 3.2 mg Cu-Zn/m³ and in all of the rats exposed to 10 mg Cu-Zn/m³. A mild type II pneumonocyte hyperplasia occurred in 27 percent of rats exposed to 3.2 mg Cu-Zn/m³, and a mild to moderate hyperplasia occurred in 77 percent of rats exposed to 10 mg Cu-Zn/m³. Recovery from type II pneumocyte hyperplasia was comparable to that observed for alveolar macrophage hyperplasia. Mild alveolitis was produced in 25 percent of the rats exposed to 3.2 mg Cu-Zn/m³, and mild to moderately severe alveolitis was produced in 82 percent of the rats exposed to 10 mg Cu-Zn/m³. Alveolitis resolved during the 4-week recovery period. After exposure to 10 mg Cu-Zn/m³, changes in bronchoalveolar lavage fluid (BALF) constituents corresponded closely to the histological changes. Changes in BALF included increased total cells, macrophages, neutrophils, lymphocytes, collagenous peptides, and beta-glucuronidase. The only significant changes produced in BALF by exposures to 3.2 mg Cu-Zn/m³ were (1) increased numbers of neutrophils, and (2) an increase in alkaline phosphatase that was not seen in rats exposed to 10 mg Cu-Zn/m³. These changes in BALF were all relatively small and represented a mild inflammatory response that resolved during the recovery period. Exposures to 3.2 or 10 mg Cu-Zn/m³ resulted in increased numbers of lymphoid cells in lung-associated lymph nodes. Although the number of antibody-forming cells/million lymphocytes was significantly depressed after recovery from exposures to 3.2 and 10 mg Cu-Zn/m³, the total number of antibody-forming cells was not different from what was observed in shamexposed rats. The only effect of inhaled Cu-Zn on respiratory function was reduced carbon monoxide diffusing capacity, produced by exposure to 10 mg Cu-Zn/m³. This suggested responses to the inhaled Cu-Zn resulted in impaired alveolar-capillary gas exchange at the membrane level. The magnitude of this functional change was small. In summary, exposures to 3.2 or 10 mg Cu-Zn/m³, 1.5 hours/day, 4 days/week for 13 weeks produced significant lesions and functional changes in the respiratory tracts of F344/N rats. The only lesion produced by exposure to 1.0 mg Cu-Zn/m³ was a mild focal atrophy of olfactory epithelium in 14 percent of the rats; this lesion resolved within 4 weeks after exposure to Cu-Zn ended. No effects were detected after exposure to $0.32 \text{ mg Cu-Zn/m}^3$. Considering the cumulative results of this study, the no observable adverse effects level (NOAEL) for exposures of F344/N rats is defined as exposures equivalent to inhalation of 0.32 mg Cu-Zn/m³, 1.5 hours/day, 4 days/week.

I. VEXECUTIVE SUMMARY

The U. S. Army Biomedical Research and Development Laboratory (USABRDL) sponsored the Lovelace Inhalation Toxicology Research Institute (LITRI) to study the inhalation toxicity of respirable aerosols of powdered Cu-Zn alloy (Cu-Zn). Toxicological information was limited for this material and the LITRI responded to the need for information by studying the inhalation toxicity of this material in F344 rats.

Studies of the inhalation toxicity of Cu-Zn were conducted in three phases. Phase I included (1) standardization of methods for generation and delivery of aerosols of test materials, (2) physical/chemical characterization of the aerosols, (3) comparisons of nose-only versus whole-body exposure systems, (4) an assessment of stress imposed on the rats during nose-only versus whole-body exposure to 100 mg Cu-Zn/m3, and (5) preliminary evaluations of toxicity of inhaled Cu-Zn. Phase II consisted of repeated intermittent exposures to determine subacute toxic effects from exposure to different aerosol concentrations of the Cu-Zn. In Phase III, a 13-week subchronic exposure of rats to selected levels of Cu-Zn was used to determine a no observable adverse effects level (NOAEL) of exposure and estimate the reversibility of any toxic lesions. This report is for Phase III studies.

F344/N rats were exposed by inhalation in nose-only exposure tubes.

Exposures were 1.5 hours per day, four days per week, for 13 weeks. Aerosol concentrations of Cu-Zn were 0 (sham), 0.32, 1.0, 3.2, or 10 mg Cu-Zn/m³. The aerosols had average mass median aerodynamic diameters of 1.1 µm and geometric standard deviations of 2.7. Rats were weighed twice weekly during the 13-week exposure series. Pulmonary function evaluations were made before starting the exposures, midway through the exposure series, after the last exposure, and again after a 4-week recovery period. Additional evaluations were made after the exposure series and again after a 4-week recovery period to determine the





kinds and magnitudes of biological responses to the inhaled Cu-Zn alloy. The evaluations quantitated indicators of biochemical and cytological changes in bronchoalveolar lavage fluid (BALF), immunologic responses, phagocytic ability of pulmonary alveolar macrophages, collagen content of lung, and histopathological changes in the respiratory tract. Table ES-1 contains a summary of significant adverse effects observed in Phase III.

No rats died during the exposures as a result of inhalation of the test material. Body weight, an indicator of morbidity or toxicity, was decreased in rats exposed to 10 mg Cu-Zn/m³. A change in pulmonary function was noted at the end of exposure only in rats exposed to 10 mg Cu-Zn/m³. Rats in this group had decreased carbon monoxide diffusing capacity that did not completely resolve during the 4-week recovery period. Exposures to 3.2 and 10 mg Cu-Zn/m³ produced changes in biochemical/cytological indicators of toxicity in bronchoalveolar lavage fluid (BALF). Specifically, \(\beta \)-glucuronidase and protein increased. Alkaline phosphatase increased in rats exposed to 3.2 mg Cu-Zn/m³. but not in rats exposed to 10 mg Cu-Zn/m³. Lactate dehydrogenase in BALF was not different from values for sham-exposed rats. These changes were resolved during the 4-week recovery period. Exposures to 3.2 or 10 mg Cu-Zn/m³ caused increased numbers of lymphoid cells in lung-associated lymph nodes, and exposure to 10 mg Cu-Zn/m³ significantly increased the total number of antibody-forming cells. These changes resolved during the 4-week recovery period. The concentration of antibody-forming cells in these lymph nodes was normal at the end of exposure in all groups of rats, but was depressed after the 4-week recovery period in rats exposed to 3.2 or 10 mg Cu-Zn/m³. Exposure to 10 mg Cu-Zn/m³ resulted in decreased phagocytic ability of pulmonary alveolar macrophages. No significant changes in pulmonary function, immunology, or phagocytic ability of macrophages resulted from the exposures to 0.32 or 1.0 mg $Cu-Zn/m^3$.

Table ES-1 Summary of Significant Adverse Effects Observed in Phase III

	Aerosol Concentration of Powdered Cu-Zn Alloy 1.0 mg/m ³ 3.2 mg/m ³ 10 mg/m ³					.g./m ³
Measure	EOE _a	REC	EOE		EOE	REC
Body Weights					Dp	
Bronchoalveolar Lavage Fluid Analyses Total Cells Neutrophils Lymphocytes Macrophages			I		I I I I	
Beta-Glucuronidase Alkaline Phosphatase Collagenous Peptides			I		ī I	
Immunology, Lung-Associated Lymph Nodes 7 Total Lymphoid Cells Antibody-Forming Cells per Million Lymphocytes Total Antibody-Forming Cells			I	D	I I	D
Macrophage Phagocytosis					D	
Respiratory Function Carbon Monoxide Diffusing Capacity					D	D
Histopathology ^C Lung Weights Nasal Epithelial Atrophy	3/22		6/44	1/43	I 15/22	7/22
Alveolar Macrophage Hyperplasia	(1.0)		(1.0) 24/44	(1.0) 10/43	(1.2) 18/22	(1.1)
Type II Pneumocyte Hyperplasia			(1.0) 12/44	(1.0) 8/43	(1.4) 17/22	(1.0) 22/22
Alveolitis			(1.0) 11/44 (1.0)	(1.0) 1/43 (1.0)	(1.2) 18/22 (1.4)	(1.0) 0/22

a EOE signifies measurements after the 13-week exposure; REC signifies measurements after the 4-week recovery period.

bThere was a statistically significant (p < 0.05) increase (I) or decrease (D) in

these measures, as compared with the sham-exposed rats.

COnly the data for lung weight are presented on the basis of statistical differences. Data for the respiratory tract lesions represent frequency of lesions, (number of rats with lesion)/(number of rats observed), and the average severity of the lesions for rats that had lesions. Average severity scores of 1.0 to 1.4 in this table indicate slight to moderate severity.

The Cu-Zn did not accumulate in lungs during the 13 weeks of exposure, indicating that it cleared rapidly. This suggests that an equilibrium concentration of the material in the respiratory tract was reached within days after the start of the 13-week subchronic exposure.

Histopathological lesions were limited to nasal airways and the pulmonary region of the respiratory tract. The nasal airways contained lesions after inhalation of 1.0, 3.2 and 10 mg Cu-Zn/m³ for 13 weeks. Focal atrophy (mild severity) of the olfactory epithelium occurred in 15 of 22 rats exposed to 10 mg Cu-Zn/m³, in 6 of 44 rats exposed to 3.2 mg Cu-Zn/m³ and in 3 of 22 rats exposed to 1.0 mg Cu-Zn/m³. After the recovery period, this lesion in the nasal airways persisted in 7 of 22 rats exposed to 10 mg Cu-Zn/m³ and in 1 of 43 rats exposed to 3.2 mg Cu-Zn/m³. It was not present after the recovery period in rats exposed to 1.0 mg Cu-Zn/m³.

Lung weights were increased at the end of exposure in rats exposed to 10 mg Cu-Zn/m³, but were normal after the recovery period. Multifocal type II pneumocyte hyperplasia, alveolitis, and alveolar macrophage hyperplasia were the principal alterations found in the lungs. All three types of lesions (mild severity) were produced in rats exposed to 3.2 and 10 mg Cu-Zn/m³, but not in rats exposed to 0.32 or 1.0 mg Cu-Zn/m³. The alveolar macrophage hyperplasia and type II pneumocyte hyperplasia persisted, but the alveolitis resolved during the 4-week recovery period.

No lesions occurred in rats exposed for 13 weeks to 0.32 mg Cu-Zn/m³, and the nasal epithelial atrophy observed after exposure to 1.0 mg Cu-Zn/m³ resolved during the 4-week recovery period. We conclude that the no observable adverse effects level (NOAEL) for exposure of F344/N rats to Cu-Zn alloy powder is equivalent to daily inhalation exposures of 0.32 mg Cu-Zn/m³ for 1.5 hours per day, 4 days/week.

II. FOREWORD

Citations of commercial organizations and trade names in this report do not constitute an official Department of the Army endorsement or approval of the products or services of these organizations.

In conducting the research described in this report, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Animal Resources Commission of Life Sciences, National Research Council (NIH Publication No. 85-23, Revised 1985).

TABLE OF CONTENTS

		Page
I.	EXECUTIVE SUMMARY	4
II.	FOREWORD	8
III.	LIST OF FIGURES	10
IV.	LIST OF TABLES	11
٧.	EXPERIMENTAL METHODS	13
	A. Test Material	13
	B. Experimental Design for Phase III	13
	C. Animals: Source, Identification and Housing	16
	D. Animal Surveillance	19
	E. Aerosol Generation and Exposure Systems	20
	1. Aerosol Generation and Delivery Systems	20
	2. Animal Exposure Chambers	22
	3. Aerosol Physical Characterization	22
	4. Exposure Chamber Aerosol Distribution Evaluations	23
	F. Animal Exposure Procedures	23
	G. Aerosol Characterization During Animal Exposures	24
	H. Biological Observations During and After Exposures	25
	I. Atomic Absorption Analyses for Cu and Zn	37
	J. Statistical Comparisons	37
VI.	RESULTS	40
	A. Exposure Aerosol Chamber Distribution Evaluations	40
	B. Aerosol Characterization During Animal Exposures	42
	C. Biological Observations During and After Exposures	42
VII.	GENERAL DISCUSSION AND CONCLUSIONS	69
VIII.	NO OBSERVABLE ADVERSE EFFECTS LEVEL OF EXPOSURE	76
IX.	QUALITY ASSURANCE STATEMENT	77
Χ.	REFERENCES	79
XI.	ACKNOWLEDGMENTS	84
XII.	APPENDICES	84
XIII.	LIST OF PUBLICATIONS	181
XIV.	PERSONNEL SUPPORTED BY PROJECT	182
XV.	DISTRIBUTION LIST	183

III. LIST OF FIGURES

		Page
Figure 1.	Aerosol Concentrations of Cu-Zn Alloy Powder During 13 Weeks of Rat Exposures in Phase III, Parts 1 and 2	43
Figure 2.	Body Weights (Mean ± SE) for Rats in Phase III, Parts 1 and 2	45

IV. LIST OF TABLES

		<u>Page</u>
Table 1.	Exposure Groups of F344/N Rats for Phase III, Parts 1 and 2	15
Table 2.	Summary of Biological Evaluations Scheduled for Phase III, Parts 1 and 2	17
Table 3.	Tissue and Organs Grossly Examined, Weighed, Saved in Fixative, and Examined Microscopically in Phase III, Parts 1 and 2	36
Table 4.	Quality Control Information for Atomic Absorption Analyses in Phase III, Part 1	38
Table 5.	Exposure Chamber Aerosol Distribution Evaluations Without Animals Present in Exposure Chambers	41
Table 6.	Summary of Cu-Zn Alloy Powder Exposure Atmosphere Concentrations and Size Distributions During 13 Weeks of Exposure for Phase IJI, Parts 1 and 2	44
Table 7.	Summary of Body Weights for Selected Times During 13-Weeks Exposure of F344/N Rats to Powdered Cu-Zn Alloy	46
Table 8.	Total Cells in Lung Lavage Fluid	48
Table 9.	Neutrophil, Lymphocyte, and Macrophage Differentials in Lung Lavage Fluid	49
Table 10.	Biochemical Analyses of Bronchoalveolar Lavage Fluid from F344/N Rats that Inhaled Powdered Cu-Zn Alloy	50
Table 11.	Collagenous Peptides in Bronchoalveolar Lavage Fluid After 13-Weeks Exposure to Powdered Cu-Zn Alloy Powder and After 4-Week Recovery Period	51
Table 12.	Total Lung Collagen After 13-Week Exposure to Powdered Cu-Zn Alloy and After 4-Week Recovery Period	53
Table 13.	Immunology Results for Tracheobronchial Lymph Nodes from Rats in Phase III	55
Table 14.	Macrophage Phagocytosis of Opsonized Sheep Red	56

		<u>Page</u>
Table 15.	Respiratory Function Results for F344/N Rats in Phase III, Parts 1 and 2 (Baseline Measurements)	58
Table 16.	Respiratory Function Results for F344/N Rats in Phase III, Parts 1 and 2 (Week Seven of Exposures)	59
Table 17.	Respiratory Function Results for F344/N Rats in Phase III, Parts 1 and 2 (End of Exposure)	60
Table 18.	Respiratory Function Results for F344/N Rats in Phase III, Parts 1 and 2 (After 4-Week Recovery Period)	61
Table 19.	Body and Organ Weight Summary for Phase III, Parts 1 and 2 for End of Exposure (EOE) and After Recovery (REC)	63
Table 20.	Summary of Respiratory Tract Lesions in F344/N Rats After 13-Week Exposure to Aerosols of Powdered Cu-Zn and After a 4-Week Recovery Period	65
Table 21.	Lung Content of Cu and Zn in F344/N Rats Exposed Nose-Only in Phase III, Part 1	68

V. -EXPERIMENTAL METHODS

A. <u>Test Material</u>

We obtained Atlantic Brass Richgold fine 1800 from Atlantic

Powdered Metals, Inc., New York, NY. This powdered metal alloy was from lot
number T-7464. We mixed the bulk material in a plastic-lined 55 gallon drum,
then transferred part of the powder to 9 approximately 2-liter sub-lots in
Teflon bottles for convenience of storage and use. The remainder of the bulk
material was returned to its shipping containers. This metal powder contained
approximately 2/3 Cu and 1/3 In by weight. In Phase I of this project we
determined the projected area diameter of bulk and aerosolized powder.
Results indicated that most of the particles in this powder were flakes,
having projected area diameters in the range 0.6 to 16.4 mm. We also
estimated the thickness of the flakes to be one-thirtieth to one-fourtieth of
the projected area diameter. Aerosols generated using this powder typically
had mass median aerodynamic diameters of approximately 0.9 to 1.2 mm, with
geometric standard deviations in the range of 3.1 to 3.5.

B. Experimental Design for Phase III

Fischer-344/N rats were used in this study to allow comparisons with specific results from other related studies and to make general comparisons with the growing inhalation toxicology data base for rats. This laboratory animal species was suitable for pulmonary function evaluations during and after exposure to the test material, and procedures for evaluating specific endpoints have been well defined for rats.

Rats were 17 weeks old at the start of their exposures. The rats were weighed during the week prior to exposure and those body weights were used to randomize them for assignment to their study groups. The

randomization procedure made use of the LITRI Path/Tox Data System (Xybion Medical Systems, Inc., Cedar Knolls, NJ) and RS/1 Computer Software (BBN Software Products Corporation, Cambridge, MA). The result of the randomization procedure was assignment of rats to the experimental groups as indicated in Table 1.

The study was conducted in two parts because of a technical problem that caused the death of the sham-exposed rats in Phase III, Part 1.

Preliminary results were available from Phase III, Part 1 at the time Phase III, Part 2 was planned. On the basis of the preliminary results, exposures to 10 mg Cu-Zn/m³ and some of the endpoint evaluations were not repeated in Phase III, Part 2. However, one additional exposure group was included in Phase III, Part 2, to extend the lowest exposure concentration to 0.32 mg Cu-Zn/m³.

Exposures were nose-only and target aerosol concentrations were 0, 0.32, 1.0, 3.2, and 10 mg Cu-Zn/m³. Exposure durations were 1.5 hr/day, exposure frequencies were 4 times per week (usually Monday thru Thursday), and the exposure series was continued for 13 weeks, followed by a recovery period of 4 weeks. Sham-exposed rats are referred to as "shams", and were exposed 1.5 hr/day, 4 times per week to filtered air.

Previous observations in Phases I and II (Snipes et al., 1986, 1988) of this project and by others (Thomson et al., 1986) indicated that the most likely responses in Phase III would involve the nasopharynx and pulmonary region of the respiratory tract. Observations and endpoints of interest therefore emphasized the respiratory tract.

The lung is a primary route of entry into the body for airborne materials. Some inhaled materials cause responses in the lung which can be

Table 1

Exposure Groups of F344/N Rats for Phase III, Parts 1 and 2^a

	Par	<u>t 1</u>	Par	t 2
Target mg Cu-Zn/m ³	Experiment Number	Number of Animals	Experiment Number	Number of Animals
O (sham)	b		4442	76
0.32			4443	44
1.0	4371	76		
3.2	4372	76	4444	76
10	4373	76		

aExposures 1.5 hours/day, 4 days/week, for 13 weeks; equal numbers
 of males and females.

bAnimals died due to technical problem during exposure.

measured by changes in composition of the lung tissue or by changes in the fluids and cells lining the bronchoalveolar airways. Since fibrosis of the lung was a possible response to the inhaled Cu-Zn, the lung tissue was analyzed for indications of developing fibrosis. Analysis of bronchoalveolar lavage fluid was used to detect an inflammatory response in the lung. This method has proven useful in previous studies on the toxicity of inhaled mineral dusts, coal combustion fly ash, and other toxicants (Beck et al., 1981, 1982; Henderson et al., 1978a, 1978b, 1979a, 1979b; Moores et al., 1980, 1981).

The measurements and endpoints (Table 2) included in Phase III of this project were selected to determine changes in important indicators of general health, the respiratory tract, or specific organ functions as a consequence of the exposures. Rats were observed daily and their body weights were recorded twice weekly during the 13-week exposure period.

Rats were randomly assigned for evaluations and for whether they would be evaluated at the end of the exposure or after the 4-week recovery period. The first groups of rats were killed three days after their last exposure to the Cu-Zn, the rest were killed 4 weeks later. The exceptions to this sacrifice schedule were the rats used for pulmonary function evaluations. Pulmonary function measurements were made prior to starting the exposures, midway through the 13 week exposure series, after the last exposure, and again after the 4-week recovery period.

C. Animals: Source. Identification and Housing

Rats were obtained from Charles River Laboratories, Kingston, NY.

They were shipped from a viral-antibody-free facility in filter crates and were 13 weeks old when they arrived at the LITRI. Prior to the animals'

Table 2
Summary of Biological Evaluations Scheduled for Phase III, Parts 1 and 2

Endpoint Category	Part 1	Part 2ª
Lavage Fluid Analyses	x	X
Clinical Chemistry	X	
Connective Tissue	x	X
Hematology	X	
Histopathology	x	X
Immunology	x	X
Lung Burdens of Cu and Zn	x	
Phagocytosis	x	X
Pulmonary Function	X	X

 $^{^{}a}$ Evaluations were limited to sham-exposed rats and rats exposed to 3.2 mg Cu-Zn/m 3 for all categories other than histopathology. All groups were evaluated for the presence of histological lesions.

arrival, the room selected for their housing was disinfected. This was accomplished by sponging or mopping all surfaces of the room with diluted Johnson's Expose (National Sanitary Supply Co., Albuquerque, NM), then fumigating the room with AN-FA-CIDE-S® (Pharmaceutical Research Laboratories, Greenwich, CT). Thereafter, quarantine procedures were followed for personnel, food, cages, bedding, and equipment taken into the room. Personnel donned shoe covers, clean laboratory coveralls, hair covers, and respiratory protection as they entered the room. All work was done while wearing disposable rubber gloves. Food, cages, and bedding were sterilized prior to placement in the room. Any equipment, such as analytical balances, was disinfected prior to placing it in the room. Access to the room was restricted to the limited number of personnel required for animal maintenance and handling animals for exposures. The rats were maintained under these quarantine conditions throughout the study.

All animals assigned to the project had unique individual identification numbers. The numbers were affixed to the animals' ears in the form of permanent metal ear tags. Ear tags were attached during the week before inhalation exposures were started. Missing ear tags were replaced as necessary to maintain positive identification of each animal.

Rats were housed two or three per cage in polycarbonate cages 20 cm H x 25 cm W x 45 cm L. Cages had polyester filter caps to reduce possible spread of disease and parasites. Cages and filter caps for the sham group were kept separate from cages and filter caps used for the rats exposed to the Cu-Zn. Also, the cages used for this study were not mixed with similar cages being used in the same housing area for other studies. Normal cage washing procedures were used, but control and exposed cages were washed separately from each other and from other cages in the building.

Cages had hardwood chip bedding which was changed twice weekly.

Certified Rodent Blox pellets (Allied Mills, Chicago, IL) and water were available ad libitum in the housing area. Food was analyzed by the Continental Grain Company, Libertyville, IL. Data sheets from analysis of Lot P07236-1 of this feed by the Continental Grain Company are included in the Appendix. This analysis was representative of the feed used during Phase III, Parts 1 and 2.

Light was provided on a 12-hour daily cycle (0600-1800). Room temperature was maintained at 20 to 24 C, and relative humidity was 30 to 50 percent.

D. Animal Surveillance

The rats for Phase III, Parts 1 and 2 were 13 weeks old when they arrived at the Institute. They were placed directly into a quarantine room where they were maintained throughout the study. Their exposures to Cu-Zn started when they were 17 weeks old. The surveillance procedures described below were the same for rats in Phase III. Parts 1 and 2.

Within 48 hours of arrival at ITRI, 5 male and 5 female rats were examined for pinworm ova by the cellophane tape preparation method. All rats were negative for pinworm ova.

Prior to beginning exposures, 5 male and 5 female rats were killed for disease surveillance, which included gross necropsy, parasitology screening, and serology. Samples of the serum were sent to Microbiological Associates, Inc. (Bethesda, MD) for serologic testing for the following diseases: pneumonia virus of mice (PVM), kilham rat virus (KRV), Toolan's H-1 virus (H-1), sendai virus, rat coronavirus-sialodacryoadeniti virus (RCV-SDA), lymphocytic choriomeningitis virus (LCM), reovirus type 3 (Reo3), mouse

adenovirus (MAD), GDVII, and <u>Mycopiasma pulmonis</u>. A cellophane tape preparation was also done on each of the 10 rats to examine for pinworm ova (<u>Syphacia muris</u>). Fecal samples from 5 males and 5 females were submitted for fecal flotation analysis.

No gross lesions were observed in any of the rats. All rats were negative for parasites on fecal flotation and cellophane tape preparations. On serology, all rats were negative for antibodies to Mycoplasma and all viruses tested.

Periodically throughout the study, 10 sentinel animals (5 male, 5 female) from Phase III, Part 1 and Phase III, Part 2 were tested for pinworm ova via the anal tape technique. All sentinel rats tested negative for pinworms prior to the conclusion of the study. At the conclusion of the study, the sentinel rats were subjected to the disease surveillance procedures described above. No gross lesions were observed, and all rats were serologically negative for Mycoplasma and all viruses tested. The majority of sentinel rats were positive for ova of Syphacia muris at this final sacrifice.

E. Aerosol Generation and Exposure Systems

1. Aerosol Generation and Delivery Systems

One requirement for this project was to minimize changes in physical and chemical characteristics of the powdered Cu-Zn alloy. This required using an aerosol generator which would not grind or otherwise alter the size and shape of the powder. In addition, a suspension of the powder was not possible, since this would require a solvent which might alter the test material physically or alter the exposure patterns for the rats. Testing in Phase I (Snipes et al., 1986) of this project indicated that the Model O101-C6S Jet-O-Mizer aerosol generator (Fluid Energy Corp., Hatfield, PA)

would be appropriate for this study. The Jet-O-Mizer, with its Accurate bulk materials feeder produced aerosols of the Cu-Zn having the desired exposure concentrations, stability, and volume production.

In all cases where aerosols of the Cu-Zn were used, the aerosol generation systems were enclosed to protect the operator(s) from exposure. These enclosures were made of 1.3 cm thick plexiglass and were equipped with glove ports and pass boxes. The enclosures were maintained at a relative negative internal pressure of 0.5-0.75 inches (1.3-1.9 cm) of hydrostatic pressure. This ensured that any leaks in the system would result in room air being drawn into the enclosure rather than test material escaping from the enclosure to contaminate the work environment and result in personnel exposures.

Each daily operation of this aerosol generation system started with a fresh supply of bulk Cu-Zn. The bulk powder was stored in 2-liter Teflon containers. Containers were physically mixed by turning them end over end 25 times prior to transfer of the bulk material. This procedure was done to obviate daily variations in aerosols due to differential settling of particles in the storage containers.

Aerosols were produced by the Jet-O-Mizer aerosol generation system using filtered air that was humidified to maintain relative humidity in the range 30 to 50 percent. Aerosols were passed through the exposure chambers or through a bypass as excess aerosol. Excess aerosol flow was drawn through a high efficiency particulate air (HEPA) filter via the exposure chamber exhaust system; the exposure chambers were exhausted through a separate HEPA filtered vacuum exhaust system.

2. Animal Exposure Chambers

Three 96-port nose-only exposure chambers were used for exposing rats to the Cu-Zn; an 80-port nose-only chamber was used to expose the shams. These multiport small animal exposure systems were similar to those described by Raabe et al. (1973). During exposures, rats were in polycarbonate nose-only exposure tubes. These tubes were designed to allow inhalation exposures of rats, while minimizing external contamination of the animals. The wall thickness of the Lexan tubes was 2.3 mm and the tube diameter was adequate to restrain the rats, but allow them space for thoracic expansion during breathing. The front end of each tube was tapered internally to conform to the shape of the rat's head and the rear end of the tube was closed by an adjustable plunger. The rats were secured in these tubes during exposure, with their noses projecting slightly past the end of the exposure tube and into the aerosol passing through the exposure chamber.

3. Aerosol Physical Characterization

Three types of aerosol samples were collected. Filter samples were collected to determine aerosol concentrations, Lovelace Multijet (LMJ) cascade impactors were used to collect samples for aerosol size determinations, and point-to-plane electrostatic precipitator (ESP) samples were collected for routine aerosol morphology evaluations.

A RAM-S real-time aerosol monitor (GCA Corporation, Bedford, MA) was used to continuously monitor the aerosol concentrations during testing and exposures. The primary use of this monitoring device was to provide real-time indications of the functional state of the aerosol generation and delivery systems. This information was used by the exposure technician to make any necessary adjustments within the systems to maintain the desired exposure conditions.

4. Exposure Chamber Aerosol Distribution Evaluations

The following procedures were used to quantitate uniformity of aerosol generator output and aerosol concentration within the exposure chambers. Three nose-only exposure systems were used for Cu-Zn and all three systems required testing prior to animal exposures. One system (10 mg Cu-Zn/m³) had been used in Phase II of this project (Snipes et al., 1988) and testing for that chamber was not repeated prior to starting exposures for Phase III, Part 1. Chambers designated for producing aerosols and exposing rats to 0.32, 1.0, and 3.2 mg Cu-Zn/m³ were tested prior to inhalation exposures of rats. Tests of generator output, stability, and uniformity of chamber distribution of the aerosols of Cu-Zn were conducted four hours per day, on three separate days with no animals in the exposure chambers. Previously identified exposure ports (Snipes et al., 1988) were sampled simultaneously to evaluate the aerosol concentration at each port. The amounts of test material were determined by weighing the filters before and after the aerosol collection intervals. Twelve simultaneous filter samples were collected, six from each side of each exposure chamber. Aerosols were collected on these filters for 40 minutes with 1 liter/minute sampling flow rates. A total of 144 samples were collected for each nose-only exposure chamber and used in the evaluation of spatial and temporal distribution patterns for the test aerosols of Cu-Zn. Lovelace Multijet impactor samples were also collected during these daily tests for aerosol size determinations.

F. Animal Exposure Procedures

It had been determined that the aerosols were almost uniformly distributed in the nose-only chambers. However, to minimize variability, a randomization procedure was used to assign each rat to its exposure location

for each exposure. A different list of exposure locations was produced for each group of rats, for every exposure. The procedure used computer software which randomized the list of rats to be exposed in each chamber and overlaid the random list of rats on the list of exposure ports available. Exposure ports were identified by a 3-digit code where each port of an exposure chamber was assigned a unique number. The procedure not only randomly assigned the rats to their exposure locations each day, the computer output file was used to generate labels which were placed on the exposure tubes at the time the rats were loaded into them. The labels facilitated accounting for each rat and reduced errors associated with handling rats for nose-only exposures and returning them to their assigned housing cages. The exposure location history for each rat in the study is in a master computer file for examination if needed.

The animals were housed in a room almost directly across a hallway afrom the exposure room. On exposure days, the rats were loaded into their spolycarbonate exposure tubes in their housing room and transported to the exposure room in the exposure tubes. Animals to be sham-exposed were always handled and transported first. After the nose-only exposures, the rats were transported back to the housing room in the exposure tubes, and were unloaded from the tubes directly into their cages.

G. Aerosol Characterization During Animal Exposures

During the animal exposures, three types of aerosol samples were collected for each exposure. These included (1) the Lovelace Multijet (LMJ) impactor samples for determining aerodynamic size distributions of the aerosols, (2) filter samples for aerosol concentration determinations, and (3) a point-to-plane electrostatic (ESP) sample for electron microscope

observations. The flow rates were set at 16.4 liters/minute for impactors, latter per minute for filter samplers, and 0.2 liters/minute for the ESP. One sample each of the LMJ and ESP were collected at the beginning and end of each exposure. Three or four filter samples were collected for the entire 1.5 hour exposures.

H. <u>Biological Observations During and After Exposures</u>

1. General

The rat housing area was inspected twice daily for dead or moribund rats. More thorough examinations occurred twice per week when all of the rats were weighed. Personnel handling rats for exposures recorded any unusual behavior, coat color, excretions, and overall general appearance, if the rats did not appear normal. Any dead or moribund rats were to be necropsied as "unscheduled deaths", as indicated in ITRI Protocols FY86-016 and FY87-009.

After their last scheduled exposure, the rats were returned to their housing as usual. Three days later, excluding the rats assigned for pulmonary function evaluations, immunology, and tissue analysis for Cu and Zn, rats to be used for biochemistry, hematology, phagocytosis, connective tissue, and histopathology analyses were transported to the LITRI necropsy facility. The rats were anesthetized with halothane, then exsanguinated by cardiac puncture. Halothane anesthesia was chosen because it resulted in the least change in baseline parameters used in a screening test for lung injury (Henderson and Lowrey, 1983). Blood was collected in syringes containing 100 units of heparin and used for hematology evaluations. Details of analytical procedures are presented below.

Rats used for immunology and evaluation of lung content of Cu and Zn were immunized 7 days prior to sacrifice. At their scheduled sacrifice time, they were anesthetized with CO₂, exsanguinated via the brachial artery, and the lungs and lymph nodes were removed for analysis as detailed below.

The same procedures were repeated four weeks later with the other rats assigned for these endpoint evaluations. Specific procedures are given below. Rats assigned to the pulmonary function evaluations were killed and discarded as biological waste after their final pulmonary function tests.

2. Lavage Fluid Biochemistry and Cytology

Evaluations were made in groups of rats killed at the end of the exposures and additional groups of rats killed after allowing 4 weeks for recovery. Rats were anesthetized with halothane and killed by exsanguination. The heart and lungs were removed en bloc. The left lung was isolated from the right lung and was used for evaluation of histopathology. The right lung of each rat was lavaged with physiological saline (2 washes of 44 mL each for females and 2 washes of 5 mL each for males). The two recovered lavage fluid washes from individual rats were combined and centrifuged at 1000 x g for 15 minutes to separate the cells from the supernatant fluid.

The supernatant was analyzed for lactate dehydrogenase (indicator of cell-death), beta-glucuronidase (lysosomal enzyme indicating high phagocytic activity and/or lysis of phagocytic cells), alkaline phosphatase (measure of type II lung cell response), and protein content (indicator of damage to the alveolar/capillary barrier). The cells in the pellet were resuspended in physiological saline and evaluated using a Coulter counter (Coulter Electronics, Hialeah, FL). An aliquot of the cell suspension was processed using a cytocentrifuge and differential cell counts were made.

Total airway collagen was measured as an indicator of possible remodeling of lung structural protein (Pickrell et al., 1975). To measure airway collagen, lavage fluid collagenous peptides were measured. These are soluble hydroxyproline-containing compounds which have leaked into alveoli and small airways and are recovered from the lung by endobronchial saline lavage. They reflect turnover of the extracellular collagenous matrix.

An aliquot of the lavage fluid supernatant was hydrolyzed in 6 N HCl (sealed under N₂) for 16 to 18 hours at 110°C to convert proteins to their individual amino acids. The acid solution was evaporated to dryness, samples were resuspended in 0.001 N HCl, and a colorimetric procedure was used to quantitate the amount of hydroxyproline present (Grant, 1965). Right lungs were hydrolyzed using the same procedure as for the lavage fluid. The acid was evaporated, the material was resuspended in 0.001 N HCl, samples were decolorized with charcoal filtration, evaporated to dryness again, and finally suspended in 0.001 N HCl. Next, the samples were analyzed for hydroxyproline using the colorimetric assay procedure. The collagen content of the samples was calculated by multiplying the lavage fluid hydroxyproline content by 7.46 to convert to collagen content. This conversion is based on the fact that collagen is approximately 13 percent hydroxyproline by weight (Neuman and Logan, 1950).

Based on data available at the time total lung collagen analyses were done, the only exposed group of rats likely to be different from controls was the group exposed to 10 mg Cu-Zn/m³. We therefore elected to evaluate total lung collagen in two steps, doing the second step only if necessary. The first step included analysis of selected groups of rats killed at the end of the 13-week exposure, and only sham-exposed rats and rats

exposed to 10 mg Cu-Zn/m³ from the animals allowed the 4-week recovery period. One half of the control animals from the group killed at the end of exposure was pooled with one half of the control animals killed after the recovery period. This was done to provide controls for these analyses, and to have controls available for additional analyses if they would have been justified.

Total lung collagen was measured for rats killed at the end of exposure to 0, 3.2, and 10 mg $Cu-Zn/m^3$. This included rats from Phase III, Parts 1 and 2 that had been exposed to 3.2 mg $Cu-Zn/m^3$, which was the only exposure level common to Parts 1 and 2. The only exposed group in which rats were evaluated after the 4-week recovery period was the group exposed to 10 mg $Cu-Zn/m^3$.

Additional lungs would have been analyzed as a second step in these evaluations if justified on the basis of observing significant changes in lung collagen for rats exposed to 3.2 mg Cu-Zn/m³. Results for collagen acontent of lung were normalized and presented as amount of collagen per gram scontrol lung, and amount per kilogram body weight.

3. Hematology and Serum Chemistry

Limited clinical tests were selected on the basis of results from previous phases of this study to determine effects, if any, in the hematopoietic system, and in other organ systems of the rats. Hematological analyses were performed at the end of inhalation exposures and 4 weeks later using a Coulter Model S-550 Hematology Analyzer. The following parameters were measured:

Hematocrit

Hemoglobin concentration

Erythrocyte count

Erythrocyte indices

Mean corpuscular volume (MCV)

Mean corpuscular hemoglobin (MCH)

Mean corpuscular hemoglobin concentration (MCHC)

Leukocyte count, total and differential

Chemistry parameters were also measured at the end of inhalation exposures and 4 weeks later using a centrifugal analyzer (Multistat, Fisher Instrumentation Laboratories, Lexington, MA). The following serum parameters were measured:

Alkaline phosphatase

Serum glutamic pyruvic transaminase (alanine aminotransferase)

Blood urea nitrogen

- Total bilirubin

Total protein

Albumin

4. Immunology

A portion of inhaled particulates translocate to the lung-associated lymph nodes which receive lymphatic drainage from the lung. The results of studies on the effects of inhaled particulates indicate that insoluble materials which reach the lung-associated lymph nodes are retained in these tissues with a long half-life, and that this exposure can alter the immune function of these lymphoid tissues (Bice et al., 1985, 1987). Therefore, the effects of inhaled Cu-Zn on immune response in the lung-associated lymph nodes was evaluated.

Immunization was by intratracheal instillation of antigen (Bice et al., 1979) seven days prior to killing the rats. The rats were anesthetized with halothane, and the trachea was intubated with a catheter. The placement of the catheter in the trachea was verified by ventilating the lungs after placement. Particulate antigen (sheep red blood cells) was instilled just above the bifurcation of the trachea. A total of 100 million red blood cells (SRBC) obtained from a single sheep were used for each rat.

The number of lymphoid cells producing IgM anti-SRBC antibody were determined in the lung-associated lymph nodes and the spleen by the Cunningham modification of the Jerne plaque assay (Cunningham and Szenberg, 1968). Evaluation of the number of anti-SRBC in the spleen after lung immunization was necessary to determine if exposure to the Cu-Zn altered the antigen-trapping capacity of the lung-associated lymph nodes. Instilled SRBC that leave the lung via the lymphatics are normally removed in the lung-associated lymph nodes. This antigen does not reach distant lymphoid tissues, since the number of antigen-forming cells in the spleen is not significantly elevated above background level (Bice et al., 1979).

Antibody-forming cell data were expressed as the number of IgM anti-SRBC antibody-forming cells per million lymphoid cells in the lung-associated lymph nodes or in the spleen. A statistical comparison of the elevel of immunity in control rats and in exposed rats was made. Results of spast studies indicated that the data are log-normally distributed (Gottlieb, 1974). Therefore, a logarithmic transformation of the data was done and the transformed data were evaluated using an unpaired Student's t-test with a BMDP computer program (BMDP, 1979).

5. Phagocytosis

As described above, lavage fluid was centrifuged and the supernatant used for biochemical analyses. The free alveolar cell fraction (pellet from the centrifugation step) was used for evaluation of phagocytosis by pulmonary alveolar macrophages (PAM). Smears of the cytocentrifuge pellets were made to allow differential cell counts. Phagocytosis of SRBC by PAM from the pellets was tested with and without surface-bound antibody (Harmsen et al., 1980).

The SRBC used in the phagocytosis assay were sensitized by incubation with anti-SRBC antibody (EA). A one percent suspension of EA was added to the alveolar macrophages obtained by lung lavage and incubated at 37°C for 60 minutes to allow time for phagocytosis. The EA and alveolar macrophages were then centrifuged, and the pellet was resuspended in distilled water to lyse any EA not phagocytized. Slides were prepared from the resuspended cells, and the number of SRBC phagocytized by 100 alveolar macrophages was counted using oil immersion with light microscopy.

6. Respiratory Function Measurements

Tests included a spectrum of measured and calculated parameters, allowing evaluation of the different facets of respiratory function: ventilation, lung mechanics, gas distribution, and alveolar-capillary gas transfer. The tests included assays that are sensitive and used most commonly in humans.

Rats were intubated with tracheal catheters, 5.5 cm long x 1.78 mm I.D., fabricated from 14 gauge intravenous catheters (Cathlon IV, No, 4428, Jelco, Raritan, NJ) as previously described (Mauderly, 1977). The breathing port in the plethysmograph wall was a Luer fitting (No, 6161,

Popper, New York, NY) drilled to 2.5 mm I.D. The frequency response of the plethysmograph-respirator-tracheal catheter system was tested and found adequate to record forced expirations of rats. The phasing of flow, volume, and transpulmonary pressure (Ptp) signals was tested by oscillating volumes into and out of the plethysmograph; no significant phase lag was detected within the frequency range of spontaneous breathing, the only condition in which phasing is critical.

Respiratory function measurements were similar to those previously published (Harkema et al., 1982; Likens and Mauderly, 1982; Mauderly, 1982). Tests were conducted using a 1.4 L combination flow (volume displacement) and pressure (constant volume) plethysmograph. Flows were determined by measuring differential pressures (MP45 transducer, Validyne, Northridge, CA) across 6 layers of 400-mesh wire cloth covering a 1.3 cm hole in the plethysmograph wall. Volumes were calculated by integrating flow (Model 6 pulmonary mechanics analyzer, Buxco, Sharon, CT). In the pressure smode, used only for measurement of functional residual capacity, the hole was sealed and volume changes were measured as pressure changes, using the same transducer. The plethysmograph was heated by a resistance element and maintained at approximately 37°C.

Transpulmonary (Ptp) pressure was measured using transducers (P23ID, Gould, Hato Rey, Puerto Rico) connected to the external airway and to a 2.2 mm O.D. esophageal catheter by liquid-filled tubes. The transducer outputs were conditioned by a differential amplifier (Buxco), which produced outputs for both transpulmonary and airway pressures.

A positive-negative pressure respirator system was used to induce quasistatic and forced expiratory movements. Reservoirs (4.6 L)

maintained at +40 and -50 cm H₂O were connected to the airway by solenoid valves. Inspiratory and quasistatic expiratory flow rates were limited by needle valves to 5 and 3 mL/second, respectively.

Inspiration was stopped automatically at a Ptp of +30 cm H_2O . Forced expiration was induced by opening a valve having a 9.5 mm diameter orifice (V52DA3012, Skinner, New Britain, CT) without intentional flow restriction between the valve and the low pressure reservoir.

The measurement sequence was as follows. The rats were anesthetized with halothane in air, intubated with the tracheal catheter, and placed prone in the plethysmograph. The esophageal catheter was inserted and adjusted to maximize the Ptp signal. Anesthetic depth was standardized by adjusting the halothane concentration to yield a respiratory frequency of 55 ± 5 breaths/minute. Respiratory frequency, tidal volume, minute volume, dynamic lung compliance, and total pulmonary resistance were measured during spontaneous breathing by the mechanics analyzer, averaged for 15-20 breaths by a data logger (DL-12, Buxco) and displayed on a teletype terminal. The measurement of dynamic lung mechanics by the mechanics analyzer was identical in principle to the method of Amdur and Mead (1958).

Prior to each subsequent test procedure, the rats were hyperventilated with a syringe to induce temporary apnea and to establish a uniform lung volume history. A quasistatic exhalation was performed by inflating the lungs to +30 cm H₂O Ptp, then slowly deflating the lungs until expiratory flow stopped. Volume and Ptp signals were recorded on a strip-chart recorder. The inspired volume was defined as inspiratory capacity, the expired volume as vital capacity, and the difference as the expiratory reserve volume. Quasistatic pressure-volume relationships were

analyzed by a microprocessor contained within the data logger, and results were displayed on a teletype terminal. Quasistatic lung compliance was measured as the chord compliance between the apneic lung volume and that volume +10 cm H_2O Ptp.

Functional residual capacity was measured using Boyle's Law (DuBois et al., 1956) by inducing apnea, blocking the breathing port, and measuring airway pressure and lung volume changes as breathing resumed. Residual volume was calculated by subtracting expiratory reserve volume from functional residual capacity, and total lung capacity was calculated by adding residual volume to vital capacity.

A forced expiration was induced by inflating the lungs to +30 cm H₂O Ptp and rapidly deflating the lung until expiratory flow stopped. The event was analyzed by a microprocessor contained within the data logger, and both the flow-volume curve and several calculated variables were displayed on a teletype terminal. These variables included forced vital capacity, peak expiratory flow rate, percent of forced vital capacity expired in 0.1 second, amean mid-expiratory flow rate, and the maximal expiratory flow rates at 10, 25, and 50 percent of forced vital capacity.

Diffusing capacity for CO was measured by a single-breath method (Ogilvie et al., 1957). The gas volume required to increase Ptp from functional residual capacity to 20 cm H₂O was determined, and that volume of test gas containing 0.4 percent CO and 0.5 percent Ne in air was injected into the lung with a syringe. After approximately six seconds, one-half the injected volume was withdrawn from the lung and the remainder (alveolar sample) was withdrawn into a second syringe. Gas concentrations in the alveolar gas sample were determined by gas chromatography (Carle Model 111).

A single-breath N_2 washout was performed as described above for quasistatic exhalation, except that the test was started by deflating the lungs to residual volume and the subsequent inflation was with O_2 instead of air. An X-Y plot of volume exhaled versus N_2 concentration (percent) of the expirate was constructed and analyzed to calculate the slope of Phase III, the alveolar plateau.

7. Necropsy and Histopathology

Eleven male and 11 female rats from each exposure group listed in Table 1 were evaluated at the end of the exposure series, and another 11 male and 11 female rats were evaluated after the 4-week recovery period. The rats were anesthetized with halothane and exsanguinated, as indicated above. Some of the rats were shared for several evaluations. For shared rats, after removal of the heart-lung bloc, the left lung and carcass were subjected to gross examination and sampling for histopathology. For other rats, the entire lung was available for gross and histopathology evaluations. Organs grossly examined, weighed, saved in fixative, and examined microscopically are listed in Table 3.

The lungs were instilled intratracheally with 10 percent neutral buffered formalin (NBF) to approximately their normal inspiratory volume. The nasal cavity was perfused with 1-3 mL of 10 percent NBF to remove air before immersion in additional fixative. The stomach was injected with 10 percent NBF and fixed for gross examination. The other tissues listed in Table 3 were fixed by immersion in 10 percent NBF.

After allowing adequate time for complete fixation, tissues were trimmed, embedded in paraffin, and sectioned at 5 microns with a microtome. The sections were mounted on glass slides, stained with

Table 3

Tissues and Organs Grossly Examined, Weighed, Saved in Fixative and Examined Microscopically in Phase III, Parts 1 and 2

		<u>Routine</u> H	listology
Tissue or Organ ^a	<u> Weighed</u>	Part 1	Part 2
Thymus		X	
Tracheobronchial Lymph Nodes		X	X
Spleen		X	
Femur		X	
Larynx		X	X
Nasal Cavity		X	X
Trachea		X	X
Lung	X	X	X
Heart		X	
Stomach		X	
Liver	X	X	
Kidneys	X	X	
Urinary Bladder		X	
Testes	X	X	
Ovaries	X	X	
Adrenals		X	
Thyroid		X	
Brain	X	X	
Lesions (if present)		X	X

aAll grossly examined and fixed in 10% neutral buffered formalin.

hematoxylin and eosin, and examined for lesions. Comparisons were made among the exposure groups for presence of lesions, types of lesions, and their severity. Results are discussed below and details for individual rats are included in the Appendix.

I. Atomic Absorption Analyses for Cu and Zn

These analyses were done only for Phase III, Part 1. Lungs were individually dried for about 15 hours at ~ 120°C, then transferred to Teflon digestion vessels containing 3.0 mL of ultrapure concentrated HNO3, 1.0 mL of ultrapure concentrated HC1, and 0.1 mL of ultrapure concentrated HF. Samples were next placed in a microwave oven, heated for 6 minutes, then cooled in an ice water bath. Cooled digestates were added to 5.0 mL of 5 percent boric acid and the solution diluted to 25 mL with 0.06 M citric acid. The diluted solutions were assayed for Cu and Zn by atomic absorption spectroscopy using an Instrumentation Laboratories IL 951 graphite furnace atomic absorption instrument. The limits of detection and quantitation (American Chemical Society Committee on Environmental Improvement, 1983), and average recoveries of standard Cu and Zn are shown in Table 4. Attempts to measure recovery of the metal powder added directly to animal tissues were not successful because of difficulty in quantitatively transferring small amounts of the Cu-Zn.

J. Statistical Comparisons

Body weight and respiratory function data were available for comparisons among groups of rats before exposures to Cu-Zn started and midway through the 13-week exposure series. Sham-exposed rats in Phase III, Part 1 were accidentally killed one day before their exposures were to end. Also, some of the endpoint evaluations in Phase III, Part 1 were not repeated in Phase III, Part 2. Therefore, some of the comparisons in Phase III, Part 1

were of necessity made between groups of rats exposed to 3.2 or 10 mg Cu-Zn/m³ and rats exposed to 1.0 mg Cu-Zn/m³. These comparisons are indicated at the appropriate places in text. Results for rats exposed to 3.2 mg Cu-Zn/m³ in Phase III, Parts 1 and 2 were statistically compared and the judgement was made that all data from Phase III, Parts 1 and 2 could be presented as one set (Appendix I) and data for rats exposed to 3.2 mg Cu-Zn/m³ could be combined. Statistical comparisons were then possible between groups of rats exposed to 0.32, 1.0, 3.2, and 10 mg $Cu-Zn/m^3$ and the sham-exposed rats from Phase III. Part 2. Therefore, with the exception of the body weight and respiratory function results, the immediate family of comparisons was limited to (1) groups of rats exposed to 3.2 or 10 mg $Cu-Zn/m^3$ in Phase III. Part 1. compared with the group of rats exposed to 1.0 mg Cu-Zn/m³. (2) comparisons between rats exposed to 3.2 mg Cu-Zn/m³ in Phase III. Parts 1 and 2, and (3) data from all exposed groups from Phase III, Parts 1 and 2 combined where possible and comparisons made with the sham-exposed rats from Phase III, Part 2. Comparisons were made between sets of data collected at the end of exposure or collected after the recovery period. Comparisons were not made between results from end of exposure and after recovery.

Unless specified otherwise, comparisons presented in this report included analysis of variance to detect overall group differences in mean and variance. Specific differences were measured using the Student's t-statistic with appropriate corrections for multiple comparisons according to the inequality of Bonferroni. We used the Levene test for equal variance to determine if we should use separate or pooled variance t values in our comparisons. If p > 0.05 for the Levene test, we used pooled variance values; for p < 0.05, we used the separate variance t.

VI. RESULTS

A. Exposure Aerosol Chamber Distribution Evaluations

In Phase III, Part 1, three aerosol concentrations of Cu-Zn were used (1.0, 3.2, and 10 mg Cu-Zn/m³). In Phase III, Part 2, two aerosol concentrations were used (0.32 and 3.2 mg Cu-Zn/m³). Temporal and spatial variation of aerosol concentrations was measured in each exposure system prior to exposures of animals. Results for the exposure system used to expose rats to 10 mg Cu-Zn/m³ were obtained as part of Phase II of this project (Snipes et al., 1988). The other three aerosols were tested in Phase III, Part 1 (1.0 and 3.2 mg Cu-Zn/m³) or Phase III, Part 2 (0.32 mg Cu-Zn/m³).

Table 5 summarizes the results for tests of the temporal and spatial variation for the target concentrations of 0.32, 1.0, and 3.2 mg "Cu-Zn/m3". Temporal variation is the variation with time at a given position, and the spatial variation is the variation from location to location at a given time, or average over a given time period. The temporal variation was ficalculated from data for a given position from all test runs; the spatial evariation was calculated from average concentrations of all sampling locations. The variation for the aerosol containing 0.32 mg Cu-Zn/m3 was larger than for the other aerosols. This was anticipated since the lower concentration of particles in the aerosol dictated a greater degree of funcertainty in quantitating the aerosol. However, the coefficient of variation was less than the acceptable value of 20 to 25 percent. We conclude (1) that all aerosol concentrations were near the target levels, and (2) the aerosols for 3.2 mg Cu-Zn/m3 were essentially identical for Phase III, Parts 1 and 2.

The aerosol size distributions as determined using the Lovelace

Multijet cascade impactor during the chamber aerosol distribution evaluations

Table 5

Exposure Chamber Aerosol Distribution Evaluations
Without Animals Present in Exposure Chambera

Target Concentration of Cu-Zn Alloy Powder	Measurement	Phase III. Part 1	Phase III. Part 2
0.32 mg/m ³	Temporal Variation (Range)	ND ND	$7.9\% \pm 4.3\%$ $(1.5\% - 14\%)$
	Spatial Variation	ND	7.6%
	Mean Concentration	ND	0.31 mg/m^3
	Particle Size: MMAD ± SD (μm) GSD ± SD	ND ND	1.13 ± 0.17 3.41 ± 1.2
1.0 mg/m ³	Temporal Variation (Range)	$4.9\% \pm 0.7\%$ (4.4% ± 5.4%)	ND ND
	Spatial Variation	5.1%	ND
	Mean Concentration	$0.97 \pm 0.05 \text{ mg/m}^3$	ND
	Particle Size: MMAD ± SD (μm) GSD ± SD	1.07 ± 0.045 3.00 ± 0.55	ND ND
3.2 mg/m ³	Temporal Variation (Range)	$2.5\% \pm 1.6\%$ (1.1% - 6.2%)	2.6% ± 1.8% (0.9% - 5.9%)
	Spatial Variation	2.5%	0.9%
	Mean Concentration	3.23 mg/m^3	3.28 mg/m^3
	Particle Size: MMAD ± SD (μm) GSD ± SD	0.984 ± 0.064 2.51 ± 0.13	0.982 ± 0.024 2.53 ± 0.058

^aAerosol distribution expressed as mean \pm standard deviation (range) of the coefficient of variation for temporal variation, and as coefficient of variation for spatial variation.

ND = not done MMAD = mass median aerodynamic diameter in μm GSD = geometric standard deviation SD = standard deviation

are also indicated in Table 5. These results were similar for all three aerosol concentrations and were comparable to those from Phase I (Snipes et al., 1986) and Phase II (Snipes et al., 1988) of this project, where we generated aerosols having 10, 40, and 100 mg Cu-Zn/m³.

B. Aerosol Characterization During Animal Exposures

Figure 1 shows the mean weekly aerosol concentrations (\pm SD) for the three exposure chambers over the 13 week period of rat exposures. The overall mean aerosol concentrations were close to the target concentrations of 0.32, 1.0, 3.2, and 10 mg Cu-Zn/m³ as shown in Table 6. The overall coefficient of variation was less than 15 percent. Also listed in Table 6 are the aerosol size distributions as determined by the LMJ cascade impactor samples during the 13 weeks of exposure. There were no significant size differences either among chambers or between exposure groups (f = 2.49; p > 0.10).

C. <u>Biological Observations During and After Exposures</u>

1. Animal Body Weights

Body weight results throughout the exposure period are summarized in Figure 2. The typical pattern for body weight was an initial drop during the first few days of the exposure series, followed by stabilization and gradual increase. Results for individual rats are in the Appendix.

Table 7 presents results for body weights taken at 5 selected times during the exposures. The only observed differences from sham-exposed rats occurred in rats exposed to 10 mg $Cu-Zn/m^3$. At the 13th week of exposure, the body weights for these rats (male and female) were statistically reduced, indicating a morbidity response associated with exposures to 10 mg $Cu-Zn/m^3$, 1.5 hours/day.




Figure 1. Aerosol concentrations (mean \pm SD) of Cu-Zn alloy powder during 13 weeks of rat exposures in Phase III, Parts 1 and 2. The upper 3 sets of data were from Part 1, and the lower two sets of data were from Part 2. Individual values are in the Appendix.

Table 6
Summary of Cu-Zn Alloy Powder Exposure Atmosphere
Concentrations and Size Distributions During 13 Weeks
of Exposure for Phase III, Parts 1 and 2

Target Concentration of Cu-Zn Alloy Powder	Measurement	Phase III, Part 1	Phase III, Part 2
0.32 mg/m^3	Concentration, Mean ± SD	ND	0.318 ± 0.041
	Particle Size:		
	MMAD ± SD	ND	1.10 ± 0.16
	GSD ± SD	ND	2.43 ± 0.43
1.0 mg/m ³	Concentration, Mean ± SD	1.03 ± 0.11	ND
	Particle Size:		
·	MMAD ± SD	0.99 ± 0.18	ND
	GSD ± SD	2.91 ± 0.44	ND
3.2 mg/m ³	Concentration, Mean ± SD Particle Size:	3.33 ± 0.33	3.24 ± 0.40
	MMAD ± SD	1.00 ± 0.15	1.19 ± 0.14
•	GSD ± SD	2.78 ± 0.37	2.67 ± 0.38
10.0 mg/m ³	Concentration, Mean ± SD Particle Size:	10.25 ± 1.30	ND
	MMAD ± SD	1.09 ± 0.20	ND
	GSD ± SD	2.91 ± 0.36	ND

ND = not done

 $\textbf{MMAD = mass median aerodynamic diameter in } \mu \textbf{m}$

GSD - geometric standard deviation

SD = standard deviation

PHASE III, PART 1




Figure 2. Body weights (mean \pm SE) for rats in Phase III, Parts 1 and 2.

Table 7

Summary of Body Weights for Selected Times During 13 Weeks Exposure of F344/N Rats to Powdered Cu-Zn Alloy (Values are Mean \pm SE)

	:		0	ay of Study Rel	Day of Study Relative to First Exposure Day	Exposure Day	
Part 1	mg Cu-Zn/m ³	Z	1-	13	34	55	83
Females	0 (Sham) 1.0 3.2 10	36 36–38 38 38	174.9 ± 1.0 174.8 ± 1.0 175.2 ± 1.0 175.1 ± 1.0	173.0 ± 0.9 172.7 ± 1.1 172.5 ± 1.0 169.6 ± 1.4	177.9 ± 1.0 175.9 ± 1.2 177.2 ± 1.0 174.5 ± 1.2	182.4 ± 1.0 179.0 ± 1.1 181.7 ± 1.0 180.0 ± 1.1	188.0 ± 1.0 185.4 ± 1.2 186.8 ± 1.1
Males	0 (Sham) 1.0 3.2 10	36 35-37 37-38 38	279.0 ± 1.6 280.1 ± 1.6 283.0 ± 1.7 280.7 ± 1.5	279.7 ± 1.6 277.9 ± 1.5 278.2 ± 1.7 275.1 ± 1.5	286.6 ± 1.7 283.5 ± 1.8 285.5 ± 1.5 279.5 ± 1.5	296.7 ± 1.9 293.4 ± 1.9 296.7 ± 1.8 290.2 ± 1.6	308.1 ± 1.9 304.4 ± 2.3 308.7 ± 1.9 299.2 ± 2.0 ^b
Part 2	mg Cu-Zn/m ³	Z		ay of Study Rel	Day of Study Relative to First Exposure Day	Exposure Day 54	98
Females	0 (Sham) 0.32 3.2	38 21-22 38	180.6 ± 1.0 179.9 ± 1.4 180.0 ± 0.9	181.2 ± 1.0 180.3 ± 1.4 180.5 ± 1.1	183.7 ± 1.0 184.0 ± 1.5 181.7 ± 0.9	187.9 ± 1.1 187.5 ± 1.3 186.8 ± 0.8	191.2 ± 1.1 191.2 ± 1.6 191.8 ± 0.9
Males	0 (Sham) 0.32 3.2	37–38 22 38	303.8 ± 1.2 305.1 ± 1.6 301.7 ± 1.2	301.9 ± 1.2 301.0 ± 2.7 299.5 ± 1.2	308.9 ± 1.3 309.0 ± 2.1 306.8 ± 1.2	315.4 ± 1.3 317.6 ± 2.0 313.8 ± 1.4	325.2 ± 1.8 327.1 ± 2.1 322.5 ± 1.5

The treated groups were compared with the sham-exposed group using Student's t-test for unequal variances when Levene's test indicated the variances were not the same. When Levene's test did not show differences between the variances, Student's t-test for equal variances was used. Probability values were adjusted for multiple comparisons using Bonferroni's inequality; p < 0.05.

bp < 0.01.

2. Lavage Fluid Biochemistry and Cytology

As indicated in Tables 8 through 10, there was a definite inflammatory response in the highest level exposure group (10 mg $Cu-Zn/m^3$), for which the lavage fluid had increased total cells, macrophages, reutrophils, lymphocytes, protein, and beta-glucuronidase activity. There were also small, but significant increases in alkaline phosphatase in rats exposed to 3.2 mg $Cu-Zn/m^3$. These changes in alkaline phosphatase were questionable and did not appear to have biological significance, since there was no increase in alkaline phosphatase associated with exposures to 10 mg $Cu-Zn/m^3$.

It is important to note that all biochemical and cytological indicators of an inflammatory response had returned to normal by 4 weeks after the end of the exposure. This suggests an initial inflammatory response to the metal powder, followed by rapid clearance of the material from the lung and recovery from the inflammatory response.

3. Airway Collagenous Peptides and Total Lung Collagen

Table 11 shows the effects of 13 weeks of exposure, and exposure followed by a 4-week recovery period, on airway (lavage fluid) collagenous peptides. Rats exposed to 10 mg Cu-Zn/m³ had increased airway collagen at the end of exposure, but not following 4 weeks recovery. No other exposures produced increased airway collagenous peptides at the end of exposure. Rats exposed to 1.0 mg Cu-Zn/m³ had increased airway collagenous peptides following 4 weeks of recovery and the biological importance of this change was nil. Rats exposed to 0.32, 3.2, and 10 mg Cu-Zn/m³ had airway collagenous peptide levels indistinguishable from those of sham-exposed rats after the recovery period.

Table 8

Total Cells in Lung Lavage Fluida
(Values are Mean ± SE)

Aerosol Concentration of Cu-Zn Alloy	N	End of Exposure	After Recovery
O (Sham)	12	1.04 ± 0.07	1.04 ± 0.05
0.32 mg/m^3	12	0.94 ± 0.03	0.95 ± 0.07
1.0 mg/m^3	12	0.88 ± 0.09	1.17 ± 0.08
3.2 mg/m ³	23-24 ^C	1.35 ± 0.10	1.07 ± 0.08
10.0 mg/m ³	12	3.15 ± 0.38 ^b	0.94 ± 0.11

^aMean \pm SE of the total cells in the lavage fluid cell pellet $(x \ 10^{-6})$.

bThe treated groups were compared with the sham-exposed group using Student's t-test for unequal variances when Levene's test indicated the variances were not the same. When Levene's test did not show differences between the variances, Student's t-test for equal variances was used. Probability values were adjusted for multiple comparisons using Bonferroni's inequality; p < 0.01.

CTwenty-four rats evaluated at the end of exposure, 23 rats after the recovery period.

Table 9

Neutrophil, Lymphocyte, and Macrophage Differentials in Lung Lavage Fluid^a (Values are Mean ± SE)

Aerosol Concentration	(0) + (1)		Neutrophils	hils	Lymphocytes	ytes	Macrophages	lages
of Cu-Zn Alloy	Alloy	2	End of Exposure	After Recovery	End of Exposure	After Recovery	End of Exposure	After Recovery
O (Sham)	(percent) (total)	12	0.4 ± 0.1 0.004 ± 0.001	$\begin{array}{cccccccccccccccccccccccccccccccccccc$	9.5 ± 1.8 0.11 ± 0.03	6.9 ± 0.9 0.07 ± 0.01	90.1 ± 1.9 0.93 ± 0.05	$\begin{array}{ccc} 92.1 & \pm & 1.0 \\ 0.96 & \pm & 0.04 \end{array}$
0.32 mg/m ³	0.32 mg/m³ (percent) (total)	12	0.4 ± 0.1 0.004 ± 0.001	0.6 ± 0.2 0.006 ± 0.002	7.1 ± 1.2 0.07 ± 0.01	7.8 ± 1.4 0.07 ± 0.01	92.4 ± 1.1 0.87 ± 0.02	91.6 ± 1.3 0.87 ± 0.07
1.0 mg/m ³	(percent) (total)	12	$3.5 \pm 0.9^{\circ}$ 0.032 ± 0.010	0.8 ± 0.2 0.009 ± 0.003	5.7 ± 1.0 0.05 ± 0.01	7.6 ± 1.2 0.09 ± 0.01	90.3 ± 1.5 0.80 ± 0.08	91.6 ± 1.2 1.07 ± 0.08
3.2 mg/m³	(percent) (total)	24	$3.3 \pm 0.5^{\circ}$ $0.043 \pm 0.007^{\circ}$	0.5 ± 0.1 0.005 ± 0.001	9.9 ± 0.8 0.13 ± 0.02	10.1 ± 0.8 0.11 ± 0.02	86.5 ± 0.7 1.17 ± 0.09	89.4 ± 0.9 0.96 ± 0.07
10.0 mg/m³ (percent) (total)	(percent) (total)	12	8.8 ± 1.2 ^C 0.273 ± 0.044 ^C	0.8 ± 0.3 0.007 ± 0.002	9.6 ± 1.0 0.30 ± 0.04b	$12.7 \pm 1.4^{\circ}$ 0.11 ± 0.01	81.0 ± 1.4 ^c 2.56 ± 0.31 ^c	86.2 ± 1.5b 0.82 ± 0.11

 $^{
m d}$ The above values are differentials taken from the lavage fluid cell pellets (x 10- 6).

bThe treated groups were compared with the sham—exposed group using Student's t-test for unequal variances when Levene's test indicated the variances were not the same. When Levene's test did not show differences between the variances. Student's t-test for equal variances was used. Probability values were adjusted for multiple comparisons using Bonferroni's inequality; p < 0.05.

Table 10

Biochemical Analyses of Bronchoalveolar Lavage Fluid From F344/N Rats That Inhaled Powdered Cu-Zn Alloy

				Aerosol C	Aerosol Concentration of Powdered	ion of Po	i	Cu-Zn Alloy.	mg/m ³		1
Lavage Fluid Constituent	Measure	O (Sham	am) REC ^a	0.32 EOE	32 REC	EOE	REC	E0E	REC	100	REC
ß-Glucuronidase (mIU)	Mean SE	1.27 0.15 12	1.13	1.62 0.26 12	1.25 0.16 12	1.42 0.18 12	1.86 0.31 12	1.61 0.16 23	1.44 0.16 24	7.08 ^b 1.11 12	1.36 0.28 12
Alkaline Phosphatase (mIU)	Mean SE	285 23 12	269 21 12	321 22 12	284 23 12	411 42 12	360 51 12	426b 28 23	254 15 24	336 38 12	279 35 12
Lactate Dehydrogenase (mIU)	Mean SE	385 32 12	446 21 12	389 26 12	488 38 12	D II N	NG CC	571 63 12	406 30 12	222	אאנ
Protein (mg)	Mean SE N	1.54 0.09 12	1.55 0.15 12	1.30 0.09 12	1.51 0.21 12	1.66 0.03 12	1.16 0.21 12	1.70 0.09 23	1, 19 0.09 24	2.82b 0.20 12	1.21 0.15 12

aEOE means the sampling time was at the end of the 13-week exposure; REC means the sampling time was after the 4-week recovery period. bthe treated groups were compared with the sham-exposed group using Student's t-test for unequal variances when Levene's test indicated the variances were not the same. When Levene's test did not show differences between the variances, Student's t-test for equal variances was used. Probability values were adjusted for multiple comparisons using Bonferroni's inequality; p < 0.01.

CNU - Results not used. No control values were available for Phase III, Part l and the values for LDH were considered invalid. Only the values from Phase III, Part 2 are presented for LDH in this table.

Table 11

Collagenous Peptides in Bronchoalveolar Lavage Fluid After 13-Week Exposure to Powdered Cu-Zn Alloy and After 4-Week Recovery Period (Values are Mean ± SE)

		Col:	lagenous Peptid	les in Lavage Fil	uid
Aerosol		End of E	xposure	After R	ecovery
Concentration of Cu-Zn Alloy	N_	μg/g <u>Control Lung</u>	µg/kg Body Weight	μg/g Control Lung	μg/kg Body Weight
O (Sham)	12	45.4 ± 2.8	216 ± 18	47.6 ± 4.2	199 ± 25
0.32 mg/m^3	12	48.6 ± 2.3	229 ± 15	61.4 ± 9.7	249 ± 33
1.0 mg/m^3	12	63.5 ± 6.0	313 ± 34	68.0 ± 6.8 ^a	306 ± 32ª
3.2 mg/m^3	23	57.5 ± 3.1	276 ± 18	54.5 ± 2.9	235 ± 15
10.0 mg/m ³	12	84.4 ± 6.2^{b}	437 ± 38 ^b	57.4 ± 3.0	265 ± 20

The treated groups were compared with the sham-exposed group using Student's t-test for unequal variances when Levene's test indicated the variances were not the same. When Levene's test did not show differences between the variances, Student's t-test for equal variances was used. Probability values were adjusted for multiple comparisons using Bonferroni's inequality; p < 0.05.

bp < 0.01.

Table 12 shows the effect of 13 weeks of exposure, followed by a 4-week recovery period, on total lung collagen. No statistically significant changes in total lung collagen were detected for the two exposure levels measured, which were 3.2 and 10 mg Cu-Zn/m³, the two highest level exposures in Phase III.

4. Immunology and Phagocytosis

The exposure of rats to 10 mg Cu-Zn/m³ significantly increased the total number of cells present in the lavage fluid (Table 8). However, the increased number of cells in lavage fluid of rats exposed to 10 mg Cu-Zn/m³ was temporary and returned to normal during the 4-week recovery period.

The increase in the number of cells in lung lavage fluid from rats exposed to 10 mg Cu-Zn/m³ was due in part to an elevated number of polymorphonuclear leukocytes (neutrophils). Exposures to 0.32 or 1.0 mg Cu-Zn/m³ did not produce increased numbers of neutrophils in lung lavage fluids, but exposures to 3.2 and 10 mg Cu-Zn/m³ (Table 9) did increase neutrophil levels. The percentages of neutrophils were normal in all exposed rats after the 4-week recovery period.

The total number of lymphocytes was elevated only in rats exposed to 10 mg $Cu-Zn/m^3$ (Table 9). This change in numbers of lung lymphocytes present in lavage fluid returned to normal during the 4-week recovery period.

A reduction in the percent and numbers of macrophages in lung lavage fluids was also observed after exposure to 10 mg $Cu-Zn/m^3$ (Table 9). Even though the percentage of macrophages was reduced, the total number was elevated. The percent of macrophages in lung lavage fluid was still low at the end of the 4-week recovery period, but the number had returned to normal.

Table 12

Total Lung Collagen After 13-Week Exposure to Powdered Cu-Zn Alloy and After 4-Week Recovery Period (Values are Mean ± SE)

			Total Lung	Collagen ^a	
Aerosol		End of E	xposure	After Re	
Concentration of Cu-Zn Alloy	<u>N</u>	mg/g <u>Control Lung</u>	mg/kg <u>Body Weight</u>	mg/g <u>Control Lung</u>	mg/kg Body Weight
O (Sham)	12 ^b	17.4 ± 0.8	76.9 ± 5.7		
O (Sham)	6	17.2 ± 1.2	81.5 ± 7.6	17.6 ± 1.3	72.3 ± 8.7
3.2 mg/m^3	20	18.7 ± 0.6	89.1 ± 2.9		
10 mg/m^3	10	18.9 ± 0.8	97.3 ± 5.5	17.5 ± 1.1	79.8 ± 6.2

^aAll samples analyzed as a batch after collection of samples for Phase III, Parts 1 and 2.

Note: The treated groups were compared with the sham-exposed group using the Student's t-test for unequal variances when Levene's test indicated the variances were not the same. When Levene's test did show differences between the variances, Student's t-test for equal variances was used. Probability values were adjusted for multiple comparisons using Bonferroni's inequality.

bResults combined for shams evaluated at the end of exposure and shams evaluated after the 4-week recovery period.

Total lymphoid cells in lung-associated lymph nodes were increased with exposures to 3.2 and 10 mg Cu-Zn/m³ (Table 13). This increase was resolved during the recovery period. The only other significant change reflected in the immunology data at the end of exposure was a significant increase in total antibody-forming cells in rats exposed to 10 mg Cu-Zn/m³, which also returned to normal during the recovery period. The reasons for the observed decrease in antibody-forming cells per million lymphocytes and in total antibody-forming cells after the recovery period for rats exposed to 3.2 and 10 mg Cu-Zn/m³ are not clear and may have no biological importance relative to inhalation of powdered Cu-Zn alloy.

The results of evaluations of the phagocytic function of macrophages obtained by lung lavage indicated that exposure to 10 mg Cu-Zn/m³ reduced phagocytic capacity (Table 14). Rats exposed to 0.32 or 1.0 mg Cu-Zn/m³ had slight, but significantly increased, phagocytic indices at the end of exposure. The reason for this is not known, but probably was associated with a normal response of the respiratory tract defences and had no adverse effects on the rats. There were no significant differences in phagocytosis by alveolar macrophages from any of the groups after the recovery period.

5. Hematology and Serum Chemistry

No significant differences relative to the appropriate comparison (comparisons between groups at the end of exposure, and between groups after four weeks recovery) were noted in the following hematology parameters:

- a. Erythrocytes (RBC)
- b. Hematocrit (PCV)
- c. Hemoglobin

Table 13

Immunology Results for Tracheobronchial Lymph Nodes from Rats in Phase III (Values are Mean ± SE)

Aerosol Concentration of Cu-Zn Alloy	Z	Total Lymphoid Cells x 10 ⁻⁶ EOE ^a REC ^a	Cells x 10 ⁻⁶ REC ^a	Antibody-Fc Per Million EOE	Antibody-Forming Cells Per Million Lymphocytes EOE REC	Total Antibody-Forming Cells EOE	-Forming Cells REC
O (Sham)	&	8.78 ± 0.71	10.00 ± 0.71	517 ± 104	1110 ± 237	4840 ± 1170	11200 ± 2740
1.0 mg/m ³	q2-9	8.21 ± 1.11	9.40 ± 1.72	1080 ± 327	907 ± 313	9360 ± 3490	10250 ± 5020
3.2 mg/m ³	15	15.58 ± 1.39 [€]	8.06 ± 0.73	598 ± 103	447 ± 94d	9810 ± 2020	4210 ± 1100
10.0 mg/m ³	7-8e	27.09 ± 3.43 ^c	10.09 ± 0.51	884 ± 115	369 ± 115d	23300 ± 3540 ^C	3930 ± 1290

aEOE means the sampling time was at the end of the 13-week exposure; REC means the sampling time was after the 4-week recovery period.

 $b_N = 7$ at end of exposure; N = 8 for recovery.

^CThe treated groups were compared with the sham-exposed group using Student's t-test for unequal variances when Levene's test indicated the variances were not the same. When Levene's test did not show differences between the variances, Student's t-test for equal variances was used. Probability values were adjusted for multiple comparisons using Bonferroni's inequality; p < 0.01.

 $d_{p} < 0.05$.

 $e_N = 7$ at end of exposure; N = 6 for recovery.

Table 14

Macrophage Phagocytosis of Opsonized Sheep Red Blood Cellsa
(Values are Mean ± SE)

Aerosol		Numbe	ers	Percen	tages
Concentration of Cu-Zn Alloy	<u>N_</u>	End of Exposure	After Recovery	End of Exposure	After Recovery
O (Sham)	12	367 ± 20	404 ± 27	74.4 ± 1.9	81.8 ± 2.5
0.32 mg/m^3	12	$490 \pm 25^{\text{b}}$	395 ± 32	79.9 ± 1.2	82.0 ± 2.2
1.0 mg/m ³	12	481 ± 30 ^b	341 ± 30	80.5 ± 1.5	76.0 ± 2.1
3.2 mg/m^3	24	405 ± 21	362 ± 28	72.4 ± 1.9	80.1 ± 2.2
10.0 mg/m ³	12	251 ± 16 ^b	299 ± 16	60.2 ± 3.6 ^C	73.2 ± 1.9

The above values show the numbers of opsonized sheep red blood cells phagocytized by 100 macrophages and the percentages of macrophages that phagocytized the cells.

bThe treated groups were compared with the sham-exposed group using Student's t-test for unequal variances when Levene's test indicated the variances were not the same. When Levene's test did not show differences between the variances, Student's t-test for equal variances was used. Probability values were adjusted for multiple comparisons using Bonferroni's inequality; p < 0.05.

 $c_p < 0.01$.

- d. Mean corpuscular volume
- e. Leukocyte (WBC) count
- f. Differential cells of the blood smear (neutrophils, eosinophils, lymphocytes, monocytes, and nucleated erythrocytes [NRBC])

Also, there were no significant dose-related responses in any of the parameters analyzed for serum chemistry. These parameters were:

- a. Alkaline phosphatase
- b. Serum glutamic pyruvic transaminase
- c. Total bilirubin
- d. Blood urea nitrogen
- e. Protein and albumin

Data for individual rats for the hematology and serum chemistry results are included in Appendix E. Since there were no differences to discuss, tabulated results for these parameters were not included in the text of the report.

6. Respiratory Function Measurements

Tables 15 through 18 summarize selected results of respiratory function evaluations. Detailed results for all of the measurements are included in the Appendix. Few statistically significant differences ($p \le 0.05$) or consistent trends related to the exposures were observed. Therefore, parameters representing key indices of respiratory function were selected for display in Tables 15 through 18. These parameters included lung volume (total lung capacity, vital capacity and functional residual capacity), lung stiffness (dynamic and quasistatic compliance), alveolar-capillary gas

Table 15

Respiratory Function Results for F344/N Rats in Phase III, Parts 1 and 2 Combined (Baseline Measurements) (Mean ± SE)

		0	Aerosol C O (Sham)	oncentra	Aerosol Concentration of Powdered Cu-Zn Alloy, mg/m ³ Sham) 1.0 3.2	owdered 3	1 Cu-Zn A11	oy, mg/m	33
Parameter	Units	(N = 32) ^a	32)ª	(91 = 16)	. 16)	3	(N = 32)	(N = 16)	. 16)
Total Lung Capacity (TLC)	E,	10.4	± 0.3	11.11	± 0.3	10.8	± 0.3	1.1	± 0.3
Vital Capacity/TLC	percent	88.7	€.0 ∓	87.7	≠ 0.8	87.0	+ 1.1	87.4	± 0.7
Functional Residual Capacity	mt	2.2	± 0.1	2.3	± 0.1	2.4	± 0.1	2.4	± 0.1
Dynamic Lung Compliance	mL/cm H20	0.43	± 0.03	0.42	± 0.03	0.46	± 0.04	0.41	± 0.03
Quasistatic Chord Compliance	mL/cm H ₂ 0	0.59	± 0.02	0.64	0.64 ± 0.02	0.61	± 0.02	0.63	± 0.0 2
CO Diffusing Capacity (DLCO)	mL/min/mm Hg	0.18	0.18 ± 0.01	0.19	0.19 ± 0.01	0.18	± 0.01	0.19	± 0.01
DLCO/Lung Volume	DLCO/mL	0.018	0.018 ± 0.001	0.017	0.017 ± 0.001	0.017	0.017 ± 0.001	0.017	0.017 ± 0.001
DLCO/kg Body Weight	DLCO/kg	0.80	0.80 ± 0.02	0.85	0.85 ± 0.03	0.80	0.80 ± 0.02	0.83	0.83 ± 0.02
Forced Vital Capacity Exhaled in 0.1 Second	percent	73.8	±].]	72.8	± 2.0	70.9	± 1.9	71.9	± 2.8
Mean Midexpiratory Flow (MMEF)	mL/sec	67.2	± 2.2	72.6	± 4.}	67.4	± 3.5	70.9	± 5.3
MMEF/Forced Vital Capacity	mL/sec/mL	7.3	± 0.2	7.3	± 0.4	7.0	± 0.3	7.1	± 0.6
Slope of Phase III of Single- Breath N ₂ Washout	percent/N2/mL	85.8	± 8.5	97.3	± 5.5	80.7	± 4.9	98.7	± 6.1

aShams from Phase III, Parts 1 and 2 were all used for comparisons of baseline measurements.

The treated groups were compared with the sham-exposed group using Student's t-test for unequal variances when Levene's test indicated the variances were not the same. When Levene's test did not show differences between the variances, Student's t-test for equal variances was used. Probability values were adjusted for multiple comparisons using Bonferroni's inequality. Note:

Table 16

Respiratory Function Results for F344/N Rats in Phase III, Parts 1 and 2 Combined (Week Seven of Exposures) (Mean ± SE)

		0	Aerosol C O (Sham)	oncentra 1	Aerosol Concentration of Powdered Cu-Ln Alloy, mg/m Sham) 3.2 3.2	wdered (3.2	y. mg/m	10
Parameter	Units	$(N = 32)^{d}$	32) ^a	2	(N = 16)	2	(N = 32)	N	(N = 16)
Total Lung Capacity (TLC)	뉱	12.1	± 0.5	11.4	± 0.4	12.5	± 0.4	1.1	± 0.3
Vital Capacity/TLC	percent	92.8	± 0.4	91.6	≠ 0.7	92.2	± 0.5	90.9	± 0.7
Functional Residual Capacity	m,	2.4	± 0.1	2.2	± 0.1	2.4	± 0.1	2.3	± 0.1
Dynamic Lung Compliance	mL/cm H ₂ 0	0.46	± 0.03	0.41	± 0.03	0.48	≠ 0.03	0.39	± 0.02
Quasistatic Chord Compliance	mL/cm H20	0.72	± 0.03	99.0	≠ 0.03	0.74	± 0.03	0.64	± 0.02
CO Diffusing Capacity (DLCO)	mL/min/mm Hg	0.21	0.21 ± 0.01	0.21	0.21 ± 0.01	0.21	± 0.01	0.19	± 0.01
DLCO/Lung Volume	DLCO/mL	0.018	0.018 ± 0.001	0.018	0.018 ± 0.001	0.017	0.017 ± 0.001	0.017	0.017 ± 0.001
DLCO/kg Body Weight	DLCO/kg	0.89	± 0.05	0.92	0.92 ± 0.02	0.91	± 0.02	0.83	± 0.05
Forced Vital Capacity Exhaled in 0.1 Second	percent	71.1	+ 1.0	69.4	± 2.3	68.8	± 1.4	72.7	± 1.5
Mean Midexpiratory Flow (MMEF)	mL/sec	78.6	± 2.9	76.4	± 4.5	77.5	± 3.2	78.1	± 2.3
MMEF/Forced Vital Capacity	mL/sec/mL	6.9	± 0.2	8.9	± 0.4	6.7	± 0.3	7.4	± 0.3
Slope of Phase III of Single- Breath N ₂ Washout	percent/N2/mL	71.8	± 3.3	82.6	± 5.8	71.7	± 3.3	81.4	± 4.8

aShams from Phase III, Parts 1 and 2 were all used for comparisons of baseline measurements.

The treated groups were compared with the sham-exposed group using Student's t-test for unequal variances when Levene's test indicated the variances were not the same. When Levene's test did not show differences between the variances, Student's t-test for equal variances was used. Probability values were adjusted for multiple comparisons using Bonferroni's inequality. Note:

Table 17

Respiratory Function Results for F344/N Rats in Phase III, Parts 1 and 2 Combined (End of Exposure) (Mean ± SE)

		!	Aerosol (Concentra	Aerosol Concentration of Powdered Cu-Zn Alloy, mg/m ³	owdered	Cu-Zn Al	loy. mg/n	m_
		0	0 (Sham)		1.0	3	3.2	· ;	10
Parameter	Units	(N = 16)	. 16)	(N = 16)	. 16)	(N = 32)	. 32)	(N = 16)	(91
Total Lung Capacity (TLC)	mL	11.4	± 0.5	11.7	± 0.4	11.7	± 0.3	11.2	± 0.4
Vital Capacity/TLC	percent	91.8	#].]	93.2	± 0.9	93.6	± 0.6	92.1	± 0.7
Functional Residual Capacity	mL	2.2	± 0.1	2.1	± 0.1	2.1	± 0.1	2.1	± 0.1
Dynamic Lung Compliance	mL/cm H20	0.41	± 0.03	0.40	± 0.05	0.43	± 0.0 2	0.37	± 0.03
Quasistatic Chord Compliance	mL/cm H20	0.68	± 0.02	17.0	± 0.03	0.72	± 0.02	0.68	≠ 0.03
CO Diffusing Capacity (DLCO)	mL/min/mm Hg	0.25	± 0.01	0.22	0.22 ± 0.01	0.25	± 0.01	0.20	± 0.01
DLCO/Lung Volume	DLCO/mL	0.022	0.022 ± 0.001	0.019	0.019 ± 0.001	0.021	0.021 ± 0.001	0.017	0.017 ± 0.001^{a}
DLCO/kg Body Weight	DLCO/kg	96.0	0.96 ± 0.03	0.92	0.92 ± 0.04	0.96	0.96 ± 0.02	0.81	± 0.03ª
Forced Vital Capacity Exhaled in 0.1 Second	percent	73.1	± 1.8	67.5	± 2.2	67.1	± 1.4	64.8	± 2.5
Mean Midexpiratory Flow (MMEF)	mt/sec	73.7	± 2.0	73.8	± 5.2	68.4	± 3.0	63.6	≠ 5.0
MMEF/Forced Vital Capacity	mL/sec/mL	7.4	± 0.4	6.4	≠ 0.4	6.2	± 0.3	5.9	± 0.5
Slope of Phase III of Single- Breath N ₂ Mashout	percent/N ₂ /mL	70.0	± 5.4	67.4	67.4 ± 5.9	69.5	± 4.9	69.4	± 6.6

The treated groups were compared with the sham—exposed group using Student's t-test for unequal variances when Levene's test indicated the variances were not the same. When Levene's test did not show differences between the variances, Student's t-test for equal variances was used. Probability values were adjusted for multiple comparisons using Bonferroni's inequality. Note:

dn < 0.01

Table 18

Respiratory Function Results for F344/N Rats in Phase III, Parts 1 and 2 Combined (After Recovery) (Mean ± SE)

			Aerosol (Concentra	Aerosol Concentration of Powdered Cu-Zn Alloy, mg/m ³	owdered	Cu-Zn Al	lov. mg/	€
		0	0 (Sham)		1.0	3	3.2		01
Parameter	Units	N.	(N = 16)	N.	(N = 16)	2	(N = 32)	3	(N = 16)
Total Lung Capacity (TLC)	mL	11.2	± 0.4	12.5	± 0.5	12.4	≠ 0.4	12.7	± 0.5
Vital Capacity/TLC	percent	92.8	± 0.7	88.7	± 0.9ª	90.5	± 0.6	88.6	≠ 0.6ª
Functional Residual Capacity	m,	2.1	± 0.1	2.7	± 0.1b	2.5	± 0.1ª	2.7	± 0.1p
Dynamic Lung Compliance	mL/cm H ₂ O	0.39	± 0.03	0.43	± 0.04	0.44	± 0.03	0.40	± 0.04
Quasistatic Chord Compliance	mL/cm H ₂ O	0.68	± 0.02	0.75	± 0.03	0.74	± 0.02	0.78	₹ 0.03
CO Diffusing Capacity (DLCO)	mL/min/mm Hg	0.24	± 0.01	0.23	0.23 ± 0.02	0.22	± 0.01	0.22	± 0.01
DLCO/Lung Volume	DLCO/mL	0.022	0.022 ± 0.001	0.018	0.018 ± 0.001	0.018	0.018 ± 0.001	0.017	0.017 ± 0.001a
DLCO/kg Body Weight	DLCO/kg	0.88	± 0.03	0.88	0.88 ± 0.06	0.83	± 0.04	0.84	₹ 0.05
Forced Vital Capacity Exhaled in 0.1 Second	percent	67.8	± 2.5	67.9	± 1.7	65.4	± 1.8	70.8	#
Mean Midexpiratory Flow (MMEF)	mL/sec	65.8	± 4.6	77.7	± 2.7	71.0	± 4.2	84.7	± 2.5ª
MMEF/Forced Vital Capacity	mL/sec/mL	6.5	± 0.5	6.4	± 0.3	0.9	± 0.3	7.0	± 0.3
Slope of Phase III of Single- Breath N ₂ Washout	percent/N ₂ /mL	65.0	± 4.5	63.2	± 5.4	63.7	± 3.8	57.0	± 4.4

The treated groups were compared with the sham-exposed group using Student's t-test for unequal variances when Levene's test indicated the variances were not the same. When Levene's test did not show differences between the variances, Student's" -test for equal variances was used. Probability values were adjusted for multiple comparisons using Bonferroni's inequality. Note:

 $^{a}p < 0.05.$

bp < 0.01.

exchange (CO diffusing capacity), airflow restriction (percentage of forced vital capacity exhaled in 0.1 second and mean midexpiratory flow), and intrapulmonary gas distribution (slope of single-breath nitrogen washout). Detailed results for all of the measurements are included in the Appendix.

There were no statistically significant differences among the mean values of respiratory function parameters of the four groups before exposures began (Table 15) or after seven weeks of exposure (Table 16).

After 13 weeks of exposure (Table 17), the only significant differences between control and exposed groups were increased DLCO/lung volume and DLCO/body weight ratios in the rats exposed to 10 mg Cu-Zn/m³. The CO diffusing capacity, lung weight, and body weight of the 10 mg/m³ group were slightly, but nonsignificantly lower than that of the other groups; therefore the significant difference was a statistical result of the combination of nonsignificant differences in lung and body weights and CO diffusing capacity. Since CO diffusing capacity is affected by lung volume, the most useful size-normalized parameter is the diffusing capacity divided by lung volume (DLCO/lung volume). This parameter was significantly reduced in the group exposed to 10 mg Cu-Zn/m³ at the end of exposure (Table 17) and after the recovery period (Table 18).

7. Necropsy and Histopathology

Table 19 presents results for body and organ weights at the time of sacrifice for rats used for histopathologic evaluations in Phase III, Parts 1 and 2. Results for individual animals are detailed in the Appendix. Comparisons among these subsets of rats from the 3 exposure groups in Part 1 indicated no significant differences in body weights at the end of exposure or after the recovery period. The same result was seen for the 3 subsets of rats

Table 19

Body and Organ Weight Summary for Phase 111, Parts 1 and 2 for End of Exposure (EOE) and After Recovery (REC)^a

(Values are Mean ± SE)

Animal	Body and Organ	SAC	P	<u>Aerosol Co</u> hase III, Part	ncentration of	Powdered Cu-Zn	Alloy, mg/m" Phase III, Part	2
Sex	Weights (g)	<u>Code</u> b	1.0	3.2	10	O (Sham)	0.32	3.2
female	Body Weight	E D E	189 ± 4.9 192 ± 1.9	188 ± 2.0 ^C 198 ± 3.2	183 ± 2.1 190 ± 2.4	195 ± 1.4 206 ± 2.0	195 ± 2.3 205 ± 2.5	194 ± 1.6 203 ± 1.4
	Lung	E O E REC	0.97 ± 0.03 0.94 ± 0.03	1.06 ± 0.03 0.96 ± 0.02	1.14 ± 0.02 ^d 1.00 ± 0.03	1.05 ± 0.03 1.07 ± 0.03	0.99 ± 0.04 1.05 ± 0.04	1.05 ± 0.02 1.11 ± 0.04
	Brain	EOE REC	1.75 ± 0.02 1.77 ± 0.01	1.76 ± 0.01 1.76 ± 0.01	1.74 ± 0.01 1.74 ± 0.03	1.79 ± 0.03 1.80 ± 0.01	1.74 ± 0.01 1.81 ± 0.01	1.75 ± 0.01 1.83 ± 0.01
	Kidneys	EOE REC	1.39 ± 0.03 1.43 ± 0.03	1.39 ± 0.01 1.46 ± 0.04	1.39 ± 0.02 1.39 ± 0.02	1.39 ± 0.02 1.45 ± 0.08	1.40 ± 0.03 1.43 ± 0.08	1.39 ± 0.02 1.51 ± 0.02
	Liver	E O E R E C	5.37 ± 0.08 5.49 ± 0.11	5.51 ± 0.08 5.72 ± 0.13	5.49 ± 0.07 5.39 ± 0.15	5.77 ± 0.09 6.30 ± 0.17	5.80 ± 0.14 6.40 ± 0.10	5.72 ± 0.12 6.31 ± 0.10
	Ovaries	E D E R E C	0.06 ± 0.006 0.005 ± 0.003	0.05 ± 0.003 0.06 ± 0.004	0.06 ± 0.004 0.05 ± 0.003	0.05 ± 0.004 0.06 ± 0.003	0.05 ± 0.004 0.06 ± 0.004	0.06 ± 0.003 0.06 ± 0.004
Male	Body Weight	E O E R E C	312 ± 4.5 325 ± 5.5	313 ± 3.9 335 ± 4.0°	296 ± 2.8 329 ± 3.8	331 ± 2.4 367 ± 5.4	334 ± 3.2 358 ± 5.2	329 ± 2.5° 361 ± 3.7
	Lung	EOE REC	1.34 ± 0.07 1.28 ± 0.04	1.36 ± 0.03 1.31 ± 0.02	1.55 ± 0.04 ^e 1.45 ± 0.03	1.42 ± 0.03 1.50 ± 0.04	1.46 ± 0.04 ^C 1.51 ± 0.07 ^C	3.47 ± 0.07 1.52 ± 0.04
•	Brain	EOE REC	1.93 ± 0.01 1.86 ± 0.07	1.90 ± 0.02 1.89 ± 0.01	1.88 ± 0.02 1.91 ± 0.01	1.93 ± 0.03 2.00 ± 0.01	1.90 ± 0.01 1.95 ± 0.01	1.91 ± 0.01 1.97 ± 0.02
	Kidneys	EOE REC	2.11 ± 0.05 2.13 ± 0.05	2.12 ± 0.04 2.22 ± 0.05	2.05 ± 0.03 2.24 ± 0.06	2.21 ± 0.04 2.49 ± 0.06	2.15 ± 0.03 2.21 ± 0.12	2.19 ± 0.04 2.28 ± 0.12
	Liver	E D E R E C	9.86 ± 0.23 9.73 ± 0.27	9.71 ± 0.19 10.40 ± 0.25	9.53 ± 0.15 10.08 ± 0.26	10.24 ± 0.28 12.04 ± 0.22	10.39 ± 0.10 11.51 ± 0.34	10.15 ± 0.24 11.66 ± 0.19
	Testes	EDE REC	1.39 ± 0.05 1.38 ± 0.04	1.38 ± 0.04 1.39 ± 0.05	1.39 ± 0.02 1.41 ± 0.02	1.41 ± 0.04 1.53 ± 0.04	1.48 ± 0.01 1.71 ± 0.09°	1.53 ± 0.03 1.67 ± 0.09

 $[\]theta$ Exposures were for 13 weeks, the recovery period was 4 weeks after the last mose-only inhalation exposure. Exposures were to aerosols containing 0 (sham), 0.32, 1.0, 3.2, or 10 mg Cu-Zn alloy powder/m³.

bEOI means the sampling time was at the end of the 13-week exposure; REC means the sampling time was after the 4-week recovery period.

 $c_N = 10$; N = 11 for all other groups.

dlie treated groups were compared with the identified exposure group (Part 1) or with the sham-exposed group (Part 2) using Student's t-test for unequal variances when Levene's test indicated the variances were not the same. When Levene's test did not show differences between the variances, Student's t-test for equal variances was used. Probability values were adjusted for multiple comparisons using Bonferroni's inequality; p < 0.01.

ep ≤ 0.05.

from Phase III, Part 2. The rats exposed to 10 mg $Cu-Zn/m^3$ had body weights that appeared low relative to the other two groups in Phase III, Part 1. However, these apparent decreased body weights (for both males and females) were not statistically different from the other two groups.

Body weight comparisons using body weights for all of the rats in Phase III, Part 1 indicated exposure to 10 mg Cu-Zn/m³ caused a decreased body weight by the end of the 13-week exposure (Table 7). Rats in all exposure groups showed increased body weight during the 4-week recovery period and were not significantly different from each other after the recovery period.

Organ weights, with the exception of lung, showed no exposure-related changes. The organ weights were slightly elevated after the 4-week recovery period, reflecting the increases in animal body weight during the recovery period. As compared with rats exposed to 1.0 mg Cu-Zn/m³, the lung weights of rats exposed to 10 mg Cu-Zn/m³ were significantly increased at the end of the 13-week exposure period (p \leq 0.05 for males and p \leq 0.01 for females). In both sexes, the lung weights were not significantly different from the other two exposure groups in Phase III, Part 1 at the end of the 4-week recovery period. There were no significant differences at the end of exposure or after the recovery period in lung weights of rats sham-exposed, or exposed to Cu-Zn in Phase III, Part 2.

Lesions produced by Cu-Zn inhaled by rats were produced only in nasal epithelium and lungs (Table 20). A summary of the fractions of rats in each exposure group with induced lesions, the average severity of those specific lesions, and the overall average severity scores for the lesions are presented in Table 20. The principal microscopic lesions were atrophy of the olfactory epithelium in a focal region of the nasal cavity, alveolar

Table 20

Summary of Respiratory Tract Lesions in F344/N Rats After 13-Weeks Exposure to Aerosols of Powdered Cu-Zn Alloy and After a 4-Week Recovery Period

		Aer	osol Concentra	tion of Cu-Zn	Alloy Powder, m	g/m ³
Lesion	Measure	O (Sham)	0.32	1.0	3.2	10
End of Exposure						
Nasal Epithelium Atrophy	Frequency of Lesions ^a Average Severity ^b Overall Severity ^c	0/22	0/22	3/22 1.0 0.14 ± 0.08	6/44 1.0 0.14 ± 0.05	15/22 1.2 0.82 ± 0.14d
Alveolar Macrophage Hyperplasia	Frequency of Lesions Average Severity Overall Severity	1/22 1.0 0.05 ± 0.05	0/22	0/22	24/44 1.0 0.55 ± 0.08 ^d	18/22 1,4 1,14 ± 0.15 ^d
Type II Pneumocyte Hyperplasia	Frequency of Lesions Average Severity Overall Severity	0/22	0/22	0/22	12/44 1.0 0.27 ± 0.07 ^d	17/22 1.2 0.91 ± 0.13d
Alveolitis	Frequency of Lesions Average Severity Overall Severity	0/22	0/22	0/22	11/44 1.0 0.25 ± 0.07	18/22 1.4 1.14 ± 0.15
After Recovery						
Nasal Epithelium Atrophy	Frequency of Lesions Average Severity	0/22	0/22	0/22	1/43 1.0 0.02 ± 0.02	7/22 1.1 0.36 ± 0.12
Alveolar Macrophage Hyperplasia	Frequency of Lesions Average Severity Overall Severity	3/22 1.0 0.14 ± 0.08	1/22 1.0 0.05 ± 0.05	0/22	10/43 1.0 0.23 ± 0.07	22/22 1.0 1.05 ± 0.05 ^d
Type II Pneumocyte Hyperplasia	Frequency of Lesions Average Severity Overall Severity	0/22	1/22 1.0 0.05 ± 0.05	1/22 1.0 0.05 ± 0.05	8/43 1.0 0.19 ± 0.06°	22/22 1.0 1.05 ± 0.05 ^d
Alveolitis	Frequency of Lesions Average Severity Overall Severity	0/22	1/22 1.0 0.05 ± 0.05	0/22	1/43 1.0 0.02 ± 0.02	0/22

^{*}Fraction of rats in each group that developed the lesion.

Daverage severity score for rats with lesions having a rating of 1 or more. The lesion rating was: 0 = no change relative to normal, lesion not present; 1 = slight degree of change, or small amount present; 2 = moderate, median, or middle severity or amount; 3 = marked severity or degree of change, large amount present.

COverall severity represents the mean \pm SE for the severity rating for each rat, including those rats with severity ratings of zero.

dThe treated groups were compared with the sham-exposed group using Student's t-test for unequal variances if Levene's test indicated the variances were not the same. When Levene's test did not show differences between the variances, Student's t-test for equal variances was used. Probability values were adjusted for multiple comparisons using Bonferroni's inequality; p < 0.01.

ep < 0.05.

macrophage hyperplasia, type II pneumocyte hyperplasia, and a focal necrotizing alveolitis. Fifteen of 22 rats exposed to 10 mg Cu-Zn/m³, 6 of 44 rats exposed to 3.2 mg $Cu-Zn/m^3$, and 3 of 22 rats exposed to 1.0 mg $Cu-Zn/m^3$ had nasal epithelial atropy at the end of exposure. Although the number of rats with this lesion was greater in the group exposed to 10 mg Cu-Zn/m³, as compared with rats exposed to 3.2 or 1.0 mg/m³, there were no significant differences in the severity of the lesion. After the recovery period, this lesion was present in 7 of 22 rats exposed to 10 mg Cu-Zn/m³ and 1 of 43 rats exposed to 3.2 mg $Cu-Zn/m^3$. At the end of the exposure period, alveolar macrophage hyperplasia was found in 18 of 22 rats exposed to 10 mg Cu-Zn/m³ and 24 of 44 rats exposed to 3.2 mg Cu-Zn/m³. This lesion did not resolve during the 4-week recovery period in rats exposed to 10 mg Cu-Zn/m³, but appeared to partially resolve in rats exposed to 3.2 mg Cu-Zn/m³. Type II pneumocyte hyperplasia was observed at the end of the exposure in 17 of 22 rats exposed to 10 mg $Cu-Zn/m^3$ and 12 of 44 rats exposed to 3.2 mg $Cu-Zn/m^3$. This lesion also persisted during the recovery period. Alveolitis was present at the end of exposure in 18 of 22 rats exposed to 10 mg Cu-Zn/m³ and in 11 of 44 rats exposed to 3.2 mg Cu-Zn/m³. This lesion resolved during the recovery period. Type II pneumocyte hyperplasia, macrophage hyperplasia, and alveolitis were not present in rats after exposure to 1.0 or 0.32 mg Cu-Zn/m³ for 13 weeks. However, the lesions were observed in a small number of rats after the recovery period. The numbers were not statistically significant and the lesion severity score was "slight degree of change". The reason these lesions were observed after the recovery period is not known, but we conclude that they were not progressively developing or delayed lesions produced by exposures to Cu-Zn since (1) they were not present in rats evaluated at the

end of the exposure period, and (2) the lesions were seen in sham-exposed rats to the same extent as they were seen in rats exposed to Cu-Zn alloy.

No exposure-induced lesions or alterations were evident in the tissue sections of larynx, trachea, or tracheobronchial lymph nodes of any of the experimental groups.

8. Lung Burdens of Cu and Zn

Results for lung content of Cu and Zn for rats analyzed at the end of the 13-week exposure series and 4 weeks later are presented in Table 21. The amounts of Cu and Zn in rats exposed to 1.0, 3.2 and 10 mg $Cu-Zn/m^3$ were not significantly different from controls and were not significantly different from each other at the end of exposure or after the 4-week recovery period.

Table 21
Lung Content of Cu and Zn in F344/N Rats Exposed
Nose-Only in Phase III, Part 1

Aerosol Concentration of Cu-Zn Alloy	<u>N</u>	<u>Measure</u>	End Cu	μg At of Expos Zn	sure <mark>a</mark> <u>Cu+Zn</u>	4 W	μg Afte eeks Rec Zn	
O (Sham)	12	Mean	2.12	23.85	25.96	NSb	NS	NS
		SE	0.16	0.84	0.88	~-		
1.0 mg/m ³	6-7 ^C	Mean	1.74	20.84	22.57	0.99	18.74	19.73
		SE	0.22	2.17	2.28	0.11	0.55	0.62
3.2 mg/m ³	7-8 ^d	Mean	2.36	21.14	23.50	1.25	17.52	18.77
		SE	0.36	1.01	1.03	0.18	0.74	0.86
10 mg/m ³	8	Mean	2.31	21.87	24.18	1.23	18.08	19.32
-		SE	0.28	1.70	1.79	0.18	0.75	0.84

^aSamples for shams taken from rats that died during exposure one day before the last scheduled exposure.

Note: The treated groups were compared with the sham-exposed group using Student's t-test for unequal variances if Levene's test indicated the variances were not the same. When Levene's test did show differences between the variances, Student's t-test for equal variances was used. Probability values were adjusted for multiple comparisons using Bonferroni's inequality.

bNo samples for shams after the recovery period, since no animals were available for this evaluation.

 $c_N = 7$ for end of exposure; N = 6 for after recovery.

dN = 7 for end of exposure; N = 8 for after recovery.

VII. GENERAL DISCUSSION AND CONCLUSIONS

Phase I of this project used exposures of F344/N rats to 100 mg Cu-Zn/m³, with exposures 2.5 hours/day, for 2 or 5 days (Snipes et al., 1987). The weekly concentration x time (C x T) product in Phase I was 1250 mg·hr Cu-Zn/m³. Adverse effects were produced in the upper respiratory tracts and pulmonary regions of those rats after 2 days of exposure. Similar responses to inhaled Cu-In were noted in Phase II (Snipes et al., 1988), where experimental conditions included aerosol concentrations of 10 or 40 mg Cu-Zn/m³ and exposures 2 or 4 days/week, 1.5 or 3 hours/day for 4 weeks. The weekly C x T products in Phase II were 0 (sham), 30, 60, 120, 240, and 480 mg·hr Cu-Zn/m³. The 60, 120, and 240 weekly C x T product exposures were produced using both 2 and 4 exposures/week. This provided the opportunity to compare effects of exposure frequency on biological responses for the same C x T product. Results of Phase II showed that exposures to Cu-Zn alloy 4 days/week were more detrimental to the rats than exposures 2 days/week for the same C x T product. Also, exposures to at least 60 mg·hr Cu-Zn/week were generally needed to produce significant biological responses in F344/N rats exposed for a period of 4 weeks.

Based primarily on the results from Phase II, the subacute exposures of F344/N rats in Phase III were designed to have a maximum weekly exposure of 60 mg·hr Cu-Zn/m³. The rats were exposed 1.5 hours/day, 4 days/week for 13 weeks to aerosols of Cu-Zn alloy containing 0 (sham), 0.32, 1.0, 3.2, or 10 mg/m³. The purpose of Phase III was to determine adverse effects of exposures to the defined air concentrations of Cu-Zn alloy by measuring specific biological parameters after the 13 weeks of exposure. In addition to evaluating the rats after the 13-week exposures, additional rats were evaluated 4 weeks later to determine if biological damage would resolve during that time period.

The Cu-Zn alloy did not accumulate in the lungs of rats. The aerosol size distributions were in the range of sizes that would be highly respirable by rats. Even with a small deposition fraction for the inhaled material, the daily lung deposition for rats inhaling 10 mg Cu-Zn/m³ would have been several μg . During the 13-week exposure, rats would have deposited mg quantities of Cu-Zn in their lungs. The absence of significant amounts of either metal after 13 weeks of exposure to aerosol concentrations as high as 10 mg Cu-Zn/m³ indicated rapid clearance of the particles of metal powder from the rat lung.

No exposure-related changes were seen in any of the serum chemistry data (alkaline phosphatase, serum glutamic pyruvic transaminase, total bilirubin, blood urea nitrogen, protein, and albumin). Values were all considered to be within the normal range for these blood serum parameters, and we conclude that the exposures to Cu-Zn had no effect on the rats that could be detected by these blood serum chemistry analyses. Bronchoalveolar lavage fluid analyses indicated a transient, exposure related inflammatory response to the inhaled Cu-Zn. The lowest exposure concentration producing significant evidence of the inflammatory response was 3.2 mg Cu-Zn/m³. The inflammatory response was completely resolved within 4 weeks after the last inhalation exposure to Cu-Zn.

Airway (lavage fluid) collagenous peptides were increased in rats after 13 weeks of exposure to 10 mg Cu-Zn/m³. Since airway collagenous peptides are soluble hydroxyproline-containing compounds which have leaked into alveoli and small airways, they probably represent turnover of the extracellular collagenous matrix associated with alveolitis and macrophage hyperplasia. Following 4 weeks of recovery, this increase in collagenous peptides had disappeared in rats exposed to 10 mg Cu-Zn/m³ but was seen in rats exposed to 1.0 mg Cu-Zn/m³. The reason for this is unknown a lit was not thought to represent an adverse effect related to the aerosol exposures.

At the end of the exposures to 10 mg Cu-Zn/m³, the total numbers of lymphocytes were increased in bronchoalveolar lavage fluid. This has been observed after inhalation of other aerosols, such as diesel exhaust, fly ash, and silica (Bice et al., 1985, 1987). However, the lymphocyte levels returned to normal during the four-week recovery period, indicating that the response was quickly resolved after exposures to Cu-Zn ended. In contrast, exposure to fly ash and silica resulted in permanently increased numbers of lymphocytes in the lung-associated lymph nodes (Bice et al., 1987). Immunology results all indicated that inhalation of Cu-Zn had minimal effects on the lung-associated lymph nodes, showing increased immune responses rather than immune suppression. The elevated immune response at the end of exposure to 10 mg Cu-Zn/m³ was not permanent and returned to normal during the 4-week recovery period following the 13-week inhalation exposure series.

Macrophage phagocytic ability was significantly increased by exposures to 0.32 or 1.0 mg Cu-Zn/m³, and was decreased by exposure to 10 mg Cu-Zn/m³. This response at the lower concentrations was not considered detrimental and may represent a normal response to inhaled materials, where the presence of foreign particles in the lung stimulates phagocytic activity. The exposures to 10 mg Cu-Zn/m³ depressed phagocytic ability of pulmonary macrophages, which represents an adverse effect. No significant differences existed among the sham-exposed and Cu-Zn-exposed rats after the 4-week recovery period.

Exposure to 10 mg Cu-Zn/m³ resulted in reduced carbon monoxide diffusing capacity in these rats, which persisted and did not resolve during the 4-week recovery period. The reduced DLCO/lung volume and DLCO/body weight ratios suggested an impairment of alveolar-capillary gas exchange at the membrane level. These findings are consistent with pathology of the lung parenchyma,

but are not specific for a single type of lesion. The magnitudes of the functional changes were small. A human subject with respiratory functional changes of a similar nature and magnitude would not likely present symptoms.

Thirteen weeks of inhalation exposure 1.5 hours/day, 4 days/week to 3.2 or 10 mg Cu-Zn/m³ produced histologic evidence of olfactory epithelial atrophy, alveolitis, macrophage hyperplasia, and type II pneumocyte hyperplasia in lung parenchyma. The focal alveolitis was associated with terminal bronchioles, proximal alveolar ducts, and adjacent alveoli. Following 4 weeks of recovery, olfactory epithelial atrophy and alveolitis had partially resolved. In contrast, alveolar macrophage hyperplasia and type II pneumocyte hyperplasia did not resolve rapidly, and these lesions were still seen after the recovery period.

The only significant lesion produced in these F344/N rats by inhalation of less than 3.2 mg Cu-Zn/m³ was nasal epithelial atrophy, produced in 3 of 22 rats exposed to 1.0 mg Cu-Zn/m³. The lesion fully resolved by the end of the 4-week recovery period. The lesions observed in sham-exposed rats and rats exposed to 0.32 or 1.0 mg Cu-Zn/m³ did not appear to be related to the inhalation of Cu-Zn and did not appear to have long-term adverse health implications. For example, one of 22 sham-exposed rats had a slight alveolar macrophage hyperplasia at the end of exposure, but none of the rats exposed to 0.32 or 1.0 mg Cu-Zn/m³ had the lesion at that time. After the 4-week recovery period, alveolar macrophage hyerplasia was observed in 3 of 22 sham-exposed rats and 1 of 22 rats exposed to 0.32 mg Cu-Zn/m³. Neither type II pneumocyte hyperplasia nor alveolitis was observed at the end of exposure in sham-exposed rats or rats exposed to 0.32 or 1.0 mg Cu-Zn/m³; after the 4-week recovery period, alveolar macrophage hyperplasia was again not seen in

sham-exposed rats, but was seen in 1 of 22 rats exposed to 0.32 or 1.0 mg Cu-Zn/m³. Also, after the recovery period, 1 of 22 rats exposed to 0.32 mg Cu-Zn/m³ had evidence of a slight degree of alveolitis, but none of the sham-exposed rats or rats exposed to 1.0 mg Cu-Zn/m³ had the lesion. All of these lesions in rats exposed to less than 3.2 mg Cu-Zn/m³ had a slight severity rating, and with the exception of the nasal epithelial atrophy produced by exposure to 1.0 mg Cu-Zn/m³, and were not observed at the end of the 13-week exposure period. Therefore, they did not appear to represent adverse biological responses to inhaled Cu-Zn alloy powder.

This study was conducted with F344/N rats to provide data to help predict the consequences of human inhalation exposures to this metal powder. It is reasonable to assume that the same or similar biological effects would be produced in the same target tissues and organs of rats and humans if the exposures of those anatomical structures were similar. Using available information about differences in the deposition of inhaled materials in the respiratory tracts of rats and humans (Schlesinger, 1985; Snipes, 1988), it is possible to estimate the relative exposure conditions needed to produce the same or similar tissue exposures and biological effects in rats and humans exposed to powdered Cu-Zn alloy. Since the Cu-Zn alloy powder clears very rapidly from the respiratory tract, this estimate does not include known differences between rats and humans in the rates of physical clearance of materials after their deposition in the respiratory tract. The assumption was made that the amount of deposited Cu-Zn dictates the type and magnitude of biological responses to the inhaled Cu-Zn.

The respiratory minute volume of F344/N rats is about 0.2 L; the minute respiratory volume of humans involved in "light activity" is about 20 L. Per

kilogram body weight, rats have minute respiratory volumes about 2.8 times greater than humans. In addition, regional deposition patterns result in markedly different exposure patterns for materials inhaled by rats and humans. Rats are obligatory nose-breathers, whereas humans breathe through their mouths or noses. Mouth-breathing humans would have a total deposition of about 50 percent (Morrow et al., 1966) of the Cu-Zn alloy aerosols used in this project, with most of the deposition in the pulmonary region. Nose-breathing humans would also deposit about 50 percent of the inhaled aerosol in the respiratory tract, but the deposition would be about equally divided between the upper respiratory tract and the pulmonary region. Rats would deposit about 40 percent of the inhaled material in the upper irespiratory tract and about 5 to 10 percent of the material in the pulmonary region. Therefore, rats breathing an aerosol containing 1 mg Cu-Zn/m³ would be expected to deposit about 0.01 to 0.02 µg Cu-Zn/minute in a 1.5 gram lung \sim (0.007 to 0.013 μ g Cu-Zn/g lung/minute). Mouth-breathing humans would deposit about 10 μg of Cu-Zn/minute in a 1000 gram lung (0.010 μg Cu-Zn/g €lung/minute); and nose-breathing humans would deposit about 0.05 μg Cu-Zn/g lung/minute and about 5 µg Cu-Zn/minute in the upper respiratory tract. Because of the species differences in respiratory minute volume, fractional pulmonary deposition, and lung size, rats would have pulmonary deposition (µg Cu-Zn/g lung) comparable to that of mouth-breathing humans and about twice as thigh as that of nose-breathing humans.

While pulmonary deposition (μg Cu-Zn/g lung/minute) for the same aerosol of Cu-Zn would be similar for rats and humans, deposition in the upper respiratory tract would be quite different. A rat with a respiratory minute volume of 0.2 L, breathing an aerosol containing 1 mg Cu-Zn/m³, would deposit

about 40 percent of the inhaled Cu-Zn (0.4 μ g/minute) in the upper respiratory tract. A nose-breathing human would deposit about 5 μ g/minute in the upper respiratory tract. Scaling the body weights of humans (70 kg) to body weights of rats (0.25 kg), and assuming the weights of nasal epithelium scale accordingly, the relative deposition of Cu-Zn in the rat's nasal epithelium could be about 20 times higher than for humans.

These comparisons for pulmonary and upper respiratory tract deposition of inhaled Cu-Zn alloy suggest that comparable exposures of the pulmonary region would result in rats and humans exposed to the same aerosol of powdered Cu-Zn alloy. The exposure of the tissues of the upper respiratory tract was estimated to be about 20 times higher for rats than for humans exposed to the same aerosol. Therefore, while lesions seen in the pulmonary region in this project might be similar for rats and humans exposed to the same aerosol of powdered Cu-Zn alloy, aerosol concentrations of Cu-Zn alloy would have to be much higher for human exposures to produce the same effects in the upper respiratory tracts as were observed in the F344/N rats.

VIII. NO OBSERVABLE ADVERSE EFFECTS LEVEL OF EXPOSURE

The no observable adverse effects level of exposure, for F344/N rats exposed to this respirable powder of Cu-Zn, is concluded on the basis of results of these studies to be an exposure equivalent to 0.32 mg Cu-Zn/m 3 , 1.5 hours/day, 4 days/week.

IX. QUALITY ASSURANCE STATEMENT

Test Chemical: Cu-Zn Alloy Powder

Study Type: Phase III: Subchronic Inhalation Exposures in F344/N Rats

This research was conducted in accordance with the Good Laboratory Practice Regulations for Nonclinical Laboratory Studies (FDA, 1978). The study phases were inspected by the LITRI Quality Assurance Unit and findings reported to study scientists and to LITRI management. The final report is in accordance to the experimental methods described in study protocols and in standard operating procedures.

Documentation records, raw data, and pathology specimens pertaining to this study shall be archived and retained at the LITRI in accordance with 21 CFR Part 58 Good Laboratory Practice for Nonclinical Laboratory Studies.

OA Unit Schedule

Experimental Phase	Inspection Date	Report Date
Protocol FY86-016 Audit	04/02/86	04/02/86
Protocol FY86-016 Approval	06/09/86	06/09/86
Path/Tox Protocol Approval	06/10/86	N/A
Animal Quarantine Room	06/24/86	06/30/86
Facility Clin Path Lab	07/08/86	07/15/86
Exposure Room Prestudy	06/24/86	06/30/86
Exposure Room (Dosing)	07/10/86	07/30/86
Animal Weighing/Observations	07/24/86	07/30/86
Necropsy	09/23/86	09/23/86
Protocol FY87-009 Audit	11/21/86	11/21/86
Protocol FY87-009 Approval	01/22/87	01/22/87
Path/Tox Protocol Approval	01/13/87	N/A
Animal Quarantine/Weights	01/14/87	01/30/87
Exposure Room (Dosing)	02/18/87	02/28/87
Animal Weighing/Observations	03/12/87	03/12/87
Necropsy	04/29/87	04/30/87
	05/27/87	05/27/87

QA Unit Schedule (Cont.)

<u>Experimental Phase</u>	<u>Inspection Date</u>	Report Date
Data Audit	12/10-11/87	12/31/87
Data Audit Final Report Data Audit	02/04-09/88 06/16-20/88	02/10/88 06/20/88
Final Report Audit	06/20/88	06/20/88

LITRI Quality Assurance Officer:

LITRI Study Director:

D. Y. Harris

1. 1/2000 S Syrift - 8/1/57

M. B. Snipes, Ph.D. 1

X. REFERENCES

- Amdur, M. O. and J. Mead. Mechanics of Respiration in Unanesthetized Guinea Pigs. Am. J. Physiol. 192: 364-368, 1958.
- American Chemical Society Committee on Environmental Improvement.

 Subcommittee on Environmental Monitoring and Analysis. Principles of Environmental Analysis. Anal. Chem. 55: 2210-2218, 1983.
- Beck, B. D., J. D. Brain, and D. E. Bohannon. The Pulmonary Toxicity of an Ash Sample from the Mount St. Helens Volcano. Exp. Lung Res. 2: 289-301, 1981.
- Beck, B. D., J. D. Brain, and D. E. Bohannon. An <u>In Vivo</u> Hamster

 Bioassay to Assess the Toxicity of Particulates for the Lungs.

 <u>Toxicol. Appl. Pharmacol.</u> 66: 9-29, 1982.
- Bice, D. E., F. F. Hahn, J. Benson, R. L. Carpenter, and C. H. Hobbs.

 Comparative Lung Immunotoxicity of Inhaled Quartz and Coal

 Combustion Fly Ash. <u>Environ. Res.</u> 43: 374-389, 1987.
- Bice, D. E., D. L. Harris, C. T. Schnizlein, and J. L. Mauderly.

 Methods to Evaluate the Effects of Toxic Materials Deposited in the

 Lung on Immunity in Lung-associated Lymph Nodes. <u>Drug Chem. Tox</u>.

 2: 35-47, 1979.
- Bice, D. E., Mauderly, J. L., R. K. Jones, and R. O. McClellan. Effects of Inhaled Diesel Exhaust on Immune Responses after Lung Immunization. <u>Fundam. Appl. Toxicol</u>. <u>5</u>: 1075-1086, 1985.
- BBN Software Products Corporation, Cambridge, MA. RS/1 for VAX and MicroVax: Release 2, 1985.
- BMDP. Biomedical Computer Programs, P-Series, 1979. (Dixon, W. J. and M. B. Brown, eds.), University of California Press, 1979.

- Cunningham, A. J. and A. Szenberg. Further Improvements in the Plaque

 Technique for Detecting Single Antibody-forming Cells. <u>Immunology</u>

 14: 599-600, 1968.
- DuBois, A. B., S. Y. Botelho, G. N. Bedeli, R. Marshall, and J. H. Comroe. A Rapid Plethysmographic Method for Measuring Thoracic Gas Volume: A Comparison with a Nitrogen Washout Method for Measuring Functional Residual Capacity in Normal Subjects. <u>J. Clin. Invest.</u> 35: 322-326, 1956.
- Gottlieb, C. F. Application of Transformations to Normalize the

 Distribution of Plaque-forming Cells. <u>J. Immunol</u>. <u>113</u>: 51-57, 1974.
- Grant, R. A. Estimation of Hydroxyproline by the AutoAnalyzer. <u>J.</u>
 Clin.Pathol.17: 685-686, 1965.
- Harkema, J. R., J. L. Mauderly, and F. F. Hahn. Effect of Oxygen

 Toxicity and Elastase-induced Emphysema on Pulmonary Function and

 Morphology. Am. Rev. Respir. Dis. 126: 1058-1065, 1982.
- Harmsen, A. G. and E. L. Jeska. Surface Receptors on Porcine Alveolar Macrophages and Their Role in Phagocytosis. <u>J. Reticuloendoth.</u> <u>Soc. 27</u>: 631-637, 1980.
- Henderson, R. F., E. G. Damon, and T. R. Henderson. Early Damage

 Indicators in the Lung. I. Lactate Dehydrogenase Activity in the

 Airways. <u>Toxicol. Appl. Pharmacol.</u> 44: 291-297, 1978a.
- Henderson, R. F., B. A. Muggenburg, J. L. Mauderly, and W. A. Tuttle.

 Early Damage Indicators in the Lung. II. Time Sequence of Protein

 Accumulation and Lipid Loss in the Airways of Beagle Dogs with Beta

 Irradiation of the Lung. Radiat. Res. 76: 145-158, 1978b.

- Damage Indicators in the Lung. III. Biochemical and Cytological Response of the Lung to Inhaled Metal Salts. <u>Toxicol. Appl.</u>

 Pharmacol. 50: 123-136, 1979a.
- Henderson, R. F., A. H. Rebar, and D. B. DeNicola. Early Damage

 Indicators in the Lungs. IV. Biochemical and Cytologic Response
 of the Lung to Lavage with Metal Salts. <u>Toxicol</u>, <u>Appl. Pharmacol</u>.
 51: 129-135, 1979b.
- Henderson, R. F. and J. S. Lowrey. Effect of Anesthetic Agents on Lavage Fluid Parameters Used as Indicators of Pulmonary Injury.

 <u>Lab. Anim. Sci. 33</u>: 60-62, 1983.
- Likens, S. A. and J. L. Mauderly. Effect of Elastase or Histamine on Single-breath N₂ Washouts in the Rat. <u>J. Appl. Physiol.</u> <u>52</u>: 141-146, 1982.
- Mauderly, J. L. Bronchopulmonary Lavage of Small Laboratory Animals.

 Lab. Anim. Sci. 27: 255-261, 1977.
- Mauderly, J. L. The Effect of Age on Respiratory Function of Fischer-344

 Rats. Exp. Aging Res. 8: 31-36, 1982.
- Moores, S. R., A. Black, J. C. Evans, N. Holmes, and A. Morgan. The

 Effect of Quartz Administered by Intratracheal Instillation on the

 Rat Lung. II. The Short-term Biochemical Response. Environ. Res.

 24: 275-285, 1981.
- Moores, S. R., S. E. Sykes, A. Morgan, N. Evans, J. C. Evans, and A. Holmes. The Short-term Cellular and Biochemical Response of the Lung to Toxic Dusts: An "In Vivo" Cytotoxicity Test. In <u>The In Vitro Effect of Mineral Dusts</u> (Brown, R. C., I. P. Gormley, M. Chamberlain, and R. Davis, eds.), Academic Press, pp. 297-303, 1980.

- Morrow, P. E., D. V. Bates, B. R. Fish, T. F. Hatch, and T. T. Mercer.

 Deposition and retention models for internal dosimetry of the human respiratory tract. Health Phys. 12: 173-207, 1966.
- Neuman, R. E. and M. A. Logan. The Determination of Hydroxyproline. <u>J.</u>
 Biol. Chem. <u>184</u>: 299-306, 1950.
- Ogilvie, C. M., R. E. Forster, W. S. Blakemore, and J. W. Morton. A

 Standardized Breath Holding Technique for the Clinical Measurement
 of the Diffusing Capacity of the Lung for Carbon Monoxide. <u>J.</u>

 <u>Clin. Invest.</u> <u>36</u>: 1-17, 1957.
- Pickrell, J. A., D. L. Harris, R. C. Pfleger, S. A. Benjamin, J. J. Belasich, R. K. Jones, and R. O. McClellan. Biological Alterations Resulting from Chronic Lung Irradiation. II. Connective Tissue Alterations Following Inhalation of ¹⁴⁴Ce Fused Clay Aerosol in Beagle Dogs. Radiat. Res. 63: 299-309, 1975.
- Raabe, O. G., J. E. Bennick, M. E. Light, C. H. Hobbs, R. L. Thomas, and M. I. Tillery. An Improved Apparatus for Acute Inhalation Exposure of Rodents to Radioactive Materials. <u>Toxicol. Appl. Pharmacol.</u> 26: 264-273, 1973.
- Schlesinger, R. B. Comparative Deposition of Inhaled Aerosols in Experimental Animals and Humans: A Review. <u>J. Toxicol. Environ.</u>

 Health 15: 197-214, 1985.
- Snipes, M. B. Species Comparisons for Pulmonary Retention of Inhaled Particles. In <u>Concepts in Inhalation Toxicology</u> (McClellan, R. O. and R. F. Henderson, eds.), Hemisphere Publishing Corporation, Washington, DC, pp. 195-229, 1988.

- Snipes, M. B., D. G. Burt, A. F. Eidson, F. F. Hahn, A. G. Harmsen, J. A. Pickrell, F. A. Seiler, and H. C. Yeh. Comparative Inhalation Toxicology of Selected Materials: Final Report for Phase I Studies, September, 1986, AD No. Al76250.
- Snipes, M. B., D. E. Bice, D. G. Burt, E. G. Damon, A. F. Eidson, F. F. Hahn, J. R. Harkema, A. G. Harmsen, R. F. Henderson, J. L. Mauderly, J. A. Pickrell, F. A. Seiler, and H. C. Yeh. Comparative Inhalation Toxicology of Selected Materials: Final Report for Phase II Studies, May, 1988.
- Thomson, S., D. C. Burnett, J. D. Bergmann, and C. J. Hixson.

 Comparative Inhalation Hazards of Aluminum and Brass Powders Using Bronchopulmonary Lavage as an Indicator of Lung Damage. <u>J. Appl. Toxicol</u>. 6: 197-209, 1986.
- Xybion Medical Systems, Inc., Cedar Knolls, New Jersey, Path/Tox Database.

XI. ACKNOWLEDGMENTS

The authors acknowledge the outstanding contributions of a number of staff members of the Lovelace Inhalation Toxicology Research Institute, without whose help these studies could not be done. Research was supported by the U. S. Army Biomedical Research and Development Laboratory, under a Memorandum of Understanding Agreement No. AT(29-2)-2138 with the Lovelace Inhalation Toxicology Research Institute, which is operated for the U. S. Department of Energy (DOE) Office of Health and Environmental Research (OHER) under DOE Contract No. DE-ACO4-76EVO1013. The facilities used for this research were fully accredited by the American Association for Accreditation of Laboratory Animal Care.

XII. APPENDICES

- A. Explanation of Symbols and Abbreviations.
- B. Daily Aerosol Concentrations of Cu-Zn Alloy Powder in Phase III.
- C. Body Weights (Grams) for Individual Animals.
- D. Animal Weights and Selected Tissue Weights at Time of Sacrifice.
- E. Endpoint Evaluation Results for Individual Animals (Hematology, Chemistry, Phagocytosis, Immunology).
- F. Atomic Absorption Analysis Results for Individual Animals.
- G. Results for Individual Animal Pulmonary Function Evaluations.
- H. Group Summaries of Histopathology Observations.
- I. Summary Tables of Endpoint Evaluations and Statistical Comparisons Between Phase III, Parts 1 and 2 for F344/N Rats Exposed to 3.2 mg Cu-Zn Alloy Powder/m³.
- J. Miscellaneous.

APPENDIX A: EXPLANATION OF SYMBOLS AND ABBREVIATIONS (Defined in alphabetical order)

- 1. AFC = Antibody-forming cells per million lymphocytes in lung-associated lymph nodes.
- AIRC = Airway collagen expressed as micrograms present in the lavage fluid.
- 3. ALB = Albumin in grams/dL serum.
- 4. ALKP = Alkaline phosphatase activity in international units/L serum.
- 5. ALKPL = Alkaline phosphatase in lung lavage fluid; milli-international units.
- 6. Animal Number = Animal number. Metal eartags were used in this study for permanent animal identification.
- 7. Assign Code = Assignment code, indicating the fate of the animals used in this study.
 - EOE = Animals killed for endpoint evaluations after the exposure period.
 - REC = Animals killed for endpoint evaluations after the recovery period following aerosol exposures.
- BGLUL = Beta glucuronidase in lung lavage fluid; milli-international units.
- 9. BWBC = Leukocyte (WBC) numbers per mm³ of blood.
- 10. BUN = Blood urea nitrogen in milligrams/dL serum.
- 11. CCORD = Quasistatic cord compliance (mL per cm water).
- 12. CDYN = Dynamic lung compliance (mL per cm of water).
- 13. DLCO = Carbon monoxide diffusing capacity (mL per minute per millimeter of mercury).
- 14. EA/100 Cells = Number of opsonized sheep red blood cells (SRBC) phagocytized per 100 pulmonary alveolar macrophages.
- 15. EF10 = Forced expiratory flow rate at 10 percent of FVC (mL per second).
- 16. EOSI = Eosinophils in blood, expressed as numbers of eosinophils per 100 leukocytes.

17. Exposure Code:

SHAM - Exposures of rats to humidified, filtered air using the same kind of nose-only exposure system as used for the Cu-Zn alloy powder. Exposures were 1.5 hr/day, 4 days/week.

Other exposure groups are expressed as mg Cu-Zn/m3 to indicate the exposure atmosphere they breathed.

- 18. Expt Number LITRI experiment number.
- 19. FEVI Percent of FVC exhaled in 0.1 second.
- 20. FRC = Functional residual capacity (mL).
- 21. FVC = Forced vital capacity (mL).
- 22. HEMA = Hematocrit = The percentage ratio of volume of packed cells to red blood cells volume of whole blood.
- 23. HGB = Hemoglobin levels in blood, expressed as grams per dL of blood.
- 24. Histopathology codes:
 - 0 = No changes relative to normal; lesion not present.
 - 1 Slight degree of change, or small amount present; mild response.
 - 2 = Moderate, median, or middle severity or amount.
 - 3 = Marked severity or degree of change, large amount present.
- 25. LDHL = Lactic dehydrogenase in lung lavage fluid; milli-international units.
- 26. LYMP = Lymphocytes in blood, expressed as numbers of lymphocytes per 100 leukocytes.
- 27. MCHV = Mean corpuscular hemoglobin concentration. The average concentration of hemoglobin in red blood cells in percent.
- 28. MCV = Mean corpuscular volume. The average volume of red blood cells in units of cubic micrometers.
- 29. MMEF Mean mid-expiratory flow rate (mL per second).
- 30. MONO = Monocytes in blood, expressed as numbers of monocytes per 100 leukocytes.
- 31. MV = Minute volume (mL per minute).
- 32. NCELL Total cells in centrifuge pellet from lavage fluid.
- 33. NEA = Number of erythrocytes phagocytized by 100 pulmonary alveolar macrophages.

- 34. NEOS Total number of eosinophils in lavage fluid.
- 35. NLYM = Total number of lymphocytes in lavage fluid.
- 36. NMAC Total number of macrophages in lavage fluid.
- 37. NPMN = Total number of neutrophils in lavage fluid.
- 38. NRBC Nucleated erythrocytes per 100 leukocytes in blood.
- 39. PAMN = Pulmonary alveolar macrophages per mm^3 of lavage fluid.
- 40. PEFR Peak expiratory flow rate (mL per second).
- 41. PEOS = Percentage of cells in lavage fluid that were eosinophils.
- 42. PLYM Percentage of cells in lavage fluid that were lymphocytes.
- 43. PMAC Percentage of cells in lavage fluid that were macrophages.
- 44. PMNN = Polymorphonuclear leukocytes per mm^3 of lavage fluid.
- 45. PPAM = Percentage of pulmonary alveolar macrophages that phagocytized one or more erythrocytes.
- 46. PPMN = Percentage of cells in lavage fluid that were neutrophils.
- 47. RBC = Erythrocytes (RBC) per mm^3 of blood.
- 48. RL = Total pulmonary resistance (cm water per mL per second).
- 49. RV = Residual volume (mL).
- 50. SBWT = Body weights of rats at the time they were killed for endpoint evaluations.
- 51. SEGM = Segmenter (neutrophil) levels in blood, expressed as numbers of neutrophils per 100 leukocytes.
- 52. SGPT = Serum glutamic pyruvic transaminase (alanine aminotransferase) activity in international units/L serum.
- 53. SIII = Slope of Phase III of a single-breath nitrogen washout (percentage of nitrogen per mL).
- 54. TBIL Total bilirubin in milligrams/dL serum.
- 55. TLC total lung capacity (mL).
- 56. Total AFC = Total IgM anti-SRBC antibody-forming cells in lung-associated lymph nodes.

- 57. Total Cells = Number of lymphoid cells in lung-associated lymph nodes $(x 10^{-6})$.
- 58. TPROL Milligrams of protein in lung lavage fluid.
- 59. TPRO = Total serum protein in grams/dL serum.
- 60. VC = Vital capacity (mL).
- 61. WBCN = White blood cells per mm³ of lavage fluid (x 10^{-3}).

APPENDIX B: DAILY AEROSOL CONCENTRATIONS OF CU-Zn ALLOY POWDER

EXPOSURE DATE	EXPERIMENT NUMBER	Cu-Zn ALLOY CONCENTRATION (mg/m3)	NUMBER OF FILTERS	SAMPLING TIME (Minutes)
6-30-86	4371	0.907	3	90
7-01-86	4371	1.075	2	90
7-02-86	4371	1.103	4	90
7-03-86 7-07-86 7-08-86	4371 4371 4371	0.879 1.083 0.903	4 4 4	90 90
7-09-86	4371	1.111	4	90
7-10-86	4371	1.176	4	90
7-14-86	4371	1.195	4	90
7-15-86	4371	1.095	4	90
7-16-86	4371	1.334	4	90
7-17-86	4371	1.086	4	90
7-21-86	4371	1.121	4	90
7-22-86	4371	1.001	4	90
7-23-86	4371	0.928	3	90
7-24-86	4371	1.153	3	90
7-28-86	4371	1.073	4	90
7-29-86	4371	0.952	4	90
7-30-86	4371	1.035	4	90
7-31-86	4371	0.987	4	90
8-04-86	4371	1.029	4	90
8-05-86	4371	0.934	3	90
8-06-86	4371	1.033	4 4	90
8-07-86	4371	0.819		90
8-11-86	4371	0.915		90
8-12-86	4371	1.133	4	90
8-13-86	4371	0.954	4	90
8-14-86	4371	0.802	4	90
8-15-86	4371	1.142	4	90
8-18-86	4371	0.914	4	90
8-19-86	4371	0.826	4	90
8-20-86 8-21-86 8-25-86	4371 4371 4371	1.059 0.953 1.059	4	90 90
8-26-86 8-27-86	4371 4371	1.074 1.051	4 4	90 90 90
8-28-86	4371	1.021	3	90
9-02-86	4371	1.046	4	90
9-03-86	4371	1.230	4	90
9-04-86	4371	1.076	4	90
9-05-86	4371	1.076	4	90
9-08-86	4371	1.001	4	90
9-09-86	4371	0.989	3	90
9-10-86	4371	0.915	4	90
9-11-86	4371	0.978	4	90

EXPOSURE	EXPERIMENT	CU-Zn ALLOY CONCENTRATION	NUMBER OF	SAMPLING TIME
DATE	NUMBER	(mg/m3)	FILTERS	(Minutes)
9-15-86	4371	1.109	4	90
9-16-86	4371	0.983	4	90
9-17-86	4371	1.175	4	90
9-18-86	4371	1.061	4	90
9-22-86	4371	1.023	4	90
9-23-86	4371	0.994	4	90
9-24-86	4371	1.126	4	90
9-25-86	4371	0.922	4	90
6-30-86	4372	3.256	4	90
7-01-86	4372	3.456	4	90
7-02-86	4372	3.273	4	90
7-03-86	4372	2.559	4	90
7-07-86	4372	3.566	4	90
7-08-86	4372	3.483	4	90
7-09-86	4372	2.992	4	60
7-10-86	4372	3.230	4	90
7-14-86	4372	3.727	4	90
7-15-86	4372	3.366	4	90
7-16-86	4372	3.190	4	90
7-17-86	4372	2.994	4	90
7-21-86	4372	3.834	4	90
7-22-86	4372	3.198	4	90
7-23-86	4372	3.431	4	90
7-24-86	4372	2.851	4	90
7-28-86	4372	3.366	4	90
7-29-86	4372	3.326	4	90
7-30-86	4372	3.016	4	90
7-31-86	4372	2.685	4	90
8-04-86	4372	3.175	4	90
8-05-86	4372	3.600	4	90
8-06-86	4372	3.218	4	90
8-07-86	4372	3.154	3	90
8-11-86	4372	3.646	4	90
8-12-86	4372	4.050 3.195	4	90
8-13-86	4372		4	90
8-14-86	4372	3.350	3	90
8-15-86	4372	3.325	4	90
8-18-86	4372 4372	2.797 4.160	3	90
8-19-86			4	90
8-20-86 8-21-86	4372 4372	3.236 3.079	3 4	90
8-25-86	4372 4372	3.079 3.108	3	90
8-25-86 8-26-86	4372	2.966	3 4	90
8-27-86	4372	2.966 3.663	4	90
0-2/-00	73/4	3.003	4	90

EXPOSURE DATE	EXPERIMENT NUMBER	Cu-Zn ALLOY CONCENTRATION (mg/m3)	NUMBER OF FILTERS	SAMPLING TIME (Minutes)
8-28-86	4372	3.367	3	90
9-02-86	4372	2.922	4	90
9-03-86	4372	3.311	. 4	90
9-04-86	4372	3.563	4	90
9-05-86	4372	3.376	4	90
9-08-86	4372	3.659	4	90
9-09-86	4372	3.249	3	90
9-10-86	4372	3.190	4	90
9-11-86	4372	3.459	4	90
9-15-86	4372	4.145	4	90
9-16-86	4372	3.134	4	90
9-17-86	4372	3.858	4	90
9-18-86	4372	3.066	4	90
9-22-86	4372	3.391	4	90
9-23-86	4372	3.210	4	90
9~24-86	4372	3.125	4	90
9-25-86	4372	3.661	4	90
6-30-86	4373	6.570	4	90
7-01-86	4373	9.882	4	90
7-02-86	4373	7.841	4	90
7-03-86	4373	10.754	4	90
7-07-86	4373	10.638	4	90
7-08-86	4373	10.580	4	90
7-09-86	4373	10.086	4	90
7-10-86	4373	10.664	4	90
7-14-86	4373	8.842	4	90
7-15-86	4373	10.357	4	90
7-16-86	4373	10.379	4	90
7-17-86	4373	11.296	4	90
7-21-86	4373	10.772	4	90
7-22-86	4373	10.382	4	90
7-23-86	4373	11.864	4	90
7-24-86	4373	8.642	4	90
7-28-86	4373	10.057	4	90
7-29-86	4373	8.909	4	90
7-30-86	4373	10.820	4	90
7-31-86	4373	10.944	4	90
8-04-86	4373	13.748	4	90
8-05-86	4373	12.665	4	90
8-06-86	4373	13.030	4	90
8-07-86	4373	11.019	4	90
8-11-86	4373	8.286	4	90
8-12-86	4373	11.951	4	90
8-13-86	4373	8.609	4	90
8-14-86	4373	9.706	4	90

		Cu-Zn ALLOY		SAMPLING
EXPOSURE	EXPERIMENT	CONCENTRATION	NUMBER OF	TIME
DATE	NUMBER	(mg/m3)	FILTERS	(Minutes)
8-15-86	4373	10.191	4	90
8-18-86	4373	12.127	4	90
8-19-86	4373	9.242	4	90
8-20-86	4373	8.954	4	90
8-21-86	4373	9.241	3 .	90
8-25-86	4373	11.740	4	90
8-26-86	4373	10.160	4	90
8-27-86	4373	8.039	3	90
8-28-86	4373	10.308	4	90
9-02-86	4373	8.983	4	90
9-03-86	4373	10.929	4	90
9-04-86	4373	9.247	3	90
9-05-86	4373	10.046	4	90
9-08-86	4373	10.845	4	90
9-09-86	4373	10.359	4	90
9-10-86	4373	10.564	4	90
9-11-86	4373	8.964	3	90
9-15-86	4373	10.006	4	90
9-16-86	4373	10.863	3	90
9-17-86	4373	10.514	4	90
9-18-86	4373	10.267	4	90
9-22-86	4373	10.637	4	90
9-23-86	4373	10.573	3	90
9-24-86	4373	10.341	4	90
9-25-86	4373	9.997	4	90
1-27-87	4443	0.445	4	90
1-28-87	4443	0.181	4	90
1-29-87	4443	0.313	3	90
1-30-87	4443	0.325	3	90
2-02-87	4443	0.319	3	90
2-03-87	4443	0.294	3	90
2-04-87	4443	0.329	4	90
2-05-87	4443	0.330	4	90
2-09-87	4443	0.287	3	90
2-10-87	4443	0.308	4	90
2-11-87	4443	0.336	4	90
2-12-87	4443	0.316	4	90
2-17-87 2-18-87	4443	0.297	4	90
2-18-87	4443 4443	0.317	4	90
2-19-87		0.316	4	90
2-20-87	4443	0.309	3	90
2-23-87 2-24-87	4443	0.230	3	90
2-24-67	4443 4443	0.399	4	90
2-25-67 2-26-87	4443	0.373 0.300	4	90
2-20-0/	7743	0.300	3	90

EXPOSURE DATE	EXPERIMENT NUMBER	CU-Zn ALLOY CONCENTRATION (mg/m3)	NUMBER OF FILTERS	SAMPLING TIME (Minutes)
3-02-87	4443	0.283	4	90
3-03-87	4443	0.358	4	90
3-04-87	4443	0.376	4	80
3-05-87	4443	0.360	4	90
3-09-87	4443	0.297	4	90
3-10-87	4443	0.364	4	90
3-11-87	4443	0.348	4	90
3-12-87	4443	0.335	4	90
3-16-87	4443	0.365	4	90
3-17-87	4443	0.336	4	90
3-18-87	4443	0.317	3	90
3-19-87	4443	0.306	4	90
3-23-87	4443	0.261	4	90
3-24-87	4443	0.321	4	90
3-25-87	4443	0.322	4	90
3-26-87	4443	0.318	4	90
3-30-87	4443	0.306	3	90
3-31-87	4443	0.271	4	90
4-01-87	4443	0.312	3	90
4-02-87	4443	0.317	4	90
4-06-87	4443	0.335	4	90
4-07-87	4443	0.330	4	90
4-08-87	4443	0.314	4	90
4-09-87	4443	0.287	4	90
4-13-87	4443	0.268	4	90
4-14-87	4443	0.297	4	90
4-15-87	4443	0.309	4	90
4-16-87	4443	0.271	3	90
4-20-87	4443	0.322	4	90
4-21-87	4443	0.326	4	90
4-22-87	4443	0.306	4	90
4-23-87	4443	0.358	4	90
1-27-87	4444	3.999	4	90
1-28-87	4444	3.618	4	90
1-29-87	4444	3.158	4	90
1-30-87	4444	3.047	4 4	90
2-02-87	4444	3.743		90
2-03-87	4444	3.450 3.143	4 4	90
2-04-87 2-05-87	4444	3.143 3.099	4	90 90
2-05-87	4444	2.570	4	90
2-10-87	4444 4444	2.960	4	90
2-10-87	4444	3.715	4	90
2-11-87	4444	3.715 3.722	4	9 0
2-12-87	4444	3.722	4	90
2-11-01	7777	3.373	-	90

EXPOSURE DATE	EXPERIMENT NUMBER	Cu-Zn ALLOY CONCENTRATION (mg/m3)	NUMBER OF FILTERS	SAMPLING TIME (Minutes)
2-18-87	4444	3.155	4	90
2-19-87	4444	3.072	4	90
2-20-87	4444	3.002	4	90
2-23-87	4444	3.119	3	90
2-24-87	4444	3.217	4	90
2-25-87	4444	3.909	3	90
2-26-87	4444	2.459	4	90
3-02-87	4444	3.099	4	90
3-03-87	4444	3.477	4	90
3-04-87	4444	3.360	4	90
3-05-87	4444	3.085	4	90
3-09-87	4444	3.347	4	75
3-10-87	4444	3.341	4	90
3-11-87	4444	2.574	4	90
3-12-87	4444	2.982	4	90
3-13-87	4444	3.274	3	90
3-16-87	4444	3.440	4	90
3-17-87	4444	3.585	4	90
3-18-87	4444	2.614	4	90
3-19-87	4444	4.023	4	90
3-23-87	4444	3.795	4	90
3-24-87	4444	3.650	4	90
3-25-87	4444	3.445	4	90
3-26-87	4444	3.200	4	90
3-30-87	4444	3.433	4	90
3-31-87	4444	3.307	4	90
4-01-87	4444	2.431	4	90
4-02-87	4444	3.553	4	90
4-06-87	4444	2.937	4	90
4-07-87	4444	3.120	3	90
4-08-87	4444	2.748	4	90
4-09-87	4444	2.896	4	90
4-13-87	4444	2.917	4	90
4-14-87	4444	2.735	4	90
4-15-87	4444	3.687	4	90
4-16-87	4444	3.041	4	90
4-20-87	4444	2.429	4	90
4-21-87	4444	3.208	4	90
4-22-87	4444	3.645	4	90
4-23-87	4444	3.617	4	90

APPENDIX C: BOOT WEIGHTS (GRAMS) FOR INDIVIDUAL ANIMALS

PHASE 111, PART 1 ---- BODY WEIGHT IN GRAMS ON STUDY DAY:

		•		•	•		ľ			•										i	1		
	į	į	!	į	!		1			-	!						1	!		1	!		! ! !
																	-		•	i	•		
	290	289	1 292	296	29.5	298	297 2	90 3	00	30.	3 307	308	306	300	306	310	305	F 60	n e	7	2		
						***	, ,,,,			2.9	9 306	309	308	311	313	317	116 3	n 91:	18 3	16 3		ñ	326
							, ,	•			1 288		284	283	293	192	2 96 2	66	02 2	97 30	08 30	3 30	312
					- 1		7 6 6 7				-	•	271		281	278	278 2	78 2	78 2	74 21	80 26	3 274	1 287
_					212	27.1	, ,,,				, ,		287		296	297	294 2	96 2	89 2	87 29	92 29	4 28	296
262					•	9) 2	7 167	w (•	•				201	2 9 9 2	95 2	97 2	91 2	98 30	2 30	308
289					799	289	284 2	× ·		67		4 (7 6					0 7 0	2 2 2	3.	30	1 30	309
284	1 283	3 285	5 285	285	286	286	284 2	2 082	60	28	× 9	N	2 8 8		687		7 000			•		. •	
283	264	1 284	1 268	289	271	271	272 2	173 2	11	27	\$ 284	1 285	2 8 6	287	269	262	7 967	× ·	7	7		, (, ,
979			269	273	275	274	278 2	173 2	279	28	2 283	1 289	286	269	296	296	298 2	91 2	8	89 2	82 58	62 2	100
						74.0	244 2	2 4 9 4	298	29	4 302	306	306	191	306	306	0 606	313 3	Ē	0.4	16 31	37.	317
					273	27.2	273 2	_	7.5	27	7 28	284	282	283	288	287	295 2	193 2	91.2	88 2	98 29	3 29(304
							281 2	7	26.5	26	9 7 9	8 270	268	270	272	274	277 2	2772	74 2	71 2	79 27	9 27	288
692					707				377	9.7	7 28		287	291	293	301	300 2	99 3	01 2	97 30	07 30	9 30	314
* / Z						, (000	•	7 9 0	9 40	29.8	292	301 2	99.3	2 00	98 3	11 30	7 301	312
274					~ (273	7 6/2	, . D (, ,	5		915	1	319 3		10	12 31	16 31	•	322
297						308	E .DE	, i		7	- 6	•	, ,		. «	806	108 3	~	2	96 30		•	3
277						787	2 992	7 783	P 0	7	, ,	• •					40		8	•	10 29	0 26	296
274					· 1	274	7 6/2												0	40	34 30	2 30	303
281					787	286	2 992		, r		, ,				. ~	27.2	282 2	*	2	107	93 29	\$ 29	1 301
276					8/2	6/7	7 617				, ,		281			290	295 2	2	~	85 29	94 29	6 29	1 299
272						٠.	, ,						303	302	(P)	306	316 3		16 3	313 3	16 21	7 32	326
278				797	9 1					2	1 28	•	298	295	304	303	306	305 3	043	00	13 31	2 31	319
272							, ,					•	306		•	314	319 3		20 3	15 3	26 32	4 32	320
382		967 5			R 7			, ,		2.8.	27.0	•	279	285	285	266	2 0 6 2	286 2	67 2	85 2	90 29	1 29:	1 299
* !							786			28	7 28	~	2.89	288	194	292	297 2	298 2	82 2	88 2	96 29	9 29	304
		,			11	27.1		274 2	174	27	4 27	7 280	276	276	283	280	287 2	282 2	79 2	73 2	84 29	29	3 293
						28.2		2 6 2	99	2.8	0 286	5 288	283	282	167	296	298 2	296 2	97 2	92 30	02 30	000	307
								278 2	•	28	6 29	0 289	181	268	293	296	295 2	188 2	91 2	83 2	96 29	1 29:	301
- :							•	2 2 2		~	3 29	291	290	292	297	299	300 2	298 2	97 2	94 2	99 30	13 28	306
112											30	•	304		312	310	310 3	304 3	10	08 3	12 31	. 31	320
29.					7		- ·	, ,		; ;						400	000	6	03 2	96	06 30	8 30	1 310
260					283	283	288	7 192				٠,							•				309
28	1 279	9 280	0 278	281	787	786	287	7 992				***	107	r 1					•				120
295	\$ 285	5 288	8 289	1 295	297	296	300 3	301 3	90	000	~ ~	5 312	308	317	4			9 9 1 5		9 () (
290		5 286	6 287	191	293	191	292 2	293 2	96	7.9	1 297	7 302	298	305	308	305	312	P -	E	D 80	n (n (326
268			6 263	1 265	267	267	272 3	169 1	1.5	2.7	2 280	3 287	263	285	287	285	285 1	185 2	··	88	87 28	5 2 8	286
																			,				

PHASE III, PART 1 ---- BODY WEIGHT IN GRAMS ON STUDY DAY:

	;			~ ○ so •
				6 1 3 1 4 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8
				191 96 192 83 196 76 166 16 32 1 16 32 1 16 32 1 01 30 8
	~ ~			
				4 182 1 179 1 174 1 174 9 174 9 104 4 106 6 296 6 296
	09 189 73 172 80 178 87 187 91 191 82 183			88 188 63 181 77 177 77 177 77 177 63 178 67 309 67 309 72 274
		199 1 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6		
		20 1 20 1 20 1 20 1 20 1 20 1 20 1 20 1		86 192 80 184 80 184 80 189 07 311 07 314 71 274
	1 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1			
400000000000000000000000000000000000000				
		4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4		
77 73 6 6 6 7 7 7 7 8 6 6 6 7 7 7 7 8 6 6 6 7 7 7 7				169 188 178 179 179 179 179 179 179 179 179 179 179
****	167 175 175 194 191 177			
800484478	175	9		101 170 1170 1170 1170 1170 1170 1170 1
2 7 7 7 8 9 9 7 7 7 8 9 9 9 7 7 7 8 9 9 9 7 7 8 9 9 9 9				
	7			7724 7724 7724 7724 7724 7724 7724 7724
24444	1 2 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	144 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1		178 1 178 1 170 1 170 1 170 1 200 2 200 2 200 2 200 2 200 2
				- 6 6 6
	7 7 9 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7	1177		
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0				17 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
				162 176 176 177 177 177 178 178 178 178 178 178 178

- 7 7 7 4 6 7 6 6 6				
				4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4
* * * * * * * * * * * * * * * * * * * *			* * * * * * * * * * * *	4 4 4 4 4 4 4 4 4

	~	307	313	308				296	284	310			289	318	290	287	301	304	288	284	303	0	278	330	go.	•	320	0	306	- 05	n c	- e	9 6	100	10				99.		6 6	182
	=	316	316		300	9 6 2			287	313					301	292	306		294	279	306	310	279	338		gn .	323			205			0 1	206	200		- I	111	187	70	167	18
	9		107			282	123	•	182		312		9 9	0			962	962	9	6	_	•	•	6					0			2 1			60 CO			23	2 9	9 9	9	
		80	303 3	49	96	291	17	96	81	•	•	293 2		_	94	98	56	297	~	82 2	300	5	278 2	ш.	294 2	_		9.6	~	-		90			 40 40		06			- (9	
,	2	90	•		-6	•	24 3	92 2	8.1	•••	9	8	88	7	92	8.4	9.1	_	_	283 2	_			0	7	~	2		00	5	2 (6)	20			- -	į			63	00	- ·	82 1
		98 3	94 3	03 3	81 2	79 2	14 3	86 2	79 2				82 2	16 3	•	17 2	6	92 2			97 3				86 2	•			93	~ 1					~ 0		~		6.		76 1	77 1
		2	0.2	07 3	88 2	86 2	20 3	90 2	82 2	00	~	84 2	2	317 3	3 2	81 2	9	1 2	~	278 2	~	8	7	320 3	8	3	_	90 2	94 2	88	288 2	96	2 00	94 2	6 3		-	74 1	181	73 1	64 1	79 1
	2 5	01 3	04 3	10 3	62 2	70	12 3	88 2	82 2	98 3	0.8	85 2	87 2	12 3	7	7	97 2	•	85 2	74 2			79 2	*	89 2	s	0.9	1	2	•	_	-	en en	~	50		•		_	_	2	- 40
DAY	1	02 3	00	12 3	84 2	91 2	19 3	92 2	84 2	97 2	08 3	89 2	84 2	17 3	89 2	81 2	99 2	90 2	89 2	77 2	01 3	7	78 2	2 3	88 2		11 3	~	7	6	~	ი •	~	2	99		-			9	- 9	-
TUBY	1 40 1	01 3	0	05 3	4	1 2	9	90 2	7 2	6	07 30	86 20	86 20	0 9	86 2	2	96 2	7	2	2	2	34 30	9	9	2	4	9	9	2	93 2	9	~	8	88	_		Ē m	-	-	11 1	~	-
0 N S	8	C	9 3	~	81 21	~	16 31	9	80 27	~	05 30	87 21	86 21	m	~	80 27	7	0		72 2			76 2		85 28	33 28	06 31	~	3	~	6 6	۲ د	~	85 21	-		-	_	_	-	 9	P 7
6			m	8	7 2	7	E	2 0	8	87 25		81 28	1 2	6	4 2	77 20	97 29	3 2	9 2	7 2	97 29	96 30	8	13 32	2	17 21	05 30	80 28	9 2	8	2	7	8	81 21	-		-	-	2	7	-	78 1.
GRAM	9	1 29	Θ	0 30		_	_	_	4 27	8	7 30	7 2	0	1 29	9 28	5	2	7 2 27	5 2	7 26	3	7 2	•	2	7 28	5 2	3	0	8 2	~	~	9	~	1 2	7		-	7	9		7	-
- ×		9 29	~	3	0		С	6 2	1 27	2		2 2	~	2 30	3	1 27	9	3 27	9	9 2 6	•		•	•	0	1 27	~	6 28	3 2	o n	8	2	~	6 2 8	2		_	1 17	_	-	3 16	7
EIGH		1 29	30	30	2.8	_	4	2 2	~	LC)	7	6 28	2	8 30	8 28	6 27	0 29	1 27	9	6 26	~	1 29	9 2	9	5 28	1 27		1 28	9	7 7	4	2	7		3 18		-	-	7	- S	2 16	0 18
3Y WE		~	1	5	~	~	•	~	0 27		7 29	7 27	2 27	7 29	1 27	12 4	1 29	0 27	6 27	2 26	6 29	7 29	4 26		7 27	9 27	9 29	3 28	1 28				6 28	0 27	3 18		17	-	3 17	-	9 1 9	0 1.8
900	3	29(27	28	29	28		28	5	27	27	2 9	28	-	2 9	27				2.9		30	27	26		28	28			2 8	28	2 8	-		17	17	17	17	15	18
1					_			_		_	_		_	_				_		_	_				_	6		_	49	_		s.		•	_		e		_		_	_
-	16	288	8	~	268	27.7	30	276	272		299	276	273	293	277	275	287	269	~				27	m	2.7	26	29	28	286	2 8	26	2.8	28	8 271	-		17	19	9 16	-	15.	9
ART	-	287	2 9	2.8	~	~	~	275	271	~	~	7	~		~		287	~	~			~	~	29		~	~	275	287	278	270	290	283	278	179		175	181	161	167	154	178
٠.	74	286	•												275		287					292			279		•		288	284	268	285	284	276	174		169	158	164	167	152	169
11	20	283		284	265	273	297	275	269	278	290	270	274	287	273	275	283	266	274	762	294	289	275	290	279	267	285	275	288	282	267	289	283	272	178	167	176	164	167	169	156	174
PHASI	=		28.6	285			300	274	270	279	289	270	27.1	285	268		280	264	273	265		289	275		281	269	289	275	286	280	266	290	282	271	181	167	177	167	172	169	159	172
_	5			e e	40	`~	ĕ	274	266	280	289	272	272	286	270	279	284	264	273	263		286		. 60	•					281	•	287		271	160	171	180	165	174	170	160	
	0 -	37.6		783	262	274	29.5	273		279	286	269	~	283	270	278	278	260	271	263	•	286	· · ·	~		260	285	273		276	256	284	278	267								
		9.7.6				, .		٠.	. 4		287	268	~		273	. 4	•	28.3	271			. 60	-	274	275	260	285	272	278	279	254	284	280	270	160	170	160	164	168	169	157	178
	-	-			, e	9.73					•	27.5	373		273	27.9	2 8 0	7 2 6	, ,	260	200	288	27.0	273	278	260	285		276	274	259	287	282	269	180	174	182	165	171	166	159	111
	7										286			7 4 6	277	28.5	786		•	2 % 2		2 9 8	373	282	277	76.5	287	277	284	280	277	291	284	274	181	174	186	15.8	172	172	166	179
	SEX	•		•																				E 3							I	¥	I	I		٤.	L	4	La.	•		•
	ARI) w						, 4			7 6 6	, 4) 4 2 7	90	690	0 7 0	071	072	073	074	837	538	639	5 40	•	542	543	4 4
	X	•																												1371	1371	1371	1371	1371	1371	1371	1371	1378	1371	4371	1371	1371

PHASE III, PART 1 ---- BODY WEIGHT IN GRAMS ON STUDY DAY:

48 52 55

4 5

-

EXPT ANI SEX -1

8.8	99	192	99	96	98	18		9	70	84	60	181	161	182	98	178	70	- - -	187	191	175	179	90	7.9	1.8	185	178	18	90	9	313	901	295	5 8 9	=			<u>C</u>	90
187	98	137	93	5			1	9		63	8	7		92	00	- 95			_	_	•	82	0				.	m	·	•		312		5	316	*	Ø.	7	60
	~			96		82		9		6.	82	7.0	68	7.9	69	7.9	89	7.0	98	98	7	7.9	82	78	7.9	88	69	-	_	•	13	*	6	6	0	0	-	9	E 40
•	188	196	184	196	188	79 1			197	- 1	84	83 1	95 1	82 1		83.1		83 1	88 1		75 1			82 1		86 1		•	1		16 3	10 3	5	99 2	13	113	•	•	0.9
•	•	10.	104	96	187	=		69	7 8 7	79	=	76	92 1	7.9		99	67	78 1	98	89	76	77 1	88	82 1	=	98	72 1	63	83	_	16 3	90	•	95 2	310 3	0.53	91 2	90	
	182	69	9.			176		92	7 0	7.8	178	72 1	88	175	83	7.4	63	172 1	82 1	80	168	7	79 1	7.4	72 1	77	68	175 1		6	•	302 3	ē	96 2	~		79 2	98 3	66
=		061	182		5	5		80	178		19		0		0	177		- E	98		92	9/		179 1	80	83	~	_			~	•		291 2	303 3	~		03 2	2 20
182		. 691		<u>.</u>		178			-	177	- -	177	961	178	190	176	164	180	981	184	175	177	185	7.8	7.8	182 1	169	_			•	901	•	m	40	 	78 2	305 3	305 3
185		193	182	193	188	180		180	182	111	184	176	. 961	181		175	. 691	182	187	1.86	178	176	184	178	182	179	170	182	182	296	308	307	_	290 2	••	003	885	003	307
183			184		104			182	182	180	180	174	187	181	190	176		182	184	•		6		175	9	176	9	•	s		~	5	90	_	302	~	281	301	0
	184	189	183	195		181		181	100	180	181	174	186	179	192	174	166	180	185	187	173	172	181	175		173	169	180	180	308	308	•	~	1 0	297		280	299	297
182		185	175	187	182	179		175	178	174	176	170		175	186	172	165	179	179	179	170	171	177	174	177		163	176	175	308	306	304	294	281	297	293		295	299
180		188	178	190		179			178		178	173			190	170	163	171	182	181	170	171	182	172	111	178	163	180	176	299	304	296	285	280	290	290	274	294	293
179		192	177	187	183	178					180		185	176	193	171	181	180	183	182	170	168	1 8 0	171	190	179	170		174	303	295	299	290		288	2 9 2	278	167	296
180		190		187	182	176		178	178	175	178	172		176			164	181	179	183	171					178	166	180	111	295	300	297	289	285	289	1 6 2	271	290	292
50	191	186	175	186	181	174		176	178	176	178	172	184	176	189	169	159	179	182	180	169	168	179	169	179	176	167	179	173	29 U	299	297	288	276	286	192	273	289	291
																			176		166	163	171	164	173	170	162	173	170										
167	174	180	165	179	173	164		165	166	167	169	161	172	164	178	160	162													295		295	286	276	285	285	269	286	167
171	177	173		179	178	169		173	171	174	172	165	176		168		152	111	177	179	168	162	173	165	167	171	163		165	289		295	284	275	284	288	266	281	286
168		178		176	171	161		163	166	168	170	161	175	164	179	160	146	172	169	175	167	159	165	160	162	168	157	171	164	296	293	294	286	276	285	290	270	283	291
174	177	184	166	177	177	165			173		176	162		170	183		154	178	173	176	166	164	168	162	166	172	160	173	168	294	291	294	281	272	284	286	269	279	287
175	182	185	165	179	176	165		170	172	170	175	162	160	169	165	165	154	174	172	179	168	166	173	163	168	169	159	173	170	296	294	293	279	271	282	288	269	278	287
=	179	185	168	180	177	170	183	172	172	171	175	166	179	171	184	167	156	176	176	177	169	169	178	164	168	171	165	171	168	297	292	288	277	269	285	285	267	277	286
																				165										294	290	283	273		285	286		278	286
180		165	168		175			172	173	167	174			168	182	18.	156	176	178	168		168		167		170	162	171	169	293	289	282	277	261	283	287		278	286
178	178	-	167	179	176	168	182	173		166	176	166		167	183		157	177	174	171	169	168	177	166	169	171	160	172	170	297	•	287	272	269	289	287	262	279	284
180	177	184	172	182	178	170	183	178	176	168	180	172	182	171	188	170	159	179	178	176	170	174	181	167	172	173	168	170	170	308	296	293	281	278	293	293	270	279	290
•	•	•	L	•	•	ts.	•	14.	•	•	•	•	•	-	•	•	•	•	•	•	t a.	L .	•	•	•	•	•	L.	•	I	3	2	I	I	I	3	I	I	I
8 4 8	=						6 6 2							•		10		ø			566	567	5 6 8	5 6 9	570	671	572	573	574	078	076	077	078	079	080		082		086
4371			4371			4371	4371	4371	4371	4371	4371	4371	4371	4371	4371	4371	4371	4371	4371	4371	4371	4371	4371	4371	4371	4371	4371	4371	4371	4372	4372	4372	4372	4372	4372	4372	4372	4372	4372

		324	300	296	313	304	326	304	11	294	29 E	287	328	301	320	308	296		70	317	302	303	305	298	289	297	308	202	200	183	9/1	961		203		60 60 7	8	36	180	9		2
	2	328	313	300	322	310	329	306	322	299		293	328		324	306	296			318	306		303	301	206	303	31	201	8	28:	8/1	5		208		202	187	200	183	187	981	•
	8	314	300	291	309	301	321	297	318			286	N	0	316	304		~	•	310	298	296	300	296	313	on .	300			178	177		9 7	201	6	30	40	26	178	60 ·	178	2
	2	321	306	297	318			302	317	292	•	•		0	316					314	301	302	308	0	317	300				183				204	0	96	104	194	178	60	183	184
	5	317	303	293	313	300	321	300	313	200	9		~	303			288		288	311	302	293	297	299	317	295			188	180	178	192		200	~	196	182	-6	179	- 0	180	180
i	5	308	296	284	306	298	313	290	307	282	288	276	-	297			279	~	277	299	295	•	297	289	308	288							D .					192			173	2 2
		311	296	266	307	299	316	295	312	286	289	281	320	299	306	304	285	278	280	308	297	294	297	294	311	293	293		183		179		*	199	182		182	194	177	183	177	1 2 8
<u>:</u>	29	316	303	286	307	300	316	297	309	281	290	283	320	299	306	301	294	277	282	303	294	295	295	290	310	294	294	194	183	182	176	189	2			194	182	190	176	181	178	180
A DA	5	312	308	289	308	297	314	298	313	286	266	283	319	191	307	300	296	276	283	302	300	297	293	294	111	297	295			185		191	*	201	184	194			190	182	- 9	183
\$100	100	313	301	285	306	300	314	292	309	281	279	280	316	298	306	301	289	278	279	301	297	300	197	289	310	295	294	192	182	183	2	188		192		192	179	196	178	180	177	171
e E	29	310	298	283	304	295	116	294	308	265	273	279	315	292	302	299	290	275	278	297	299	299	289	291	305	167	292	194	182							195	181	195		182		160
RAMS	0	311	299	285	301	291	308	293	302	278	269	279	314	295	306	295	288	274	277	292	291	296	208	288	304	167	287	188	179	180	173	184	99	191	175	187	178	188	172	175	171	176
Z C	9	296	291	279	295	205	303	289	298	275	283	273	306	289	295	290	281	269	269	293	294	288	287	287	305	288	285	192	180	183	117				178	187	176	193	175	181	178	175
E H C	=	298	292		301	292	310	269	302	276	283	277	310	268	297	290	282	275	272	293	291	290	289	287	309	289	287		182						162	189	181	193	172	179	176	177
WE 1	36	296	286	278	294	289	303	287	294	276	283	273	308	181	296	162	276	269	269	290	291	289	285	285	304	284	281	190	160	183	179	184	12	195	180	189	179	190	173	178	176	175
BODY	34	293	287	271	208	201	293	284	295	268	279	273	303	285	289	287	276	268	268	289	290	286	284	282	299	285	282	190	179						176	186	177	199	171	174	172	172
:	32	! !																										186	175	176			168	189		183	173	198	169	174	168	170
	3.	296	283	►	288	285	297	281	293	276	279	272	303	286	292	284	273	270	265		289	288	285	•	303	284	282															
-	27	293	288	270	288	282	297	276	289	197	278	269	296	282	293	280	269	268	266	285	285	285	284	285	299	286	283	184	176	178	171	179	162		175	178	172	182	167	171	169	167
٧.	72	29.0	· ě	268	268	~	297	275	288	279	270	272	298	281	294	276	268	269	267	284	269	263			300		283	184	172	173	167	170	160	185	174	179	174	182	171	169	166	166
111	20	566	•		265	~	293	272			277	267	2 9 5	282	285	279	262	269	6	281	287	281		•	•		279	186	171	175	168	173	189	187	176	178	173	163	169	172	164	164
HASE	12	766	•	262		•	•				16	~				273								90			275	181	173	174	166	179	160	183	175	162	111	181	165	173	167	169
<u>.</u>	٠		•		•	-			•		~	264	•	280	278	274	280	268	261	275	•		27.8			282	275	183	173	178	170	178	165	186	176	160	174	182	170	175	171	169
	10	700			•	278	90			72	1	264	9.2				9	,			277	7.5				28	273	~	174	177	169	176	167	187	176	163	172	184	171	175	168	169
	-		•			1							~		_	73		,	269								~		173	175	170	176	163	187	174	182	170	188	171	176	168	168
		786											-			_	_		_					. «			. ~	-	178	176	170	175	15	166	171	186	16.8		171	174	167	169
	-																										6.			_	172	~	187		178			•		175	172	169
	SEX	,													_			. 3				_													_					•	•	•
	ANE				•						•	•									? •						::	878	878	877	878	878	880	200	582	863	584		909	587	588	5 8 9
	EXPT A																													~				~	~		. ~	. ~		. ~		~
	۵		;				;			•	•	•		•	•			•	•	•	•				•	•	•		•	•	•	7	*	4	•		•	•	•	4	•	•

184	S # X	-	-		10	13	=	20	24	27 3		3,		7	1 45	-	6 52	 	5	62	9	9	73	2	2	S	5
		180 1	79.1	78 1	72 1	73 1	172 1	69	73 1			8 18	100	3 18:	184	1 2 3	981.6	182	186	185	186	183	190	1 8 9	100	194	=
	- 4				_	•	99	69	99		10		17	9 18	2 181	180	183	182	182	182	186	181	190	188	188	100	
			_	_	167 1		165	66	99	67	-		4 17	4 17	176	171	176	177	179	176	177	176	183	191	171	193	=
			_			-	65 1	99	-	2.5	9	•	2 17	4 17	5 176	174	180	177	182	178	19	111	182	182	163		69
						168 1	63	-	65 17	7.0	16	•	_	5 17	174	172	181	180	181	180	183	178	182	198	- - -	98	-
		_	_			175 1	74 1	7	75 -	73	17	_	_	4 18	3 163	179	185	183	185	184	187	177	193	197	184		82
W 6 4		-	9.	176 1	1771	178	75 1	2 1	79 17	9.	17		=	~	185	183	188	184	189	183	189	101	187	189	188	99	8
			_			170 1	5	68 1	73 17	14	17		_	2 18	5 183	181	185	186	188	185	188	180	188	192	188	183	80
			_		-	83	76 -	•	-	7.7	18	_	_	-	186	183	187	185	190	190	169	183	190	191	188	188	9.7
						171	69	2	_	0.	17	_	_	-	8 178	178	1 183	182	187	182	182	179	190	188	188	161	~6
						-		-		-	16		_	-	170	169	-	170	175	172	173	169	174	175	174	76	7.
		-				178 1		_	-	7.3	17	~	_	_	178	175	_	182	183	181	182	174	~	184	182	185	
					, -	170 1		· -	-	: =	-	2 17!		8 17(8 178	176	-	179	182	179	179	172	~	183		99	90
		, ,							-		17	-	_	-	184		187	187	187	184	185	181	187	189	187	189	06
							63				9	17	3 17	-	175		-	180	184	180	179	176	181	181	176	179	7.8
			-			R 7	79		-		16	_	2 17	-	172		175	-	173	172	173	169		178	•	1 80	5
						1 62 1	82 1	-	-	-	2	~	6 18	-	_	186	-		192	189	189	183	•	190	~	190	91
		-	,		_		87 1		-	67	16	_	3 18	1 180	_	178	8 182	182	-	180	182	178		188	n	98	9 2
		•		:	_	73 1	73 1		-		17	6 17	6 17	_	_	175	_		-	182	184	180	•	187	183	189	99
	. <u>`</u>				•	180	79 1	_	~	9	-	_		_	_	190	-	191	-	194	195	185	196	190	•	961	9.4
	. Ac	-	. ~			99	99	_	•		9	6 173		7 172	2 175	174	178	177	179	179	176	174				180	7.8
		_			_	65	65 1	_	-	6	16	_		_	_	165	5 173	170	176	173	178	171	~			179 1	7.8
2				. ~	-	166 1	1 1	_	-	63	16	6 172	2 17	2 17	170	170	176	176	179	176	177	169	40	180	176	178	
-	. 3						291 2	9	93 24	9 2	5	29		2		1 297		292	~	298	293	292				306	197
: :	. 3						289 2	89 2	1 2	90 28		28		7		1 296	10	299	•	299	296	293	~			310	86
	. 3						286 2	7	0	0	=	28		2		300	0 303	304	303	308	304	301				320	Ξ
	: 3	-	18		1.		_	7 2	7 2	•		2 8		1 28	3 279	284	1 283	286	285	284	286	264	~	293	•	293	187
117	: =				~			276 2	7 2	74 27	7	27:	2 27	3 28	0 274	1 281	1 282	287	288	286	288	284		296	•	296	162
	=				~		294 2		00 2	96 30	9	29		2 30	7 307	313	313		316	312	318	314	325	327	319	330	21
	: 3	-		~	_	282 2	284 2	8	87 2	84 28		28	3 28	2 28	8 283	1 291	1 293		291	291	291	290	295	299	_	300	~62
120	: 3					264 2	268 2	8	8	64 26	9	7 8	•	6 27	1 274	1 272	281	281	280	277	283	282	290	291	•	286	7.0
	. 3						•	7	1 2	_	0	27	1 27	2 27	8 273	127	7 280		279	282	281		282	287	n	292	82
1 2 3		- 45			6	~	96	9	97 2	93 29	9	29	6 29	7 30	2 294	308	3 3 1 0	314	312	31	313	314	315	323	312	323 3	==
	. 3						0,	1 2	7	7	19	26	5 26	9 26	8 270	272	282	282	286	283	288	282	289	294	285	296.	8 8
	: 3			28.2	~		•	7	7	71 26		27	2 27	8 28	0 276	277	7 284	283	289	281	285	279	290	292	286	296	~ 6
2 2	: 3	•			280 2		•	8 2	7	8	9.4	28	4 28	6 29	2 287	294	1 297	293	292	298	296	294	297	301	294	305	663
126	=						274 2	1 2	9 2	77 21	*	27	5 28	0	1 282	283	3 286	290	287	285	289	283	288	291	288	296 2	88
127	=	~			~		•	9	5	61 26	55	27	2 27	3 27	7 276	279	1 282	282	283	284	284	284	290	291	284	294 2	9 0
128	: 1	. ~					7	5 2	8	77 27		28	_	3 28	8 284	288	3 290	294	297	293	796	296	296	181	298	307	\$ 1
	: 3				2	•	7.8	3 2	9 2	78 28	81	28	•	7	8 282	283	3 288	292	290	294	293	289	299	300	294	264 7	2 8
	: 3						92	273 2	76 2	8	-	27	•	6	2 277	7 280	282	287	286	282	285	279	187	289	283	289 2	187
	E		,	,	•		,)																			

PHASE III, PART 1 ---- BODY WEIGHT IN GRAMS ON STUDY DAY:

		į	=	Ξ	=	Ξ	=	=	_	Ĩ	=	=	Ξ	Ξ	-	=	=	=	=	= i
	2		180	190	1 00	197	170	169	190	185	183	170	180	190	193	187	6	176	183	180
	2		176	188	179	196	186	162	189	179	181	167	178	187	190	182	183	172	180	177
1	2		178	190	180	196	169	1 5 1	188	185	185	169	176	187	193	184	187	178	184	180
	5			181			8 9		. 82	183		178	99	16	183	82	178	7.5	-	176
	:		69	90	13	93	67 1	7.0	9.5	183	8 2	187	1.	79	-	-	•	67	-	72
	:		175 1	1 1	7.0 1	96	70 1	72 1	1 98	188	00	6.9	74 1	8.7	1 69	180	80	73 1	79 1	172 1
•	29		175 1	188	7.8	93 1	68 1	172 1	- 19	180	79 1	70 1	75 1	183 1	188 1	182 1	•	_	1 9 1	172 1
DAY	5		179 1	186	1 09	1 66	69		186 1	185 1	82 1	1 0 1	76 1	187 1	189 1	183 1	-	76 1	1 6 2	175 1
STUDY	2.0	! !	178 1	186 1	1 80	195 1	169	167 1	184 1	179 1	181	167 1	178 1	182 1	1 98	181	_	177 1	178 1	172 1
S NO	82	<i>!</i>	1 80	88	79 1	9.0	- 19	169 1	185 1	182 1	182 1	1691	176 1	183 1	189	82 1	78 1	7.4	78 1	177 1
GRAMS		!	174 1	1 63 1	176 1	1 2 1	163	168 1	181	179 1	178 1	167 1	171	1 8 1	182 1	175 1	1 921	1 1 1	1 1 1 1	169 1
S E			172	182	179	194	691	. 891	182	00	179	991	170	191	70	921	921	- 12	921	172
	Ę		173	182	111	9 2	167	9 9 1	181	10	09	291	172	693	187	. 221	5	. 21	175	69
WE I GHT	8		69	69	178	88	162	164	90	181	9.2	99	691	80	10	175	179	69	170	173
BODY	34		166	101		168	164	164	182	182	174	_	-	_	182	172	177	165	171	166
1	32		163	101	172	185	157	161	177	175	172	162	151	172	179	171	172	165	170	991
į	3.																			
	2		53	7.7	69	182	5.4	5.8	7.5	172	9	16.2		7	173	99	69	162	187	63
PART.	24	İ	60	74		-	58	09	73	7.1			-	72	7.	991	173	161	167	165
111,	92		79	6 /	2	6	25	88	7.7	9		•		73	99	170	187	185	- 12	091
PHASE	=	į	-				20	29	7.8	2					173	89	69	58	172	163
.	=======================================		6.2	9 8		6	13	88	5.					7		89	172	69	. 621	63
	9	į			7 8 7			•	7.5						172	6	171	158	172	163
	-																			16.5
	.1 3 6																			169
	7	į																		16.7
	SEX	1						. 4								. 16			. 14	
		į	•	?		n e				n (7	7	, ,		14.7	47		6 5 0
	EXPT AND																			4373

= = ~ -7.7 = 7 .. 31. 7 9 6 1 308 310 316 304 294 287 315 320 314 316 316 318 321 321 304 310 310 3 8 6 -~ ~ EXPT ANS SEX = = -1442 114 1442 116

PHASE III, PART 2 --- BODY WEIGHT IN GRAMS ON STUDY DAY:

19 23 26 30 33 37 40 44 47 51 54 58 61 65 68 72 75 79 82 86 89 an tar tel 164 164 200 193 196 196 197 196 194 196 194 194 195 200 196 206 206 209 208 PHASE III, PART 2 --- BODY WEIGHT IN GRAMS ON STUDY DAY. 12 16

~

EXPT ANT SEX

The control of the	1442 603			•	-	-		_	<u>.</u>	76	76	200		0 E		197		194	96	96	- ·	•	N .		~ ·	08 20	202 9	D (
The control of the	Z	•	171	172	168	173	_	173	173	178	176	7.0	- 1	- 1				_			- ·		,		-	-		
The control of the	=	••	18	_	188	187	_	9 0 7	191	196	=	198	193	193			7	-		-	_	-	-	-	~	0	4 20:	-
1		-	183	_	176	111	_	176	175	178	178	179	177	182		180	178	_	-	-	<u>-</u>	-	-	-		7	-	=
The control of the	6		176	177	171	183	175	176	177	178	176	183	182	182		180	175	-	~	~	<u>-</u>	-		-	-		=	=
	8	<u>.</u>		179	177	180	182	101	181	187	184	190	179			191	178	- ·	-	-	-	-	_	_	_	-	_	=
1	5	•	178	180	176	176	177	178		179	181	182	181			183	90	-		-	Ē	-	-	7	-	~	-	=======================================
1	-	_	=	179	177	160	-	180	168	181	179	188	183	187	184	1 8 8	182	-	-	-	7	5	7	-	-	-		19
The control of the	Ξ	-	170	170	160	169	_	173	174	178	176	180	178		181	184	160	7		6	7	7	_	-	2	-	9 190	=
F 180 180 180 180 180 181 182 181 182 181 182 181 182 184 187	7	•	174	172	173	173	175	177	175	174	173	171			175	175	171	_	_	-	-	-		-	_	-	9 17.	17
F 183 144 180 184 185	-	-	1 9 0	189	184	185	190	189	191		193	193	191	192	197	191	192 1	-	-	_	-	-	0	_	-	5	9	=======================================
F 152 164 160 161 163 163 165 165 165 165 165 165 167 167 167 197 192 197 199 191 192 191 191 191 191 191 191 191	=		169	172	169	168	_	175	173		177	111	176	174	178	177	178	_	_	-	-	-	0	-	7	_	171	19
F 155 165	-		183	184	180	181	-	183	187	185	185	185				187	187 1	7	7	7	2	_	•	-	_	-	191	=
F 188 188 188 188 188 180 180 180 180 192 197 199 190 195 191 192 191 191 191 194 194 194 194 195	=		179	180	178	180	_	1.7	184	185	184	190	186			184	188	7	-	-	7	-		_	-	-	1 189	- 1
F 188 189		_	185	184	185	186		188	188	188	186	192	189	192		197	1 89 1	-	-	7	_	7	~	_	_	4	2 194	Ě
F 152 175 175 175 175 175 175 175 185 186 185 197 190 189 186 185 185 185 187 177 177 179 185 187 189 185 189 185 189 189 189 189 189 189 189 189 189 189	=	_	18	188	187	189	190	187	195	193	197		198	200		196	92 1	9	-	-	7	-	~	2	1 2	7 2	0 203	<u>.</u>
F 175 175 175 175 175 175 175 176 176 176 166 164 165			162	183			182	117	163	185	186		187	190		186	98	-		-	7	7	•	_	7	-	_	191
F 182 181 179 179 179 179 179 180 180 180 180 180 181 184 183 180 186 183 180 188 185 185 185 185 189 180 186 183 189 180 180 180 180 180 180 180 180 180 180	2		175	175			173	173	173	176	~		178			181	7.8	-	_	-	7	_	•	-	_	2	-	18:
F 182 181 179 178 178 178 179 180 184 187 180 186 186 187 184 180 180 180 180 187 180 189 190 194 195 185 186 189 189 189 189 189 189 189 189 189 189	7	•	18	187	181	183	167	186	185	190	188		181	164		183	181	-	-	-	_	2		_	_	-	_	=
F 176 177 177 175 176 185 185 185 185 185 185 185 185 185 185	22	-	182	181	179	179	176	179	180	184	184		183	186		187	184	_	-	7	-	7		_	-	_	-	19
F 175 176 177 177 177 175 176 176 186 186 190 191 192 190 194 193 191 180 185 185 185 185 180 182 185 186 189 199 199 199 199 199 199 199 199 199	23	•	183	184	183		189	183	189	190	189	190	187	188	188	187	186	_	_	7	7	_	.	_	-	-	_	191
F 150 192 166 167 190 180 186 190 191 192 190 194 193 191 180 191 193 195 195 196 192 191 193 195 196 197 197 179 177 179 179 179 179 170 170 170 170 170 170 170 170 170 170	7	•	175	176	177	117	175	174	174	178		181	117	180	181	182	179 1	7	2	-	_	_	~	-	_	_	-	18
F 184 185 182 194 186 186 186 186 187 187 179 179 179 189 185 187 186 181 180 181 183 184 186 187 187 189 185 187 189 189 189 189 189 189 189 189 189 189	25		190	192	188	187	190	188	186	190	191	192	190	194	193	191	88 1	_	_	-	-	7		-	2	-	_	190
F 184 185 182 184 186 186 186 186 186 186 186 187 187 189 185 188 187 187 189 185 189 189 189 189 185 200 179 178 176 179 177 173 176 176 176 176 176 176 176 176 176 176	26		177	179			179	178	178	184	181	183	179		180	179	1 6 1	7	7	-	_	_	_	~	-	-	_	-
F 126 179 176 174 177 173 176 178 179 176 176 176 176 180 180 179 181 180 179 179 179 170 185 185 185 185 185 185 185 185 185 185	27	•	184	185			186	186	182	190	186	186	186	187	187	189	85 1	-	-	-	-	-		_	_	2 19	~	197
F 172 174 174 176 176 176 176 182 182 182 182 182 181 180 186 185 184 182 186 186 186 187 189 189 189 189 189 189 189 189 189 189	28	.	- 8	179	176	174	177	173	176	178	179	178	176	176	178	1 80	79 1	_	_	_	_	-	_	-	-	9 + 6	_	198
F 166 167 192 191 169 166 194 192 194 191 191 169 169 169 191 196 192 191 191 181 184 185 199 199 199 199 199 199 199 199 199 19	23	-	174	177	178		179	111	178	182	182	190	181	182	182	183	_	83 1	_	_	-	_	~	-	_	5 18	_	=
F 166 162 162 165 166 166 166 166 166 169 169 169 169 160 160 160 160 160 190 190 190 190 190 190 190 190 190 19		, t.	172	174	174		173	174	176	101	180	180	179	178	182	182	87 1	-	_	-	_	_	_	_	_	9 18	-	17
F 166 162 163 166 166 166 165 166 169 169 169 160 160 160 160 160 160 160 160 160 160	5	•	185	186	187		191	189	188	194	192	194	191	191	188	189		91	-	7	_	_		_	_	9	3 198	193
F 166 163 163 166 166 167 163 166 167 163 166 167 163 166 167 163 166 167 163 164 166 167 163 166 169 169 169 169 169 169 169 169 169	32	•	185	102	183	13	186	185	185	186	188	189	189	186	181	182	1	_	_	_	_	-	m	_	_		-	18
F 166 163 163 166 165 166 167 153 168 153 151 151 158 150 158 150 152 151 150 165 165 165 151 152 152 153 159 156 156 156 156 156 157 157 158 150 158 152 153 153 159 156 156 156 156 157 157 157 157 158 159 159 159 159 159 159 159 159 159 159	33	_	177		178	179		181	160	187	1 8 3		181	184		183	92 1	-	_	_	_	-	•	_	_	-	_	=
6 F 184 184 178 181 182 182 182 183 189 188 188 186 187 187 189 182 192 192 180 189 187 182 191 192 191 192 194 189 179 179 189 183 187 183 185 184 183 180 184 183 189 180 189 180 180 180 180 180 180 180 180 180 180	40	•	186		183		189	186	187	193	188		191	191		190	9.0	-	~	_	_	-		_	_	7	_	=
F 181 182 175 176 180 179 179 189 189 180 181 182 187 183 180 181 184 202 201 186 187 184 189 190 191 192 197 192 191 194 202 201 196 198 194 197 201 200 202 198 F 184 183 178 179 180 179 183 179 180 180 180 180 187 185 187 187 189 180 184 183 188 188 188 188 188 188 188 188 188	35	•	184	104	178		162	182	183	183	189		186	186			87 1	_	~	_	_	_	~	~	_	1 19	_	-
7 F 179 160 178 179 163 164 163 169 190 193 192 197 192 193 191 194 202 201 196 198 194 197 201 200 202 198 8 F. 184 163 178 179 163 179 160 167 165 166 184 183 186 184 183 185 187 185 185 186 181 184 185 186 188 186 187 9 M 299 297 292 289 299 296 303 303 308 316 310 314 313 316 319 318 319 314 319 314 319 319 314 320 324 9 M 303 304 296 292 302 296 303 305 306 311 308 311 309 311 314 313 316 315 319 312 319 312 319 313 320 320 1 M 302 303 295 295 295 300 310 310 312 310 309 316 320 316 320 321 321 325 327 332 326 330 336 2 M 316 316 311 306 311 307 316 319 317 321 322 325 316 324 326 329 321 326 327 327 328 338 336	36	•	181	182	175		180	179	179	183			183	185		183	80	~	_	_	_	_	•	_	_	2 19	_	- 19
B F. 184 183 178 179 183 179 180 187 185 186 184 183 186 184 183 185 187 185 186 186 186 186 186 186 188 186 188 88 182 8 297 292 289 299 296 303 303 308 316 310 314 313 315 319 318 319 314 319 314 319 319 314 313 325 324 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8	37	•	179	160	178		183	184	183	189			192	197		193	16	7	~	_	_	_	4	~	~	0 20	_	<u>-</u>
9 M 299 297 292 289 299 296 303 303 308 316 310 314 313 316 310 319 318 319 314 319 314 312 313 326 324 0 M 303 304 296 292 302 296 303 305 306 311 308 311 319 311 314 313 316 316 319 319 312 319 313 320 320 10 M 302 303 203 203 203 203 318 310 309 316 320 316 320 318 321 325 327 332 328 339 336 3 M 316 316 311 306 311 307 316 319 317 323 321 322 325 316 324 326 329 321 326 320 338	9	•	184	183	178		183	179	160	187			184	183		184	63 1	~	7	_	_	-	_	_	_	-	1 1 0 2	183
0 M 301 304 296 292 302 296 303 305 306 311 308 311 311 309 311 314 313 316 315 319 312 319 319 323 320 320 1 M 302 303 303 295 295 300 310 310 312 312 319 315 320 316 320 318 321 321 321 322 326 330 336 2 M 316 316 311 306 311 307 316 319 317 323 321 322 325 316 324 326 329 321 326 320 327 324 328 333 336	33	X	299	297	292		299	298	303	303		316	310	314	313	316 3	10 3	6	9	ص ص	n -	9	-			-	324	329
1 M 302 303 295 295 299 295 300 310 310 312 310 309 316 320 316 320 318 321 321 325 327 332 322 328 330 338 2 M 316 316 311 306 311 307 316 319 317 323 321 322 325 316 324 326 329 321 326 320 327 324 328 333 336	9	X	303	304	296	•	305	296	303	308	306	116	80		311	309	=======================================		3		m	9	~	n	<u>د</u>	9	320	313
2 M 316 316 311 306 311 307 316 319 317 323 317 321 322 325 316 324 326 329 321 326 320 327 324 328 333 336 3	=	I	302	303	295	•	299	295	300	310		312	310	309	316	0	16 3	20 3	18 33	<u>-</u>		ر ا	~	6	2 3	6 33	~	330
	7	I	316	316	311		311	307	316	319	317			321	•	2 5	=	4	6		_	6 3	0	7 32	4	8 33		330

<u>=</u> <u>=</u> = -1 0 3 . ---- BODY WEIGHT IN GRAMS ON STUDY DAY: -Ŧ = -PHASE 111, PART 2 <u>.</u> 1 80 _ **=** • <u>=</u> • = ~ ~ EXPT ANI SEX 2 **9 6.4.5** 1443 655 1443 556 1443 657 139 6714 1443 663 1443 180 1443 540 1443 642 1443 544 1443 646

								PHASE	36 11	-	T H Y		1) i				1		1		į		į
EXPT	ANI	SEX	7	~		•	12		-	23	26	90	33	37	04	;	4	51	•	60 1	9 - 9	9		2 7	5 7		2 86	
	Ì					į												 										
****		3	200	7.6	241	281	292	290	295	299	300	300	296	296 2	•	93 2	90 29	Ē	00	~	94 30	0	n		e -	7	m	
		: 2				9 7 6	2 8 6		70.	293	298	301	•	297	296 2	•	8.8 29	93 2	97 29	7 7	17 29		8	ë e	e.	9	•	0
		E :						:		906		308	40	03	306 2		99 30	60	= 3	0.9	13 31		1 32	0 31	9 32	- 3	9 321	3
		E :	867								406	2.5			~	1113	0.8 31		23 3	22 3	24 32	0 32	5 32	4 32	0	1 33	337	33
***	•	X :) D D			967									· •	07.3	2 3	04 3	10 3	2	12 30	8 31	1 31	6 31	5 32	4 32;	2 322	32
7 7 7 7	=	x	205		282	293	567	7	867	9 6					٠ د			8	96 2	98 2	96 30	5 30	5 30	9 30	7 31	0 31	31.	3
***	-	I	292			582	290	192	762	8 6	• • • •								6 7		03 30	7 3	5 30	9 31	3 31	3 31	5 313	3
111	167	3	300	305		90	304	782	006	2 D					, 6		•	•	· •		6	6	4	4 31	0 31	1 31	3 3 1 2	3
7777	168	X	308	303	301	2 3 3	303	287	7 6 7			7 6 7	p 1	, , , ,						•	•	•	· •	4 30	9	5 30	307	30
1111	=======================================	X	304	364	302	304	307	299	304			_	~ (2		· •	· •		, ,	, -		•	-	-		324	32
***	170	x	303	308	303	304	304	299	303			9			8 .		2	, .	, r	, ,		, -		7	•	•	316	-
1111	171	I	304	304	298	293	297	297	304	303		906		<u>~</u>	=		•	n (,	, (, i		•					
1111	172	I	316	319	110	314	311	309	300	316	320	326	323	_	6 1	 2	29 3	m -		, .	י פ		.	,	, ,	, ,		
7777	173	=	29B		291	289	291	291	304	308	307	309	308	308	304 3		0.6	—	-	60 60	60 60	M N	m D	M	M (7
***		=	287	006	294	299	301	294	308	306	910	311	309	309	304 3	0.4	01 30	7	ñ O	4	E	e e	n 0	m ~		n	_	
		: 3				306	30.7	312	3 10	309	318	318	316	317	320 3	118 3	7	20 3	27 3	22 3		5 32		—	6 6	en 	337	
		: :							90	9 9 3	291		309	313	~	14 3	0	19 3	19 3	18 3	20 32	4 31	e e	0 32	m m	33	330	
		t :	,						5		314	913		316	~	19 3	17 3	0	ю С	9	-			6	9	6 33	n	
		E 2						287	6	292				_	60	90	97 3	07 3	0.0		10 31	6	7		6	7 31	•	=======================================
		E :								916	314	-	~	314	0	16 3	16 3	n	2 3	20 3	11 32	4 32	_	3 33	-	7 33	9 333	
		2	,				ָ ֭֓֞֝֞֝			307	312		~	60	313 3	10 3	0.8	0	7	9	20 31	1 31	_	6 31	4	5 31	9	335
		. 3	;					29.8		304	307			_	70	102 3	0.1	07 3			~	•	_	•	7	8 31	7 319	
		R :											80	0	0	10 3	6	2		14 3	15 31	2 30	9 31	5 31	-3	6 31	•	
		E :	ה ה ה											-	70	0.0	013	0	ص ص	10 3	06 30		•	5 31		2 32	1 324	31
		x :	299		887	60 7		- 6	, ,					4	80		05 3	6	0	13 3	08 31	0 30	~	8 31	7 32	1 32	4 329	31
***		x :	290		187			,	7 6				•	•	4	20	04 3	9	6	0.8	17 31	6 30	9 31	6 32	0	2 33	0 321	
		K :	7		667									_	23	19 3	17 3		6	19	~			5 32	4 32	8 32	7 327	325
		E :					, ,				200	310	6	10	0	06 3	0.6	07 3	6	96 3	٠	0 31	0 31	8 31	5 32	4 32	9 331	326
										, c		-	0	6	90	00 2	99 3	04 3	~	09	10 31	0 31		3 31	4	8 31	•	
	0 .	E 2					100	292			310	299	=======================================	_	00	0	00	04 3	0.9	06 3	08 31		~		9	4 33	2 326	324
						181			ĕ	-					311 3	000	09 3	7 3	m	17 3	14 31	6 30		=	e 0	1	1 317	
			י ה י ה			286	,					303		•	4		03 3	10 3	10 3	12 3	11 31		ë	6	4 32	4 32	•	
						2.57		2			303		0		309 3	300	0.5	12 3	m	22 3	19 32	~	5	2	-	3 32	3 326	322
							2 6					304		306	306 3	901	05 3	06 3	n	06 3	08 30	7 30	6 31	0	7		303	
			9 6								=				6	117 3	17 3	18 3	C	23 3	32 33		0 33	D	4	6 34	336	338
			9 6						ָ ֭֓֞֞֜֜֝			-		٠	2	•	15 3	17 3	9	5	9	5 31	1 31	9 31	9 32	6 32	1 321	324
			9 6									~	314	317	319 3	123 3	14 3	23 3	•	18 3	24 32	7 32	0 32	7 32	7 32	0 33	334	32
		. 3	, ,			705		296	30		309		308	305	309 3	~	07 3	11 3	15 3	1.4 3	15 31	7 31	2 32	-	6	3	3 324	
				, ,		11.	3 2		•				322	319	321 3	118 3	17 3:	24 3	31 3	28 3	35 33	2 33	9	3 33	1 33		331	330
	•			;					-	178		181	191	183	162 1	181	=		-	88 1	34 18	91 9	5 18	9 18	9 19	7	198	18
	99				- :								18.6	188		1 63 1	7	1 88	1 1	8.8	85 16	8 18	_	7 18	7		195	9
***	295	-	9		5) -	2	=	P -	9	0	5																	

PHASE III, PART 2 .--- BODY WEIGHT IN GRAMS ON STUDY DAY:

7.6 - 69 7.7 = = * Ŧ **\$** 1 8 8 3, 7.6 Ç .03 = -= • ~ -61 ~ EXPT ANI SEX 7 9 9 8 8 8 : : *** *** *** *** ;;;

PHASE III, PART 2 ---- BUDY WEIGHT IN GRAMS ON STUDY DAY:

APPENDIX B. ANIMAL WEIGHTS AND SELECTED TISSUE WEIGHTS AT TIME OF SACRIFICE

	1								1			
1.0 mg/m3	EXFI	CONCENTRATION OF Cu-Zn	NUMBER	*	CODE	ANIMAL	Z :	KIONEYS	LIVER	LUNG	165168	OVARIES
1.0 mg/m3		4		3	101			2.3	•	. 2.1	1.48	
1.0 mg/m3			•	2 7 7 7		324.3		2.22	11.0		1.40	
1.0 mg/m3	4371			MALE	3 6	298.1	1.88	1.95	.	1.158	1.33	
1.0 mg/m3	4371			MALE	EOE	311.2	1.93	1.84	•	1.359	1.47	
1.0 mg/m3	4371			MALE	EOE	299.0	1.96	1.92	•	1.479	1.50	
1.0 mg/m3	4371		-	MALE	EOE	325.4	1.93	2.08	9.6	1.332	1.43	
1.0 mg/m3	4371		•	MALE	REC	305.8	1.93	1.91	8.0	1.216	1.36	
1.0 mg/m3	4371		049	MALE	EOE	314.2	1.92	2.41	10.2	1.946	1.55	
1.0 mg/m3	4371		0 2 0	MALE	REC	340.0	1.95	2.21	10.8	1.206	1.36	
1.0 mg/m3	4371		-	MALE	REC	322.8	1.58	1.99	•	1.411	1.46	
1.0 mg/m3 055 MALE REC 313.3 1.93 1.90 6.0 1.190 1.35 1.0 mg/m3 056 MALE REC 326.7 1.20 2.10 9.7 1.649 1.32 1.0 mg/m3 056 MALE REC 345.9 1.91 2.20 10.6 1.204 1.03 1.0 mg/m3 061 MALE REC 304.7 1.96 2.09 9.7 1.649 1.33 1.0 mg/m3 061 MALE REC 304.7 1.96 2.14 10.0 1.233 1.0 mg/m3 065 MALE REC 304.7 1.96 2.14 10.0 1.233 1.0 mg/m3 065 MALE REC 304.7 1.96 2.14 10.0 1.233 1.0 mg/m3 065 MALE REC 304.7 1.96 2.14 10.0 1.233 1.0 mg/m3 065 MALE REC 304.8 1.96 2.15 10.9 1.204 1.504 1.0 mg/m3 067 MALE REC 304.8 1.98 2.11 10.7 1.392 1.51 1.0 mg/m3 070 MALE REC 304.8 1.98 2.32 10.1 1.292 1.50 1.0 mg/m3 540 FEMALE REC 188.7 1.78 1.35 6.3 0.987 1.0 mg/m3 541 FEMALE REC 188.2 1.81 1.37 5.3 0.987 1.0 mg/m3 542 FEMALE REC 194.5 1.78 1.46 5.9 1.045 1.0 mg/m3 544 FEMALE REC 194.5 1.78 1.46 5.9 1.045 1.0 mg/m3 554 FEMALE REC 195.0 1.75 1.35 6.3 0.984 1.0 mg/m3 554 FEMALE REC 195.0 1.75 1.36 5.4 0.994 1.0 mg/m3 554 FEMALE REC 195.0 1.75 1.36 5.4 0.994 1.0 mg/m3 554 FEMALE REC 195.0 1.75 1.36 5.5 1.005 1.0 mg/m3 554 FEMALE REC 195.0 1.77 1.75 1.36 5.5 1.005 1.0 mg/m3 554 FEMALE REC 195.0 1.77 1.75 1.36 5.5 1.005 1.0 mg/m3 554 FEMALE REC 195.0 1.77 1.75 1.36 5.5 0.996 1.0 mg/m3 554 FEMALE REC 195.0 1.77 1.75 1.36 5.5 0.996 1.0 mg/m3 554 FEMALE REC 195.0 1.77 1.75 1.36 5.5 0.996 1.0 mg/m3 554 FEMALE REC 195.0 1.77 1.75 1.56 5.5 0.996 1.0 mg/m3 554 FEMALE REC 195.0 1.77 1.77 1.44 5.9 1.007	4371	_	052	MALE	EOE	294.6	2.00	2.09	8.4	1.153	1.32	
1.0 mg/m3 055 MALE REC 285.0 1.20 2.10 9.7 1.649 1.32 1.0 mg/m3 055 MALE RCE 285.0 1.86 2.09 9.4 1.107 1.33 1.0 mg/m3 050 MALE RCE 285.0 1.91 2.09 9.4 1.107 1.33 1.0 mg/m3 062 MALE RCE 311.9 1.87 2.16 9.8 1.204 1.09 1.0 mg/m3 062 MALE RCE 311.9 1.87 2.16 9.8 1.204 0.90 1.0 mg/m3 062 MALE RCE 310.7 1.96 2.11 10.7 1.392 1.51 1.0 mg/m3 063 MALE RCE 310.0 1.90 2.13 10.7 1.392 1.51 1.0 mg/m3 072 MALE RCE 310.0 1.90 2.32 9.7 1.263 1.47 1.0 mg/m3 072 MALE RCE 310.0 1.90 2.32 9.7 1.203 1.47 1.0 mg/m3 072 MALE RCE 310.0 1.90 2.30 10.1 1.293 1.50 1.0 mg/m3 0.72 MALE RCE 187.0 1.76 1.96 1.0 10.2 1.203 1.47 1.0 mg/m3 541 FEMALE RCE 188.7 1.78 1.37 5.3 0.864 1.066 1.0 mg/m3 541 FEMALE RCE 180.2 1.71 1.33 6.3 0.864 1.066 1.0 mg/m3 541 FEMALE RCE 191.0 1.76 1.76 1.36 5.0 0.864 1.006 1.0 mg/m3 554 FEMALE RCE 195.0 1.76 1.76 1.36 5.0 0.864 1.006 1.0 mg/m3 554 FEMALE RCE 195.0 1.76 1.36 5.0 0.864 1.006 1.0 mg/m3 554 FEMALE RCE 195.0 1.78 1.38 5.8 1.045 1.0 mg/m3 554 FEMALE RCE 195.0 1.75 1.36 5.0 0.864 1.006 1.0 mg/m3 554 FEMALE RCE 195.0 1.75 1.36 5.0 0.864 1.006 1.0 mg/m3 554 FEMALE RCE 195.0 1.75 1.36 5.0 0.906 1.0 mg/m3 554 FEMALE RCE 195.0 1.75 1.36 5.0 0.906 1.0 mg/m3 554 FEMALE RCE 195.0 1.75 1.36 5.2 0.906 1.0 mg/m3 554 FEMALE RCE 195.0 1.75 1.36 5.2 0.906 1.0 mg/m3 554 FEMALE RCE 195.0 1.75 1.36 5.2 0.906 1.0 mg/m3 554 FEMALE RCE 195.0 1.77 1.44 5.9 1.007 1.0 mg/m3 554 FEMALE RCE 195.0 1.77 1.44 5.9 1.007 1.0 mg/m3 550 FEMALE RCE 195.0 1.77 1.44 5.9 1.007 1.0 mg/m3 550 FEMALE RCE 200.9 1.77 1.44 5.9 1.007 1.0 mg/m3 550 FEMALE RCE 200.9 1.77 1.44 5.9 1.007 1.0 mg/m3 550 FEMALE RCE 200.9 1.77 1.44 5.9 1.0004	4371		055	MALE	REC	313.3	1.93	1.90	8.8	1.198	1.39	
1.0 mg/m3	120		056	MALE	REC	326.7	1.20	2.10	9.7	1.549	1.32	
1.0 mg/m3	1371		0 8 9	MALE	EOE	8.5	1.86	2.09	9.4	1.107	1.33	
1.0 mg/m3	1371			MALE	REC	343.9	16.1	2.20	10.5	1.204	1.09	
1.0 mg/m3	1371		061	MALE	EOE	911.9	1.87	2.16	e 6	1.284	06.0	
1.0 mg/m3	1161	•		MALE	REC	304.7	36.1	2.14	10.0	1.233	1.50	
1.0 mg/m3	1371	•	063	MALE	EOE	36	1.98	2.11	10.7	1.392	1.51	
1.0 mg/m3	4371	6		MALE	REC	331.0	1.90	2.28	10.9	1.263	1.47	
1.0 mg/m3	4371		067	MALE	REC	356.8	1.98	2.32	~ . 6	1.360	1 0	
1.0 mg/m3	1371	6	070	MALE	REC	334.8	1.88	2.38	10.1	•	1.50	
1.0 mg/m3	1371	•	072	MALE	£0£	309.3	1.94	2.08	10.2	•	1.38	
1.0 mg/m3 540 FEMALE REC 188.7 1.78 1.55 6.3 0.987 0.0 1.0 mg/m3 541 FEMALE RC 188.2 1.61 1.37 5.3 0.064 0.0 1.0 mg/m3 543 FEMALE RC 191.8 1.71 1.33 6.3 0.064 0.0 1.0 mg/m3 544 FEMALE RC 191.8 1.78 1.46 6.6 1.115 0.0 1.0 mg/m3 544 FEMALE RC 194.5 1.0 mg/m3 540 FEMALE RC 195.0 1.78 1.34 5.9 1.045 0.0 1.0 mg/m3 550 FEMALE RC 195.0 1.76 1.37 5.7 0.944 0.0 1.0 mg/m3 554 FEMALE RC 195.0 1.75 1.38 5.6 1.038 0.0 1.0 mg/m3 555 FEMALE RC 195.0 1.75 1.36 5.4 0.904 0.0 1.0 mg/m3 556 FEMALE RC 198.0 1.00 1.57 5.5 0.998 1.0 mg/m3 556 FEMALE RC 198.0 1.00 1.57 5.5 0.998 1.0 mg/m3 550 FEMALE RC 199.0 1.77 1.44 5.9 1.007 0.0 mg/m3 550 FEMALE RC 199.0 1.77 1.44 5.9 1.007	1371	0	537		£0£	187.0	1.78	1.47	₹	1.066		0.022
1.0 mg/m3 541 FEMALE REC 188.2 1.71 1.33 5.3 0.864 90 1.0 mg/m3 543 FEMALE EOE 168.2 1.71 1.33 5.3 0.816 90 1.0 mg/m3 544 FEMALE EOE 191.8 1.78 1.46 5.6 1.115 90 1.0 mg/m3 544 FEMALE EOE 194.5 1.88 1.54 5.9 1.045 90 1.0 mg/m3 549 FEMALE EOE 195.0 1.78 1.32 5.1 0.938 90 1.0 mg/m3 550 FEMALE EOE 195.0 1.75 1.33 5.6 1.038 90 1.0 mg/m3 554 FEMALE REC 195.0 1.75 1.78 1.38 5.6 1.038 90 1.0 mg/m3 555 FEMALE REC 194.5 1.78 1.36 5.4 0.904 90 1.0 mg/m3 556 FEMALE REC 198.0 1.80 1.57 5.5 0.998 90 1.0 mg/m3 558 FEMALE REC 198.0 1.80 1.57 5.5 0.998 90 1.0 mg/m3 558 FEMALE REC 198.0 1.77 1.44 5.9 1.007 90 1.0 mg/m3 550 FEMALE REC 199.0 1.77 1.44 5.9 1.007	1371		540	FEMALE	REC	188.7	1.78	1.55	6.3	0.987		0.080
1.0 mg/m3	1371	0		FEMALE	REC	188.2	1.81	1.37	5.3	. 86		0.074
1.0 mg/m3	1371			FEMALE	EOE	168.2	1.7.1	1.33	6.3	. 8		0.069
1.0 mg/m3	1769	0	•	FEMALE	REC	191.8	1.78	1.46	9 .	•		0.039
1.0 mg/m3 548 FEMALE EOE 195.0 1.76 1.32 5.1 0.938 0 1.0 mg/m3 549 FEMALE EOE 195.0 1.75 1.57 5.7 0.944 0 1.0 mg/m3 550 FEMALE RCC 195.0 1.75 1.38 5.6 1.038 0 1.0 mg/m3 555 FEMALE RCC 194.5 1.78 1.36 5.2 0.967 0 1.0 mg/m3 556 FEMALE RCC 198.0 1.80 1.57 5.5 0.998 0 1.0 mg/m3 558 FEMALE RCC 199.0 1.77 1.44 5.9 1.007 0 1.0 mg/m3 550 FEMALE RCC 200.9 1.77 1.44 5.9 1.007 0 1.0 mg/m3 550 FEMALE RCC 200.9 1.77 1.51 5.3 0.804 0	1371	•		FEMALE	EOE	g.	1.88	1.54	æ.	•		0.067
1.0 mg/m3 549 FEMALE EOE 195.0 1.76 1.57 5.7 0.944 0 0 1.0 mg/m3 550 FEMALE REC 195.0 1.75 1.38 5.6 1.038 0 0 1.0 mg/m3 554 FEMALE REC 232.3 1.73 1.28 5.2 0.967 0 1.0 mg/m3 555 FEMALE REC 194.5 1.78 1.36 5.4 0.904 0 1.0 mg/m3 558 FEMALE REC 198.0 1.80 1.57 5.5 0.998 0 1.0 mg/m3 558 FEMALE REC 199.0 1.77 1.44 5.9 1.007 0 1.0 mg/m3 560 FEMALE REC 200.9 1.73 1.51 5.3 0.804	1371		546	FEMALE	EOE	184.3	1.78	1.32	 	•		0.085
1.0 mg/m3 550 FEMALE REC 195.0 1.75 1.38 5.6 1.038 0 0 1.0 mg/m3 554 FEMALE E0E 232.3 1.73 1.26 5.2 0.967 0 0 1.0 mg/m3 555 FEMALE REC 194.5 1.78 1.36 5.4 0.904 0 0 1.0 mg/m3 558 FEMALE REC 198.0 1.80 1.57 5.5 0.998 0 1.0 mg/m3 558 FEMALE REC 199.8 1.77 1.44 5.9 1.007 0 1.0 mg/m3 560 FEMALE REC 200.9 1.73 1.51 5.3 0.804 0	4371		549	FEMALE	EOE	195.0	1.76	1.57	5.7	. 94		0.059
1.0 mg/m3	4371	•		FEMALE	REC	195.0	1.75	1.38	8. 8	٠		0.051
1.0 mg/m3 556 FEMALE REC 194.5 1.78 1.36 5.4 0.904 0 0 1.0 mg/m3 556 FEMALE REC 198.0 1.80 1.57 5.5 0.998 0 1.0 mg/m3 558 FEMALE REC 199.8 1.77 1.44 5.9 1.007 0 1.0 mg/m3 560 FEMALE REC 200.9 1.73 1.51 5.3 0.804 0	4371		3	FEMALE	EOE	232.3	1.73	1.28	5.2	•		0.034
1.0 mg/m3 656 FEMALE REC 198.0 1.87 5.5 0.998 0.03 1.0 mg/m3 558 FEMALE REC 199.8 1.77 1.44 5.9 1.007 0.05 1.0 mg/m3 560 FEMALE REC 200.9 1.73 1.51 5.3 0.804 0.04	4371			FEMALE	REC	194.5	1.78	1.36	9 .	90		0.057
1.0 mg/m3 558 FEMALE REC 199.8 1.77 1.44 5.9 1.007 0.05 1.0 mg/m3 560 FEMALE REC 200.9 1.73 1.51 5.3 0.804 0.04	4371			FEMALE	REC	198.0	1.80	1.57	•	.99		0.034
1.0 mg/m3 560 FEMALE REC 200.9 1.73 1.51 5.3 0.804 0	4371		40	FEMALE	REC	199.8	1.77	1.44	٠.	00.		. 0 5
	4371		9	FEMALE	REC	200.9	1.73	1.51	5.3	•		0.044

							EIGHT	IN GRAMS			
KXPT	CONCENTRATION OF CU-Zn	ANIMAL	SEX	SACRIFICE	ANIMAL	SIAR	KIONEYS	LIVER	LUNG		OVARIES
				1 1 1 1 1 1					1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	1 1 1 1 1	
1111	1.0 mo/m3	562	FEMALE	REC	181.6	1.78	1.37	5.2	0.831		0.040
4371		663	FEMALE	REC	192.1	1.73	1.38	7.9	0.933		0.063
4371		564	FEMALE	EOE	190.2	1.79	1.38	8.2	0.884		0.059
4371		9 9	FEMALE	REC	182.9	1.77	1.33	6.4	ુ 88∵ 0		0.048
4371		867	FEMALE	EOE	184.0	1.70	1.50	9.9	1.121		0.044
4371		569	FEMALE	EOE	162.3	1.76	1.37	2.5	0.988		0.091
4371		670	FEMALE	EOE	178.2	1.71	1.29	8.2	0.943		0.042
4371		671	FEMALE	EOE	187.7	1.70	1.25	5.3	0.931		0.083
4373		0.75	MALE	EOE	320.6	1.95	2.15	10.6	1.349	1.02	
4372		0.76	MALE	REC	356.8	1.96	2.21	11.0	1.294	1.52	
4373	•	079	MALE	REC	332.2	1.89	2.29	11.3	1.267	1.42	
4373		000	MALE	EOE	319.8	1.95	2.06	6	1.299	1.47	
1373		180	MALE	EOE	313.5	1.98	2.14	9.6	1.421	1.49	
		860	MALE	E 0 E	313.0	1.85	2.10	4.6	1.325	1.51	
****		980	MALE	EC C	330.6	1.91	2.21	10.2	1.376	1.61	
777	•	780	MALE	EOE	330.6	1.69	2.23	10.7	1.574	1.25	
7154			1	25	328.5	1.86	2.39	10.3	1.307	1.39	
7764		6	MALE	EOE	322.1	1.90	2.08	10.2	1.153	1.47	
4372		0 0 0	MALE) E	365.4	1.92	2.57	11.7	1.384	1.44	
7777			MALE	a E	331.5	1.91	2.14	10.3	1.384	1.50	
776	•		MALE	REC	323.2	1.90	2.20	8.6	1.283	1.42	
777	. •	9 6	MAIR	SEC.	329.7	1.89	2.04	e.	1.155	1.33	
4373	•	100	MALE	EOE	323.1	1.83	1.99	9.6	1.381	1.32	
4373		101	MALE	EOE	310.9	1.88	2.01	9.8	1.403	1.45	
4372	. ^	102	MALE	REC	323.3	1.82	2.12	1.1	1.212	1.34	
4372		103	MALE	EOE	285.6	1.94	1.93	9.	1.382	1.40	
4372		104	MALE	EOE	298.6	1.85	2.24	.	1.339	1.41	
4372	~	109	MALE	EOE	303.1	1.89	2.34	9.0	1.345	1.42	
4372	~	111	MALE	REC	330.6	1.87	2.02	9.0	1.383		
4372	~	112	MALE	REC	338.5	1,90	2.16	10.2	1.335	- 0.	
4372	~	575	FEMALE	EOE	199.4	1.76	1.38	•	1.021		0.046
4372	~	576	FEMALE	REC	192.2	1.79	1.40	9.	0.978		0.081
4372	~	578	FEMALE	REC	189.3	1.74	1.30	9 .	0.890		0.048
4372	~	6 7 9	FEMALE	REC	213.7	1.7.1	1.73	6.5	1.025		•
4372		580	FEMALE	EOE	183.0	1.71	1.38	4.0	1.003		0.039
4372	. ~	584	FEMALE	REC	197.5	1.72	1.52	2 . 5	1.012		0.043
4373			FEMALE	REC	207.2	1.82	1.59	9.4	0.936		0.065
4373	: ^	60	FEMALE	EOE	182.9	1.74	1.37	5.2	0.955		0.041
4372	. ~		FEMALE	EOE	192.8	1.79	1.42	9 . 0	1.166		0.056
1											

							WE I GHT	IN GRAMS			
RXPT		ANIMAL	SEX	SACRIFICE	ANIMAL	BRAIN	KIONEYS	LIVER	רהאם	16.976.9	OVARIES
		1 1 1 1 1 1	: ! ! !	; 6 1 1 1 1 1							÷
4372	3.2 mg/m3	169	FEMALE	REC	213.7	1.77	1.53	9.	0.983		0.056
4372		592	FEMALE	EOE	160.0	1.76	1.40	6.2	1.195		0.084
4372		693	FEMALE	£0£	1.88.1	1.67	1.42	9.	1.104		0.033
4372	-	598	FEMALE	REC	206.3	1.79	1.40	& •	0.941		0.042
4372		898	FEMALE	EOE	191.8	1.78	1.44	e.	1.061		0.086
4372		600	FEMALE	BEC	189.9	1.75	1.44	6.3	0.923		0.038
4372		602	FEMALE	MEC	189.0	1.76	1.42	9 .	1.026		0.060
4372		603	FEMALE	EOE		1.82	1.39	9 .	1.006		_
4372	~	604	FEMALE	REC	184.4	1.71	1.31	5.7	0.863		0.058
4372		608	FEMALE	EOE	182.7	1.71	1.34	6.3	0.975		0.042
4372	~	909	FEMALE	REC	195.5	1.77	1.42	8. S	0.970		0.075
4372		808	FEMALE	EOE	184.9	1.76	1.33	8.8	0.968		0.044
4372	3.2 ma/m3	609	FEMALE	EOE	193.7	1.82	1.40	6.7	1.231		0.062
4373	10 mg/m3		MALE	EOE	299.2	1.90	2.13	10.1	1.810	1.36	
4373	10 mg/m3	1.6	MALE	REC		1.87	2.80	9.	1.593		
4373		117	MALE	REC	328.8	1.94	2.25	٠.	1.410	1.36	
4373		-	MALE	MEC	317.4	1.96	2.19	10.9	1.390	1.34	
4373		122	MALE	REC	360.1	1.91	2.25	₹.	1.568	1.47	
4373		125	MALE	EOE	302.6	1.80	2.13	æ. 6	1.431	1.49	
4373		126	MALE	EOE	291.9	1.88	2.04	9.5	1.661	1.48	
4373		127	MALE	REC	322.6	1.92	2.25	10.7	1.300	1.39	
4373	10 mg/m3	128	MALE	EOE	304.9	1.93	2.20	6.7	1.598	1.46	
4373		130	MALE	EOE	294.7	1.83	1.91	₹.	1.604	1.21	
4373	10 mg/m3	132	MALE	EOE	283.1	1.8.	1.91	- 6	1.443	1.36	
4373	10 mg/m3	133	MALE	EDE	289.9	1.94	2.06	٠.	1.482	1.35	
4373	10 mg/m3	134	MALE	REC	335.2	1.94	2.27	9 .0	1.550	1.40	
4373	10 mg/m3	135	MALE	REC	324.1	1.66	2.12	10.5	1.434	1.45	
4373	10 mg/m3	136	MALE	EOE	293.1	1.94	2.04	e.	515	1.32	
4373	10 mg/m3	140	MALE	EOE	284.0	1.80	1.90	٠. •	1.336	1.4	
4373	10 mg/m3	141	MALE	EOE	312.0	1.89	2.16	6	1.620	2	
4373	10 mg/m3	142	MALE	£0£	304.8	1.91	2.04	10.2	1.649	1.39	
4373	10 mg/m3	141	MALE	REC	330.2	1.89	2.29	10.1	1.542	1.48	
4373		147	MALE	REC	323.5	1.87	2.04	6.3	1.451	1.44	
4373	10 mg/m3	148	MALE	REC	329.0	1.87	2.04	9.7	1.254		
4373		149	MALE	BEC	322.4	1.91	2.02	6	1.455	1.25	
4373		615	FEMALE	EOE	182.6	1.76	1.42	2 .	1.156		0.074
4373		919	FEMALE	REC	192.1	1.75	1.45	6.3	0.930		0.055
4373		617	FEMALE	EOE	182.5	1.76	1.45	9.	1.104		0.045
4373		618	FEMALE	REC	185.1	1.75	1.40	9 .4	0.994		0.059

								WE I GHT	WEIGHT IN GRAMS			
EXPT	CONC	CONCENTRATION OF CU-Zn	ANIMAL	SEX	SACRIFICE	ANIMAL	BRAIN	KIONEYS	LIVER	LUNG	TESTES	OVARIES
	1		!	1	1 1 1 1 1 1 1 1 1 1	: ! ! ! !	6 6 1 1	9 1 3 6 6 6 7 7 8	 			
6373	-	me/m3	620	FEMALE	EOE	166.1	1.74	1.39	8.8	1.308		
4373	-		624	FEMALE	BEC	192.8	1.75	1.38	6.3	1.082		0.051
4373	=		6.25	FEMALE	EOE	191.9	1.74	1.44	9.9	1.156		0.081
£273	-		6.26	FEMALE	2	199.5	1.78	1.50	5.7	1.120		0.038
4171	=		627	FEMALE	AEC C	186.6	1.49	1.45	8.8	1.062		0.068
4373	=		62A	FEMALE	E0E	175.0	1.79	1.43		1.166		0.081
27.5	? =		630	FEMALE	EOE	187.5	1.72	1.35	5.3	1.156		0.050
2 4 5 4	2 5		631	FEMALE	3 6	169.0	1.79	1.36	6.1	1.056		0.036
,,,,	? =		632	FEMALE	E 0 E	179.6	1.72	1.31	5.4	1.0.1		0.058
7				FEMALE	E 0 E	176.3	1.77	1.26	6.3	1.158		0.047
	? =		769	FFWALF	1 E	6	1.74	1.42	8.2	1.050		0.037
7	? =			FEMALE	EOF	197.0	1.76	1.42	9	1.184		0.048
	2 5	mo/m3		FEMALE	, E	175.5	1.67	1.35	5.3	1.087		0.043
7	? \$		•	FEMALE	3 E	197.7	1.78	1.37	5.4	0.994		0.038
	2 5		642	FEMALE	2 2 2	174.3	1.70	1.22	4.3	0.821		0.052
,,,,	2 5		6.43	FEMALE	E 0.5	175.4	1.75	1.44	6.2	1.041		0.067
			848	FEMALE	2 2	181.4	1.78	1.32	5.3	0.950		0.038
	-		0 20	FEMALE	AEC	184.3	1.78	1.45	9.9	0.960		0.058
4442	•	•	109	MALE	REC	380.7	2.04	2.88	12.3	1.499	1.55	
4442	•	(SHAM)	100	MALE	REC	372.5	2.00	2.45	12.2	1.394	1.62	
4442	•	(SHAM)	111	MALE	EOE	315.0	1.90	2.24	9 .	1.267	1.36	
4442	•	(SHAM)	112	MALE	£ 0 €	331.0	1.94	1.94	6.6	1.293	1.47	
4442	•	(SHAM)	-	MALE	REC	362.3	1.97	2.64	12.0	1.196	1.48	
4442	•	(SHAM)	118	MALE	EOE	339.6	1.98	2.33	1.6	1.464	1.52	
4442	•	(SHAM)	116	MALE	EOE	325.0	1.84	2.07	9.6	1.501	1.44	
4442	0	(SHAM)	118	MALE	REC	338.5	1.95	2.41	10.9	1.515	1.38	
4442		(SHAM)	119	MALE	EOE	321.2	1.99	2.26	9.1	1.408	1.37	
4442	0	(SHAM)	120	MALE	EOE	333.5	1.88	2.32	10.1	1.332	1.25	
4442	0	(SHAM)	121	MALE	REC	364.1	1.93	2.45	13.2	1.632	1.92	
4442	0	(SHAM)	122	MALE	EOE	336.2	1.92	2.16	1.3	1.498	1.09	
4442	•	(SHAM)	123	MALE	REC	352.1	2.00	2.15	9.1	1.539	1.44	
4442	•	(SHAM)	127	MALE	EOE	338.0	1.95	2.20	10.1	1.514	1.58	
4442	•	(SHAM)	128	MALE	EOE	328.9	1.98	2.39	 	1.351	1.48	
4442	0	(SHAM)	130	MALE	REC	384.8	2.00	2.74	13.1	1.459	1.50	
4442	0	(SHAM)	131	MALE	REC	336.5	1.99	2.30	11.3	1.620	1.45	
4442	0	(SHAM)	132	MALE	REC	392.0	2.04	2.38	12.6	1.490	1.52	
4442	0	(SHAM)	134	MALE	REC	374.1	2.00	2.48	11.7	1.697	1.60	
4442	•	(SHAM)	136	MALE	EOE	341.3	1.89	2.24	10.8	1.432	1.50	

								WE I GHT	IN GRAMS		,	
EXPT	CONCEN	CONCENTRATION Of Cu-Zn	ANIMAL	SEX	SACRIFICE CODE	ANIMAL	BRAIN	KIONEYS	LIVER	LUNG	7697ES	OVARIES
	1				1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	! ! ! !	 	1 5 1 1 1	 		
1113		CHAM	137	MALE	REC	375.4	2.02	2.52	11.5	1.467	1.42	
	_	(SHAM)	. T	MALE	EOE	333.0	1.91	2.11	9.5	1.569	1.49	
	-	(MAN)		FEMALE	EOE	193.9	1.78	1.31	9.9	988		0.082
		(N = 1	•		3 6	204.8	1.75	1.39	9	1.198		0.048
		(E C E C E C E C E C E C E C E C E C E		FEMALE) E	201.6	1.79	1.52	6.9	1.020		0.083
7	- `	(244		FEMALE	BEC	192.1	1.80	1.45	6.2	1.053		0.061
2000		(MY M)		FEWALE) U	213.4	1.79	1.64	- 9	1.123		0.064
2999		MAR)		FELAIF) U	206.1	1.81	0.70	6.1	1.042		0.057
2442	- •			FEMALE) E	210.1	1.85	1.57	8.9	1.251		0.062
7	- `	(ECE)		FEMALE	EOE	199.2	2.03	1.38	5.8	1.204		0.068
2 8 8 9	- •	(HVH0		FEMALE	: U	216.2	1.79	1.58	7.5	1.021		0.018
2000	- •	(EVE :		FEWALE	. u	200.0	1.81	1.51	8.8	1.037		0.050
4442	- •	(MVM)		FEMALE		1.001	1.75	1.41	5.3	1.058		0.046
2777	-			FEWALE) E	205.0	1.83	1.60	9.9	1.043		0.078
2 7 7 7		(MVE)		FEMALE) W	206.3	1.80	1.57	8.2	1.003		0.061
7 7 7 7	_			FEMALE	EOE	191.2	1.7.1	1.44	8.8	0.933		0.048
2 4 4 4				FFMALE	EOE	188.5	1.76	1.42	₹.\$	0.962		0.088
7	-		527	FEMALE	EOE	198.7	1.78	1.39	7.	1.108		0.049
		(MAN)		FEMALE	BEC	200.9	1.8.1	1.57	4.9	0.931		090.0
	_	CHAM)	631	FEMALE	EOE	200.7	1.77	1.34	6.1	1.043		0.041
	_	SHAM	632	FEMALE	£0£	1.961	1.83	1.38	5.7	1.060		0.088
		SHAM	833	FEMALE	EOE	1.061	1.76	1.27	8.5	0.970		9.
	-	SHAM	838	FEMALE	REC	207.6	1.77	1.47	7.9	1.038		.05
		(SHAM)	538	FEMALE	EOE	191.4	1.71	1.45	e. 8	1.183		0.051
	0.3	.32 ma/m3	139	MALE	REC	357.1	1.98	2.48	12.1	1.553	1.56	
4443	0.32	2 mg/m3	140	MALE	REC	364.2	1.98	2.38	12.4	1.699	2.26	
4443	0.32		141	MALE	EOE	344.0	1.94	2.10	10.6	1.589		
4443	0.31		142	MALE	REC	376.0	1.99	1.18	12.5	. 169	1.44	
4443	0.32		143	MALE	REC	357.8	1.92	2.34	7.	1.526	2.06	
4443	0.32		144	MALE	EOE	328.2	1.90	2.29	10.2		10.1	
1443	0.32		145	MALE	EOE	328.7	1.87	2.08	10.7	. 536		
4443	0.32		146	MALE	EOE	338.1	1.96	2.28	10.6	1.475	1.53	
4443	~	~	147	MALE	REC	370.1	1.98	2.60	12.2	1.343		
4443	ຕ		148	MALE	EOE	337.2	1.84	1.98	10.1	1.349	1.47	
4443			149	MALE	EOE	318.6	1.88	2.18	6	1.473	7	
6443			150	MALE	REC	329.8	1.95	2.19	8.7	1.348	1.51	
4443	0.32		151	MALE	REC	367.7	1.99	2.36	12.0	0	1.49	
4443	0.32		152	MALE	REC	375.8	1.90	2.19	11.5	1.931		
4443	0.32		153	MALE	EOE	333.8	1.95	2.21	10.4	1.476	5 · ·	

							1 1 1 1 1				
EXPT	CONCENTRATION OF Cu-Zn	NUMBER	SEX	CODE	ANIMAL	2	KIDNEYS	LIVER	LUNG	TESTES	OVARIES
1	1	 	 				:	•	•		
1113	0.37 .4g/m3	154	MALE	E0E	324.4		61.7	- 1	7 4		
6444	0.32 mg/m3	155	MALE	PEC	350.7	E 6.	7 . 3 .	9.	000.	, , ,	
4443	0.32 mg/m3	156	MALE	EOE	346.7	. 6	2.10	•	1.214		
2777		157	MALE	E0E	354.0	1.89	2.26	0.0	1.554	. . .	
	32	150	MALE	BEC	361.8	1.93	2.08	11.9	1.314	1.70	
		159	MALE	EOE	327.6	1.92	2.12	10.2	1.365	1.61	
			MALF	3	323.3	1.94	2.01	10.1		1.51	
			FMALE	3 6 6	203.5	1.77	1.49	9.	1.222		0.074
			FEMALE	EOE	193.9	1.75	1.45	9.9	0.984		0.038
		=	FEMALE	JEC .	190.5	1.77	0.65	.	0.896		0.068
	; ;		FMALE	EOE	207.5	1.80	1.49	8.8	0.923		0.066
		: ;	FEMALE		206.3	1.86	1.64	6.7	1.217		0.089
	CE/BE 75.0	; ;	FEMALE	1 C 1	196.2	1.71	1.35	5.5	0.972		0.041
M * * *		•	FEMALE		220.7	1.80	1.55	6.7	0.970		0.048
4443			FEMALE) <u> </u>		1.73	1.34	8.9	1.027		0.000
1113		9 (FMACE			1 73	1.40	-	198.0		0.053
4443		4	FEMALE	# O #	8.69.		•		410.1		0.050
4443		- -	FEMALE	E C	216.8	70.1					9.00
4443	0.32 mg/m3	6 4 9	FEMALE	EOE	200.1	1.78	* n				
4443	0.32 mg/m3	0 2 9	FEMALE	REC	204.1	1.77	7.46	- ·	990.		0.0
4443	0.32 mg/m3	551	FEMALE	EOE	208.3	1.70	1.51		0.920		260.0
4443	0.32 mg/m3	5 5 2	FEMALE	REC	204.6	1.81	1.38	°.	6.963		0.067
4443		653	FEMALE	REC	207.1	1.81	1.49	6.7	1.145		0.00
4443		554	FEMALE	REC	201.0	1.77	1.56	5.4	1.156		0.080
1113		5	FEMALE	EOE	192.4	1.69	1.32	₹.9	0.834		0.044
4443		56	FEMALE	REC	198.5	1.83	1.53	7 . 9	0.853		0.060
4443		57	FEMALE	REC	206.7	1.84	1.53	6.5	1.018		0.060
1113	0.32 mg/m3	85 83	FEMALE	EOE	194.6	1.80	1.54	9	1.039		0.051
4443	0.32 mg/m3	629	FEMALE	EOE	191.5	1.73	1.31	e. 6.	0.953		Ö
4443	0.32 mg/m3	9 8 0	FEMALE	EOE	187.1	1.68	1.32	o. •	1.314		0.041
1111	3.2 mg/m3	170	MALE	REC	368.5	1.95	2.24	1.5	1.662	1.65	
,,,	3.2 mg/m3	171	MALE	REC	332.4	2.11	2.27	10.9	1.314	1.52	
7777	3.2 me/m3	173	MALE	REC	365.8	1.91	2.37	12.9	1.628	2.34	
	3.2 ms/m3	174	MALE	REC	351.3	1.97	2.40	<u>-</u> -	1.518	1.62	
		175	MALE	E 0 E	344.2	1.89	2.16	10.8	1.388	1.68	
		177	MALE	REC	366.7	1.93	2.26	11.4	1.666	2.19	
***		179	MALE	REC	378.8	2.05	2.63	11.7	1.507	1.33	
		180	MALE	£0£	325.5	1.86	2.03	6. 6	1.402	1.44	
		181	MALE	EOE	329.3	1.89	2.22	10.8	1.406	1.52	
,	•									•	

									1		
NUMBER	CONCENTRATION OF Cu-2n		SEX	CODE	ANIMAL	BRAIN	KIDNEYS	LIVER	LCNG	16 GT 69 T	OVARIES
! !		i f f l l l	! ! ! !	; ; ; ; ; ; ;	; ; ; ;	; ! ! ! !					
1111	3.2 mg/m3	184	MALE	REC	356.3	2.01	2.39	11.6	1.542	1.61	
7777	3.2 mg/m3	•	MALE	EOE	323.6	1.89	2.34	9.0	1.407	1.84	
1111	3.2 mg/m3	186	MALE	REC	359.1	1.97	2.52	11.3	1.636	1.65	
***	3.2 mg/m3		MALE	EOE	334.3	1.68	2.20	9.6	1.257	1.47	
***	3.2 mg/m3	100	MALE	REC	357.9	1.92	2.24	1.1	1.380	1.58	
1111	3.2 mg/m3	169	MALE	EOE	329.7	1.98	2.48	10.3	1.696	1.67	
1111	3.2 mg/m3	190	MALE	£0£		1.94	2.18	. 6	1.279	1.58	
4444	3.2 mg/m3	191	MALE	EOE	314.8	1.90	2.06	6.7	1.235	1.64	
***		192	MALE	EOE	332.2	1.94	2.12	10.9	1.842	1.52	
1111	~	195	MALE	REC	366.8	1.94	1.19	11.7	1.359	1.50	
1111		196	MALE	REC	370.2	1.94	2.58	12.8	1.557	1.58	
1111		197	MALE	EOE	330.9	1.91	2.02	10.5	1.552	1.28	
***	~	869	FEMALE	REC	208.5	1.80	1.51	9	1.150		0.089
1111	3.2 mg/m3	870	FEMALE	REC	196.0	1.87	1.47	9.9	1.093		0.084
4444	~	673	FEMALE	EOE	184.1	1.74	1.37	6.3	1.093		0.071
4444	3.2 mg/m3	674	FEMALE	EOE	195.9	1.73	1.34	9.	0.938		0.084
***	3.2 mg/m3	878	FEMALE	REC	197.2	1.92	1.52	. .	1.235		0.083
4444	3.2 mg/m3	576	FEMALE	REC	204.0	1.86	1.47	6.2	1.091		0.043
***	3.2 mg/m3	577	FEMALE	REC	205.4	1.78	1.54	ē. S	0.989		0 . 0 6 0
1111	~	578	FEMALE	EOE	187.3	1.70	1.32	8.2	0.907		0.058
1111	~	580	FEMALE	REC	204.4	1.84	1.34	9 .4	1.083		0.061
4444	~	581	FEMALE	EOE	193.1	1.79	1.46	4.	1.072		0.048
1111	3.2 mg/m3	582	FEMALE	REC	210.1	1.83	1.55	6.9	1.110		0.055
***	3.2 mg/m3	583	FEMALE	EOE	195.8	1.73	1.49	6.3	0.984		90.
1111	3.2 mg/m3	585	FEMALE	REC	205.0	1.77	1.61	6.5	0.960		0.053
1111	3.2 mg/m3	588	FEMALE	EOE	199.4	1.82	1.32	5.5	1.057		0.043
1111	3.2 mg/m3	888	FEMALE	EOE	202.7	1.78	1.38	6.8	1.080		0.052
111	~	583	FEMALE	EOE	195.5	1.72	1.32	5.7	1.048	•	0.057
***	3.2 mg/m3	690	FEMALE	EOE	198.5	1.17	1.36	0.9	1.171		0.052
4444	3.2 mg/m3	169	FEMALE	MEC	196.7	1.82	1.51	9.9	1.470		0.076
1111	3.2 mg/m3	592	FEMALE	REC	201.5	1.85	1.56	8.9	1.026		0.048
4444		₽69	FEMALE	EOE	195.4	1.75	1.45	5.7	1.092		0.077
4444		595	FEMALE	REC	206.0	1.82	1.50	8 .5	6.995		0.083
, , , ,								•			

APPENDIX E. ENDPOINT EVALUATION RESULTS FOR INDIVIDUAL ANIMALS (HEMATOLOGY, CHEMISTRY, IMMUNOLOGY, PHAGOCYTOSIS)

1. NEMATOLOGY BATA

0F Cu-Zn										•				2	
	HOMON	ROMBER	SEX	C00E	30 C	HEMA	0 5	Z C	MCHV						
			7 7 7 7			6.14	18.0	53	35.8	2.0	20	~	7.8	•	•
THE DIE						4 17	16.2	62	36.4	4.6		-	9	-	0
1.0 mg/m3			3142			•	4	· 5	38.4	4.1	30	-	29	~	•
1.0 mg/m3	1/64			2 6				: :	- C		5	~	9	-	^
1.0 mg/m3	4371	- 50	MALE	E E	97.8		9 1	u (•		•	7	6	•
1.0 mg/m3	4371	0 \$ 2	MALE	EOE	8.09	42.2	15.1	E 9	30.0	8.9		• •	; ;	•	•
•	4371	0 5 5	MALE	REC	90.0	42.3	16.3	53	38.8	* .	<u>-</u>	.	9.	>	•
	4371	990	MALE	REC	7.94	40.6	15.8	2 9	38.9	4 .3	5	-	•	N	-
	4371	059	MALE	EOE	7.89	40.7	14.6	52	38.9	3.7	25	-	73	-	-
	4371	090	MALE	BEC	8.17	41.7	16.0	82	38.4	3.6	90	m	9	-	₩
	4371	1 20	MALE	EOE	8.16	42.2	15.4	25	36.5	1.4	7	~	9	0	0
	4371	K 4.7	FFMALE	E05	7.45	41.5	14.9	67	35.9	2.8	-	n	7.9	~	n
٠.	4371	474	FFMALE	£0£	7.41	41.2	14.7	56	35.7	3.0	-	0	87	~	•
	A371	20 14	FEMALE) W	7.81	42.3	16.0	40	37.8	9 .	7	•	63	~	•
	4371	48	FFMALE	EOE	7.69	40.4	14.9	63	36.9	2.9	•	-	83	-	~
	A371	- 46 - 46	FEMALE	2	7.37	39.6	15.5	5.4	1.60	3.6	02	-	11	~	◀
	4371		FEMALE	2	7.23	39.0	15.4	9	39.8	4.7	6	-	7.9	-	-
		58.2	FFMALE	386	7.66	41.5	15.8	10	38.1	4.3	=	_	89	0	~
	7373		FEMALE	3 1 2	7.96	42.5	16.2	\$4	38.1	5.0	=	~	83	-	0
		, c	FEMALE	10 H	7.71	41.7	15.3	85	36.7	4.0	3.5	-	63	-	•
CE/SE 0	4371	57.5	FEMALE	E 0 E	7.64	42.4	15.1	10 10	35.6	3.8	=	_	81	,	•
1.5 mg/m3	4372	0.75	MALE	EOE	8.18	42.7	15.3	53	35.8	3.1	30	-	9	-	•
	4373			101	8.30	42.3	15.6	52	36.9	3.5	20	-	11	~	-
3.2 mg/m3	6373	. 40	MALE	E 0 E	7.87	40.3	15.2	52	37.7	3.5	2 5	-	7.4	0	-
	4372	0.00	MALE	REC	8.01	40.9	15.9	52	38.9	4.8	42	_	99	-	₩
	4372	080	MALE	EOE	7.76	39.8	14.7	52	37.2	3.7	39	-	0	-	~
3.2 mg/m3	4372	092	MALE	REC	8.42	42.6	16.3	5 1	38.3	. s	5	-	67	-	
3.2 mg/m3	4372	960	MALE	REC	7.59	39.0	15.8	2	40.0	4.9	*	0	.	~ (
2 2 26/23	4173	5	Z	303	7.40	40.6	14.9	29	36.7	3.9	36	~	2 9	0	m

CONCENTRATION	EXPT	ANIMAL	ANIMAL	SACRIFICE						!	•				
0F Cu-Zn	NUMBER	NUMBE R	SEX	C00E	30 C	HEMA	#C9	KCV	MCHV	200		1027			
9 6 6 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1		! ! ! !	; 	 											•
3 2 mo/m3	4372	111	MALE	BEC	7.62	39.5	15.6	2 9	39.8	₹.	77		6	•	•
	4372	112	MALE	REC	8.15	41.5	16.1	2 5	38.8	9.	9	-	-	~	.
	4173	£7.E	FEMALE	280	7.41	39.8	15.2	54	36.8	3.3	_	0	•	_	
5. E	4177		FEMALE	2	7.80	42.0	18.8	9	37.6	3.1	7	~	78	~	~
	4373		FEMALE		7.69	42.0	15.4	9 9	36.7	1.2	7.7	-	11	0	•
			FEMALE		7 79	42.4	16.2	9 9	38.2	1.4	98	.	2	~	•
	7/54	D 4	FEMALE		7. 43	41.2	18.0	9	36.4	3.3	10	~	e	•	•
			FEMALE	, C	7.48	38.4	14.9	8.2	30.8	6.4	7.7	0	11	-	~
			FEMALE		7.87	43.3	15.5	99	35.8	3.3	2 8	-	*	•	•
	7754		FEMALE		7 . 67	41.3	16.4	9	37.3	5.1	7.7	-	11	0	-
	7		FEMALE		7.92	44.3	16.1	5.7	36.3	3.6	7.7	-	9 2	•	_
	7		FEMALE		6.73	36.7	13.5	50	36.8	3.5	2.7	-	7.5	0	
	1313		MAIR	3 15	7.80	39.2	15.5	5	3.9.5	2.8	21	0	73	•	.
TH/BH OI		7 7 7	MAIG	. C	0.03	40.5	15.5	5.1	38.3	- :	7.7	~	76	•	0
TE/BE OF		125	MAIR) L	90.8	42.3	15.5	53	36.6	5.3	20	-	7.8	-	~
	7373		MALE	303	7.95	40.7	14.9	2 9	36.5	3.2	33	~	7 9	-	-
	7		MAIG	. E	6.31	42.1	15.9	5 1	37.8	4.8	9	-	•	~	•
			MAIR) U	8, 19	41.5	9.8		38.3	3.8	27	•	7 9	•	_
			MALE		8.37	43.8	16.0	63	36.8	3.9	38	-	62	~	~
TE/BE DI		•			7.67	39.3	14.5	62	36.9	3.1	37	6	09	•	•
TW/DW DI			7716	בי בי בי	11.6	4.1.4	16.3	6.2	0.76	6.4	26	•	12	~	~
				. C	. O. E	41.2	16.3	5 2	39.6	8.2	S.	~	82	-	^
			FEMALE	E 0 E	7.37	41.3	15.0	57	36.3	9.6	30	-	40	-	-
	6373		FEMALE) EC	7.08	37.8	15.2	5.4	40.2	1.7	11	-	-	-	•
	6373	B 2.7	FEMALE	BEC	7.45	39.4	15.5	5.4	39.3	4 .8	23	n	~	n	•
	4373	628	FEMALE	EOE	7.82	43.1	15.8	20	36.7	S.0	78	0	ø.	en -	•
		6 3 3	FEMALE	EOE	7.58	40.7	15.3	9	37.6	1.2	9	~	-	-	-
	6113		FEMALE	EOE	7.84	43.5	15.8	20	36.3	5.7	34	-	~	n	.
	7373		FEMALE	256	7.11	37.7	15.1	5.4	40.1	3.1	20	•	0.	~	•
	4373	84 2	FEMALE	EC EC	7.35	39.3	15.5	5.4	39.4	7.8	•	.	7.9	~	0
		543	FEMALE	EOE	7.64	41.0	15.1	₽	36.8	3.6	33	~	e •	-	m
	4173		FEMALE	E C	7.36	39.4	15.1	9	36.3	3.e	20	~	7.	-	•
>41. Au	•))		1											

TPRO ... 6.3 6.3 -= **181**L -. 0.2 0.2 0.0 .. 0.0 0.2 1.0 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 -.0 0.0 0.2 0.3 0.2 0.2 0.2 21.9 25.5 18.0 25.8 22.4 30.7 27.4 22.4 21.6 23.9 22.8 31.3 22.1 25.6 21.6 23.7 24.1 18.9 12.1 23.6 21.8 21.9 23.2 26.7 24.1 NO S 59.2 33.7 42.2 12.7 55.9 35.2 37.9 35.3 37.5 38.8 41.0 43.8 37.0 4.14 49.6 10.7 8. O. 6.01 41.6 71.1 40.3 19.1 80.5 1.1 SGPT ALKP 85.2 90.6 73.0 80.0 88.0 91.0 17.8 72.5 64.9 15.4 82.8 95.2 96.0 76.7 82.2 79.2 83.4 97.2 86.7 79.7 99.8 1.08 72.1 9.9 83.1 0.02 94.2 SACRIFICE CODE EOE EOE REC EOE EOE REC REC EOE EOE EOE E 0 E REC E0E EOE EOE EOE EOE REC **E0**E ANIMAL MALE FEMALE MALE HALE MALE MALE MALE MALE FEMALE FEMALE FEMALE FEMALE FEMALE FEMALE MALE MALE MALE MALE MALE MALE MALE FEMALE FEMALE FEMALE SEX AN IMAL NUMBER 0.85 052 2 9 2 263 670 571 075 547 0.61 2. SERUM CHEMISTRY DATA EXPT 4372 4372 4371 4371 4371 4371 4371 4371 4371 4372 4372 4372 4371 4371 4371 4371 4371 4371 4371 4371 4371 4371 4371 4371 4372 1372 4372 4372 4372 CONCENTRATION mg/m3 Em/8m Em/8m mg/m3 mg/m3 mg/m3 Em/ Bm Em/8m mg/m3 mg/m3 mg/m3 **TE/BE** mg/m3 LE/GE me/m3 mg/m3 mg/m3 mg/m3 mg/m3 mg/m3 Em/Bm mg/m3 Em/9m mg/m3 **EE/8E** mg/m3 mg/m3 Em/8m mg/m3 Em/8m OF Cu-Zn 0.1 9. • 0.1 • 0.1 0. 0. 0. 0. 0. 3.2 3.2 2.6 3.2 • • 0. 0. 0. <u>.</u> 3.2 3.2 3.2 3.2 •

							1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1			
1.2 ms/m3			 							
	4372	9 / 6	FEMALE	FC	1.18	38.2	25.8	0.3	6.7	7.
3.2 mg/m3	4372	888	FEMALE	REC	9.69	43.7	22.7	0.3	6.3	4.7
~	4372	5.90	FEMALE	EOE	91.5	41.8	29.4	. 0	e	9
~	4372	800	FEMALE	RC	93.3	48.5	24.6	. 0	. so	4.2
~	4372	50.00	FEMALE	EOE	89.8	34.2	28.5	0.1	9.9	4.8
~	4372	602	FEMALE	MEC	73.3	40.1	22.3	0.2	6.2	6 . 2
~	4372	603	FEMALE	EOE	92.0	91.9	25.2	1.0	7.8	4.0
~	4372	909	FEMALE	REC	83.5	38.7	23.5	1.0	8 .8	3.9
~	4372	608	FEMALE	£0£	60.3	47.1	25.9	0.1	8.8	8.2
~	4372	609	FEMALE	EOE	84.1	25.4	22.1	0.2	7.0	8.8
=	4373	122	MALE	REC	73.8	41.2	20.7	- . 0	9·9	2.9
10 mg/m3	4373	127	MALE	REC	88.8	68.0	23.6	0	7.2	3.1
	4373	128	MALE	EOE	98.0	33.9	21.0	0.0	6.9	7 .
10 mg/m3	4373	130	MALE	£0£	82.8	37.8	29.5	0.3	6 . 5	9.4
10 mg/m3	4373	134	MALE	REC	91.9	53.2	23.1	1.0	9	4.6
10 mg/m3	4373	135	MALE	REC	88.2	52.4	27.8	· ·	• · •	3.8
10 mg/m3	4373	136	MALE	EOE	73.0	40.9	27.2	0.3	7.2	8.9
10 mg/m3	4373	=	MALE	EOE	93.4	39.1	19.8	0.3	7.3	8.2
10 mg/m3	4373	142	MALE	EOE	83.4	40.9	25.2	٠.	e .	9.4
10 mg/m3	4373	1.49	MALE	REC	63.4	49.8	23.0	0.5	5.7	1.1
10 mg/m3	4373	615	FEMALE	EOE	83.9	35.1	29.9	0	7.7	9. 9.
10 mg/m3	4373	616	FEMALE	REC	58.2	46.2	26.6	0.2	7.9	3.9
10 mg/m3	4373	627	FEMALE	REC	92.5	54.0	20.1	0.2	8.2	4.5
10 mg/m3	4373	628	FEMALE	EOE	8.18	40.8	27.2	0.0	7.3	5.1
10 mg/m3	4373	632	FEMALE	E O E	94.8	46.3	33.0	0.3	6.7	9.9
10 mg/m3	4373	. 633	FEMALE	EOE	93.8	36.7	27.4	1.0	7.1	•
10 mg/m3	4373	639	FEMALE	REC	63.0	97.9	23.9	0.2	5.7	 •:
10 mg/m3	4373	642	FEMALE	REC	71.6	40.2	18.6	0.0	4 . 9	3.3
10 mg/m3	4373	643	FEMALE	EOE	88.8	49.7	24.7	1.0	6.7	9.0
10 mg/m3	4373	650	FEMALE	REC	82.7	41.6	25.0	0.0	6.7	4.5

3. IMMUNOLOGY DATA FROM EVALUATIONS WITH LUNG-ASSOCIATED LYMPH NODES

CONCENTRATION OF CU-Zn	EXPT. NUMBER	ANIMAL NUMBER	SEX	SAC CODE	TOTAL LYMPHOID -6 CELLS×10	ANTIBODY- FORMING CELLS PER MILLION LYMPHYCYTES	TOTAL ANTIBODY- FORMING CELLS
1.0 mg/m3	4371	042	М	REC	14.7	2235	32861
1.0 mg/m3	4371	045	М	EOE	6.6	315	2083
1.0 mg/m3	4371	053	М	EOE	7.6	1080	8208
1.0 mg/m3	4371	054	М	EOE	9.9	2925	28958
1.0 mg/m3	4371	058	M	EOE	6.9	812	5583
1.0 mg/m3	4371	065	М	REC	12.7	1203	15278
1.0 mg/m3	4371	073	M	REC	3.3	404	1333
1.0 mg/m3	4371	539	F	EOE	3.6	829	2953
1.0 mg/m3	4371	545	F	REC	10.6	13	139
1.0 mg/m3	4371	546	F	REC	9.0	763	68 61
1.0 mg/m3	4371	561	F	EQE	10.6	1120	11875
1.0 mg/m3	4371	568	F	REC	6.1	824	5028
1.0 mg/m3	4371	574	F	EOE	12.3	474	5833
3.2 mg/m3	4372	077	М	EOE	19.9	668	13292
3.2 mg/m3	4372	078	M	REC	7.5	478	3583
3.2 mg/m3	4372	880	M	REC	6.8	1181	8028
3.2 mg/m3	4372	091	M	EOE	15.1	1325	20000
3.2 mg/m3	4372	094	М	EOE	21.8	835	18208
3.2 mg/m3	4372	097	M	EOE	25.7	1090	28000
3.2 mg/m3	4372	106	М	REC	7.2	31	222
3.2 mg/m3	4372	577	F	REC	8.3	238	1972
3.2 mg/m3	4372	583	F	REC	9.8	283	2778
3.2 mg/m3	4372	589	F	REC	4.3	116	500
3.2 mg/m3	4372	595	F	EOE	10.3	299	3083
3.2 mg/m3	4372	596	F	EOE	12.5	1210	15125
3.2 mg/m3	4372	597	F	EOE	6.2	785	4875
3.2 mg/m3	4372	610	F	REC	8.7	434	3778
10.0 mg/m3	4373	115	М	REC	11.1	10	111
10.0 mg/m3	4373	120	М	EOE	31.6	976	30833
10.0 mg/m3	4373	121	М	EOE	43.3	718	31083
10.0 mg/m3	4373	123	М	EOE	22.3	867	19333
10.0 mg/m3	4373	129	М	REC	9.8	241	2361
10.0 mg/m3	4373	131	М	REC	10.5	476	5000
10.0 mg/m3	4373	138	М	REC	9.8	828	8111
10.0 mg/m3	4373	619	F	REC	9.1	49	444
10.0 mg/m3	4373	621	F	EOE	18.8	758	14250
10.0 mg/m3	4373	622	F	REC	12.2	779	9500
10.0 mg/m3	4373	637	F	EOE	25.4	1453	36917
10.0 mg/m3	4373	641	F	EOE	17.1	950	16250
10.0 mg/m3	4373	645	F	REC	10.8	496	5361
10.0 mg/m3	4373	646	F	REC	7.4	71	528
10.0 mg/m3	4373	649	F	EOE	31.1	466	14500

						ANT I BODY -	
					TOTAL	FORMING	TOTAL
					LYMPHOID	CELLS PER	ANTIBODY-
CONCENTRATION	EXPT.	ANIMAL		SAC	-6	MILLION	FORMING
OF Cu-Zn	NUMBER	NUMBER	SEX	CODE	CELLS×10	LYMPHYCYTES	CELLS
O (SHAM)	4442	113	М	EOE	6.2	63	389
O (SHAM)	4442	117	M	REC	13.3	357	4750
O (SHAM)	4442	124	M	EOE	7.8	435	3389
O (SHAM)	4442	125	M	REC	9.9	1395	13806
O (SHAM)	4442	126	M	REC	7.6	826	6278
O (SHAM)	4442	129	M	REC	11.2	2556	28625
O (SHAM)	4442	133	M	EOE	9.3	287	2667
O (SHAM)	4442	135	М	EOE	6.9	390	2692
O (SHAM)	4442	514	F	REC	9.4	1333	12528
O (SHAM)	4442	521	F	REC	9.6	822	7889
O (SHAM)	4442	525	F	EOE	11.3	492	5556
O (SHAM)	4442	528	F	REC	7.4	777	5750
O (SHAM)	4442	529	F	EOE	11.9	896	10667
O (SHAM)	4442	534	F	REÇ	11.6	826	9583
O (SHAM)	4442	536	F	EOE	9.0	910	8194
O (SHAM)	4442	537	F	EOE	7.8	662	5167
3.2 mg/m3	4444	169	M	EOE	6.2	67	417
3.2 mg/m3	4444	172	М	EOE	16.7	391	6528
3.2 mg/m3	4444	176	M	REC	10.3	833	8583
3.2 mg/m3	4444	178	M	EOE	17.3	300	5194
3.2 mg/m3	4444	183	М	REC	12.7	954	12111
3.2 mg/m3	4444	193	M	REC	3.6	85	306
3.2 mg/m3	4444	194	М	EOE	18.8	284	5333
3.2 mg/m3	4444	198	М	REC	7.4	188	1389
3.2 mg/m3	4444	571	F	EOE	18.0	315	5667
3.2 mg/m3	4444	572	F	REC	14.2	921	13083
3.2 mg/m3	4444	579	F	REC	7.4	556	4111
3.2 mg/m3	4444	584	F	REC	7.0	302	2111
3.2 mg/m3	4444	587	F	EOE	12.5	307	3833
3.2 mg/m3	4444	593	F	EOE	17.0	225	3833
3.2 mg/m3	4444	597	F	EOE	15.7	876	13750
3.2 mg/m3	4444	598	F	REC	5.7	107	611
_							

4. PHAGOCYTOSIS AND BRONCHOPULMONARY LAVAGE FLUID CELL DIFFERENTIAL DATA

CONCERTRATION	EXPT	ANIMAL	•	SACRIFICE	فعو										
0f Cu-Zn		RUMBER	SEX	CODE	NCELL	NEA	PPAM	PLYM	Z Z	PMAC	PEOS	RLYM	27.2	MAC	S 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
			!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!		† 	; 	; ; ; ; ;	; ; i i i	; ; ; ; ;						
	•	•	3	¥0.	0.73	492	92	4.7	1.7	93.7	0	3.4	1.24	4.09	•
			: 3		0.82			1.7	2.3	96.0	•	-	1.89	7.8.7	•
			: 3		1.20	6	9	2.3	4.0	92.7	1 .0	9. 2	4.80	111.2	1.2
•			: 3		06.1			4.3	1.7	94.0	0	.	2.21	122.2	•
			t 3		9 -	787	26	5.7	•	94.0	0.3	6.3	•	103.4	
			: 3		6.5	183	7.	8.0	0	95.0	•	7.5	•	142.5	0
		- c	E 2			6		0.	12.3	17.7	-	9.0	12.30	17.1	-
		7 1	. :			306		18.7	0.7	93.7	•	15,7	0.70	63.7	•
•		A 4	t :) C		312	. 2	13.7	. ·	85.0	•	15.1	1.43	93.8	•
•			E :			: ;				0.06	0,3	2.8	1.45	39.8	
•	4371	B (E :		•) ¥			95.3		•	1.62	133.4	•
•			E :) i				•		88.7		0.6	2.00	88.7	
1.0 mg/m3	4371		I I	ָרָהָ עָרָהָ מיניים		•	2	•		7 . 50		.	44.0	86.8	0.2
1.0 mg/m3	4371		L	3 4		•	;) r				•		36.3	6.0
1.0 mg/m3	4371	847	•	E0E	9.0	482	: ;		•	· ·	•		**	7. 57	7.0
	4371	8 4 8	•	EOE	0.64		*	· •	E (n. - (
1.0 m4/m3	4371	550	<u>.</u>	REC	1.30	312	7	.	٥.٦	90.3	Ð		16.0	• • • • • • • • • • • • • • • • • • • •	• (
	4371	554	•	EOE	1.30	802	82	-		93.7	•	e.		121.8	.
1.8 mg/m3	4371	80 S0	14.	REC	1.40	315	00	5.7	0	94.3	•	.	0	132.0	9 (
	4371	660	•	REC	1.40	326	90	.	2.3	91.0	0	9.5	3.22	127.4	•
	4371	562	•	REC	0.71	190	7.8	3.3	0.3	96.3	0	2.3	0.21	7.99	D
	4371	563	L	REC	1.20	299	7.1	10.0	6	90.0	•	12.0	0	108.0	0
	4371	564		EOE	0.99			3.3	0.7	96.0	0	3.3	0.69	95.0	•
•	4371	570		EOE	0.94	888	9	9.0	1.3	93.0	0.7	4.7	1.22	87.4	0.1
•	4371	871		EOE	1.20	396	06	13.3	1.7	85.0	•	16.0	7.04	102.0	•
	4173	0.75	. 3	£0£	1.60	359	7.2	6.3	5.7	88.0	•	10.1	9.12	. 04	•
	4372	180	.	E0E	1.40	249	*	10.0	3.7	85.7	0.7	14.0	5 . 1 8	120.0	•. -
: •	4372	60	I	EOE	0.69	327	6.2	10.7	4.0	84.7	0.7	7.4	2.78	86.4	
: •	4372		I	MEC	1.70	310	93	7.6	0.7	89.3	0.3	9.9	1.19	151.	. .
	4373	740	7	E 0 E	2.80			10.3	1 .3	88.0	0.3	26.8	3.38	228.8	.
•			: 3	£0£	1.10	336	63	1.3	11.3	87.3	•	*	12.43	96.0	•
		6	: 3	316	1.90	212	73	10.7	0.7	88.3	0.3	20.3	1.33	167.8	•
			: 3		1.00			8.3	0	91.7	•	8.3	0	7.16	•
	***		: 3	. C	0.97	302	9	10.7	0.3	0.69	0	10.4	0.29	86.3	•
•			: 3	<u> </u>	2.20	381	7.2	1.0	4.3	93.0	1.7	2.2	9.46	204.6	3.7
	1372	-	: 3) E	1.50	507	7.9	6.9	0.3	91.3	0	12.5	0.45	137.0	•
•		:	: 3					19.0	0.3	80.3	0.3				
1.2 mg/m		:) ;											

CONCENTRATION	EXPT	AHIMAL	•	SACRIFICE											
- PO 10	RUMBER	RCHOER	36 X	CODE	NCELL	NEA	PPAH	PLYM	N N N	PMAC	PEOS	RLYM	RPER	WAC	NEO S
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1) 1 2 1 1 1	1 0 1 1 5 6 6 8	! ! !	5 1 1 2 1 1	; ; ; ; ; ; ;										
3.2 mg/m3	4372	878	L .	BEC	0.05	285	5	0 .	•	96.0	•	3. A	0	81.6	•
	4372	909	L	REC	0.17	-	69	1 6 .0	•	84.0	•	12.3	•	64.7	•
	4372	690	•	E 0E	1.50	324	11	10.7	2.2	86.3	0.3	16.1	4.05	129.8	
	4372	593	•	EOE	1.20			6.3	9	86.3	0.3	10.0	.00	103.6	₹.
	4372	898	•	3EC	1.70	133	29	19.9	1.2	78.8	0	33.8	2.04	134.0	•
3.2 mg/m3	4372	661	•	EOE	1.86	263	\$	11.3	3.7	84.3	0.7	21.0	6.88	156.8	
	4372	709		BE C	1.80	373	5	11.0	6.0	88.7	9	19.8	0.64	159.7	•
	4372	603	•	EOE	0.94	366	09	11.0	4.7	83.3	1.0	10.3	4.42	76.3	•.0
	4372	*0	•	REC	•			10.7	3.0	96.0	6.0	٠.	1.80	8.1.8	0.2
	4372	909		REC	•	339	00	16.0	0.3	83.3	0.3	17.6	0.33	9 .1.	6.0
	4372	00	•	EOE	0.85	349	7.9	18.0	4.0	60.3	7.0	12.8	3.40	66.3	•.•
	4372	609	L.	EOE	1.33	333	63	14.7	3.3	82.0	•	19.6	4.39	109.1	•
	4373	122	I	REC	•	246	63	18.0	0.1	81.0	•	19.8	1.10	89.1	•
10 mg/m3	4373	121	I	REC	0.73	271	7.5	9.3	0	90.4	0.3	9.	•	0.99	0.2
10 mg/m3	4373	126	x	EOE	2.28	241	90	6.3	12.7	80.7	0.3	14.2	28.70	182.4	6.7
10 mg/m3	4373	130	I	EOE	4.50	246	7.5	13.3	3.7	81.3	1.1	69.9	16.65	365.9	7.7
10 mg/m3	4373	132	I	EOE	2.20			11.7	0.6	11.1	1.7	25.7	19.80	170.9	3.7
10 mg/m3	4373	134	x	REC	1.00	331	7.	0.0	0	5.16	0.3	8 .0	•	91.7	0.3
10 mg/m3	4373	135	I	REC	0.61	253	7.9	13.6	6.0	85.7	0	8.3	0.18	62.3	0
10 mg/m3	4373	136	I	£0£	•	228	7.1	0.4	7.7	87.7	0.7	11.2	21.56	245.6	7.0
10 mg/m3	4373	::	2	E 0E	•	234	29	7.0	8.7	84.3	•	35.0	43.50	421.5	•
10 mg/m3	4373	142	I	EOE	•	194	41	7.0	18.0	73.0	0.3	20.7	42.84	173.7	0.7
10 mg/m3	4373	148	I	MEC	1.30			6.3	2.0	89.7	0	10.8	2.60	118.6	0
10 mg/m3	4373	149	ı	BEC	•	296	69	7.7	0.3	92.0	•	14.6	0.57	174.8	•
10 mg/m3	4373	6 1 8	•	EOE	•	253	88	6.9	6.7	83.3	0.7	20.9	15.08	187.4	1.8
10 mg/m3	4373	•	•	REC	•	284	9	17.0	1.0	82.0	0	10.2	0.60	49.2	6
10 mg/m3	4373	625	. .	101	•			Ð. 6	3.3	1.18	•	22.5	8.25	219.3	•
10 mg/m3	4373	627	L	REC	•	303	7.6	20.9	e.0	78.7	•	17.1	0.28	64.5	•
10 mg/m3	4373	6 2 8	-	EOE	5.77	254	•	9.0	10.0	91.0	0.	46.2	87.70	467.4	9 .
10 mg/m3	4373	631	•	REC	•			12.0	0	88.0	0	13.2	•	96.9	0
10 mg/m3	4373	632		E 0E	•	334	=	14.0	11.7	74.3	0	46.2	36.61	245.1	•
	4373	6 33	•	E0E	٠	-	+	6	7.7	83.3	0.3	29.5	•	273.2	o. -
10 mg/m3	4373	609	.	REC	•	380	11	18.7	7.0	80.7	•	16.3	0.61	70.2	•
10 mg/m3	4373	642	4	REC	0.77	382	•	7.7	•	92.3	•	e.	•	71.1	•
10 mg/m3	4373	643	.	EOE	•	343	8	15.3	6.3	77.7	0.7	23.0	9.45	116.6	-:
10 mg/m3	4373	650	•	MEC	•	246	7.0	10.7	0.4	82.0	3.3	5.1	1.92	39.4	•
G (SHAM)	4442	109	I	REC	1.20	308	18	0.4	٥٠٠	95.3	•	.	0.84	114.4	•
O (SHAM)	4442	9	I	REC	1.40	537	93	6.4	2.3	93.3		9 .0	3.22	130.6	
G (SHAM)	4442	112	¥	E 0E	1.10	307	69	10.0	9.0	89.6	•	0	0.55	9.06	•
O (SHAM)	4442	•:-	I	REC	1.20	246	63	0.6	3.0	98.0	•	9.01	3.60	105.6	•
G (SHAM)	4442	1.9	¥	EOE	1.10	253	92	- - -	7.0	88.3	0	12.1	0.77	1.76	0

CONCER	CONCENTRATION	EXPT	AHIMAL		SACRIFICE						;	1	1	1	•	
0 F C	OF Cu-Zn	3	NUMBER	SEX	CODE	NCELL	MEA	PPAH	PLYH	M M	PMAC	FEOS	#LYM			
					1	! ! ! !	! ! !	6 6 6 1 1								
		****	::	3	40	0.83	316	7.5	9.0	0.7	94.3	•	4.2	0.58	78.3	•
•	SHAM	, ,		: 3		-	147	. 6	7.3	•	92.7	•	0.0	0	102.0	0
	(MAM)	7		: 2						-	91.0	•	6.0	•	1.001	•
_	(MAN)	7	• • •	E ;	N 6						6.40	•	9.	0	3 6	0
_	(MYNS	2 7 7 7	051	E :) (, ,				42.7	0	6.7	1.70	92.7	•
_	(SMAN)	~ * * * * * * * * * * * * * * * * * * *	751	k :) W			3 =			E . G	•	13.6	0	126.4	•
•	(MY MS	7 7 7 7		E 3			3 7 6				9.2.8	•	1.4	0	40.7	•
_	SHAM)	7	2 6	E 4) W				0.11	0.2	0.88	•	4.6	0.85	74.8	0
S)	SEAM	2 9 9 9	600		2 4						18.7	0	2.8	0.84	73.7	0
: •	SHAM)	7 4 4 5	E C) (E (2 6	2 4		. ~	0.74	•	13.6	0.77	95.7	•
_	SHAM)	7445			ב ב ב ב		3 40	n #			0.05	•	11.2	0.84	108.0	•
S :	SHAM)	7 7 7 7	n (86.7	0	12.4	2.20	95.4	0
5 : 0 :	SHAM)	2000	226) () Y	9 6	2.8	. e.	8.16	•	7.2	0.26	80.8	•
5	SHAM	7 * * *	679) (•		1.70	•	3.7	0	71.3	0
S.	SEAM)	4442	929	la. 8	# OF	6.6	- 70		n -				3.1	0	89.9	0
s) 0	SHAM)	4442	D :	• 1	י בי בי	n (676	2 ;					2.0	0	63.1	0
S) 0	SHAM)	1112	531	L	EOE	9 .	P 1	• ;					42.0	1.50	106.5	•
S) B	SHAM)	4442	633	.	E 0 E	06.1	116	21	0.67	• •		. «	-	9 0	88.3	0
S) 0	SHAM)	7113	60 00 00	.	3 4	76.0	475	D 1	n .	· •) (•		0.27	84.6	0
•	SHAM)	4442	60 60 60		EOE	0.00	420	* 1	· .	7 1				6, 6	E .	0
. 0.32 m	mg/m3	4443	-	I	3 3 3 4	00. -	5.5	9	is.	2.0		• •				
0.32	mg/m3	4443	142	I	REC	1.50	26 R	7.2	2.3	٥.٧	97.0	.	e (- (, ,
.32	Em/m3	4443	145	I	EOE	06.0	351	11	4.0	•	96.0	0	ю. •	9	•	• •
32	H4/#3	4443	146	I	E 0 E	1.00	675	48	4 .0	900.0	95.0	0	0.	900.0	0.68	.
26	ma/m3	4443	147	x	REC	0.85	336	83	12.0	0.7	87.3	•	10.2	0 . 60	74.2	5 (
6	ma/m3	4443	1.48	I	EOE	96.0	472	73	8.3	1.0	90.7	•	0.0	96.0	87.1	ь .
	me/m3	6443	150	I	REC	0.99	227	7.1	8.0	6.9	94.7	0	8.0	0.30	93.8	.
	me/m3	4443	151	I	REC	1.30	477	0	10.7	0.7	88.7	0	13.9	. 16.0	115.3	D (
3	me/m3	4443	154	I	EOE	1.10	802	90	15.6	0	84.4	•	17.2	0	92.8	9 (
2	ma/m3	4443	5.6	2	EOE	0.94	476	7.5	3.3	•	96.7	0	J.	0	6. O	.
32	me/m3	4443	158	3	REC	0.79	404	63	11.0	0	88.7	6.9	۵.۷	•	70.1	7.0
3	ma/m3	4443	159	1	EOE	1.10	909	70	4.4	7.0	2.06	•	ø.	0.77	10 · 10 · 10 · 10 · 10 · 10 · 10 · 10 ·	.
32	ma/m3	4443	641	٠.	REC	0.81	355	4	9.3	0.7	96.0	0	2.7	. 8.0	9.77	> (
3	mo/m3	4443	642	•	EOE	96.0	604	94	0 . 0	0.003	92.0	5	7.7	0.003	D .	5 (
:	(1)	1413	548		REC	0.88	8 2 6	8.7	4.7	0.3	95.0	0	- .	0.26	83.6	ь .
: :		1443	2 7 9		EOF	0.89	429	11	3.7	0.3	96.0	•	3.0	0.24	76.B	•
; ;	, m, j m	1413	547	•	EOE	0.80	4 8 8	82	9.4	1.3	94.0	0	3.7	1.04	75.2	•
: :		1113	4 6	•	MEC	0.87	186	8 2	4.0	0.3	95.7	0	a.s	0.26	63.3	6
: :		1113	•	14.	EOE	0.87	511	83	0.4	0.1	95.0	0	3.5	0.87	82.7	6
; ;		•			A C	0.78	425	28	19.0	0	0.18	0	14.8	0	63.2	0
	(m/bu)	1443	1 40 1 40		EOE	76.0	378	7.5	7.3	0.3	92.4	0	7.1	0.29	9.6	0
; ;	(m)	6443		L .	REC	0.87	270	8.8	7.0	2.3	7.06	•	.	2.001	78.9	•
;	,					•										

CONCENTRATION	ON EXPT	ANIMAL		SACRIFICE	w										
0f Cu-Zn	NUMBER	R NUMBER	SEX	CODE	NCELL	NEA	PPAN	PLYM	PMM	PMAC	PEOS	NLVM	I I I	MMAG	XEO S
 		1	1	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1						1	† 	; ; ; ; ;	 		; ; !
0.32 ms/m3	4443	557	•	3	0.76	539	5	8.7	0.3	91.0	•	8.	0.23	89.2	•
0.32 ms/m3	4443	•		E 0 E	0.91	4.85	S	13.3	0.3	86.3	•	12.1	0.27	78.8	0
	***		3	3	0.66	336	8	7.6	0.3	90.0	0	6.3	0.26	17.4	0
3.2 mg/m3	777		I	BEC.	0.69	396	8	6.9	0.7	90.0	•	8.3	0.62	1.09	•
	***		I	E0E	1.00	543	11	11.0	1.0	98.0	0	11.0	1.00	0.88	0
3.2 mg/m3	***		1	E0E	1.10	472	-	7.0	0.003	93.0	0	7.7	0,0033	102.3	•
3.2 mg/m3	***		I	EOE	1.20	472	7.5	10.3	2.0	87.7	•	12.4	2.40	105.2	0
	7777		3	EC.	0.85	361	83	10.6	•	89.4	0	0.6	•	78.0	•
	***		I	101	1.60	600	1.4	11.0	2.3	87.0	0	17.6	3.68	139.2	•
	***		I	MEC	0.85	265	7.0	7.3	0.3	92.3	•	8.2	0.26	78.8	0
	***		1	EOE	2.00	413	89 80	16.3	0.7	83.1	0	32.6	1.40	166.2	0
	7777		x	REC	1.00	238	7.2	6.3	•	93.7	•	6.3	0	93.7	•
	***	196	I	REC	1.30	478	69	0.8	0.3	91.7	0	10.4	0.39	119.2	0
	4444		I	E 0 E	1.40	457	7.5	12.0	7.0	80.0	•	16.8	9.80	112.0	•
	4444		-	SEC	0.73	623	6.0	9.0	0	95.0	•	3.7	0	69.4	0
	4444		•	EOE	0.99	386	7.6	7.0	3.7	69.3	•	6.9	3.66	88.4	0
	4444		•	REC	0.84	622	9.2	6.7	0	93.3	•	5.6	•	78.4	0
	1111		•	REC	0.62	486	96	7.0	0	92.0	0	€.4	0.62	67.0	0
	4444		L	EOE	1.30	645	9	10.0	2.0	98.0	•	13.0	2.60	114.4	0
	1111			MEC	1.10	452	63	1.0	0.1	88.0	0	12.1	1.10	8.96	0
	1111			E 0 E	0.92	386	63	10.7	0.1	87.0	1.3	£0.	0.92	80.0	1.2
	1111		•	REC	0.84	420	16	10.0	0	90.0	0	4.0	•	75.6	•
	7777		•	EOE	1.60	471	-8	9.9	3.3	91.0	0	9.0	5.28	145.6	0
	7777		L	REC	0.85	425	99	0.7	0.3	92.7	•	0.9	0.26	78.8	0
3.2 mg/m3	1111		L	E 0 E	1.30	365		14.0	0.3	85.7	0	18.2	0.39	111.4	0
	4444	590	•	EOE	0.73	419	9	11.0	1.0	98.0	•	9.0	0.73	64.2	0

5. BRONCHOALVEOLAR LAVAGE FLUID BIOCHEMISTRY DATA

<u>,</u>	!		0	_	_	_	_			••		_		۵.				٠.	_	_	_	_			
TPROL		1.67	1.70	1.70	7.	1.20	1.69	2.01		2.26			1.85	0.62	1.67	1.67	1.07	1.72	0.80	0.50	1.03	0.99	0.95	1.81	1.95
LDHL		~	1588	4	196	828	4	∞	84	2926	747	1172	774	587	1474	2550	507	585	281	231	836	529	494		314
ALKPL		372	502	568	323	392	432	57	283	888	427	349	515	225	457	604	306	365	288	246	327	256	320	430	310
BGLUL		0.38	7	0	1.51	1.26	2.27	0.89	2.39	4.79	1.13	2.52	2.05	1.21		2.82	~			1.21		0.81	1.11	1.62	1.62
SAC		EOE	EOE	EOE	REC	REC	REC	EOE	REC	REC	EOE	REC	EOE	REC	EOE	EOE	REC	EOE	REC	REC	REC	REC	EOE	EOE	EOE
AN IMAL SEX		Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Σ	Ŀ	L	ഥ	L	L	Ŀ	L	Ŀ	L.	u.	L	Ŀ
ANIMAL		038	043	046	048	020	051	052	055	056	059	090	061	541	547	548	550	554	555	260	562	563	564	570	571
EXPT. NUMBER		4371	က	4371	4371	4371	n	4371	4371			4371	4371	4371	4371		4371	4371	4371	B		4371		4371	4371
CONCENTRATION OF CU-Zn		1.0 mg/m3								1.0 mg/m3															

CONCENTRATION OF CU-Zn	EXPT. NUMBER	AN IMAL NUMBER	AN I MAL SEX	SAC	BGLUL	ALKPL	LDHL	TPROL
	1	 			1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1		1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
3.2 mg/m3		1	Σ	EOE		4		2.39
3.2 mg/m3	4372	081	Σ	EOE	۲.	Ø		1.85
	4372	085	Σ	EOE	0.89	363	718	1.91
3.2 mg/m3	4372	086	Σ	REC		4	761	1.14
3.2 mg/m3	4372	087	Σ	EOE		489	1563	2.30
.2	4372	060	Σ	EOE		S	1163	2.37
.2 E	4372	092	Σ	REC		269	767	0.75
7	4372	093	Σ	REC		9	687	1.02
8	4372	960	Σ	REC		~	996	
8	4372	100	Σ	EOE		6	2598	
•	4372	111	Σ	REC		4	480	1.60
7	4372	112	Σ	REC	9	Ø	581	0
	4372	576	L.	REC	4	263	430	တ
8	4372	585	L.	REC	Ø	9	793	1.14
.2 E	~	590	IL.	EOE		3	4	1.70
Ņ	4372	598	Ŀ	REC	3.53	3	1812	2.10
Ö	4372	599	Ŀ	EOE	1.71	4	1323	1.48
E		602	LL.	REC	2.02	0	1802	1.01
.2 E	4372	603	L	EOE	1.91	0	1693	1.52
E	4372	604	L.	REC	0.70	196		2
3.2 mg/m3	4372	909	ir.	ш	0.90	188	652	0.86
.2 E	4372	809	L.	0	1.31	9		1.65
3.2 mg/m3	4372	609	ii.	EOE	2.52	401	1621	1.63

CONCENTRATION OF CU-Zn	EXPT.	ANIMAL	ANIMAL	SAC	BGLUL	ALKPL	LDHL	TPROL
10 mg/m3	က		Σ	REC	2.01	286	794	
10 mg/m3	4373		Σ	REC	0	625	B	2.25
	4373	128	Σ	EOE	<u>ө</u>	353		2.87
	~		Σ	EOE	ь.	285	1541	S.
10 mg/m3	4373		Σ	EOE	5.42	235	3	٠
	1		Σ	REC	.5	220	900	1.40
10 mg/m3	4373	135	Σ	REC	0.76	390	971	1.47
			Σ	EOE	8.57	687	4	2.91
	4373		Σ	EOE	ი.	374	<u> </u>	0
	4373	142	Σ	EOE	.5	449	3721	4.06
	1	148	Σ	REC	0	253	591	
	~		Σ	REC	0	205	476	თ.
	4373	_	L	EOE	2.52	262	1802	2.64
	~	-	iL.	REC	ი.	210	978	0
	7	2	L	EOE	9.	231	934	თ
	1	0	L	REC	<u>.</u>	170	498	.5
	4373	628	L.	EOE	12.20	298	2811	3.22
		3	u.	REC	1.21	226	718	0
10 mg/m3	7	3	iL.	EOE	3.73	262	940	0
_	4373	3	Ŀ	EOE	Ġ	373	3892	m
_	1	3	L.	REC	٠.	262	710	
_	7	4	L.	REC	0.50	282	700	1.45
10 mg/m3	4373	643	L	EOE	4	221	813	1.62
10 mg/m3	4373		L	REC	1.62	214	949	

CONCENTRATION OF CU-Zn	EXPT.	ANIMAL	AN IMAL SEX	SAC	BGLUL	ALKPL	LDHL	TPROL
O (SHAM)	4	109	Σ	Ш	1.26	339	566	0.98
O (SHAM)	4442	110	Σ	ш	S	280	486	1.95
O (SHAM)	4442	112	Σ	EOE	5	304	389	Ō
O (SHAM)	4442	114	Σ	REC	2	290	458	œ
O (SHAM)	4442		Σ	EOE	1.64	392	451	1.86
O (SHAM)	4442	122	Σ	EOE	9	300	324	
O (SHAM)	4442	127	Σ	EOE	1.76	394	456	1.62
O (SHAM)	4442	128	Σ	EOE	_	307	189	1.96
O (SHAM)	4442	130	Σ	REC	0.50	391	537	1.64
O (SHAM)	4442	132	Σ	REC	1.26	290	389	
_	4442	136	Σ	EOE	1.26	363	383	7
_	4442	137	Σ	REC	1.01	359	327	2.57
O (SHAM)	4442	509	L	EOE	1.21	106	452	1.43
<u> </u>	4442	513	щ	REC	0.90	204	434	0.94
O (SHAM)	4442	518	Ŀ	REC	2.05	302	489	1.98
O (SHAM)	4442	_	LL.	EOE	1.31	250	412	1.42
O (SHAM)	4442	522	LL.	REC	~	206	358	1.34
_	4442	2	Ŀ	REC	က	194	385	1.13
O (SHAM)	4442		L.	EOE	.6	240	283	1.52
O (SHAM)	4442	3	Ŀ	REC	5	LD.	491	0.86
O (SHAM)		က	L	EOE	0	~	230	
O (SHAM)	4442	G	ıŁ	EOE	2.25	248	588	1.02
O (SHAM)	4442	535	LL.	REC	1.31	-	431	1.51
O (SHAM)	4442	6	ш.	EOE		242	463	1.36

CONCENTRATION OF CU-Zn	EXPT.	AN I MAL NUMBER	ANIMAL	SAC	BGLUL	ALKPL	רסאר	TPROL
•	6443		2	נו נו		•	0	7
	7		E :	ני ני ני			٥ (•
.32 mg	4443		Σ	REC	0.88	4	C	2.47
ი.	4443	145	Σ	EOE	1.13	481	377	1.80
.32 mg	4443	146	Σ	EOE	3.53	323	480	1.40
რ.	4443	147	Σ	REC	1.63	256	308	1.99
.32 mg	4443	148	Σ	EOE	1.51	396	476	1.30
0.32 mg/m3	4443	150	Σ	REC	9	257	420	0.28
.32	4443	151	Σ	REC		364	546	1.88
.32 mg	4443	154	Σ	EOE	1.13	273	413	1.39
.32	4443	156	Σ	EOE	0	426	554	1.86
.32 mg	4443	158	Σ	REC	2.26	389	543	2.52
.32	4443	159	Σ	EOE	_	221	280	1.14
. 32	4443	4	ıL	REC		183	514	
.32	4443	542	LL.	EOE	1.01	274	301	0.87
.32	4443	545	L.	REC	0.80	231	374	1.92
.32	4443	4	LL.	EOE	1.21	288	338	1.19
.32	4443	4	L	EOE	1.01	320	407	1.57
ი.	4443	548	LL.	REC	1.61	302	459	1.98
.32	4443	551	IL.	EOE	1.91	308	267	0.93
ი.	4443	552	L	REC	1.31	215	496	1.22
.32	4443	555	ш	EOE	3.22	291	324	1.10
.32 mg	4443	556	Ŀ	REC	06.0	198	375	
.32 mg	4443	S	iL.	REC	4	262	505	
0.32 mg/m3	4443	260	Ŀ	EOE	0.61	256	450	1.07

CONCENTRATION OF CU-Zn	EXPT. NUMBER	ANIMAL	ANIMAL	SAC	BGLUL	ALKPL	LDHL	TPROL
8	4444	171	Σ	REC	1.76	244	389	1.90
•	4444	173	Σ	REC	1.51	237	502	1.56
8	4444	175	Σ	EOE	1.64	366	705	1.76
ä	4444		Σ	EOE	1.76	410	506	1.32
8	4444	182	Σ	EOE	1.01	175	795	1.32
8	4444	184	Σ	REC	0.63	258	438	1.30
3.2 mg/m3	4444	187	Σ	EOE	1.26	388	501	2.11
ņ	4444	188	Σ	REC	Θ.	217	269	0.95
8	4444	190	Σ	EOE	0.38	683	702	1.77
8	4444	195	Σ	REC	1.13	261	559	1.45
8	4444	196	Σ	REC	1.39	341	577	2.08
Ö	4444	197	Σ	EOE	0.88	507	489	2.00
'n	4444	569	L	REC	1.41	191	461	1.10
7	4444	574	ıL	EOE	1.21	328	526	1.13
Ņ	4444	576	L.	REC	1.06	163	374	0.81
Ņ	4444	577	ıL	REC	0.80	150	298	1.17
Ņ	4444	578	Ŀ	EOE	1.41	378	346	1.06
7	4444	580	Ŀ	REC		118	346	1.27
8	4444	581	IL.	EOE	1.11	303	255	1.24
3.2 mg/m3	4444	582	ır	REC	4	194	286	1.29
'n	4444	583	L	EOE	3.42	809	996	2.29
۲,	4444	B	Ŀ	REC	1.01	202	371	1.15
3.2 mg/m3	4444	586	IL.	EOE	1.62	362	169	1.36
7	4444	290	L.	EOE	1.01	240	295	1.09

6. DATA FOR BRONCHOALVEOLAR LAVAGE FLUID CONTENT OF COLLAGEN

ш	EXPT	ANIMAL	ANIMAL	SAC	i	kg BODY WT
of Cu-zn	NUMBER	NUMBER	SEX	CODE	LUNG (ug/g)	(ug/kg)
1.0 mg/m3	4371	038	MALE	EOE	38.84	169.5
E	4371	043	MALE	EOE	63.77	289.9
	4371	046	MALE	EOE	55.44	241.1
	4371	052	MALE	EOE	39.22	188.4
Ē	4371	059	MALE	EOE	45.33	224.4
E	4371	061	MALE	EOE	47.96	217.5
1.0 mg/m3	4371	547	FEMALE	EOE	102.88	529.1
E	4371	548	FEMALE	EOE	75.52	409.7
	4371	554	FEMALE	EOE	87.88	378.3
	4371	564	FEMALE	EOE	49.96	262.7
	4371	570	FEMALE	EOE	80.85	451.2
	4371	571	FEMALE	EOE	74.92	399.2
	4371	048	MALE	REC	107.84	456.3
E	4371	020	MALE	REC	65.68	250.0
	4371	051	MALE	REC	70.04	280.7
Ē	4371	055	,ALE	REC	37.62	155.4
	4371	056	MALE	REC	83.11	329.2
E	4371	090	MALE	REC	75.68	284.8
	4371	541	FEMALE	REC	41.89	217.4
Ē	4371	220	FEMALE	REC	36.09	180.8
E	4371	555	FEMALE	REC	61.25	307.7
BE	4371	260		REC	62.02	301.6
1.0 mg/m3	4371	562	FEMALE	REC	68.26	367.2
	4371	563	FEMALE	REC	107.04	544.3

COLLAGEN IN LUNG PER:

ш		ANIMAL	ANIMAL	ANIMAL SACRIFICE		kg BODY WT
of Cu-Zn	NUMBER	NUMBER	SEX	CODE	LUNG (ug/g)	(ug/kg)
	1					
3.2 mg/m3	4372	075	MALE	EOE	43.11	190.3
E	4372	081	MALE	EOE	70.73	319.3
8	4372	085	MALE	EOE	41.00	185.3
7	4372	087	MALE	EOE	53.93	230.8
7	4372	060	MALE	EOE	53.60	235.5
8	4372	100	MALE	EOE	71.34	312.4
3.2 mg/m3	4372	590	FEMALE	EOE	57.34	297.3
8	4372	599	FEMALE	EOE	75.58	394.1
ÿ	4372	603	FEMALE	EOE	66.74	353.4
3.2 mg/m3	4372	809	FEMALE	EOE	43.94	237.7
3.2 mg/m3	4372	609	FEMALE	EOE	80.32	414.8
Ö	4372	086	MALE	REC	58.08	227.3
8	4372	092	MALE	REC	74.34	263.3
Ö	4372	093	MALE	REC	82.53	322.1
7	4372	960	MALE	REC	72.75	285.5
ä	4372	111	MALE	REC		268.0
8	4372	112	MALE	REC	49.65	189.8
8	4372	576	FEMALE	REC	51.79	263.3
8	4372	585	FEMALE	REC	49.21	232.0
ä	4372	298	FEMALE	REC	63.05	298.6
•	4372	602	FEMALE	REC	84.96	439.2
8	4372	604	FEMALE	REC	52.54	278.4
3.2 mg/m3	4372	909	FEMALE	REC	61.99	309.8

COLLAGEN IN LUNG PER:

)	
CONCENTRATION of CU-Zn	EXPT	ANIMAL	ANIMAL	ANIMAL SACRIFICE SEX CODE	GRAM CONTROL LUNG (ug/g)	kg BODY WT (ug/kg)
1 1 1 1 1 1 1 1 1	; ; ; ; ; ; ;	; { { { { { { { { { { { { { { { { { { {		 		
10 mg/m3	4373	128	MALE	EOE	ь. С	386.7
Ε	4373	130	MALE	EOE	61.28	294.3
E	4373	132	MALE	EOE	78.30	91.
10 mg/m3	4373	136	MALE	EOE	68.61	331.2
	4373	141	MALE	EOE	104.14	•
	4373	142	MALE	EOE	76.01	52.
10 mg/m3	4373	615	FEMALE	EOE	102.16	
	4373	625	FEMALE	EOE	74.56	388.8
	4373	628	FEMALE	EOE	135.90	•
	4373	632	FEMALE	EOE	о О	440.1
	4373	633	FEMALE	EOE	90.04	504.9
	4373	643	FEMALE	EOE		
E	4373	122	MALE	REC		•
E	4373	127	MALE	REC	67.35	270.2
E	4373	134	MALE	REC		204.0
	4373	135	MALE	REC		54.
	4373	148	MALE	REC		218.8
	4373	149	MALE	REC		128.7
	4373	616	FEMALE	REC	•	283.7
	4373		FEMALE	REC	•	308.7
	4373	631	FEMALE	REC	69.00	356.6
	4373	639	FEMALE	REC	69.32	351.4
	4373	642	FEMALE	REC	54.77	306.9
	4373	650	FEMALE	REC	58.68	311.1

COLLAGEN IN LUNG PER:

			,		- 1	
CONCENTRATION of Cu-Zn	EXPT	AN MAL NUMBER	ANIMAL	ANIMAL SACRIFICE SEX CODE	GRAM CONTROL LUNG (ug/g)	kg BODY WT (ug/kg)
! ! ! ! ! ! !	; - - - - - -	; { { { { { { { { { { { { { { { { { { {	, , , , , , ,	1	 	
O (SHAM)	4442	112	MALE	EOE	38.78	165.8
O (SHAM)	4442	119	MALE	EOE	44.39	195.5
O (SHAM)	4442	122	MALE	EOE	34.84	146.6
O (SHAM)	4442	127	MALE	EOE	42.19	176.6
O (SHAM)	4442	128	MALE	EOE	30.24	130.1
O (SHAM)	4442	136	MALE	EOE	44.31	183.7
O (SHAM)	4442	609	FEMALE	EOE	43.69	225.3
O (SHAM)	4442	519	FEMALE	EOE	59.39	297.0
O (SHAM)	4442	526	FEMALE	EOE	65.85	349.3
O (SHAM)	4442	531	FEMALE	EOE	51.72	257.7
O (SHAM)	4442	533	FEMALE	EOE	Ŋ	238.5
O (SHAM)	4442	538	FEMALE	EOE	44.17	230.7
O (SHAM)	4442	109	MALE	REC	6	133.5
O (SHAM)	4442	110	MALE	REC		132.7
O (SHAM)	4442	114	MALE	REC	41.70	148.9
O (SHAM)	4442	130	MALE	REC	40.51	136.2
O (SHAM)	4442	132	MALE	REC	36.46	120.4
O (SHAM)	4442	137	MALE	REC	43.84	151.1
O (SHAM)	4442	513	FEMALE	REC	•	175.1
O (SHAM)	4442	518	FEMALE	REC	57.48	259.7
O (SHAM)	4442	522	FEMALE	REC	40.18	191.5
O (SHAM)	4442	523	FEMALE	REC	0.3	ω
O (SHAM)	4442	3	FEMALE	REC	87.18	423.9
O (SHAM)	4442	535	FEMALE	REC	57.93	272.7

COLLAGEN IN LUNG PER:

CONCENTRATION	EXPT	ANIMAL	ANIMAL	ANIMAL SACRIFICE	GRAM CONTROL	kg BODY WT
of Cu-Zn	NUMBER	NUMBER	SEX	CODE	LUNG (ug/g)	(ug/kg)
,						
რ.	6. 6.	145	MALE	EOE	56.46	243.1
ь.	4443	146	MALE	EOE	52.88	221.3
<u>ن</u>	4443	148	MALE	EOE	42.18	177.0
ь.	4443	154	MALE	EOE	42.96	187.4
ь.	4443	156	MALE	EOE	52.36	217.4
ь.	4443	159	MALE	EOE	32.99	142.5
.32 mg/m	4443	542	FEMALE	EOE	46.64	224.7
.32 mg/m	4443	546	FEMALE	EOE	54.62	283.0
.32	4443	547	FEMALE	EOE	61.36	333.6
.32 mg/m	4443	551	FEMALE	EOE	40.60	194.9
0.32 mg/m3	4443	555	FEMALE	EOE	48.50	252.1
.32 mg	4443	260	FEMALE	EOE	_	276.1
.32	4443	140	MALE	REC	51.52	183.0
.32	4443	142	MALE	REC	75.72	260.6
.32	4443	147	MALE	REC	51.65	180.6
რ.	4443	150	MALE	REC	40.09	157.3
. 32	4443	151	MALE	REC	43.74	153.9
რ.	4443	158	MALE	REC	163.19	583.7
რ.	4443	541	FEMALE	REC	54.06	277.3
რ.	4443	545	FEMALE	REC	51.00	225.8
.32 m	4443	548	FEMALE	REC	66.80	301.0
.32 m	4443	Ŝ	FEMALE	REC	44.35	211.8
რ.	4443	556	FEMALE	REC	48.06	236.5
0.32 mg/m3	4443	222	FEMALE	REC	46.96	221.9

COLLAGEN IN LUNG PER:

	NUMBER	NUMBER	SEX	ANIMAL SACRIFICE SEX CODE	GRAM CONTROL LUNG (ug/g)	kg BODY WT (ug/kg)
	444	175	MALE	EOE	41.67	171.3
E	4444		MALE	EOE		209.1
.2 mg	4444	187	MALE	EOE	50.66	214.4
.2 mg	4444	190	MALE	EOE	3	216.3
•	4444	197	MALE	EOE	42.32	181.0
.2 mg	4444	574	FEMALE	EOE	8	327.8
.2 mg	4444	578	FEMALE	EOE	6.2	300.5
.2 mg	4444	581	FEMALE	EOE	57.68	298.7
8	4444	583	FEMALE	EOE	8.0	361.6
.2 mg	4444	586	FEMALE	EOE	ω.	ဖ
.2 mg	4444	590	FEMALE	EOE	36.06	181.6
'n	4444	171	MALE	REC		137.1
.2 mg	4444	173	MALE	REC	46.64	165.0
.2 mg	4444	184	MALE	REC	32.69	118.7
.2 mg	4444	188	MALE	REC	46.36	167.6
Ņ	4444	195	MALE	REC	50.15	176.9
.2 mg	4444	196	MALE	REC	43.10	150.7
'n	4444	569	FEMALE	REC	43.13	202.1
•	4444	576	FEMALE	REC	۲.	204.8
.2 mg	4444	577	FEMALE	REC	45.99	218.7
.2 mg/m	4444	580	FEMALE	REC	<u>о</u>	301.0
.2 mg/m	4444	582	FEMALE	REC	40.35	187.7
E	4444	585	FEMALE	REC	49.20	234.5

DATA FOR TOTAL COLLAGEN CONTENT OF LUNG

					1			
CONCENTRATION of Cu-Zn	EXPT NUMBER	AN IMAL NUMBER	ANIMAL	SACRIFICE	BODY WEIGHT IN GRAMS	VEIGHT IN GRAMS	mg/g CONTROL LUNG	mg/kg Boby Weight
			3	9	320.6	06.1	17.20	75.91
	2/54	n -	MAL 6		3.8	1.60	20.97	94.64
	4372	- 4	MALE	101	313.0	1.29	18.58	83.98
3.5 mg/m ²	4372		MALE	E 0 E	322.1	1.37	17.03	74.82
•	6373	-	MAIF	£0£	323.1	1.47	19.49	85.38
3.5 mg/m3	4373		FEMALE	EOE	192.8	1.05	16.95	87.92
•	4372	•	FEMALE	E0E	191.8	1.19	19.84	103.47
	4372	609	FEMALE	E0E	188.9	1.08	18.34	97.11
	4372	80 9	FEMALE	101	184.9	0.88	16.23	87.81
• •	4372	60 G	FEMALE	E0E	193.7	1.05	16.35	84.41
	4373	122	MALE	38.0	360.1	1.52	17.52	62.97
	4373	127	MALE	360	322.6	1.39	12.81	51.39
	4373	128	MALE	E0E	304.9	1.86	19.74	91.63
	4373		MALE	E 0 E	294.7	1.59	16.13	77.44
	4373	761	MALE	200	335.2	1.67	22.09	85.29
	4373	50.	MALE) H	324.1	1.30	15.26	60.94
	4373	98	MALE	EOE	293.1	1.4.	19.14	92.42
	4373		MALE	E0 E	312.0	1.73	20.91	94.81
	4373		MALE	E 0 E	304.8	1.62	17.95	83.32
	4373		MAIR	. E	322.4	1.36	10.02	83.93
	4373	· ·	FEMALE	E0E	182.6	1.25	21.47	117.60
	4373		FEMALE	386	192.1	0.93	18.19	92.61
	4373	6.27	FEMALE	3 2 2	186.8	1.15	12.04	62.32
				202	476.0	1.31	21.96	125.46

					3		1	
20.148	FXPT	ANIMA	ANIMAL	SACRIFICE	WEIGHT	WEIGHT	mg/g CONTROL	mg / kg
of Cu-Zn	NUMBER	NUMBER	SEX	CODE	IN GRAMS	IN GRAMS	LUNG	BODY WEIGHT
	1		; ; ; ;		1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	1	· · · · · · · · · · · · · · · · · · ·	
(m) on 01	4373	632	FEMALE	EOE	179.6	0.72	13.23	73.57
	4373	•	FEMALE	EOE	178.3	1.24	20.02	112.53
	£3.53	9 F	FEMALE	REC	192.7	06.0	19.10	96.81
	4373	542	FEMALE	3	174.3	0.89	16.62	87.55
	4373	6 43	FEMALE	EOE	175.4	1.09	18.23	103.96
	4373	6 50	FEMALE	REC	184.3	1.16	21.56	114.33
•	4442	110	MALE	REC	372.5	1.24	16.62	57.73
•	4442	6	MALE	EOE	321.2	1.29	14.12	62.21
-	4442	128	MALE	EOE	326.9	1.43	15.38	66.18
_	4442	132	MALE	REC	392.0	1.35	19.80	65.37
_	4442	136	MALE	EOE	341.3	1.24	17.67	73.23
-	4442	137	MALE	REC	375.4	1.20	11.83	40.78
	4442	519	FEMALE	EOE	200.0	1.21	21.52	107.59
· ~	4442	522	FEMALE	REC	205.0	0.94	17.78	84.75
_	4442	523	FEMALE	REC	206.3	0.87	18.47	87.46
_	4442	533	FEMALE	EOE	190.7	0.89	15.12	79.28
_	4442	538	FEMALE	REC	207.6	0.98	20.79	97.86
(SHAM)	4442	538	FEMALE	E0E	191.4	0.97	19.29	100.77
^ ~	4444	176	MALE	EOE	344.2	1.49	16.55	68.03
. "	4444	180	MALE	£0£	325.5	1.62	26.42	114.87
	***	182	MALE	EOE	323.8	1.64	18.10	79.09
	4444	187	MALE	EOE	334.3	1.35	18.96	80.26
	4444	190	MALE	EOE	324.3	1.29	16.31	71.17
	4444	574	FEMALE	E0E	195.9	1.05	21.00	107.17
	4444	581	FEMALE	EOE	193.1	1.19	20.43	105.79
	***	583	FEMALE	EOE	195.8	0.98	20.59	105.20
	444	5.06	FEMALE	£0£	199.4	1.00	18.64	93.51
: 1	• • •			1		•	30 41	- C - C - C - C - C - C - C - C - C - C

APPENDIX F: ATOMIC ABSORPTION ANALYSIS RESULTS FOR INDIVIDUAL ANIMALS

					9 20 3	Š	MICHOGRAPHS MEINE IN LONG				
CONCENTRATION	EXPT	ANIMAL	ANIMAL	SACRIFICE CODE	WEIGHT IN GRAMS	20	Zn	Cu+Zn	20	Zn	Cu+Zn
				1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1			1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1		; ; ; ; ;		
	;	•	3	9	-	6	26.8	29.8	2.59	23.3	26.0
O (SHAM)	0/64	6 I	E 2				21.3	23.5	1.91	18.4	20.3
_	4370	· · ·	E 3	,			27.5	29.4	1.63	23.8	25.6
	9/64) ·	E 3	101		2.57	21.9	24.4	2.23	19.0	21.2
_		9 4	. 3			20.0	28.0	28.1	1.60	22.6	24.4
O (SMAM)	9/64	670	. 3			7.0.1	28.3	30.2	1.71	24.5	28.2
O (SHAM)		670	Ew			2.73	24.7	27.4	3.07	27.8	30.
				, ,		1.67	21.9	23.6	1.88	24.6	26.8
_			. 4	E C E		2.75	21.7	24.5	3.09	24.4	27.5
			. 4	E 0.F	6	1,14	19.8	21.0	1.28	22.3	23.6
	27.0		- 44	303	69.0	06.1	21.1	23.0	2.14	23.7	25.8
(MARC) D	77.0	3 P S		E0E	69.0	1.53	25.3	26.8	1.72	28.4	30.2
(MARC) 0	4375	. 40	. 2	E06	0.99	2.04	26.8	28.7	2.06	26.9	28.9
	7373	1,40	*	#0#	1.14	2.33	21.7	24.1	2.04	19.1	21.1
		440	: 3	E0E	1.05	1.33	25.8	26.9	1.27	24.3	25.6
			.	E0E	0.99	2.52	25.5	28.0	2.55	25.7	28.3
	4371	042	.	3 2 2	1.12	1.13	19.2	20.3	1.01	17.1	18.1
	4371		.	SEC.	1.16	1.10	20.8	21.9	96.0	17.9	16.9
	4371	0.73	3	200	-:-	0.69	18.7	19.4	0.61	16.4	17.0
	4371	. e		EOE	0.98	1.11	13.5	15.2	1.81	13.7	15.8
	4371			EOE	0.76	1.05	12.8	13.8	1.38	16.8	18.2
	4371	8.74		EOE	0.76	1.12	20.3	21.4	1.47	26.7	28.2
	4371	. 4		360	0.78	0.62	16.6	17.3	0.79	21.3	22.1
	4371	15	L	REC	0.85	1.33	18.5	19.9	1.56	21.8	23.4
C		, ,			•	,	4 61		1.33	23.8	24.9

				,	CENC	3049 IM	MICHOGRAMS METAL			PION PARTIE SECTIONS	
U L	RXPT	ANIMAL	SEX	SACRIFICE	WEIGHT IN GRAMS	30	Z 2	Cu+2n		22	Cu+2n
	4373	977	3	<u> </u>	1.12	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	22.2	26.5	2.99	19.6	22.8
3.2 me/m3	4372		: 2	E 0 E	1.09	4.05	18.6	22.9	3.72	17.3	21.0
	4372	460	Ξ.	EOE	1.12	2.08	23.7	25.8	1.88	21.2	23.0
	4372	160	I	EOE	1.09	1.97	22.6	24.4	1.81	20.6	22.4
	4372	070	I	REC	1.17	2.43	20.4	22.9	2.08	17.6	19.6
	4372	990	1	REC	1.12	1.22	19.0	20.2	1.09	16.9	16.0
	4372	106	2	REC	1.11	1.06	17.4	18.4	96.0	18.7	16.6
	4372	101	I	REC	1.06	1.38	19.6	20.9	1.30	10.6	19.6
	4372	80 80 80	•	EOE	99.0	1.71	24.2	25.9	1.99	28.1	30.1
	4372	896		EOE	0.87	1.48	17.2	18.7	1.67	19.8	21.8
	4372	897		EOE	99.0	1.93	19.4	21.3	2.24	22.8	24.8
	4372	877	•	REC	0.83	0.87	16.7	17.5	1.05	20.1	21.1
	4372	5.83	•	REC	96.0	0.76	17.6	18.4	0.79	18.3	1.6.
	4372	589		MEC	08.0	1.11	14.4	15.6	1.39	1.8.1	19.4
	4372	610		REC	0.83	1.15	15.1	16.3	1.39	18.2	19.6
10 mg/m3	4373	120	I	EOE	1.33	2.59	23.0	25.6	1.95	17.3	19.2
10 mg/m3	4373	121	1	EOE	1.39	3.65	19.8	23.4	2.63	14.2	16.8
10 mg/m3	4373	123	1	EOE	1.23	1.98	20.3	22.3	1.61	16.5	1.8.1
10 mg/m3	4373	137	I	EOE	1.41	3.20	31.1	34.3	2.27	22.1	24.3
10 mg/m3	4373	115	I	REC	1.30	2.18	20.3	22.5	1.68	15.6	17.3
10 mg/m3	4373	129	I	REC	1.17	96.0	1.02	21.0	0.81	17.1	18.0
10 mg/m3	4373	131	1	REC	1.08	1.66	17.8	19.2	1.53	16.3	17.8
10 mg/m3	4373	138	1	REC	1.15	1.19	21.0	22.2	1.03	18.3	19.3
10 mg/m3	4373	621		EOE	9.95	2.00	20.1	22.1	2.11	21.1	23.2
10 mg/m3	4373	637	•	E 0 E	66.0	1.37	26.4	27.6	1.38	26.7	28.0
10 mg/m3	4373	641	•	EOE	1.02	1.64	17.1	18.7	1.61	16.8	18.4
10 mg/m3	4373	649	L	E 0 E	1.01	2.04	17.3	19.3	2.07	17.1	1.61
10 mg/m3	4373	619	•	MEC	0.92	1.31	17.0	19.1	1.42	19.3	20.8
10 mg/m3	4373	622		REC	0.65	0.64	16.5	17.1	0.78	19.4	20.1
10 mg/m3	4373	645	u.	REC	1.16	0.73	18.7	16.5	0.63	13.6	14.2
10	1111	***	•	200	9.84	1.21	15.7	17.0	1.44	18.7	20.5

Mote: For the sham-exposed rats which died prior to the last exposure lung weights used for calculation purposes were the means of the exposed rats for males and females, respectively.

1.03 1.10 1.02 1.0 0.80 0.68 1.04 0.92 0.94 0.85 0.63 0.94 0.85 0.78 \$111 1.25 9.96 0.58 0.90 0.74 1.1 1.02 99.0 1.0 0.59 0.94 1.00 1.24 0.65 0.49 0.92 0.81 0.80 96.0 1.24 8.0 4.7 7. 4.3 *. 4.2 . EF 13 74.8 87.8 85.5 86.2 61.9 83.4 69.2 87.9 83.3 54.7 62.9 77.9 80.5 64.9 64.3 68.7 78.7 FEF 7.07 82.0 13.2 83.7 8.001 101.4 116.6 109.4 96.8 108.0 100.0 104.2 109.8 116.0 115.5 117.8 122.5 111.2 108.0 101.6 124.6 11.0 108.9 110.8 110.3 102.6 118.2 99.9 109.8 124.0 901 112.8 116.9 113.4 110.6 0.00 102.1 PEFA FEV1 69 . 7.2 73 20 63 7 FVC 10.2 . 11.0 11.5 10.3 11.2 1.5 11.7 11.6 1.4 11.4 10.9 1.3 1.6 10.6 1.6 1.6 10.8 10.5 10.9 --9.3 10.3 10.4 11.6 11.3 10.2 10.6 11.6 10.7 11.1 11.6 0.23 0.23 0.23 0.22 0.22 0.21 0.21 0100 0.18 0.24 0.24 0.21 0.19 0.22 0.23 0.24 0.24 0.21 0.17 0.17 0.17 0.20 0.24 0.22 0.21 0.21 0.18 0.23 0.18 0.21 <u>.</u> .. 2 0.2 9. *: • 2.2 2 .. 3.1 2.3 1.7 2.1 -. : • • ~ <u>.</u> _ = -2.0 3.9 3.3 FRC 2.0 2.9 2.7 2.2 2.7 2.7 8.2 2.9 7.0 2.9 2.4 2.2 2.3 2.3 2.7 RESULTS FOR INDIVIDUAL ANIMAL PULMONARY FUNCTION EVALUATIONS 9. 2.9 2.7 3.3 2.7 2.6 3.1 2.2 2.7 11.0 11.2 10.8 9.01 10.9 10.9 8.01 11.2 11.3 11.2 1.1 10.5 6.01 11.3 7.01 11.2 10.2 0.1 0.0 9.0 . **6** 10.6 10.5 11.3 10.5 1:1 10.4 10.5 10.2 9.7 = Š 13.9 13.5 13.1 13.2 12.3 11.1 12.5 11.9 12.2 12.3 12.5 12.9 12.4 12.6 13.0 12.6 . 110 12.5 12.5 12.7 0.68 0.60 0.69 0.77 0.76 0.74 0.78 0.74 0.72 0.73 0.72 0.69 0.74 0.75 0.71 0.70 0.69 0.72 0.69 0.73 0.74 0.67 0.70 0.11 0.64 0.77 0.72 CCORD 0.71 0.71 9.14 0.03 0.08 9.19 0.15 0.24 0.14 0.29 0.14 9.10 0.13 0.14 0.16 0.12 0.16 9.14 60.0 0.19 0.14 0.15 0.17 0.14 0.14 0.14 0.22 0.14 0.17 0.17 0.61 0.21 0.57 Ę 0.50 0.42 0.34 0.47 0.50 0.44 0.45 17.0 0.51 0.43 0.32 CDYN 0.49 0.63 0.63 0.43 0.51 0.27 0.35 4.0 0.72 0.49 0.38 0.63 0.63 0.55 0.33 0.47 17.0 91.7 75.9 73.0 70.2 71.7 64.7 85.8 81.1 68.1 88.7 78.2 84.1 90.8 83.4 98.4 52.7 67.2 90.0 72.9 88.8 74.7 92.1 74.9 89.4 8.4.8 9.98 83.8 83.8 ž EXPT ANIMAL GRAMS 276 177 201 272 . 278 278 174 271 9 2 274 287 295 285 276 275 283 290 284 271 280 11 9 77 81 660 523 017 026 027 039 9 9 0 6 9 0 120 074 082 860 0.0 80 100 = 124 139 5 145 = 50 603 809 621 622 023 -0 \$ 7 0.83 084 034 047 4372 4372 1372 1372 1372 1372 1373 1373 1373 1373 4373 1373 1373 1373 1370 1370 1370 4372 1372 1370 1370 1370 1370 1371 1111 1370 1370 1370 1111 1371 1261 1371 1371 4371 APPENDIX G: BASE-1 BASE-1 1-38 F 14 SE-1 BASE-1 145E-1 1ASE-1 BASE-1 BASE-1 148E-1 14 SE-1 145E-1 1-35 V 143E-1 BASE-1 BASE-1 BASE-1 BASE-1 3ASE-1 14 SE-1 14 SE-1 14 SE-1 38 E-1 BASE-1 DA 3E-1 BASE-1 14 SE-1 BASE-1 143E-1 BASE-1 3ASE-1 38 E-1 BASE-1 BASE-1 1-38 V 1A SE-1 TIME

Ì

15	EXPT ANIMAL GRAMS					֡	****				1 1 1 1 1 1						
66.4 67.2 <th< td=""><th></th><th></th><td>1</td><td></td><td></td><td>6</td><td>•</td><td>•</td><td>,</td><td>9</td><td>41.</td><td>~</td><td></td><td></td><td></td><td>9.</td><td>6.82</td></th<>			1			6	•	•	,	9	41.	~				9.	6.82
67.2 0.24 0.49 10.1 0.2 1.5 0.14 0.17 0.2 0.24 0.24 0.24 0.24 0.24 0.24 0.24 0.24 0.24 0.24 0.25 0.24 0.24 0.25 0.24 0.24 0.25 0.25 0.24 0.25 0.24 0.	-			0.30		99.0	0.0		7.7	6.	0.13		6.	106.3	77.2		0.0
8.6 6.2 6.2 6.2 6.2 6.1 6.2 6.1 6.2 6.1 6.2 <th></th> <th>_</th> <td>65.2</td> <td>0.24</td> <td></td> <td>0.49</td> <td>10.1</td> <td>9.0</td> <td>2.4</td> <td>3.5</td> <td>0.14</td> <td>-:</td> <td>16</td> <td>92.4</td> <td>69.8</td> <td>9.</td> <td>0.68</td>		_	65.2	0.24		0.49	10.1	9.0	2.4	3.5	0.14	-:	16	92.4	69.8	9.	0.68
68.4 0.42 0.42 0.42 0.43 0.44 0.65 0.67 0.66 0.7 1.7 0.9 0.16 9.1 9.6 0.1 0.16 9.1 0.6 0.1 0.16 0.1 0.1 0.16 0.1	17	_	80.4	0.28		0.59	10.4	9.2	2.2	1.2	0.17	6.3	20	74.6	10.8	2.6	1.14
1.6. 0.40 0.08 0.70 1.6 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.16 0.17 77 0.16 0.17 77 0.16 0.17 77 0.16 0.17 77 0.16 0.17 77 0.16 0.17 0.16 0.17 77 0.16 0.17 77 0.16 0.17	17		68.4	0.42	0.53	0.87	9.6	6.7	1.7	6.0	0.16	8.8	7.4	99.9	88.4	4.0	0.73
78.2 0.28 0.28 0.29 0.28 0.29 0.10 <th< td=""><th>17</th><th>_</th><td>89.8</td><td>0.40</td><td></td><td>0.60</td><td>9.3</td><td>8.7</td><td>9.</td><td>9.0</td><td>0.18</td><td>9.1</td><td>7.9</td><td>105.7</td><td>76.4</td><td>6.1</td><td>1.04</td></th<>	17	_	89.8	0.40		0.60	9.3	8.7	9.	9.0	0.18	9.1	7.9	105.7	76.4	6 .1	1.04
18.1 0.12 0.12 0.66 11.1 9.1 2.0 11.1 9.1 2.0 11.1 9.1 2.0 11.0 0.15 0.15 0.60 11.1 0.15<	Ξ	1	76.3	0.26		0.56	9.6	9.0	5 . 0	1.2	0.18	.	83	111.4	83.0	8.8	1.10
76.6 9.27 0.61 9.7 7.7 96.9 9.4 4.0 9.0	Ξ	=	78.2	0.38	0.12	09.0	1.1	9.1	7.0	2.0	0.16		8 2	108.1	90.7		1.32
66.4 0.17 0.65 9.4 9.4 2.0 1.0 0.12 8.7 78 94.4 71.1 4.7 86.6 0.00 0.02 10.6 9.4 2.1 1.1 0.15 10.1 7.7 11.4 6.5 10.1 10.5 9.0 2.6 1.7 0.15 9.2 47 7.7 11.4 7.7 11.4 6.5 9.0 9.0 2.6 1.7 0.15 9.2 47 7.7 11.4 11.4 7.7 11.4 6.5 9.0 9.0 9.0 1.2 1.7 0.15 9.2 47 7.7 11.4 9.2 47 9.7 1.4 1.2 1.1 0.15 9.2 1.0 1.0 9.0 1.0 9.0 1.0 9.0 1.0 9.0 1.0 9.0 1.0 9.0 1.0 9.0 1.0 9.0 1.0 9.0 9.0 9.0 9.0 9.0 9.0 9.0 9.0	Ξ	•	76.9	0.27		0.57	8.6	8.3	2.3	1.6	0.16	9.7	11	95.9	68.3	.	1.18
85.6 0.66 0.64 0.63 10.6 3.4 2.1 1.1 0.15 10.1 74.6 11.4 74.6 11.4 74.7 11.4 74.7 11.4 74.7 11.4 11.8 0.2 47.7 11.9 11.	-	9	88.4	0.38		0.55	4.6	9 .	2.0	0.	0.12	8.7	7.0	94.4	1.17	4.7	0.80
77.3 0.29 0.25 0.26 10.0 0.2 2.6 1.7 0.14 6.5 37 47.7 19.1 1.9 0.8 10.0 0.2 1.7 0.16 0.2 47.7 19.1 19.8 0.2 0.2 1.7 0.16 0.2 47.7 19.1 19.2 0.1 0.2 0.1 0.2 0.1 0.2 0.1	Ξ	2	85.6	09.0	∹	0.63	10.5	4.6	2.1	-:	0.15	10.1	7.5	111.4	74.6	9.0	0.80
66.6 6.25 0.25 0.62 10.6 9.0 2.6 1.7 0.15 9.2 47 79.4 1.5 0.16 9.6 10.6 9.6 9.7 10.6 9.6 9.7 10.6 9.6 9.7 10.6 9.6 9.7 10.6 9.6 9.7 10.6 9.6 9.7 10.6 9.7	Ξ	82	73.3	0.29		0.53	10.0	8.2	2.6	1.7	0.14	8.8	37	47.7	19.1		0.93
96.5 0.22 0.24 0.54 9.2 2.0 1.2 0.16 6.6 79 100.1 63.5 6.1 66.0 0.37 0.15 0.54 9.3 6.2 2.3 1.1 0.15 6.6 79 100.1 6.6 82.5 6.7 6.0 9.7 100.1 6.6 82.2 73.3 6.7 82.2 73.3 8.7 70.1 82.2 73.3 8.7 73.3 8.7 73.3 8.7 73.3 8.7 73.3 8.7 73.3 8.7 73.3 73.3 73.3 73.3 73.3 73.3 73.3 73.3 73.3 73.3 73.3 74.4 73.3 74.4 74.5 74.4 74.5 74.4 74.5 74.4 74.5 74.4 74.5 74.4 74.5 74.4 74.5 74.4 74.5 74.4 74.5 74.4 74.5 74.4 74.5 74.4 74.5 74.4 74.4 74.4 74.4	_	2	65.8	0.35	0.23	0.62	10.6	9.0	2.5	1.7	0.15	9.2	41	19.4	15.5	8.0	1.02
60.0 0.31 0.15 0.54 9.3 9.1 1.1 0.15 9.6 79 100.1 65.6 9.7 1.0 0.15 9.7 1.0 0.15 9.7 1.0 0.15 9.7 9.1 9.1 2.4 1.3 0.15 9.4 9.1 2.0 1.0 95.2 <	-	0	96.5	0.32	0.20	0.57	. s	6.3	2.0	1.2	0.16	8.6	7 0	104.8	83.5	.	1.38
56.6 0.37 0.16 0.62 10.3 9.1 2.4 1.3 0.15 9.4 60 102.0 95.4 85.6 85.6 85.6 85.6 85.7 74 95.4 95.4 95.4 95.4 97.1 1.0 0.17 0.4 95.4 85.8 <th>-</th> <th>11</th> <td>80.0</td> <td>0.31</td> <td>0.15</td> <td>0.54</td> <td>9.3</td> <td>8.2</td> <td>2.3</td> <td>-:</td> <td>0.15</td> <td>8.5</td> <td>7.9</td> <td>1001</td> <td>69.6</td> <td>8.2</td> <td>1.42</td>	-	11	80.0	0.31	0.15	0.54	9.3	8.2	2.3	-:	0.15	8.5	7.9	1001	69.6	8.2	1.42
78.0 0.48 0.16 0.55 9.1 2.0 1.0 0.13 9.5 95.4 68.5 9.6 9.7 1.0 0.17 9.7 6.0 9.7 <td< td=""><th>_</th><th>9</th><td>56.6</td><td>0.37</td><td>0.10</td><td>0.62</td><td>10.3</td><td></td><td>7.4</td><td>1.3</td><td>0.15</td><td>9.4</td><td>80</td><td>102.8</td><td>82.2</td><td>8.4</td><td>0.79</td></td<>	_	9	56.6	0.37	0.10	0.62	10.3		7.4	1.3	0.15	9.4	80	102.8	82.2	8.4	0.79
76.0 0.32 0.16 0.54 9.4 9.3 1.9 1.2 0.16 8.4 80.3 73.5 72.6 0.31 0.20 0.61 9.9 9.4 2.2 1.6 0.17 6.7 6.6 86.6 35.9 1.6 73.6 0.46 0.12 0.46 9.6 1.0 0.17 10.0 74 10.1 11.0 <td< td=""><th>-</th><th>7.</th><td>88.0</td><td>0.48</td><td>0.16</td><td>0.55</td><td>9.1</td><td>9.1</td><td>2.0</td><td>1.0</td><td>0.13</td><td>8.3</td><td>7.8</td><td>95.4</td><td>88.8</td><td>6.1</td><td>1.44</td></td<>	-	7.	88.0	0.48	0.16	0.55	9.1	9.1	2.0	1.0	0.13	8.3	7.8	95.4	88.8	6.1	1.44
71.0 0.26 0.26 0.46 2.2 1.5 0.17 6.4 86.6 36.8 1.6 1.6 71.0 0.26 0.26 0.46 9.6 2.1 1.0 0.17 6.6 36.2 10.1 1.5 49.9 0.24 0.12 0.23 0.22 0.60 10.4 9.7 2.4 1.0 0.17 9.1 70.7 4.5 61.1 0.25 0.61 10.4 9.2 2.4 1.0 0.17 76 91.8 80.2 10.1 1.5 67.1 0.26 10.4 9.7 2.4 1.5 0.17 76 91.8 70.7 77.7 67.2 0.26 0.10 0.27 0.26 0.17 0.26 0.2 0.1 0.2 0.1 0.2 0.2 0.2 0.1 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2	-	73	76.0	0.32	0.18	0.54	7.6	B.3	6.	1.2	0.16	9.4	90	92.2	73.3	8.2	1.1
71.0 0.28 0.28 0.28 2.1 1.0 0.16 6.6 36 6.2 10.1 1.5 75.4 0.44 0.12 0.61 10.7 9.7 2.0 1.0 0.17 10.0 74 10.5 74 10.5 4.5 49.9 0.23 0.61 10.7 9.7 2.0 1.0 0.17 10.0 74 10.5 74 10.5 74 10.5 74 10.5 74 10.5 74 10.5 74 10.5 74 10.7 76 91.5 77 4.5 81.1 0.26 0.10 0.60 10.60 10.60 10.60 10.60 10.60 10.60 10.60 10.60 10.60 10.70 90.2 10.70 90.1 90.1 90.2 10.70 90.1 90.1 90.2 10.70 90.1 90.1 90.2 90.1 90.1 90.2 90.1 90.1 90.2 90.1 90.1	_	101	72.5	0.31	0.20	0.61	6	4.0	2.2	1.5	0.17	8.7	8	88.8	38.9	1.8	1.27
75.4 0.44 0.12 0.61 10.7 9.7 2.0 1.0 0.17 10.0 74 105.6 71.7 4.5 49.9 0.23 0.25 0.61 9.5 8.4 2.4 1.0 0.12 8.9 86 107.6 80.2 8.6 81.1 0.39 0.22 0.60 10.4 8.9 2.4 1.5 0.13 9.1 76 91.8 8.1 4.5 82.0 0.40 0.11 0.43 9.7 8.4 2.3 1.4 0.15 0.15 8.2 <th>_</th> <th>178</th> <td>71.0</td> <td>0.26</td> <td></td> <td>0.48</td> <td>9.6</td> <td>9.</td> <td>2.1</td> <td>0.</td> <td>0.18</td> <td>9.8</td> <td>38</td> <td>58.2</td> <td>10.1</td> <td></td> <td>1.49</td>	_	178	71.0	0.26		0.48	9.6	9.	2.1	0.	0.18	9.8	38	58.2	10.1		1.49
49.9 0.23 0.25 0.61 9.5 8.4 2.4 1.0 0.12 8.9 86 107.6 90.2 6.6 81.1 0.39 0.22 0.60 10.4 8.9 2.4 1.5 0.13 9.1 76 91.8 71.3 4.5 82.0 0.40 0.11 0.49 9.7 8.4 2.3 1.4 0.15 9.1 70.2 2.0 0.15 9.3 70.2 8.4 6.6 9.1 6.9 8.4 8.4 8.4 9.1 6.0 9.0 9.1 9.1 8.4 8.4 9.1 9.1 8.4 8.7 9.1 9.2 8.7 9.1		189	15.4	0.44	0.12	0.61	10.7	9.7	7.0	9.1	0.17	10.0	7.4	105.8	71.7	4.5	1.15
81.1 0.39 0.22 0.60 10.4 0.9 2.4 1.5 0.13 9.1 76 91.6 71.3 4.5 82.0 0.40 0.11 0.49 9.7 8.4 2.3 1.4 0.16 8.6 63 109.2 82.4 6.9 87.3 0.20 0.10 0.16 0.60 11.0 9.0 2.0 0.15 9.3 70.8 82.4 6.9 87.3 0.20 0.10 0.10 0.20 13.1 12.4 0.7 0.23 12.7 69 11.0 8.0 11.0 8.0 11.0 8.0 11.0 9.0 <th< td=""><th></th><th>176</th><td>49.9</td><td>0.23</td><td>•</td><td>0.51</td><td>9.6</td><td>8.4</td><td>7.4</td><td>1.0</td><td>0.12</td><td>8.9</td><td>98</td><td>107.6</td><td>90.2</td><td>•</td><td>0.78</td></th<>		176	49.9	0.23	•	0.51	9.6	8.4	7.4	1.0	0.12	8.9	98	107.6	90.2	•	0.78
82.0 0.40 0.11 0.49 9.7 8.4 2.3 1.4 0.16 6.6 63 109.2 62.4 6.9 67.3 0.36 0.40 0.11 0.40 0.60 11.0 9.0 2.0 0.15 9.3 76 0.9 76 6.9 76.6 8.7 70 0.36 0.10 0.10 0.53 9.1 12.4 2.2 0.7 0.25 12.7 69 110.6 0.3 8.0 100.0 0.10 0.10 0.12 12.4 2.2 0.7 0.25 12.7 69 110.5 0.1 10.0 0.10 0.10 0.10 0.76 12.7 12.9 12.3 2.3 0.6 0.26 120.7 69 110.5 0.4.1 10.0 0.7 10.0 0.7 12.9 12.1 7.0 101.9 0.8 25.0 0.0 0.1 0.7 12.9 12.1 2.4 0.7 0.25 12.1 70 101.9 0.8 25.0 0.1 0.5 0.0 0.7 12.9 12.1 2.4 1.1 0.22 11.6 70 101.9 0.8 25.0 0.1 0.5 0.7 12.9 11.0 0.2 11.0		172	1.19	0.39	0.12	09.0	10.4	6.9	2.4	5.5	0.13	9 . 1	92	91.8	71.3	4.5	0.70
64.5 0.41 0.11 0.53 9.1 6.2 1.0 0.15 9.3 78 09.6 78.6 8.7 6.9 6.1 10.6 0.10 0.10 0.10 0.10 0.10 0.10		175	82.0	0.40	0.1	0.49	9.1	₩.	2.3	• :	0.16	8.8	63	109.2	82.4	6.9	1.12
64.5 0.41 0.11 0.53 9.1 6.2 1.8 0.9 0.16 6.6 55 110.6 63.6 6.0 6.0 10.0 0.10 0.10 0.10 0.10 12.4 2.2 0.7 0.23 12.7 69 116.5 84.1 16.0 100.1 0.50 0.17 0.62 12.8 12.7 11.9 2.3 0.6 0.26 13.0 68 126.4 85.6 23.0 100.3 0.60 0.10 0.76 12.7 11.9 2.3 0.6 0.24 12.5 88 126.4 78.1 27.0 100.3 0.60 0.10 0.75 12.9 12.1 2.4 0.7 0.25 12.1 70 101.9 89.8 25.0 10.5 0.56 0.09 0.73 12.9 12.7 12.0 12.1 70 0.27 13.5 69 135.7 91.6 19.0 10.5 0.64 13.6 12.3 11.3 2.4 11.1 0.22 11.8 71 116.9 82.6 20.0 10.6 0.72 12.3 11.3 2.4 11.1 0.22 11.8 71 116.9 82.6 20.0 10.0 0.72 12.9 11.6 2.3 10.0 12.1 12.9 12.9 12.9 12.9 12.9 12.9 12.9		183	67.3	0.38	•	09.0	11.0	9.0	3.0	2.0	0.15	6.9	7.8	89.8	78.6	2.4	1.03
92.0 0.30 0.19 0.80 13.1 12.4 2.2 0.7 0.23 12.7 69 118.5 84.1 18.0 62.0 0.36 0.17 0.02 12.0 12.3 2.3 0.6 0.26 13.0 68 126.4 65.8 23.0 100.3 0.60 0.10 0.76 12.7 11.9 2.3 0.6 0.24 12.5 68 126.4 78.1 27.0 81.9 0.74 0.12 0.73 12.9 12.1 2.4 0.7 0.25 12.1 70 101.9 89.8 25.0 101.9 0.54 0.13 0.64 13.6 12.7 2.7 1.0 0.27 13.6 69 135.7 91.6 19.0 83.6 19.0 10.0 10.0 10.0 10.0 10.0 10.0 10.0		181	64.5	0.41	9.1	0.53		8.2	9.	0.9	0.16	9.0	9 2	110.6	83.8	• ·	-:-
62.0 0.36 0.17 0.62 12.9 12.3 2.3 0.6 0.24 12.5 68 126.4 78.1 27.0 94.9 0.74 0.72 0.24 12.5 68 126.4 78.1 27.0 94.9 0.74 0.72 0.73 12.9 12.1 2.4 0.7 0.25 12.1 70 101.9 89.6 25.0 81.9 0.66 0.13 0.84 13.6 12.7 2.7 1.0 0.27 13.5 69 135.7 81.6 19.0 84.8 0.66 0.09 0.73 12.3 11.3 2.4 11.1 0.22 11.0 71 11.0 71 11.0 71 11.0 71 11.0 71 11.0 71 11.0 71 11.0 71 11.0 71 11.0 71 11.0 71 11.0 71 11.0 71 71 71 72 72 72		286	92.0	0.30	0.18	0.80	13.1	12.4	7.7	0.7	0.23	12.7	6.9	118.5	84.1	18.0	0.48
94.9 0.74 0.12 0.73 12.9 12.1 2.4 0.7 0.25 12.1 70 101.9 89.8 25.0 81.9 0.74 0.12 0.73 12.9 12.1 2.4 0.7 0.25 12.1 70 101.9 89.8 25.0 81.9 0.84 0.13 0.84 13.6 12.7 2.7 1.0 0.27 13.5 69 135.7 91.6 19.0 89.8 25.0 89.8 25.0 0.9 0.73 12.3 11.3 2.4 1.1 0.22 11.0 71 116.9 82.6 20.0 0.95 0.73 12.9 12.9 11.5 2.5 1.3 0.4 0.21 112.9 62 110.4 74.9 6.0 77.0 0.40 0.16 0.79 13.2 12.9 11.6 2.3 11.3 0.24 12.3 66 109.3 77.1 16.0 77.0 0.40 0.16 0.79 13.2 12.6 2.6 0.26 13.9 63 110.6 86.0 14.0 77.0 0.40 0.15 0.75 11.6 11.7 2.9 1.3 0.25 12.8 63 111.7 72.7 14.0 67.5 0.34 0.16 0.75 11.6 11.1 2.0 0.25 12.8 67 109.0 89.1 18.0 79.1 0.36 0.15 0.26 13.6 12.6 12.6 12.6 13.6 13.4 68 118.1 88.6 11.0 0.75 12.6 12.6 12.6 12.6 12.6 12.6 12.6 12.6		286	82.0	0.38	0.17	0.82	12.8	12.3	2.3	9.0	0.26	13.0	89	126.4	92.9	23.0	0.51
94.9 0.74 0.12 0.73 12.9 12.1 2.4 0.7 0.25 12.1 70 101.9 89.8 25.0 01.9 0.13 0.04 13.6 12.7 2.7 1.0 0.27 13.5 69 135.7 91.6 19.0 04.6 0.09 0.73 12.3 11.3 2.4 1.1 0.22 11.6 71 116.9 82.6 20.0 09.6 0.73 12.3 12.9 17.5 2.5 1.3 0.23 12.9 62 110.4 74.9 6.0 77.0 0.40 0.73 13.2 11.6 2.5 1.3 0.24 12.3 66 109.3 77.1 14.0 75.9 0.36 0.75 11.6 2.6 0.26 13.9 63 110.4 74.9 6.0 75.9 0.30 0.15 0.75 11.6 2.6 12.0 0.26 13.9 63 110.0			00.3	09.0	0.10	0.78	12.7	11.9	2.3	9.0	0.24	12.5	88	126.4	78.1	27.0	0.72
0.14 0.15 0.13 0.04 13.6 12.7 2.7 1.0 0.27 13.6 69 135.7 91.6 19.0 0.3.6 0.05 0.73 12.3 11.3 2.4 1.1 0.22 11.6 71 116.9 82.6 20.0 0.4.6 0.05 0.72 12.9 11.5 2.5 1.3 0.23 12.9 62 110.4 74.9 6.0 77.0 0.40 0.75 12.9 11.6 2.5 1.3 0.24 12.3 66 109.3 77.1 14.0 77.0 0.40 0.16 0.79 13.2 12.6 2.6 0.26 13.9 63 110.4 74.9 6.0 75.9 0.36 0.15 0.79 11.7 2.9 1.3 0.23 12.8 63 110.5 86.0 14.0 75.9 0.36 0.15 0.75 11.6 0.75 12.8 67 114.0		276	94.9	0.74	0.12	0.73	12.9	12.1	7.4	0.7	0.25	12.1	70	101.9	89.8	28.0	0.52
63.6 0.56 0.09 0.73 11.3 2.4 1.1 0.22 11.6 71 116.9 71 116.9 82.6 20.0 64.6 0.06 0.08 13.3 12.9 2.3 0.4 0.21 13.7 67 120.6 83.7 14.0 78.6 0.73 0.72 12.9 11.5 2.5 1.3 0.23 12.9 62 110.4 74.9 6.0 77.0 0.40 0.16 0.75 13.2 13.6 2.6 0.26 13.9 63 110.4 74.9 6.0 75.9 0.30 0.15 0.75 11.6 2.6 12.3 63 110.5 86.0 14.0 67.5 0.34 0.16 0.75 11.6 11.7 2.9 1.3 0.23 12.3 63 111.7 72.7 14.0 67.5 0.34 0.16 0.75 11.6 0.25 12.3 60 114.0		302	81.9	0.84	•	0.84	13.6	12.7	2.7	0.	0.27	13.8	69	135.7	9 . 1	19.0	0.67
64.6 0.06 0.06 13.3 12.9 2.3 0.4 0.21 13.7 67 120.6 63.7 14.0 78.6 0.73 0.09 0.75 12.9 11.6 2.5 1.3 0.23 12.9 62 110.4 74.9 6.0 77.0 0.40 0.16 0.79 13.2 12.6 2.6 0.26 13.9 63 110.4 74.9 6.0 75.9 0.40 0.16 0.79 13.2 12.6 2.6 0.26 13.9 63 110.5 86.0 14.0 75.9 0.30 0.15 0.75 11.6 11.7 2.9 1.3 0.23 12.8 63 111.7 72.7 14.0 67.5 0.34 0.16 0.75 11.6 11.1 2.0 0.25 12.3 70 114.0 0.8 79.1 0.35 0.25 12.6 2.4 1.0 0.25 12.4 68		281	83.6	9.9	•	0.73	12.3	11.3	7.4	-:	0.22	11.8	7	116.9	82.6	20.0	0.72
78.6 0.73 0.00 0.72 12.8 11.5 2.5 1.3 0.24 12.9 62 110.4 74.9 6.0 77.0 0.40 0.16 0.79 13.2 12.6 2.6 0.24 12.3 66 109.3 77.1 16.0 75.9 0.40 0.16 0.79 13.2 12.6 2.6 0.26 13.9 63 110.5 86.0 14.0 75.9 0.36 0.15 0.75 11.6 11.7 2.9 1.3 0.23 12.8 63 111.7 72.7 14.0 67.5 0.36 0.75 11.6 11.1 2.0 0.25 12.3 70 114.0 86.7 10.0 58.1 0.36 0.76 13.6 13.6 12.6 12.6 12.6 13.4 10.0 89.1 11.0 79.1 0.38 0.15 0.6 13.6 10.0 22.4 11.0 0.25 11.6 70.19.4 76.9 11.0		287	84.8	0.64	•	0.85	13.3	12.9	2.3	4.0	0.21	13.7	4	128.6	83.7	0.4.	0.65
78.6 0.74 0.09 0.75 12.9 11.6 2.3 1.3 0.24 12.3 66 109.3 77.1 14.0 77.0 0.40 0.16 0.79 13.2 12.6 2.6 0.6 0.26 13.9 63 110.5 88.0 14.0 75.9 0.36 0.15 0.73 13.0 11.7 2.9 1.3 0.23 12.6 63 111.7 72.7 14.0 67.5 0.34 0.16 0.75 11.6 11.1 2.0 0.25 12.3 70 114.0 68.7 10.0 58.1 0.35 0.20 0.76 12.6 11.6 2.2 1.0 0.25 12.8 67 109.0 69.1 18.0 79.1 0.36 0.15 0.64 13.6 12.4 10.9 2.4 1.6 0.25 11.6 70 119.4 76.9 18.0		296	89.8	0.73	•	0.72	12.8	11.5	2.5	1.3	0.23	12.9	62	110.4	74.9	9 .0	0.63
77.0 0.40 0.16 0.79 13.2 12.6 2.6 0.6 0.26 13.9 63 110.6 86.0 14.0 15.9 0.30 0.15 0.73 13.0 11.7 2.9 1.3 0.23 12.6 63 111.7 72.7 14.0 87.5 0.34 0.16 0.75 11.6 11.1 2.0 0.5 0.25 12.3 70 114.0 85.7 10.0 56.1 0.35 0.20 0.76 12.8 11.8 2.2 1.0 0.25 12.8 67 109.0 89.1 18.0 79.1 0.38 0.15 0.84 13.6 12.6 2.4 1.0 0.27 13.4 68 118.1 88.8 11.0 97.8 0.60 0.07 0.73 12.4 10.9 2.4 1.5 0.25 11.6 70 119.4 76.9 18.0		290	78.6	0.74	•	0.75	12.9	11.6	2.3	1.3	0.24	12.3	9 9	109.3	17.1	16.0	0.64
75.9 0.38 0.15 0.73 13.0 11.7 2.9 1.3 0.23 12.8 63 111.7 72.7 14.0 67.5 0.34 0.18 0.75 11.6 11.1 2.0 0.5 0.25 12.3 70 114.0 65.7 10.0 58.1 0.35 0.20 0.76 12.8 11.8 2.2 1.0 0.25 12.8 67 109.0 89.1 18.0 79.1 0.38 0.15 0.64 13.6 12.6 2.4 1.0 0.27 13.4 68 118.1 88.6 11.0 97.8 0.60 0.07 0.73 12.4 10.9 2.4 1.5 0.25 11.6 70 119.4 76.9 18.0		292	77.0	0.40	Ξ.	0.79	13.2	12.6	9.2	9.0	0.26	13.9	63	110.5	88.0	14.0	0.80
67.5 0.34 0.18 0.75 11.6 11.1 2.0 0.5 0.25 12.3 70 114.0 68.7 10.0 58.1 10.0 58.1 0.35 0.20 0.76 12.8 11.8 2.2 1.0 0.25 12.8 67 109.0 89.1 18.0 79.1 0.38 0.15 0.64 13.6 12.6 2.4 1.0 0.27 13.4 68 118.1 88.6 11.0 97.8 0.60 0.07 0.73 12.4 10.9 2.4 1.5 0.25 11.6 70 119.4 76.9 18.0		279	75.9	0.38		0.73	13.0	11.7	8.8	1.3	0.23	12.8	63	111.7	72.7	14.0	0.82
58.1 0.35 0.20 0.76 12.6 11.8 2.2 1.0 0.25 12.8 67 109.0 89.1 18.0 79.1 0.38 0.15 0.64 13.6 12.6 2.4 1.0 0.27 13.4 68 118.1 88.6 11.0 97.8 0.60 0.07 0.73 12.4 10.9 2.4 1.5 0.25 11.6 70 119.4 76.9 18.0		270	67.5	0.34	٦.	0.75	11.6	-:	2.0	9 · O	0.25	12.3	7.0	114.0	65.7	10.0	0.63
79.1 0.38 0.15 0.84 13.6 12.6 2.4 1.0 0.27 13.4 68 118.1 88.6 11.0 0 97.8 0.60 0.07 0.73 12.4 10.9 .2.4 1.5 0.25 11.6 70 119.4 76.9 18.0 1		280	50.1	0.35	•	0.76	12.8	11.8	2.2	1.0	0.25	12.8	29	109.0	89.1	18.0	0 . 0
97.8 0.60 0.07 0.73 12.4 10.9 2.4 1.5 0.25 11.6 70 119.4		289	1.61	0.38	•	0.84	13.6	12.6	7.4	0.1	0.27	13.4	6.8	118.1	88.8	1.0	0.48
		274		09.0	•	0.73	12.4	10.9	7.4	5.1	0.25	11.6	7.0	119.4	76.9	16.0	1.05

1126	EXPT	EXPT ANIMAL	GRAMS	È	CDYR	1	CCOAB	116	٠ ۲	5	}	0010	FVC	FEVI	PEFR	PAMER	EF 10	1118
										1 1 1 1	! ! !	! ! !						
			•		7	71.0	0.79	13.3	12.0	2.5	.3	0.25	12.3	6 9	106.9	88.3	12.0	0.79
			28.7		0.52	-	0.82	13.8	12.4	2.5	-:	0.28	11.8	+	73.8	36.4	10.0	
			2 2 2	78.8	0.8	0.17	0.85	13.8	13.0	2.4	9.0	0.29	13.4	89	107.4	26.8	78 . 0	
	411	980	301	0.66	0.62	0.06	0.68	12.4	11.8	1.8	٠.	0.22	12.5	6 2	119.4	67.3	25.0	9.8
					0.43	0.15	0.84	13.8	12.8	2.8	1.0	0.24	13.8	7.2	133.4	97.0	17.0	7 . 0
			290	101.1	. 0	0.08	0.78	13.8	12.6	2.8	£	0.29	13.2	29	11.0	93.6	17.0	0.84
			282		9.0	0.10	0.78	12.9	12.1	2.3	8.0	0.20	12.9	7.1	127.2	90.3	9.0	. e
	7		2 8 2	90.0	63	0.23	0.78	13.4	12.6	7.4	6.0	0.24	12.7	6.7	112.7	98.4	24.0	0.72
	****	2 :	700		0.35	0.21	0.75	13.2	12.3	2.8	6.0	0.28	13.7	63	117.8	82.0	12.0	•
	7 7 7 7	: :	,		0.39	0.17	0.68	12.3	-0.	2.5	1.2	0.22	11.8	6.4	110.4	88.8	15.0	1.02
		=======================================	306	92.3	0.84	0.09	0.76	12.4	11.5	2.3	6.0	0.23	12.0	9	111.2	0.02	22.0	0.77
	777	1.7	288	78.8	0.48	0.12	0.75	12.4	11.2	2.1	7.5	0.18	12.1	15	124.4	98.1	9.	. 6
			283	78.3	0.45	0.13	0.67	12.3	10.9	3.0	1.3	0.22	11.7	7.0	107.3	83.9	20.0	•
			286	79.0	0.62	0.09	0.74	11.7	11.3	2.1	7.0	0.21	11.7	67	115.8	71.8	23.0	0.92
	6767	4	285		0.40	0.14	0.73	11.8	11.1	2.0	9.0	0.24	12.1	5 9	113.4	49.9		92.0
	4171		271	70.8	0.32	0.23	0.87	11.6	10.2	3.2	.	0.24	11.8	7	112.5	9.70	٥.	-
		180	284	87.0	0.55	0.12	0.72	12.7	11.4	2.8	£.7	0.22	12.5	63	112.3	66.2	1.0	0.82
	27.5		18.	0	0.26	0.26	0.62	10.0	9.3	9 .	ø. 0	0.17	10.4	7.8	115.4	87.2	0.0	6.0
			183		0.22	0.28	0.63	10.6	9.6	6.1	0.1	0.17	10.1	7.	110.4	88.8	23.0	0.82
	4378	821	061	91.4	0.34	0.21	0.63	10.7	9.6	1.1	6.0	0.23	10.3	7.8	118.2	86.7	18.0	0.92
	4370	622	178	78.6	0.32	0.21	99.0	11.3	10.4	2.4	1.0	0.20	<u></u>	7.2	116.2	11.2	0.4	9
	4370	828	9	85.8	0.41	0.14	0.54	9.3	6.0	1.7	9.0	91.0	6.9	-	87.4	37.4	•	
	4370	828	175	79.6	0.26	0.22	0.54	9.1	9.8	1.1	9.8	0.16	8.8	80	104.5	71.4	20.0	1.17
	4370	6 3 2	98-	87.8	0.83	0.11	0.65	10.8	9.7	1.1	-:	0.21	10.1	15	105.2	79.8	20.0	.0
	4370	836	177	74.2	0.38	0.18	0.58	8	- 6	e	0.7	0.15	9.9	*	108.3	73.2	• •	= :
	4371	542	173	63.9	0.24	0.23	0.54	9.8	8.8	2.0	0.7	0.15	9.3	90	104.0	78.4	23.0	8.0
	4371	851	181	87.8	0.30	0.23	0.59	10.4	9.7	1.9	0.7	0.17	10.8	7.5	112.0	82.2	0,0	
Ī	4371	683	180	68.3	0.34	0.21	0.50	9.5	8.0	2.0	1.2	0.17	6.7	7	54.9	20.5		*O.
	4371	557	173	72.0	0.37	0.19	0.58	9.6	6	8 .	7.0	0.16	6. 6	63	92.2	1.6	8	B .
	4371	80 80 80 80	177	80.2	0.27	0.21	0.51	9.3	8.8	.	9.0	0.19	7.	7.9	110.3	78.8	0.4	01.1
	4371	8 6 8	182	87.6	0.61	0.08	95.0	10.0	4.	2.9	+ :	0.17	7 .01	0	120.1	D .	9.9	e
	4371	672	168	62.4	0.30	0.25	0.52	9.2	•	9 .	•.	0 . 1	7.	9	87.2	9.97	• ·	
•	4371	673	9	70.0	0.43	0.10	0.69	10.		9. 2	0.	0.17	- 0 -	11	112.3	82.1	26.0) i
	4372	681	194	8.8	0.45	0.11	0.65	11.7	10.5	5 . 6	1.2	0.21	• =	2	11.0	9. 9.	24.0	6 / · ·
	4372	882	178	67.0	0.38	0.19	99.0	10.3	10.0	1.7	7.0	0.17	10.8	70	107.8	21.8	72.0	17.0
	4372	80	175	80.9	0.37	0.22	0.65	1.1	9.6	5 .6	.	0.17	10.3	24	83.3	29.3	٧.	0.62
3	4372	587	111	85.0	0.34	0.20	0.62	1.01	4.6	÷.	9.0	0.19	9.6	7.9	107.2	78.6	17.0	
1	4372	76.9	174	69.3	0.26	0.25	09.0	9.3	9.	6.	0.7	0.16	•	6.2	67.3	7.	9.0	*
	4372	109	170		0.27	0.21	0.49	9.8	9.0	2.3	6.0	0.16	9 .	9 2	110.5	86.2	0	FD. 1
N O I	4372	807	178		0.31	0.23	0.54	9.5	9.	7.0	6.0	0.18	9.5	11	101.3	75.1	0.4	
M10-1	4372	611	168	6.99	0.67	0.12	0.52	9.2	8.8	1.7	9.0	0.15	6.9	7.4	94.6	73.3	15.0	B F O

3417	EXPT	EXPT ANIMAL GRAMS	GRAMS	È	COVE	1	CCOND	116	٥ ٧	7 BC	2	DLCO	FVC	FEVI	PRFR	FACE	EF10	11.0
			1	-	1	1		!	! ! ! !	? ! ! !	 							
		:		4	66.	91.0	9, 56	9.0		2.0	0.0			82	106.9	84.2	16.0	96.0
					0.25		0.58	9.	8.8	9.0	6.0	0.16	9.2	7.9	106.8	80.7	19.0	0.10
					0.30	0.19	0.60	10.6	9.6	2.2	9.	0.17	10.0	2.8	112.4	84.2	23.0	1.0
٠			181	8.8	0.34	0.19	0.84		6.7	2.3	1.2	0.16	4 .6	=	112.4	84.7	12.0	00.
	7373		176	2 · 2	0.30		0.61	9.7	8.3	.	7.0	0.14	9.8	11	97.9	19.8	21.0	0.73
				74.3	0.37		0.56	6		2.1	8.0	0.17	9.7	11	107.2	78.8	15.0	. 63
					2.8		0.61	10.	9.4	2.3	1.2	0.18	10.3	7.2	99.0	78.8	12.0	9.69
			2 .	6	0.34	0.22	0.60	10.1	6.9	2.3	1.2	91.0	9.6	7.4	109.7	68.7	18.0	9.74
	7			112.8	09.0		90.0		11.9	2.4	2.3	0.29	12.9	67	118.4	80.8	12.0	0.80
1 - 10 - 10 - 10 - 10 - 10 - 10 - 10 -					0.42	0.18	0.84	14.2	13.2	2.9	0.	0.23	13.9	9	118.0	89.2	23.0	0.41
		947		111,1	0.42	0.19	0.83	13.2	12.3	2.5	6.0	0.20	12.9	9	117.0	91.0	16.0	0.39
	A371	957		142.9	0.36	0.21	0.83	13.4	13.1	2.2	0.3	0.20	13.4	8	124.8	91.3	25.0	0.42
	4371	4		83.8	0.36	0.17	9.76	13.2	12.3	7.4	6.0	0.27	12.8	8	125.7	90.0	19.0	9 . 4
	4371			103.2	0.38	0.25	0.88	14.0	13.2	7.4	9.0	0.20	13.8	9	121.6	82.3	22.0	0.48
	4371	07.1		104.8	0.31	0.18	0.76	11.7	10.6	1.1	-:	0.27	9 . 1 .	6	108.1	76.9	14.0	0.84
	1257	074		99.4	0.41	0.07	0.73	11.5	11.5	.	0.0	0.29	11.7	7.8	119.8	91.9	24.0	
	4372	082		140.4	0.65	0.10	0.88	14.6	13.6	2.8	0.	0.22	14.3	82	125.7	81.8	9.10	0.43
	4272	0.0		118.7	0.67	0.13	66.0	14.3	14.1	2.7	6.9	0.33	14.1	6 2	121.1	80.2	18.0	0.42
	4372	780		93.6	0.67	1.0	0.92	14.8	13.8	2.5	6.0	0.24	14.3	62	119.7	81.3	18.0	0.43
	4372			111.0	0.38	0.20	0.87	13.1	12.8	1.7	0.3	0.34	13.3	9	126.8	79.3	28.0	0.8
	4372	60		113.5	0.55	0.10	96.0	13.4	13.1	7.8	0.3	0.34	13.6	2	109.0	42.8	o.	0.38
	4372	10.		113.0	0.49	0.0	09.0	13.3	12.5	2.2	e. 0	0.32	12.9	3	124.8	73.8	24.0	0.63
	4372	108		123.7	0.43	0.14	19.0	12.7	12.2	2.0	o . s	0.32	12.9	69	127.0	82.8	28.0	9.0
	4372	-		125.5	0.34	0.25	0.85	14.5	13.1	5 . 6	1.3	0.37	13.5	63	117.6	78.4	28.0	0.38
	4373			120.0	0.71	0.10	0.73	12.5	12.0	7.4	9.0	0.20	12.5	09	109.2	58.9	• -	0.42
	4373	118	329	118.8	0.45	0.13	0.78	13.0	11.7	7.4	1.2	0.32	12.0	8	111.8	70.1	20.0	
	4373	124		104.8	0.29	0.21	0.77	12.9	11.6	2.4	1.2	0.23	12.4	7.8	119.0	104.3	0. 2	
	4373	139	310	86.3	0.38	0.18	0.78	12.9	12.1	2.4	e. 0	0.27	12.5	6	112.3	87.3	21.0	9 ·
	4373	143	104	108.8	0.41	0.18	0.77	1.8	-:	2.1	0.7	0.19	= :	1 0	3.6	67.0	25.0	0.59
	4373	146	295	117.8	0.41	0.22	0.75	12.7	1.5	2.7	7.	0.78	12.2	6 0	83.4	- 9	9	D .
	4373	===	286	118.1	0.27	0.22	0.66	13.4	11.5	2.5	•·	0.25	14.3	62	125.7		31.0	. S. A.
	4373	150	303	117.9	0.57	0.15	0.88	13.1	12.8	2.2	0	0.25	12.7	60	107.0		B .	
	4371	842		83.1	0.52	0.15	0.65	10.3	9.7	1.9	9.0	0.16	10.2	69	87.4	67.3	•	0.70
	4371		191	92.8	0.48	0.14	0.65	10.9	10.0		6.0	0.20	10.7	83	86.2	39.6	9	1.12
	4371	883	188	75.9	0.49	0.19	0.63	10.6	9.4	2.1	0.	9.19	0.0	6 /	106.4	87.3	22.0	9.0
	4371	687	184	16.8	0.39	0.19	0.60	8.8	8.9	1.8	9.0	0.17	7.6	2 9	70.0	42.4	9.9	96.0
	4371	59		106.5	0.28	0.30	0.55	9.3	9.0	4 .	0.3	0.19	9.3	9.2	106.0	78.5	18.0	0.91
	4371	86.5		107.5	0.26	0.23	0.60	10.7	10.0	2.1	2.0	0.22	10.5	78	111.2	82.6	22.0	9.6
	4371	672		90.9	0.34	0.22	0.59	9.8	0.6	9 .	9.0	0.21	B.7	9	6.89	22.5	• •	.03
	4371	573	185	67.3	0.30	0.15	0.67	10.9	6.6	2.1	- -	0.20	10.6	7.7	119.3	96.5	23.0	9.0
	4372	5.81	205	95.8	95.0	0.09	0.73	11.5	11.0	2.0	9.2	0.21	9. =	63	96.2	64.2	15.0	9.20

4372 4372 4372 4372 4373 448 4373 4														
4372 888 190 78.1 690 89.2 690 890 890 890 890 890 890 890 890 890 8										,	,	•	•	
4372 4372 4372 4372 4372 4373 4373 4373	-	0.24	0.74	10.6	10.2	•:	7.0	0.21	10.4	2	73.1	7		
4372 887 184 41.0 4372 801.0 100.5 601 1001.0 60	1.1 0.38	0.17	0.67	-	9.7	2.3	9.	0.18			,	•	•	
4372 684 186 47.0 4372 611 181 67.0 4373 613 181 181 181 87.0 4373 614 182 182 182.3 4373 644 182 182.2 4373 644 182 70.3 4371 647 182 70.3 4371 655 332 71.1 4372 665 332 71.1 4372 665 332 71.1 4372 665 332 71.1 4372 665 332 71.1 4372 665 332 71.1 4372 106 325 66.7 4373 116 325 66.7 4373 124 331 166.5 4373 124 331 166.5 4373 146 331 166.5		9.10	0.68	10.1		9.	9.0	0.15	10.0	9	88.4	0.0	9.	<u>-</u>
4372 4372 4373 4373 4373 4373 4373 4373 4373 4373 4373 4373 4373 4373 4373 4373 4373 4373 4371 4371 4371 4371 4371 4372 4373		0.21	0.87	•	9.5	•	4.0	0.18	9.	92	99.3	• · ·	• •	1.36
4372 611 181 185 130.6 61373 613 182 182 183 183 183 183 183 183 183 183 183 183		0.21	0.87	9.	9.5	1.9	•	0.17	•	02	99.3	-	•	1.36
4372 611 181 65.3 4373 614 182 182.3 4373 623 198 112.2 4373 640 190 120.0 4373 641 182 70.3 4371 641 182 70.3 4371 641 182 70.3 4371 659 170 00 0 4371 659 180 120.0 4372 662 180 171 0 4372 663 180 171 0 4372 663 180 171 0 4372 100 325 66.7 4373 110 345 66.7	7.0	0.24	09.0	6.7		• .	0.7	9.16	1.8	7.8	104.8	77.0	e -	0.82
4373 613 187 101.9 4373 623 138 138 112.2 4373 644 138 68.9 4373 644 138 70.0 4371 641 138 70.0 4371 651 138 140 0 4372 651 138 140 0 4372 651 108 108 10 0 4372 651 108 108 10 0 4372 651 108 108 10 0 4373 110 134 108 108 10 0 4373 110 134 108 108 10 0 4373 110 134 135 108 10 0 4373 114 13 134 168 7 4373 146 130 147 168 7 4373 146 130 134 168 7 4373 146 136 136 186 7 4373 148 139 134 186 7 4373 148 139 134 186 7 4373 148 139 134 186 7 4373 148 139 134 186 7 4373 148 138 186 7 4373 148 138 186 7	•	0.10	0.63		1.6	9.	9.0	0.19	9.3	70	104.0	9. 9	9 .	0.83
4373 614 186 89.1 4373 624 182 182 182 182 182 182 182 182 182 182		0.10	97.0		7.5	1.1	9.0	0.15	8.3	7.4	74.8	. .	20.0	1.42
4373 642 112 2 4 5 5 6 6 7 6 6 7 6 6 7 6 6 7 6 6 7 6 7 6	6.0	0.18	0.50	6.1	9.7	2.0	7.0	0.16	9.3	7.2	87.1	8.4	9.0	0.72
4373 644 182 483 68 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8		0.52	0.59	6.6		6.	0.	0.19	9.5	20	83.9	62.4	20.0	0.99
4373 644 198 459 451 451 451 451 451 451 451 451 451 451	0	0.27	0.62	4.6	8.7	9.	•.	0.14	9.5	7.5	102.8	70.2	18.0	0.81
4373 644 190 120.0 4373 644 190 120.0 4371 647 190 70.3 4371 647 328 88.4 4371 658 328 71.1 4372 662 328 81.1 4372 662 328 81.1 4372 662 328 81.1 4372 100 328 83.6 4373 110 324 82.6 4373 110 324 88.8 4373 110 324 88.0 4373 110 324 88.0 4373 110 324 88.0 4373 110 324 88.0 4373 110 324 88.0 4373 110 324 88.0 4373 110 324 88.0 4373 110 324 88.0 4373 110 324 88.0	4.0	0.14	0.58	6.0	9.3	1.9	0.7	0.18		99	5 8 . 6	43.1	13.0	0.62
4373 644 192 70.3 4373 644 192 70.3 4371 041 328 88.8 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	•	0.40	0.63	10.0	9.2	1 .8	0.7	0.16	9.6	7.	97.2	72.6	- -	0.70
4373 4371 4371 4371 4371 4371 4371 4372 4373	0.0	0.15	0.59	11.0	6.6	1.1	1.2	0.15	10.5	2 9	4. 18	40.2	13.0	9.00
4371 639 331 71.0 4371 647 314 90.8 4371 669 322 71.1 4371 671 336 94.8 6372 663 324 86.2 4372 663 334 86.2 4372 663 334 86.2 4372 663 334 86.2 4372 663 334 86.2 4372 106 325 66.7 4373 110 345 88.6 4373 114 337 120.1 4373 124 331 60.5 4373 124 333 100.5 4373 146 321 88.7 4373 146 321 88.7	•	0.27	0.59	9.7	8.8	. .	6.0	0.15	9.5	20	6.0	62.4	20.0	B
4371 4371 4371 6471 6571 6572 6571 6572 6572 6572 6572 6572 6572 6572 6572	0.5	0.33	0.84	12.2	11.3	2.3	6.0	0.23	12.9	9 9	119.8	76.2		9 . 6
4371 067 314 90.8 4371 066 327 71.1 4371 071 336 91.1 4372 063 356 91.1 4372 063 328 65.2 4372 063 334 92.6 4372 068 351 63.6 4372 108 336 74.3 4373 110 345 66.7 4373 114 332 78.0 4373 116 374 96.7 4373 116 324 65.0 4373 116 324 65.0 4373 116 324 65.7	0	91.0	0.88	18.4	13.6	3.7		0.19	15.6	7	140.	64.7	24.0	9.70
4371 0667 332 60.8 4371 0669 3589 91.1 4371 071 336 94.8 4372 062 328 65.2 4372 063 334 66.2 4372 063 334 92.6 4372 106 326 74.3 4373 110 345 66.7 4373 114 332 78.0 4373 114 332 78.0 4373 116 373 100.5 4373 116 324 85.0 4373 117 347 96.7 4373 118 371 120.1		0.10	0.77	13.3	11.6	7.6	1.7	0.22	12.8	9	108.5	9 . 9	23.0	0.68
4371 066 327 71.1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0		0.13	96.0	14.8	13.9	2.7	6.0	0.22	14.8	62	135.4	9.09	32.0	0.38
4371 069 368 91.1 4371 071 338 91.1 64372 062 338 93.6 6 6 7 4372 068 338 103.6 6 6 7 4372 108 348 351 452 6 6 7 4372 110 348 66.7 66.8 67 7 67 7 67 7 67 7 67 7 67		90.0	90.0	16.2	12.8	3.6	2.4	0.32	14.4	•	127.6	- 0	D :	9.41
4371 071 336 94.8 6372 4372 082 328 85.6 6 6 7 8372 082 328 85.6 6 6 7 8372 108 338 103.6 6 6 7 8372 110 348 86.7 6 6 7 8373 110 348 86.7 6 6 7 8373 110 348 86.7 6 6 7 8373 110 348 86.7 6 6 7 8373 110 348 86.7 6 6 7 8373 110 348 86.7 6 6 7 8373 110 348 86.7 6 6 7 8373 110 3473 110 3473 110 3473 110 3473 110 3473 110 6.8 6.7 6 6 7 8373 110 6.8 6.7 6 6 7 8373 110 6.8 6.7 6 6 7 8373 110 6.8 6.7 6 6 7 8373 110 6.8 6.7 6 6 7 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8	_	0.12	88.0	15.0	13.1	3.2	9.	0.37	14.8	09	124.9	73.7	9.0	0.42
4372 074 331 86.2 4372 082 334 83.6 4372 084 351 83.6 4372 089 350 74.3 4372 108 348 78.6 4372 110 348 78.6 4373 111 332 78.0 4373 114 370 120.1 4373 124 333 100.5 4373 146 321 88.4 4373 146 321 88.7		0.05	0.78	13.3	11.5	7.7	1.0	0.32	13.1	99	126.0	78.0	23.0	0.50
4372 082 329 83.6 6 3 4 372 083 334 92.6 6 6 4 3372 088 338 103.4 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6		0.26	0.80	12.0	11.1	2.0	6.0	0.20	12.8	8	106.7	62.5	21.0	8
4372 083 334 92.6 4372 088 351 83.4 4372 098 350 74.3 4372 108 328 78.6 4372 110 345 88.7 4373 110 345 88.7 4373 114 370 120.1 4373 124 333 100.5 4373 145 321 88.4 4373 146 321 88.7		0.13	0.79	16.3	16.2	3.4	1.2	0.19	16.2	-	132.3	92.2	27.0	. e.
4372 084 351 83.4 0 4372 098 308 100.0 4372 108 328 78.6 0 4373 110 328 78.7 0 4373 112 332 78.0 0 4373 124 333 108.8 0 4373 146 333 108.8 0 4373 146 321 88.4 0 4373 146 321 88.4 0		0.08	96.0	16.5	14.7	J. 1	6.	0.24	15.6	6	133.3	90.0	25.0	77.0
4372 099 350 74.3 0 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9		0.12	0.93	16.4	14.0	3.2	7.4	0.21	18.7	S	133.4	79.8	29.0	24.0
4372 108 138 103.0 0 4372 108 108 108 108 108 108 108 108 108 108		0.14	1.00	15.5	14.1	8.8	* :	0.22		•	145.5	8. 18.	0.82	
4372 108 348 78.8 0 4372 110 345 86.7 0 4373 110 345 89.8 0 4373 112 342 79.0 0 4373 124 333 108.8 0 4373 148 321 88.0 0 4373 146 321 88.4 0 4373 150 338 96.7 0	0.71	0.15	0.87	14.8	13.4	e	-:	0.18	7.7	2	122.4	9.701		
4372 110 348 66.7 0 4373 110 348 66.7 0 4373 124 332 160.5 0 4373 143 347 96.7 0 4373 146 321 00.8 0 4373 146 321 00.8 0 4373 146 321 00.7 0 4373 150 338 96.7 0	8.6 0.75	0.07	16.0	18.3	13.6	3.2	7.7	0.20	14.8	6 0 (129.2	B. 61	0.02	
4372 110 345 89.8 0 4373 118 370 120.1 0 6 4373 124 333 36.8 0 6 4373 145 324 98.7 0 6 4373 146 321 88.7 0 6 4373 146 321 88.7 0 6 4373 150 338 86.7 0 6 4373 150 338 86.7 0 6 4373 150 338 86.7 0 6 4373 150 338 86.7 0 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6	•	0.1	0.97	15.2	13.7		¥.	0 . 20	16.2		1.04.			
4979 119 332 78.0 0 4979 124 349 36.7 0 4979 149 349 88.0 0 4979 148 321 88.0 0 4379 146 321 88.7 0 4379 150 315 86.7 0	•	0.08	09.0	14.9	13.3	~ .	9	9.1	9.4	* .	138.6	7.99		
4373 118 370 120.1 4373 139 343 108.8 4373 143 347 96.7 4373 146 321 89.4 4373 150 338 96.7	-	0.08	0.83	14.3	12.4	3.2	D. 7	0.31		2	7.01.			
4979 139 343 400.8 0 4979 149 347 98.7 0 4979 146 321 89.4 0 4373 146 309 73.9 0 4377 150 338 96.7 0	•	0 . 19	96.0	14.6	13.3	D. 6	e	0.23	14.2			9.5		
4373 139 343 88.0 0 4373 148 321 89.4 0 4373 146 303 73.9 0 4373 150 338 86.7 0		0.13	1.08	9.9	- 2	8 . 8	P.	0 . 20	e .	0	7 · RC			
4373 145 347 96.7 0.3 4373 146 321 89.4 0.3 4373 146 309 73.9 0.4 4373 150 335 96.7 0.7	•		0.80	13.6	1.7	4.6	9 .	0.33	12.8	6	125.6		5.62	2 ;
4373 146 321 89.4 0.3 4373 146 309 73.9 0.4 4373 150 336 96.7 0.7 4371 542 194 65.3 0.4		0.13	9.85	13.9	12.4	s · 2	* :	0.21	13.9	•	9.90	82.9	D . 62	7.0
4373 146 309 73.9 0.4 4373 150 336 96.7 0.7 4371 542 194 65.3 0.4	0	0.19	06.0	12.9	11.4	2.8	1.8	0.20	12.5	20	123.5		D . 7 .	D
4371 542 194 85.3 0.4	.9	0.12	0.80	13.9	12.3	9.6	9.	0.15	13.3	~	126.4	7.05	27.0	
4371 542 194 65.3 0.4	. 7	60.0	06.0	15.3	13.8	3.2	5.	0.21	15.1	5	132.4	6.6	13.0	16.0
	.3 0.	0.07	0.64	10.4	0.01	1.1	7.0	0.24	10.8	7.8	116.9	91.2	25.0	76.0
205 71.8 0.2	1.8 0.29	0.20	0.73	12.3	10.5	7.4	1.1	0 . 16	• -	Ξ.	122.0	7.87	9.	7 6. 9

7 1 ME	EXPT	ANIMAL	GRAMS	Ž	CDYN	Ę	CCORD	110	ر د	FRC	2	DICO	FVC	FEVI	PEFA	MEF	6710	===
1		1				, 	; ; ; ;					l I						
		:	•	86.2	0.47	0.15	0.67	1.1.	10.4	3.8	0.	0.19	11.2	73	108.0	82.9	24.0	1.13
			:		. 6	0.09	0.69	11.2	•	3.6	•.	0.22	10.9	73	118.6	78.4	21.0	0.70
				77.0	0.34	0.15	0.64	10.3	9.5	2.4	-:	0.22	10.0		118.6	1.1	28.0	9.9
				7	0.32	0.19	0.67	12.9	1.0	2.9		0.21	11.9		130.6	98.0	23.0	0.84
7 - 0 - 0						0.32	0.81	9.	8.3	2.3	-:	0.20	-:		9.0	7.	٠.	9.0
HEC-1					06.0	0.21	0.74	11.3		2.6	1.6	0.10	10.7	7.8	109.4	67.3	28.0	00.0
MEC-1	1160					-	18.0	11.9	11.2	2.4	2.0	0.19	12.0		124.2	86.9	22.0	0.74
7EC-1	4372		277				. 6.		9.	1.7	6.0	0.19	9.0		84.2	24.8	•	9.0
- D M	7/60							10.2		7.7	-	0.18	6.6		110.2	78.4	26.0	0.0
RC-1	4372		061					717		2.2		0.17	10.8		116.1	9.1.	21.0	0.83
AEC-1	4372	284	9 6	2.2	? .				•	2.0	0.	0.14	10.4		121.3	93.9	27.0	0.97
NEC-1	4372	5 9 A	9 1		97.0	9 6			•			61.0	9.6		11 1	36.0	10.0	0.94
REC-1	4372	5	- 2	 	0.27	22.0	7.0		•		-	7 6	9		103.	7.8.7	16.0	0.47
NEC-1	4372	101	138	74.4	0.7	0.25	9.0	n :		: :						7 97	-	55.0
REC-1	4372	=	186	62.3	0.31	0.10	0.65	9.0		7.	-							7
NEC-1	4373	613	199	79.6	0.36	0.21	0.65	10.2	D	7 . 7			- (
BEC-1	4373	614	197	1.87	0.28	0.14	0.68	0. E	en •	7.7	-	71.0	. 0.					
	6373	623	214	105.7	0.32	0.16	0.80	12.3		5 .	7.7	0.18	9 .		123.4	~	23.0	7
			:	74.1	0.22	0.26	0.62	10.7	9.0	7. 8	1.7	0.23	10.2		109.8	92.4	9.12	9.0
					36.	9.14	0.68	1 . 6	9.9	4.4		0.14	10.9		122.0	98.9	20.0	0.13
	7				0.29	0.18	0.62	10.8	9.5	2.3	1.3	0.22	10.3		123.7	93.1	22.0	0.70
					0.32	0.19	0.76	11.8	10.3	2.6	.	0.17	1.4		122.2	95.7	28.0	89 .0
1-246			•		0.28	61.0	0.65	10.7	. 6	2.5	1.2	0.23	10.3		115.7	72.1	22.0	0.62
MEC-1						0.03	0.68	11.2	10.0	2.3	1.1	0.24	10.7		101.7	72.7	20.0	99.0
BASE-Z	7 1 1	3	9 6			0.0	. 6	11.5	9.6	2.6	6.	0.19	6.6		99.5	8.8	26.0	0.70
BASE-2	2 7 7 7	102		? .			6	10.4	6.7	9.1	9.0	0.22	9.1		95.9	71.4	22.0	0.89
BASE-2	4442	E01	296	P. C		:		10.4	10.6	2.1	9.0	0.26	10.2		9.111	75.4	24.0	0.51
BASE-2	2442		207				4.6		6	2.0	9.0	0.24	6.9		69.9	72.6	15.0	0.63
BASE-2	2000		707				. C	9.	10.8	2.2	0	0.21	6.6		98.9	10.9	26.0	0.72
6ASE-2	7 7 7 7		7 .				9	10.0	10.4		0.2	0.23	10.3		102.7	71.8	18.0	0.89
BASE-2	4442		767				88.0	10.2	•	.	.	0.14	9.0		97.8	61.1	20.0	0.56
BASE-2	2 5 5 5		667						10.7	6.	6.0	0.19	10.4		105.9	6.9	22.0	99.0
BASE-2	***		582			3				•	8.0	0.19	8.6		99.8	66.2	18.0	0.72
BASE-2	***		997	: :					10.2	6.	9.0	0.21	6.6		105.1	83.3	21.0	0.71
BASE-2	444		182	9.79		2 6	. C	9.01	4.6	2.2	. .	0.23	10.3		97.7	7.8.7	28.0	0.54
DASE-2	7777		303	D .						•	-	0.22			96.4	63.2	9.6	16.0
BASE-2	4444		308		1.19			•				2.0	10.3		96	74.0	19.0	0.97
BASE-2	7777	168	290	4 B . B	7.0	* D		7.11		: :						71.3		. 54
BA SE - 2	7777	187	302	89.3	0 . 60	-	0.74	12.9	9. [* .	•	67.0	: :					•
BASE-2	1111	168	309	88.3	0.52	0.12	0.73	12.5		7.7	.	77.0	F. 1		, e			
BASE-2	4442	501	175	52.2	0.20	0.28	0.80	- •	~	· ·	•		: :		· ·	, ,	2 -	
BASE-2	4442	503	181	6.8	0.31	0.19		۷.0	~ .	.		<u>.</u>						2, 0
BASE-2	4442	503	191	64.3	0.52	0.09	0.53	6	-	2.0	D .	e	-		D D	> •) •	:

MARF EFIS SIII

DLCO FVC FEVT PEFA

1114	EXPT	EXPT ANIMAL GRAMS	GRAMS	≩	COVN	1	CCORD	716	2	2 2	2	01.00	1					
	•													;				;
3 - 4	4443	104	171	17.1	0.28	0.21	0.53	9.3	6.3	.	o. -	0.11	7.	ĩ	C . 3	6 · · · · · · · · · · · · · · · · · · ·	•	? D
	4442	80	193	61.7	6.48	0.11	0.57	9	8.7	2.1	9.0	0.19	7.	7.		61.9	18.0	0.47
		101		63.7	0.25	0.26	0.36	1.4	6.3	9 .	-:	9.16	•	_	_	30.8	- - -	0.70
		203	178	4.10	0.26	0.27	0.84	-:	9 .1	2.0	6.0	0.18	-	73		70.3	20.0	
		808	173		0.25	0.22	0.41	7.8	9.	9.	6.0	0.18	٧.٥		_	74.1		0.72
		=	171	8.6	0.26	0.28	09.0	9.3		1 .9	1.2	9.16	8.2	0	_	71.7	17.0	0.76
7-3646			173		0.34	0.14	0.55	9.8	9.7	2.2	0.8	0.15	6.3	79	_	67.3	9.0	. 6
7-10-0				1.87	9.14	0.13	0 . 48	9.1	7.4	2.5	9.	0.13	7.8	7.5	_	6.0	14.0	0.73
7-1646				5.8.2	0 . 70	0.14	0.58	9.7	8.7	2.1	1.0	0.23	6.9	7.2	_	87.6	22.0	9.0
7-3646					0.29	0.19	0.44	9.0	8 .1	2.0	6.0	0.16	6.3	5	90.9	77.8	22.0	0.64
7-3646			182	8.	9.34	0.18	94.0	4.4	7.3	6.1	1.1	0.13	3 .	62		88.8	19.0	0.36
7-3646					0.21	0.36	0.32	10.1	6.9	4.8	4.2	9.11	-:	43		13.0	9.0	0.64
7-36-6				41.4	0.28	0.17	0.63	9.5	7.8	2.3	9.	0.12	7.1	6 2	66.2	39.1	16.0	99.0
7-36-7				74.2	0.49	0.09	0.65	12.2	11.1	2.9	1.1	0.24	11.6	70	_	80.7	21.0	0.58
7-012				109.7	0.71	0.04	96.0	19.1	18.8	3.7	9.0	97.0	17.7	70	-	123.8	41.0	0.48
7-014					. 4	0.11	0.82	13.4	12.6	3.8	6.0	0.25	12.4	8 9	116.5	57.5	24.0	0.64
7-016				105.2	0.53	60.0	0.75	13.2	12.0	8.2	1.2	0.28	11.9	67		72.6	27.0	0.83
7-014				101	0.62	0.27	1.1	10.5	17.2	0.4	1.3	0.23	16.9	11		12.1	32.0	6.63
				161.7	08.0	0.08	1.13	18.2	17.3	3.1	6.0	0.23	16.1	9 9		91.8	29.0	0.44
	***	107		- M	0.50	0.12	0.79	12.4	11.3	7.7	-:	0.23	12.2	29	_	76.5	9.0	
	4442		329	4.78	0.61	0.08	0.74	12.2	11.3	2.3	6.0	0.23	11.9	5		83.4	24.0	0.50
M10-2	7117	19	290	9.1.6	0.59	0.10	0.77	13.4	12.1	2.6	. J	0.23	11.8	69	_	17.8	24.0	9.38
MID-2	7777	162	194	118.0	0.75	0.03	1.14	18.3	16.9	3.2	.	0.24	16.4	73	168.4	121.8	33.0	9.0
E 10-2	1111	163	296	1.68	0.39	0.12	0.92	15.3	13.3	3.2	2.0	0.28	13.2	7		78.6	26.0	8.58
M10-2	***	164	310	0.69	0.39	0.21	0.48	13.8	12.5	2.7	1.3	0.29	12.3	9	_	77.0	23.0	9.60
M10~2	1111	165	309	73.2	0.82	0.03	0.82	14.2	13.0	7.6	1.3	0.26	13.1	69	123.6		26.0	9.0
10.1	7777	186	293	96.5	0.43	0.10	0.79	12.8	12.5	2.5	0.3	0.26	12.0	7		66.7	9.6	9.26
M10-2	7777	187	303	89.8	0.52	0.13	0.62	13.5	12.5	2 . 6	0.	0.21	12.7	-		45.9	20.0	0.52
M10-2	1111	1 2 2		103.8	0.55	0.09	0.81	1.1	12.8	2.8	9.	0.26	12.6	99	_	75.5	23.0	9.39
M10-2	4442	501		66.8	0.46	0.13	0.55	0 .6	8.8	•	9.5	0 . 1 \$	4 .	0	_	70.4	21.0	99.0
M10-2	4442	209	185	74.5	0.31	0.15	0.84	9.4	8.8	6.	9.0	0.14	2.7	-		67.5	21.0	9.0
M10-2	4442	603	196	80.9	0.32	0.21	0 . 60	9 .4	- 6	7.0	9.	6 ·	n .	9 (
M10-2	4442	804	181	69.9	0.38	0.18	0 . 59		6.	2.4	7.5	e	en .	29				
M10-2	4442	808	195	80.8	0.31	0.19	0.63	•	-	•. -	۸.۵	5		ς ;				
M10-2	4442	909	182	95.9	0.39	91.0	0 . 0	14.2	13.1	3 . 8	-:	0.17	12.7	1.		203.5	9.75	20.0
K10-2	4442	607	184	81.3	0.32	0.29	99.0	10.4	9.7	8 .	٥.٦	91.0		7.5		69.4	0.12	79.0
M10-2	4442		184	65.1	0.39	0.21	0.48	9.3	9.1	2.8	1.2	0.19	9.8	76	_		21.0	99.0
M10-2	***		181	92.1	0.45	0.14	9.0	15.9	14.3	3.7	9.	0.18	14.0	7.2		6.76	25.0	66. D
M10-2	***	562	186	82.3	0.49	0.09	1.00	16.1	14.8	2.9	1 .3	9.14	14.7	9			32.0	09.0
H10-2	4444	563	117	99.9	0.53	90.0	19.0	10.2	6.7	6.	9.0	9.20	6.9	9 /	105.3	73.2	9.62	
M10-2	4444	564	190	64.5	0.52	0.14	0.69	10.5	٠. •	2.3	-	9		2	~	B. 9	D . 6 Z	• • •

									5 .					•				
1 I M C	EXPT	EXPT ANIMAL GRAMS	GRAMS	Ì	CDYN	ī	CCOND	116	^ C	FRC	2	orco	rvc	TEV-	PEF8	MAEF	EF10	
M10-2	1111	8 8 8	182	119.6	0.48	0.10	0.93	16.3	14.2	3.3	-:	0.21	14.0	7.3	139.6	106.6	31.0	0.83
MI 0-2	1111	9 9 9	183	48.7	0.41	0.14	0.56	9.2	8.8	₹.	0.3	0.14	9.8	11	92.8	70.0	14.0	0.70
M10-2	***	199	184	65.4	0.25	0.19	0.71	10.8	. 5	2.2	0.	0.18	9.6	73	99.8	68.7	21.0	0.62
M10-2	1111	:	187	1.99	0.83	0.14	0.64	10.0	- 6	2.1	6.0	0.18	4.6	7.8	93.1	78.8	23.0	0.89
E0E-2	4442	101	303	78.3	0.45	0.15	0.73	14.0	12.4	2.8	1.6	0.27	11.8	9	116.6	76.8	18.0	0.63
£0E-2	4442	102	331	79.2	99.0	0.10	0.75	12.2	11.4	2.7	9.0	0.25	10.9	7.6	107.9	88.8	27.0	0.77
E0E-2	4442	103	314	72.3	0.44	0.17	0.72	11.7	1.1	9.	0.3	0.25	10.7	11	107.7	72.6	27.0	0.61
£01-2	4442	104	328		0.34	9.14	0.93	13.1	12.1	2.2	0.	0.32	11.8	2	116.0	78.3	28.0	0.53
E0E-2	4442	101	916	79.8	0.56	0.0	0.70	13.4	12.4	7.7	0.	0.31	12.1	6.7	116.8	74.1	23.0	0.63
E0E-2	4442	0	340	78.4	0.43	0.0	0.65	1.8	1.0	2.1	8.0	0.33	11.3	09	89.6	57.7	20.0	0.88
E0E-2	4442	101	333	68.3	0.37	0.12	0.64	12.2	0.1	2.8	1.2	0.30	10.6	7.0	95.2	74.1	20.0	0.36
E0E-2	4442	100	344	76.4	09.0	0.11	0.91	14.2	12.8	2.8	9.	0.32	12.7	6.9	117.8	56.3	20.0	1.03
E0E-2	***	=	317	64.3	95.0	0.10	0.63	10.8	10.4	1.8	4.0	0.29	10.4	7.0	105.8	68.7	20.0	1.22
E0E-2	***	162	313	0.4.0	0.58	0.15	0.10	1.9	10.8	2.1	.	0.27	10.5	7.	102.3	73.8	17.0	0.42
E0E-2	111	163	337	78.9	0.42	0.17	0.17	13.0	11.7	2.4	1.3	0.28	11.5	69	100.7	82.9	23.0	1.02
E0E-2	1111	791	333	96.6	0.35	9.14	0.74	13.8	12.4	2.9	* .	0.34	12.2	8.8	116.4	78.3	22.0	0.57
EOE-2	***		328	71.2	0.82	0.12	0.75	12.8	11.3	5.6	1.3	0.27	12.1		117.7	76.0	24.0	0.89
E0E-2	1111	16	314	68.7	9.36	0.18	0.78	12.8	12.0	2.3	8.0	0.30	12.3	29	103.8	8 1.4	26.0	0.68
£0£-2	***	187	324	78.9	0.42	0.22	0.74	11.1	10.9	2.1	0.2	0.29	11.5	9	91.8	74.0	22.0	0.69
E0E-2	4444	=	329	96.0	0.39	9.18	0.78	13.6	12.3	2.8	£.	0.27	1.9		114.2	79.0	21.0	9.80
E05-2	4442	601	188	8.8	0.39	0.17	0.68	7.6	9.0	2.0	7.0	0.21	6.9		96.2	72.1	23.0	0.81
E0E-2	4442	802	193	74.9	0.32	0.19	0.69	9.1	8.8	9.	0.3	0.19	2.9	7.6	9.98	68.4	19.0	0.0
E0E-2	4442	803	208	96.7	0.47	0.14	0.69	10.3	10.1	1 .	0.2	0.23	4.6		99.7	76.7	23.0	0.43
E0E-2	4442	804	191	70.5	0.34	0.17	0.68	10.2	4.6	2.1	7.0	0.21	4.6	7.8	97.4	79.0	22.0	9.0
E0E-2	4442	808	206	56.1	0.24	0.22	0.67	13.1	10.5	3.9	5.8	0.21	10.3		109.2	84.1	22.0	0.47
£0E-2	4442	808	193	11.1	0.32	0.18	0.54	9.1	8 . 7	•	e. -	0.17	7.6	8	93.1	74.4	. o	- 15
E0E-2	4442	507	200	72.7	0.39	0.15	0.65	10.4	9	2.2	6.0	0.20	. s	. 22	8.8	72.4	22.0	
E0E-2	4442	808	197	88.4	0.23	0.22	0.57	.	6.3	1.7	9.0	0.20	8.2	8 2	97.1	77.0	e .	90
E0E-2	4444	561	201	63.6	0.28	0.22	0.61	10.4	10.0	6.	4.0	0.19	.	5	103.8	79.5	9.	. 50 50 50 50 50 50 50 50 50 50 50 50 50 5
E0E-2	1111	862	200	60.3	0.51	0.24	0.61	9.7	9.3	6.	9.0	0.22	8.2		72.0		D. M	16.0
E0E-2	1111	863	189	84.5	0.32	0.19	0.68	10.4	4.6	2.1	6.0	0.22	4 .	49	107.7	79.3	22.0	9.20
£06-2	1111	9 9	204	66.4	0.38	0.16	0.67	1.5	10.4	2.3	-:	0.22	10.3	92	112.0	80.9	27.0	0.55
E0E-2	1111	8 6 8	190	62.3	0.31	0.14	0.58	1.9	8.8	- .5	0.2	0.21	8.5	73	4.68	6.3	20.0	9.40
E0E-2	1111	866	199	87.9	0.28	0.17	0.59	9.6	6.0	.	6.0	0.18	8.7	7.2	92.2	68.8 8.8	20.0	0.58
E0E-2	***	567	200	40.3	0.28	0.20	0.65	10.6	9.3	2.0	-:	0.16	9.3	8 8	100.7	58.6	22.0	0.83
E0E-2	***	8 8 8	196	75.4	0.32	0.31	0.63	9.9	9.4	6.	9.0	0.19		11	88.0	74.3	24.0	90
REC-2	4442	101	339	75.5	0.32	0.17	0.79	12.6	11.8	3 . 6	9 .0	92.0	9 . E	69	110.0	74.5	26.0	9.38
REC-2	4442	102	355	73.3	0.74	0.07	0.78	11.7	11.3	6.	٠.	0.31	4 . E	69	104.8	17.1	27.0	98.0
REC-2	4442	103	341	94.9	0.33	0.14	0.81	13.2	12.3	2.3	6.0	0.24	12.0	70	110.9	86.4	26.0	0.85
REC-2	4442	104	361	96.3	0.46	0.12	0.85	13.6	12.6	2.8	<u>-</u>	0.28	12.0	29	117.6	76.4	21.0	0.67
REC-2	4442	105	347	70.3	0.34	0.25	0.75	11.8	11.3	2.2	0.3	0.31	11.7	63	97.2	8.8	18.0	0 . 48

4	EXF. ARIMAL CHATS		Ì		;								1		,		
		1			1		! ! !	!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!	! ! !	! !			\ \				
		•	7.4	7	-	0.63	12.1	9.1	1.1	0.	0.30	11.4	.	97.1	63.3	28.0	0.81
•							-		-	6.0	0.34	10.8	7	93.6	17.8	20.0	0.82
•							1, 1	-	7.7	-	0.28	11.6	63	108.0	63.1	24.0	0.60
•		77.	? .				:	•			0.30	11.7	0,2	110.0	9.19	24.0	0.68
•			B . 6	. D	9		? .			: :	,,	11.2	7.	116.2	82.8	21.0	9.0
•		337	68		0.13	67.0	6.21	•	•	: :		12.0	. 4	112.8	17.1	22.0	0.89
•		98	81.2	9 .	E - 13	0.74	D. 6					:		16.9	94.4	24.0	0.57
•		9 9 9	90°	9.0	60.0	0.77	13.2	12.1	7 . 7	<u> </u>				117.7	6.00	26.0	0.74
*****	168	358	17.8	0.45	0.10	0.82	13.	12.4	7.7	1.2	0.20	9.7.	2 ;			17.0	0.54
•		346	1.1	0.65	0.10	0.71	- - -	12.6	e.	2.1	0.30	6.31	. :				67.0
•		347	102.0	0.44	0.20	0.73	12.9	12.0	8 . 8	e.	0 . 28	12.0	•	* · · · · · · · · · · · · · · · · · · ·			
Ī		348	100.4	0.59	0.07	0.80	14.2	12.8	3.1	▼ .	0.26	12.8	5	112.8	9.60	0.62	
•		194	74.1	0.49	0.15	0.64	10.4	9.5	2.2	-:	0.20	8 .3	e •	74.9		D	6 (
166-7 444		202	93.3	0.29	0.20	0.65	10.0	6	5.	6.0	0.17	0	6	60 . 50 .	26.1	•	29.0
		221	105.5	0.37	0.17	0.69	10.4	10.1	2.3	0.2	0.23	10.2	9.	102.8	8.9	58.0	0.49
		201	53.2	0 . 29	0.17	0.54	9.3	8.8	2.1	0.7	0.17	8.2	8 2	97.0	17.4	21.0	0.87
		20.0	73.4	00.0	0.18	0.69	11.5	10.3	2.5	1.2	0.19	9.7	4.7	72.1	28.7	.	0.85
			73.2	0.28	0.27	95.0	8.8	8.3	-	9.0	9.16	8.2	7.5	81.2	84.6	18.0	9.0
					-	0.50		8.7	9.	6.0	0.21	•	7.9	100.8	69.4	19.0	0.39
-						. B. C.	•	8.8		8.0	0.21	9.8	7.9	91.6	75.1	19.0	0.88
							10.4	-	2.2		0.21	10.6	7	76.8	20.1	• •	0.48
_							•	-		0.3	0.18	8.3	63	74.9	1.1	- - -	0.77
							. :	-		-	0.20	10.2	70	1.66	71.3	22.0	0.56
			* .							-	0.21	10.6	80	89.4	42.7	13.0	0.51
		211			77.0		•		•		y	•	7.8	80.3	64.2	19.0	0.77
		201	84.2	E . D	6 7 . 0	00.0	• •		•	? .				102.0	78.7	24.0	0.86
-		208	67.1	0.49	0.18	79.0	F. 91	D	n (70.6	7.0	0.	0.43
		211	17.1	0.39	0.46	0.63	10.2	50 ·	F (7 (, ,		•	0 4	98
REC-2 444		201	58.9	0.26	0.28	0.63	9.6	6	٥.	~	0.17	D .	9	0.0	n	•	

NOTE: Time codes are defined as BASE = base level evaluations made prior to exposure; MID = evaluations made mid-way through the 13-week exposure; EDE = evaluations made after the 4-week recovery peried. The code with -1 and -2 indicate evaluations relate to Phase III, Part 1 or Phase III, Part 2, respectively.

APPENDIX M: GROUP SUMMARIES OF MISTOPATHOLOGY OBSERVATIONS

HASSIL ALYCOLOGN TATE TYPE 11 4371 1.0 mg/m3 0 0.37 HALE ECG 0							HE STIMALOUT LANCE				
### CONFINATION EAR ANIMAL SACRIFICE EPITHELIAL MACROPHAGE ####################################							NASAL	ALVEOLAR	TYPE 11		MASAL
4371 1.0 mg/m3 0 037 MALE E0E 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	EXPT	CONCENTRATION OF CU-Zn	EAR		ANIMAL	SACRIFICE	EPITHELIAL Athophy	MACROPHAGE	PNEUMOCYTE Hyperplasia	ALVEOL1718	GOBLET CELL HYPERPLASIA
1.0 mg/m3		3 4 4 1 1 1 1 1 1 1 5 5 5 5 5 5 5 5 5 5 5		!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!		1 1 1 1 1 1 1 1 1	I .	; 1 1 1 1 1 1 1 1 1	1 	1 1 1 1 1 1 1 1 1	i
1.0 mg/m3	4371		0	037	MALE	EOE	•	•	•	0	0
1.0 mg/m3	4371		•	038	MALE	E 0 E	•	6	0	0	•
1.0 mg/m3	4371		•	040	MALE	REC	0	0	0	0	B
1.0 mg/m3	4371		•	043	MALE	E0 E	0	•		6	0
1.0 mg/m3	4371		•	4 4 0	MALE	E0E	0	0	0	•	•
1.0 mg/m3	4371		•	046	MALE	EOE	0	0	0	0	0
1.0 mg/m3	4371		•	048	MALE	REC	0	•	-	•	•
1.0 mg/m3	4371		•	049	MALE	E0 E	0	0	0	•	•
1.0 mg/m3	4371		•	020	MALE	REC	0	•	6	6	•
1.0 mg/m3	4371		•	051	MALE	REC	0	6	•	•	•
1.0 mg/m3	4371		•	052	MALE	E0E	0	•	0	•	•
1.0 mg/m3	4371		•	055	MALE	BEC	0	6	0	•	•
1.0 mg/m3	4371	•	0	056	MALE	REC	0	6	ò	•	0
1.0 mg/m3	4371	•	σ	059	MALE	EOE	-	•	•	0	0
1.0 mg/m3	4371	•	•	090	MALE	REC	0	•	•	•	•
1.0 mg/m3	4371	0	0	190	MALE	EOE	0	0	•	0	•
1.0 mg/m3	4371		•	7 9 0	MALE	BEC	Đ	0	•	0	•
1.0 mg/m3	4371	0	o	063	MALE	EOE	0	•	0	0	0
1.0 mg/m3	4371	•	•	990	MALE	REC	6	•	•	0	0
1.0 mg/m3	4371	_	•	790	MALE	REC	0	•	•	0	0
1.0 mg/m3	4371	_	•	070	MALE	REC	0	6	•	0	•
1.0 mg/m3	4371	•	•	072	MALE	EOE	_	•	•	•	•
1.0 mg/m3	4371	0	0	637	FEMALE	EOE	-	•	•	0	•
1.0 mg/m3	4371	0	•	540	FEMALE	REC	0	•	0	9	•
1.0 mg/m3	4371	0	•	541	FEMALE	REC	•	•	•	•	0
1.0 mg/m3	4371	0	•	543	FEMALE	E0E	•	•	•	0	•
371 1.0 mg/m3 0 547 FEMALE E0E 0 0 371 1.0 mg/m3 0 549 FEMALE E0E 0 0 371 1.0 mg/m3 0 550 FEMALE REC 0 0 371 1.0 mg/m3 0 554 FEMALE REC 0 0 371 1.0 mg/m3 0 555 FEMALE REC 0 0 371 1.0 mg/m3 0 556 FEMALE REC 0 0	4371		σ	544	FEMALE	REC	•	•	0	0	•
371 1.0 mg/m3 0 548 FEMALE E0E 0 0 371 1.0 mg/m3 0 550 FEMALE REC 0 0 371 1.0 mg/m3 0 554 FEMALE REC 0 0 371 1.0 mg/m3 0 555 FEMALE REC 0 0 371 1.0 mg/m3 0 556 FEMALE REC 0 0	4371	0	σ		FEMALE	E 0 E	•	•	0	0	0
371 1.0 mg/m3 Q 549 FEMALE EOE O O O O O O O O O O O O O O O O O	4371	0	•	548	FEMALE	E 0E	0	0	•	0	0
371 1.0 mg/m3 Q 550 FEMALE REC 0 0 0 371 1.0 mg/m3 Q 554 FEMALE REC 0 0 0 371 1.0 mg/m3 Q 556 FEMALE REC 0 0 0 0 371 1.0 mg/m3 Q 556 FEMALE REC 0 0 0	4371	0	•	549	FEMALE	EOE	0	•	•	6	0
371 1.0 mg/m3 Q 554 FEMALE 371 1.0 mg/m3 Q 555 FEMALE 371 1.0 mg/m3 Q 556 FEMALE	4371	•	σ	550	FEMALE	REC	•	0	•	6	0
371 1.0 mg/m3 Q 555 FEMALE 371 1.0 mg/m3 Q 556 FEMALE	4371	0	σ	554	FEMALE	EOE	0	0	•	0	0
1.0 mg/m3 Q 556 FEMALE	4371		σ	555	FEMALE	REC	•	•	•	•	0
	4371	0	σ	8	FEMALE	MEC	•	•	0	•	•

RESPINATORY TRACT LESION CATEGORY AND SEVERITY OF LESION

						TASAN	ALVEOLAR	TYPE 11		14245
	HOLLERTER! SH	EAR	ANIMAL	ANIMAL	SACRIFICE	EPITHELIAL	MACROPHAGE	PNEUMOCYTE		GOBLET CELL
E 3 GMD E	0 CC - 2 3	146	NUMBER	SEX	CODE	ATROPHY	HYPERPLASIA	HYPERPLASIA	ALVEOLITIS	HYPERPLASIA
		•				•	c	6	•	0
4371	1.0 mg/m3	•	0	FMALE) U E	•		. (•	c
4371	1.0 mg/m3	•	860	FEMALE	RC	•	6	B	> (•
4371		0	562	FEMALE	REC	•	•	•	0	.
4371		ø	563	FEMALE	MEC	ø	0	•	•	•
77.7		•	564	FEMALE	EOE	•	•	•	0	•
4371		0	9 9 9	FEMALE	REC	•	•	0	0	0
		0	567	FEMALE	EOE	•	0	0	•	0
		•	. S.	FEMALE	EOE	•	6	•	•	•
	•	•	570	FEMALE	EOE	•	•	•	0	0
		•	571	FEMALE	EOE	•	6	•	0	0
4372	. ~	•	075	MALE	EOE	0	-	-	-	•
4372		•	076	MALE	REC	•	0	0	0	•
4372		•	079	MALE	REC	0	-	-	0	0
4372	~	•	080	MALE	EOE	0	-	-	0	0
4372	~	•	180	MALE	EOE	-	0	•	0	•
4372	~	•	0.85	MALE	EOE	•	0	•	0	•
4372		•	980	MALE	REC	-	•	•	0	0 (
4372	3.2 mg/m3	•	087	MALE	EOE	•	-	0	0	5 (
4372	3.2 mg/m3	•	060	MALE	EOE	-	-	-	-	0 1
4372		•	0 9 2	MALE	REC	0	•	•	o	o (
4372		•	093	MALE	BEC	•	0	•	0	o (
4372		•	860	MALE	BEC	0	-	•	0	0 (
4372		•	960	MALE	REC	•	0	0		o (
4372	~	•	100	MALE	EOE	•	-	-	-	0
4372		0	101	MALE	EOE	•	0	0	6	0 (
4372		•	102	MALE	REC	•	-	-	0	D (
4372	3.2 mg/m3	•	103	MALE	EOE	•	-	•	0	D (
4372		•	104	MALE	EOE	•	•	0	0	D (
4372	~	•	109	MALE	EOE	•	-	-	-	
4372		•	:	MALE	MEC	•	0	0	•	•
4372	3.2 mg/m3	•	112	MALE	NEC	0	•	0	0	0
4372	3.2 mg/m3	•	878	FEMALE	EOE	•	-	•	0	0
4372		•	576	FEMALE	REC	•	-	-	•	o
4372	~	0	578	FEMALE	REC	•	0	•	6	6
1372	~	0	5 7 9	FEMALE	REC	0	6	•	0	•
4372	~	•	580	FEMALE	EOE	•	6	•	0	0

RESPIRATORY TRACT LESION CATEGORY AND SEVERITY OF LESION

EXPT	CONCENTRATION	EAR	ANIMAL	ANIMAL	SACRIFICE	EPITHELIAL	MACROPHAGE	PNEUMOCYTE		GOBLET CELL
-	OF Cu-Zn	TAG	NUMBER	SEX	CODE	ATROPHY	HYPERPLASIA	HYPERPLASIA	ALVEOLITIS	HYPERPLASIA
; ; ; ; ; ;										
4372	3.2 mg/m3	0	6.6.5	FEMALE	REC	6	-	-	•	•
4372	3.2 mg/m3	•	5.8.8	FEMALE	EOE	6	-	0	0	0
4372	3.2 mg/m3	o	290	FEMALE	E0E	0	-	0	_	0
4372		0	163	FEMALE	REC	0	•	•	0	•
4372		0	592	FEMALE	EOE	0	0	0	•	•
4372		0	593	FEMALE	EOE	•	0	0	•	•
4372	~	0	598	FEMALE	REC	6	0	•	•	•
4372	~	0	8 6 9	FEMALE	EOE	•	-	-	-	•
4372	~	6	909	FEMALE	REC	•	0	•		
4372	~	•	802	FEMALE	REC	•	0	0	•	•
4372	~	•	603	FEMALE	EOE	-	-	-	-	•
4372	~	σ	604	FEMALE	REC	0	0	•	•	•
4372	~	•	808	FEMALE	E0E	0	-	0	•	0
4372		ø	909	FEMALE	REC	•	0	•	•	•
4372		0	808	FEMALE	EDE	•	0	•	6	•
4372		0	609	FEMALE	EOE	•	-	•	•	0
4373	10 mg/m3	•		MALE	EOE	-	~	-	~	0
4373	10 mg/m3	o	1.6	MALE	REC	-	-	-	•	0
4373	10 mg/m3	0	117	MALE	AEC	~	-	-	•	0
4373	10 mg/m3	0	119	MALE	REC	•	-	-	•	0
4373	10 mg/m3	0	122	MALE	REC	0	-	-	•	0
4373	10 mg/m3	0	125	MALE	EOE	-	•	0		0
4373	10 mg/m3	•	126	MALE	£0£	~	•	0	•	0
4373	10 mg/m3	0	127	MALE	REC	•	-	-	0	•
4373	10 mg/m3	•	128	MALE	EOE	-	-	-	-	0
4373	10 mg/m3	•	130	MALE	EOE	-	-	-	-	0
4373	10 mg/m3	•	132	MALE	EOE	-	-	-	-	•
4373	10 mg/m3	•	133	MALE	EOE	-	-	-	-	0
4373	10 mg/m3	•	134	MALE	REC	•	-	-	0	0
4373	10 mg/m3	•	135	MALE	REC	-	~	~	0	0
4373	10 mg/m3	•	136	MALE	EOE	_	~	~	~	0
4373	10 mg/m3	•	140	MALE	EOE	0	-	-	-	0
4373	10 mg/m3	0	-	MALE	EOE	~	~	7	~	6
4373	10 mg/m3	•	142	MALE	EOE	~	~	-	7	6
4373	10 mg/m3	0	**	MALE	REC	0	-	-	6	6
4373	10 mg/m3	•	147	MALE	REC	-	-	-	0	0

RESPIRATORY TRACT LESION CATEGORY AND SEVERITY OF LESION

#UMBER 4373 4373 4373 4373 4373 4373 4373	10 mg/m3 10 mg/m3 10 mg/m3 10 mg/m3 10 mg/m3 10 mg/m3	170	NUMBER	· ;	CODE	ATROPHY	HYPERPLASIA	HYPERPLASIA	ALVEOLITIS	HYPERPLASIA
) 	;		ì				1
		•								
			149	MALE	REC	•	-	-	•	•
		σ	615	FEMALE	EOE	- -	~	~	~	•
		•	616	FEMALE	REC	0	-	_		•
		0	617	FEMALE	EOE	-	~	-	~	•
		•	618	FEMALE	REC	•	-	-	•	•
		•	620	FEMALE	EOE	0	~	-	~	•
		•	624	FEMALE	REC	-	-	-	0	•
		•	628	FEMALE	EOE	•	-	-	-	0
		0	626	FEMALE	REC	•	-	_	•	0
	10 mg/m3	•	627	FEMALE	REC	•	-	-	•	•
	10 mg/m3	•	628	FEMALE	EOE	-	-	-	-	•
	10 mg/m3	•	630	FEMALE	E0E	•	-	-	-	6
4373	10 mg/m3	•	631	FEMALE	REC	•	-	-	0	6
4373	10 mg/m3	•	632	FEMALE	E0E	•	-	-	-	6
4373	10 mg/m3	o	633	FEMALE	EOE	-	-	-	-	ø
	10 mg/m3	•	634	FEMALE	REC	-	_	-	0	0
4373	10 mg/m3	•	636	FEMALE	EOE	-	0	•	0	•
4373	10 mg/m3	•	638	FEMALE	E0E	•	0	•	0	0
4373	10 mg/m3	•	639	FEMALE	REC	-	-	-	0	•
4373	10 mg/m3	•	642	FEMALE	REC	0	-	-	0	0
4373	10 mg/m3	0	643	FEMALE	EOE	0	-	•	-	0
4373	10 mg/m3	•	648	FEMALE	REC	0	-	-	•	0
4373	10 mg/m3	0	650	FEMALE	REC	•	-	-	•	0
4442	O (SHAM)	G	109	MALE	REC	0	0	•	•	•
4442	O (SHAM)	ø	1.0	MALE	REC	0	•	•	•	0
4442	O (SHAM)	9	-11	MALE	£0£	0	•	•	•	•
4442 0	(SHAM)	9	112	MALE	EOE	0	•	•	•	0
4442 0	(SHAM)	•	1.1	MALE	BEC C	0	•	0	•	•
4442 0	(SHAM)	œ.	115	MALE	EOE	0	•	0	0	•
4442 0	(SHAM)	G	1.6	MALE	EOE	0	•	0	•	•
4442 0	(SHAM)	G	116	MALE	REC	0	•	•	0	•
4442 0	(SHAM)	•	119	MALE	EOE	0	•	0	•	0
4442 0	(SHAM)	9	120	MALE	EOE	0	•	•	•	•
4442 0	(SHAM)	o	121	MALE	REC	0	•	0	•	0
4442	(SHAM)	G	122	MALE	EOE	0	•	0	•	0
4442 0	(SHAM)	o	123	MALE	REC	0	•	•	•	•
4442 0	(SHAM)	o	127	MALE	EOE	0	•	0	•	•

RESPIRATORY TRACT LESION CATEGORY AND SEVERITY OF LESION

						HASAL	ALVEOLAR	TYPE II		MASAL
EXPT	CONCENTRATION OF Cu-Zn	EAR TAG	ANIMAL	ANIMAL Sex	SACRIFICE CODE	EPITHELIAL Atrophy	MACROPHAGE	PNEUMOCYTE Hyperplasia	ALVEOLITIS	GOBLET CELL Hyperplasia
					1	1	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1			
4442	((() () () ()	•	128	MALE	EOE	0	•	•	•	•
4442		8	130	MALE	REC	0	0	6	0	•
4442	_	o	131	MALE	MEC	0	•	0	0	•
4442	O (SHAM)	9	132	MALE	R C	0	•	0	•	•
4442	G (SHAM)	•	134	MALE	REC	6	0	•	•	•
4442	O (SHAM)	v	136	MALE	EOE	0	0	0	0	•
4442	O (SHAM)	•	137	MALE	REC	•	0	•	•	0
4442	O (SHAM)	G	138	MALE	EOE	•	0	•	•	0
4442	O (SHAM)	G	609	FEMALE	EOE	•	0	•	•	•
4442	_	9	510	FEMALE	REC	•	0	•	•	0
4442	_	0	118	FEMALE	REC	•	-	•		0
4442		9	612	FEMALE	REC	•	0	0	•	•
4442	O (SHAM)	•	513	FEMALE	REC	•	6	•	•	0
4442	O (SHAM)	U	5 1 5	FEMALE	MEC	•	0	0	•	0
4442	O (SHAM)	G	818	FEMALE	REC	0	0	•	•	0
4442	O (SHAM)	ø	517	FEMALE	EOE	•	-		0	0
4442	O (SHAM)	9	518	FEMALE	MEC	0		0	•	6
4442	(SHAM)	•	519	FEMALE	EOE	•	0	•	•	0
4442	O (SHAM)	O	520	FEMALE	EOE	•	•	•	•	•
4442	O (SHAM)	9	522	FEMALE	REC	•	-	•	•	0
4442	O (SHAM)	•	523	FEMALE	REC	•	0	•	•	•
4442	O (SHAM)	G	524	FEMALE	EOE	0	0	0	•	0
4442	O (SHAM)	G	526	FEMALE	EOE	0	0	•	•	•
4442	G (SHAM)	G	527	FEMALE	EOE	0	0	0	•	0
4442	O (SHAM)	G	530	FEMALE	REC	0	-	0	•	•
4442	O (SHAM)	o	531	FEMALE	EOE	•	•	0	0	•
4442	G (SHAM)	5	632	FEMALE	EOE	0	0	0	0	•
4442	O (SHAM)	ی	633	FEMALE	EOE	0	•	0	0	•
4442	O (SHAM)	•	838	FEMALE	REC	0	•	0	•	0
4442	O (SHAM)	G	538	FEMALE	EOE	0	•	0	•	•
4443	0.32 mg/m3	9	139	MALE	REC	•	•	6	0	•
4443	0.32 mg/m3	6	140	MALE	REC	0	0	0	•	6
4443	. 0.32 mg/m3	•	=	MALE	EOE	•	•	0	•	•
4443	0.32 mg/m3	9	142	MALE	REC	0	•	•	0	0
4443	0.32 mg/m3	ø	143	MALE	REC	0	•	0	0	0
4443	0.32 mg/m3	G	:	MALE	£0£	0	•	0	•	0
4443	0.32 mg/m3	Ç	145	MALE	EOE	٥.	•	0	0	•

RESPIRATORY TRACT LESION CATEGORY AND SEVERITY OF LESION

						MASAL	ALVEOLAR	TYPE 11		MASAL
			1477744	******	SACRIFICE	EPITHELIAL	MACROPHAGE	PNEUMOCYTE		COBLET CELL
ROMDER	OF Cu-Zn	176	NUMBER	9E X	CODE	ATROPHY	HYPERPLASIA	HYPERPLASIA	ALVEOLITIS	HYPERPLASIA
			1		1		 			
		c	146	MALE	E0 E	•	0	•	0	•
			147	MALE	REC	0	6	•	6	•
		• •	148	MALE	E0 E	6	0	0	0	0
4443	32	•	149	MALE	EOE	0	9	0	o	.
	3.3	•	150	MALE	MEC	0	0	•	0	•
2443		• •	151	MALE	360	0	0	•	0	•
			152	MALE	MEC	0	0	0	0	•
6669			153	MALE	EOE	0	0	0	•	•
777		6	154	MALE	EOE	•	•	•	0	•
		• •	1 6 6	MALE	REC	0	0	•	•	•
	6	•	156	MALE	E0E	0	0	0	0	0
		•	157	MALE	EOE	0	0	•	0	•
6000		•	158	MALE	REC	0	0	•	0	•
	3.2	•	159	MALE	EOE	0	0	•	•	•
6663	32	•	160	MALE	REC	•	6	0	0	•
4443		•	839	FEMALE	REC	•	0	0	•	•
6443		G	540	FEMALE	EOE	•	0	•	•	•
4443		G	541	FEMALE	REC	0	0	•	0	0
4443		G	542	FEMALE	E0 E	•	Đ	•	0	•
4443		•	543	FEMALE	REC	0	0	•	0	•
4443		0	544	FEMALE	EOE	•	0	•	•	5 (
4443		5	545	FEMALE	REC	•	6	•	0	.
4443		•	546	FEMALE	EOE	•	•	0	o 1	9 (
4443		G	547	FEMALE	EOE	•	0	•	0 1	5 (
4443		G	548	FEMALE	REC	•	•	•	B (.
4443		g	649	FEMALE	EOE	•	0	•	6 (5 (
4443		o	650	FEMALE	REC	0	0	.	D (.
4443		9	551	FEMALE	E 0 E	•	-	5	5 (5 (
4443		o	552	FEMALE	REC	•	0	•	ъ,	-
4443	0.32 mg/m3	v	653	FEMALE	REC	•	-	- 1	- (.
4443	0.32 mg/m3	9	554	FEMALE	REC	•	0	•	5 (.
4443	0.32 mg/m3	9	655	FEMALE	E 0 E	•	0	0	D (.
4443		•	556	FEMALE	BEC	•	6	•	o (5 (
4443	.32	g	557	FEMALE	REC	•	6	0	6	5 (
4443	.32	9	558	FEMALE	EOE	•	•	0	0 1	5 (
4443	32	G	5 5 9	FEMALE	EOE	•	•	•	6	.
4443	.32	o	960	FEMALE	£0£	e	6	6	0	Ð

RESPIRATORY TRACT LESION CATEGORY AND SEVERITY OF LESION

						MASAL	ALVEOLAR	11 3411		37578
RXPT	CONCENTRATION OF CU-Zn	EAR	ANIMAL NUMBER	ANIMAL Sex	SACRIFICE	EPITHELIAL Atrophy	MACHOFIAGE	NYPERPLASIA	ALVEOLITIS.	MYPERPLASIA
,	3.2 mg/m3	•	170	MALE	ນ ຮ		•	•	•	•
111		•	171	MALE	350	6	•	•	•	•
***		5	173	MALE	REC	•	-	•	0	•
4444		•	174	MALE	REC	•	•	•	•	•
1111	~	O	175	MALE	EOE	•	0	•	0	•
4444		•	111	MALE	BEC	•	-	-	_	•
****		•	179	MALE	REC	•	•	•	•	•
***	3.2 mg/m3	9	180	MALE	EOE	0	-	•	0	•
***		•	181	MALE	EOE	0	-	-	0	•
***		•	182	MALE	EOE	0	•	•	•	•
***		G	184	MALE	REC	0	-	-	6	0
***	3.2 mg/m3	5	185	MALE	EOE	0	-	-	-	•
***		9	186	MALE	REC	0	0	0	0	•
1111		ø	187	MALE	EOE	0	6	•	0	0
1111	3.2 mg/m3	9	188	MALE	REC	0	•	8	0	0
1111	3.2 mg/m3	9	189	MALE	EOE	-	0	•	•	•
***	3.2 mg/m3	•	190	MALE	EOE	•	-	-	-	0
***		G	191	MALE	EOE	-	-		-	0
***	3.2 mg/m3	5	192	MALE	EOE	-	-	•	•	•
***	3.2 mg/m3	G	195	MALE	BEC	0	•	•	•	0
***	3.2 mg/m3	G	196	MALE	REC	0	•	0	•	•
***	3.2 mg/m3	o	197	MALE	E0E	•	-	0	-	•
1111	3.2 mg/m3	9	. 699	FEMALE	REC	0		•	0	0
****	3.2 mg/m3	•	570	FEMALE	REC	6	-	-	•	0
****	3.2 mg/m3	ø	573	FEMALE	EOE	0	•	•	•	6
1111	3.2 mg/m3	U	574	FEMALE	EOE	6	-	0	0	0
***	3.2 mg/m3	O	575	FEMALE	REC	•	-	-	•	•
***	3.2 mg/m3	0	576	FEMALE	REC	0	•	•	0	•
***	3.2 mg/m3	O	677	FEMALE	REC	6	6	6	0	0
1111	3.2 mg/m3	9	678	FEMALE	EOE	•	0	•	•	•
***	3.2 mg/m3	o	580	FEMALE	REC	0	•	0	•	0
***	3.2 mg/m3	o	581	FEMALE	EOE	•	0	•	0	•
***	3.2 mg/m3	U	582	FEMALE	REC	•	0	0	0	0
***	3.2 mg/m3	9	683	FEMALE	EOE	•	0	6	0	•
***	3.2 mg/m3	U	6.85	FEMALE	REC	•	6	•	0	•
***	3.2 mg/m3	O	586	FEMALE	EOE	0	•	•	0	•
•	•									

CONCENTRATION EAR ANIMAL SACRIFICE EPITHELIAL MACROPHAGE PNEUMOCYTE 3.2 mg/m3 G 509 FEMALE EOE 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0							MESFLAAICH	T THACT LESSON	TOTAL TOTAL CONTRACT CONTRACT PART OF THE CONTRACT OF THE CONT		
G 599 FEMALE G 590 FEMALE G 592 FEMALE G 595 FEMALE G 595 FEMALE G 595 FEMALE	- W - W - W - W - W - W - W - W - W - W	CONCENTRATION OF Cu-2n	# # # # # # # # # # # # # # # # # # #	ANIMAL	ANIMAL	SACRIFICE	NASAL EPITHELIAL ATROPHY	ALVEOLAR MACROPHAGE HYPERPLASIA	TYPE 11 PNEUMOCYTE HYPERPLASIA	ALVEOLITIS	MASAL GOBLET CELL NYPERPLASIA
3.2 mg/m3 G 690 FEMALE 3.2 mg/m3 G 691 FEMALE 3.2 mg/m3 G 694 FEMALE 3.2 mg/m3 G 695 FEMALE 3.2 mg/m3 G 696 FEMALE	<u> </u>	3.2 36/83	ø	6	FEMALE	E 0E	•	-	-	•	•
3.2 mg/m3 G 691 FEMALE 3.2 mg/m3 G 694 FEMALE 3.2 mg/m3 G 695 FEMALE 3.2 mg/m3 G 696 FEMALE	-	3.2 mg/m3	•	980	FEMALE	E0E	•	0		0	0
3.2 mg/m3 G 692 FEMALE 3.2 mg/m3 G 694 FEMALE 3.2 mg/m3 G 696 FEMALE 3.2 mg/m3 G 696 FEMALE	=	3.2 mg/m3	•	169	FEMALE	REC	0	6	•	0	0
3.2 mg/m3 G 594 FEMALE 3.2 mg/m3 G 595 FEMALE 3.2 mg/m3 G 696 FEMALE	=	3.2 mg/m3	8	692	FEMALE	BEC	0	0	•	0	•
3.2 mg/m3 G 595 FEMALE 3.2 mg/m3 G 696 FEMALE	=	3.2 mg/m3	•	694	FEMALE	EOE	•	0	•	•	•
3.2 mg/m3 G 696 FEMALE	=	3.2 mg/m3	9	595	FEMALE	REC	•	6	•	0	•
	=	3.2 mg/m3	ø	969	FEMALE	EOE	0	6	•	0	•

APPENDIX I. SUMMARY TABLES OF ENDPOINT EVALUATIONS AND STATISTICAL COMPARISONS BETWEEN PHASE III, PARTS 1 AND 2 FOR F344/N RATS EXPOSED TO 3.2 mg Cu-Zn ALLOY POWDER/m³

This appendix presents tabulated data for Phase III, Parts 1 and 2, and a summary table of statistical comparisons between the results for rats exposed to 3.2 mg Cu-Zn in Phase III, Parts 1 and 2. With few exceptions, results were the same for exposures to 3.2 mg Cu-Zn/m³ in Phase III, Parts 1 and 2. Overall, we felt justified in combining results for the two parts of Phase III wherever possible and comparing all exposed groups of rats with the sham-exposed rats from Phase III, Part 2.

Table I~1 Biochemical Analyses of Bronchoalveolar Lavage Fluid^a From F344/N Rats That Inhaled Powdered Cu-Zn Alloy

					Aerosol Ca	Concentratio	ration of Powdered Cu-2n Alloy, mg/m ³	lered Cu-	In Alloy.	mg/m ³			
Lavage Fluid Constituent	Measure	1.0	REC	Phase 111. 3.	Part 1 2 REC	10	REC	0 (Sham) EQE R	REC	hase 111 0.3	Part 2	EOE	REC
ß-Glucuronidase (mIU)	Mean	1.42 0.18 12	1.86 0.31 12	1.84 0.23 11	1.79 0.26 12	7.08	1.36 0.28 12	1.27 0.15 12	1.13 0.13 12	1.62 0.26 12	1.25 0.16 12	1.39 0.22 12	1.11 0.13 12
Alkaline Phosphatase (mIU)	Mean SE M	411 42 12	360 51 12	469 39	293 18 12	336 38 12	279 35 12	285 23 12	269 21 12	321 22 12	284 23 12	387 38 12	215 17 12
Lactate Dehydrogenase (mIU)	Mean SE N	1124 186 12	793 213 12	1658 165 11	827 144 12	2047 316 12	839 99 12	385 32 12	446 21 12	389 26 12	488 38 12	571 63 12	406 30 12
Protein (mg)	Hean SE	1.66 0.09 12	1.16	1.87	1.04 0.14 12	2.82 0.20 12	1.21 0.15 12	1.54 0.09 12	1.55 0.15 12	1.30 0.09 12	1.51 0.21 12	1.54	1.34

atotal amount of B-glucuronidase, alkaline phosphatase, lactate dehydrogenase, and protein in lavage fluid from right lung of F344/N rats in this study.

Table I-2

Total Cells in Lung Lavage Fluida (Mean ± SE)

Aerosol	Evaluati	on Time
Concentration of Cu-Zn Alloy	End of Exposure	After Recovery
Phase III. Part 1		
1.0 mg/m ³	0.88 ± 0.09	1.17 ± 0.08
3.2 mg/m ³	1.44 ± 0.16	1.26 ± 0.14
10.0 mg/m ³	3.15 ± 0.38	0.94 ± 0.11
Phase III. Part 2		
Sham	1.04 ± 0.07	1.04 ± 0.05
0.32 mg/m^3	0.94 ± 0.03	0.95 ± 0.07
3.2 mg/m^3	1.26 ± 0.10	0.89 ± 0.05

^aThe above values show the mean and SE of the total cells counted for the alveolar macrophage phagocytosis assay x 10^6 (N = 12 per group).

Table I-3

Neutrophil Differential in Lung Lavage Fluida (Mean ± SE)

Aerosol	Evaluati	on Time
Concentration of Cu-Zn Alloy	End of Exposure	After Recovery
Phase III. Part 1		
1.0 mg/m ³ (percent)	3.49 ± 0.89	0.75 ± 0.22
(total)	0.032 ± 0.010	0.009 ± 0.003
3.2 mg/m ³ (percent)	4.48 ± 0.70	0.59 ± 0.24
(total)	0.060 ± 0.009	0.007 ± 0.002
10.0 mg/m ³ (percent)	8.79 ± 1.17	0.80 ± 0.34
(total)	0.273 ± 0.044	0.007 ± 0.002
Phase III, Part 2		
Sham (percent)	0.41 ± 0.12	1.01 ± 0.29
(total)	0.004 ± 0.001	0.012 ± 0.004
0.32 mg/m ³ (percent)	0.41 ± 0.14	0.58 ± 0.17
(total)	0.004 ± 0.001	0.006 ± 0.002
3.2 mg/m ³ (percent)	2.03 ± 0.56	0.33 ± 0.11
(total)	0.027 ± 0.008	0.003 ± 0.001

^aThe above values are differentials taken from the lavage of rats used for the alveolar macrophage phagocytosis assay. N=12 per group and the total numbers are given x 10^6 cells.

Aerosol	Evaluatio	on Time
Concentration of Cu-Zn Alloy	End of Exposure	After Recovery
Phase III. Part 1		
1.0 mg/m ³ (percent)	5.7 ± 1.0	7.6 ± 1.2
(total)	0.05 ± 0.01	0.09 ± 0.01
3.2 mg/m ³ (percent)	9.2 ± 1.3	12.0 ± 1.4
(total)	0.13 ± 0.02	0.15 ± 0.03
10.0 mg/m ³ (percent)	9.6 ± 1.0	12.7 ± 1.4
(total)	0.30 ± 0.04	0.11 ± 0.01
Phase III. Part 2		
Sham (percent)	9.5 ± 1.8	6.9 ± 0.9
(total)	0.11 ± 0.03	0.07 ± 0.07
0.32 mg/m ³ (percent)	7.1 ± 1.2	7.8 ± 1.4
(total)	0.07 ± 0.01	0.07 ± 0.01
3.2 mg/m ³ (percent)	10.5 ± 0.9	8.2 ± 0.6
(total)	0.14 ± 0.02	0.07 ± 0.01

a The above values are differentials taken from the lavage of rats used for the alveolar macrophage phagocytosis assay (N = 12 per group), and the total numbers are given x 10^6 cells.

Table I-5 $\begin{tabular}{ll} \begin{tabular}{ll} \begin{tabula$

Aerosol	Evaluati	on Time
Concentration of Cu-Zn Alloy	End of Exposure	After Recovery
Phase III. Part 1		
1.0 mg/m ³ (percent)	90.3 ± 1.5	91.6 ± 1.2
(total)	0.80 ± 0.08	1.07 ± 0.08
3.2 mg/m ³ (percent)	85.8 ± 1.0	87.2 ± 1.4
(total)	1.25 ± 0.15	1.11 ± 0.12
10.0 mg/m ³ (percent)	81.0 ± 1.4	86.2 ± 1.5
(total)	2.56 ± 0.31	0.82 ± 0.11
Phase III. Part 2		
Sham (percent)	90.1 ± 1.9	92.1 ± 1.0
(total)	0.93 ± 0.05	0.96 ± 0.04
0.32 mg/m ³ (percent)	92.4 ± 1.1	91.6 ± 1.3
(total)	0.87 ± 0.02	0.87 ± 0.07
3.2 mg/m ³ (percent)	87.3 ± 1.0	91.5 ± 0.6
(total)	1.10 ± 0.08	0.82 ± 0.05

^aThe above values are differentials taken from the lavage of rats used for the alveolar macrophage phagocytosis assay. N=12 per group and the total numbers are given x 10^6 cells.

Table I-6

Collagen in Lavage Fluid After 13-Week Exposure to Cu-Zn Alloy Powder and After 4-Week Recovery Period (N = 12, Values are Mean ± SE)

		Evaluati	on Time	
Aerosol	End of E	xposure	After Re	
Concentration of Cu-Zn Allov	μg/g Control <u>Lung Weight</u>	μg/kg <u>Bodv Weight</u>	µg/g Control Lung Weight	μg/kg <u>Body Weight</u>
Phase III. Part 1				
1.0 mg/m ³	63.5 ± 6.0	313 ± 34	68.0 ± 6.8	3 06 ± 32
3.2 mg/m^3	59.8 ± 4.2^{a}	288 ± 24^{a}	64.1 ± 3.6	281 ± 18
10.0 mg/m ³	84.4 ± 6.2	437 ± 38	57.4 ± 3.0	265 ± 20
Phase III. Part 2				
O (Sham)	45.4 ± 2.8	216 ± 18	47.6 ± 4.2	199 ± 25
0.32 mg/m^3	48.6 ± 2.3	229 ± 15	61.4 ± 9.7	249 ± 33
3.2 mg/m^3	55.1 ± 4.6^{a}	264 ± 27ª	44.9 ± 2.2	189 ± 14

 $a_N = 11.$

Table I-7

Total Lung Collagena After 13-Week Exposure to Cu-Zn
Alloy Powder and After 4-Week Recovery Period
(Mean ± SE)

			Evaluat	ion Time	
Aerosol		End of E		After R	ecovery
Concentration of Cu-Zn Alloy	<u>N</u> _	mg/g Control Lung Weight	mg/kg Body Weight	mg/g Control Lung Weight	mg/kg Body Weight
Phase III. Part 1					
3.2 mg/m ³	10	18.1 ± 0.5	88 ± 3		
10.0 mg/m ³	10	18.9 ± 0.8	97 ± 5	17.5 ± 1.1	80 ± 6
Phase III. Part 2					
O (Sham)	6	17.2 ± 1.2	82 ± 8	17.6 ± 1.3	72 ± 9
O (Sham) ^b	12	17.4 ± 0.8	77 ± 6		
3.2 mg/m^3	10	19.3 ± 1.0	91 ± 5		•

^aAll samples analyzed as a batch after collection of samples for Phase III, Part 2.

bResults combined for shams evaluated at the end of exposure and after the 4-week recovery period.

Table I-8

Immunology Results for Tracheobronchial Lymph Nodes from Rats in Phase III, Parts 1 and 2 (Values are Mean \pm SE; N = 6-8)

of Cu-Zn Alloy EOE Phase III. Part 1		,	Antibody-F	Antibody-Forming Cells	Total An	Total Antibody-
Phase III. Part 1	Lympho1d E	Total Lymphoid Cells x 10-6 EOE REC	Per Million EOE	Per Million Lymphocytes EOE REC	Forming Cells EOE	Cells REC
1.0 mg/m³ 8.21 ±	± 1.11	9.40 ± 1.72	1080 ± 327	907 ± 313	9360 ± 3490	10250 ± 5020
3.2 mg/m ³ 15.93 ±	± 2.60	7.51 ± 0.66	887 ± 133	394 ± 144	14700 ± 3280	2980 * 992
ີປ.0 mg/m³ 27.09 ±	± 3.43	10.09 ± 0.51	884 ± 115	369 ± 115	23300 ± 3540	3927 ± 1290
Phase III, Part 2						
0 (Sham) 8.78 ±	± 0.71	10.00 ± 0.71	517 ± 104	1110 ± 237	4840 ± 1170	11200 ± 2740
3.2 mg/m³ 15.28 ±	± 1.46	8.54 ± 1.27	346 ± 83	493 ± 131	5570 ± 1340	5290 ± 1850

Table I-9

Macrophage Phagocytosis of Erythrocytes^a
(Mean ± SE)

Aerosol	Evaluati	on Time
Concentration of	End of Exposure	After Recovery
Phase III. Part 1		
1.0 mg/m ³	481 ± 30	341 ± 30
3.2 mg/m^3	331 ± 12	289 ± 39
10.0 mg/m^3	251 + 16	299 ± 16
Phase III. Part 2		
O (Sham)	367 ± 20	404 ± 27
0.32 mg/m^3	490 ± 25	395 ± 32
3.2 mg/m^3	467 ± 26	417 + 31

^aThe above values show the mean and SE of number of erythrocytes phagocytized by 100 macrophages (N=12).

Table I-10 $\label{eq:percentages} \mbox{ Percentages of Macrophages that Phagocytized Erythrocytes} \mbox{a} \mbox{ (Mean \pm SE)}$

Aerosol	Evaluati	on Time
Concentration of Cu-Zn Alloy	End of Exposure	After Recovery
Phase III. Part 1		
1.0 mg/m^3	80.5 ± 1.5	76.0 ± 2.1
3.2 mg/m^3	$67.3 \pm 2.5^{\text{b}}$	72.9 ± 2.8
10.0 mg/m ³	$60.2 \pm 3.6^{\text{b}}$	73.2 ± 1.9
Phase III. Part 2		
O (Sham)	74.4 ± 1.9	81.8 + 2.5
0.32 mg/m^3	79.9 ± 1.2	82.0 ± 2.2
3.2 mg/m^3	76.6 ± 2.1	85.6 ± 2.2

a The above values show the mean and SE of the percent macrophages that have phagocytized one or more erythrocytes (N=12 per group).

Table I-11 Pulmonary Function Results for Rats in Phase III, Parts 1 and 2 (Baseline Measurements) (Values are Mean \pm SE; N = 16)

					Phase III	Part 1			Phase III, Part 1		Phase [1]	I. Part 2
Parameter	Units	O (Sham)	(W)		0.1		3.2		10	0	O (Sham)	3.2
Total Lung Capacity (TLC)	겉	11.4	0.4	<u> </u>	* 0.4	11.4	₹ 0.4	1.1	± 0.3	9.5	± 0.4	10.3 ± 0.3
Vital Capacity/TLC	percent	86.4 ±	6.0	87.7	* 0.8	86.3	₹ 0.9	87.6	* 0.7	91.2	± 1.4	89.5 ± 0.9
Functional Residual Capacity	ť	2.5 *	0.1	2.3	± 0.1	5.6	± 0.1	2.4	₹ 0.1	9.6	± 0.1	2.1 ± 0.1
Dynamic Lung Compliance	mL/cm H20	0.43 *	0.03	0.42	± 0.03	0.45	₹ 0.04	0.41	± 0.03	0.43	\$ 0.05	0.48 ± 0.06
Quasistatic Chord Compliance	ML/cm H20	0.65 *	0.05	0.64	± 0.02	99.0	± 0.03	0.63	* 0.0 2	0.53	± 0.05	0.58 * 0.02
E CO Diffusing Capacity (DLCO)	mac/min/mm Hg	0.18 *	0.01	0.19	± 0.01	0.18	± 0.01	0.19	± 0.01	0.19	₹ 0.01	0.19 \$ 0.01
DLCO/Lung Volume	DLCO/mL	0.017 *	0.001	0.017	0.017 ± 0.001	0.017	± 0.001	0.018	0.018 ± 0.001	0.018	0.018 ± 0.001	0.018 ± 0.001
DLCO/kg Body Weight	DLCO/kg	0.81 ±	0.03	0.85	± 0.03	0.81	* 0.02	0.83	± 0.02	0.80	0.80 ± 0.03	0.78 ± 0.04
Forced Vital Capacity Exhaled in O.1 Second	percent	71.8 ±	1.4	72.8	± 2.0	70.5	± 3.1	9.17	± 2.8	75.8	± 1.5	73.2 ± 1.5
Mean Midexpiratory Flow (MMEF)	mL/sec	68.5 ±	3.4	72.6	± 4.1	69.5	± 5.5	70.9	± 5.3	62.9	± 2.8	68.8 ± 2.9
MMEF/Forced Vital Capacity	mL/sec/mL	₹ 6.9	0.3	7.3	± 0.4	6.9	₹ 0.6	7.1	₹ 0.6	7.9	₹ 0.4	7.5 ± 0.4
Slope of Phase III of Single-Breath No Mashout	percent N2/mL	102.6 *	* 16	97.3	± 5.5	95.4	± 7.5	98.7	± 6.1	68.9	± 4.0	66.1 ± 3.9

Pulmonary Function Results for Rats in Phase III, Parts 1 and 2 (Week Seven of Exposures) (Values are Mean ± SE; N = 16) Table 1-12

		l			Phase III, Part 1	I. Part					Phase 111	I. Part 2	7
Parameter	Units	O (Sham)	ham)		0.	3.	3.2		9	9	O (Sham)	(1)	7
Total Lung Capacity (TLC)	¥	11.6	± 0.4	11.4	± 0.4	11.7	± 0.5	1.1	* 0.3	12.6	* 0.9	13.1	* 0.7
Vital Capacity/TLC	percent	93.2	* 0.5	91.6	± 0.7	92.4	± 0.7	1.16	± 0.7	92.4	* 0.6	91.5	± 0.7
Functional Residual Capacity	¥	2.2	± 0.1	2.2	* 0.1	2.3	* 0.1	2.3	± 0.1	2.5	± 0.2	5.6	# 0.1
Dynamic Lung Compliance	mL/cm H20	0.45	± 0.04	0.41	₹ 0.04	0.46	₹ 0.04	0.39	± 0.03	0.47	± 0.04	0.51	* 0.0
Quasistatic Chord Compliance	mL/cm H20	0.10	± 0.03	0.66	* 0.03	0.69	* 0.03	0.64	* 0.02	0.74	₹ 0.05	0.79	* 0.05
CO Diffusing Capacity (DLCO)	mt/min/mm Hg	0.21	± 0.01	0.21	± 0.01	0.21	± 0.01	0.18	* 0.02	0.21	* 0.01	0.21	± 0.01
DLCO/Lung Volume	DLCO/mL	0.018	₹ 0.001	0.019	0.019 * 0.001	0.018	± 0.001	0.016	0.016 ± 0.001	0.019	0.019 ± 0.001	0.018	1 * 0.001
DLCO/kg Body Weight	DLCO/kg	0.92	* 0.03	0.92	\$ 0.02	0.93	₹ 0.03	0.83	± 0.0 2	0.86	± 0.03	0.89	± 0.03
Forced Vital Capacity Exhaled in O.1 Second	percent	70.8	* 1.3	69.4	± 2.3	67.4	± 2.4	72.7	± 1.6	71.4	± 1.5	70.8	± 1.3
Mean Midexpiratory Flow (MMEF)	mt/sec	78.3	* 3.2	76.4	± 4.5	72.4	± 4.9	78.1	± 2.3	80.3	4.6	61.9	± 3.8
MMEF/Forced Vital Capacity	mL/sec/mL	6.9	± 0.3	8.9	₹ 0.4	6.5	₹ 0.5	7.4	± 0.3	7.0	* 0.3	7.0	± 0.2
Slope of Phase III of Single-Breath M2 Mashout	percent N2/mL	75.7	± 5.6	82.6	÷ 5.8	79.4	± 4.6	81.4	± 4.9	67.9	± 3.4	65.6	± 4.3

Table L_-13 Pulmonary Function Results for Rats in Phase III, Parts 1 and 2 (End of Exposure) (Values are Mean \pm SE; N = 16)

				Aerosol Concenty Phase III, Part	Aerosol Concentration of Powdered Cu-2n Alloy, mg/m ³ Phase III, Part 1	ton of F	owdered	N-Zn Al	loy, mg/m ³ Phase III.	3 1. Part 2	
Parameter	Units		0.	7	.2		10	0	0 (Sham)		2
Total Lung Capacity (TLC)	4	11.7	₹ 0.4	12.0	* 0.5	11.2	* 0.5	11.4	± 0.5	11.2	± 0.4
Vital Capacity/TLC	percent	93.3	₹ 0.9	94.4	₹ 0.7	92.2	₹ 0.7	91.9	# 1.1	92.7	± 0.8
Functional Residual Capacity	귤	2.1	± 0.1	2.1	≠ 0.1	2.1	₹ 0.1	2.2	± 0.1	1.2	* 0.1
Dynamic Lung Compliance	mL/cm H ₂ 0	0.40	± 0.02	0.47	★ 0.03	0.37	₹ 0.03	0.41	* 0.03	0.39	* 0.03
Quasistatic Chord Compliance	mL/cm H ₂ 0	0.71	0.71 \$ 0.03	0.77	★ 0.04	0.68	₹ 0.03	0.68	* 0.03	0.68	* 0.0 2
CO Diffusing Capacity (DLCO)	mL/min/mm Hg	0.22	0.22 ± 0.01	0.25	* 0.02	0.20	₹ 0.01	0.25	0.25 ± 0.01	0.24	0.24 \$ 0.01
DLCO/Lung Volume	DLCO/mL	0.018	0.018 ± 0.001	0.019	0.019 ± 0.001	0.016	0.016 ± 0.001	0.020	0.020 \$ 0.001	0.020	0.020 * 0.001
DLCO/kg Body Weight	DLCO/kg	0.92	0.92 \$ 0.04	0.97	± 0.03	0.80	0.80 ± 0.03	96.0	0.96 ± 0.03	0.95	± 0.03
Forced Vital Capacity Exhaled in O.1 Second	percent	67.5	± 2.2	64.6	± 1.5	64.8	± 2.5	73.1	± 1.8	€9.4	* 2.2
Mean Midexpiratory Flow (MMEF)	mL/sec	73.8	± 5.2	0.79	* 3.8	63.6	₹ 5.0	13.7	* 2.0	9.69	4.6
MMEE/Forced Vital Capacity	ml/sec/ml	6.4	± 0.4	5.7	± 0.3	5.9	± 0.5	7.4	± 0.4	6.7	± 0.4
Slope of Phase III of Single-Breath N ₂ Mashout	percent N2/mL	67.4	± 5.9	69.4	* 8.3	₹.69	¥ 6.6	70.0	± 5.4	9.69	± 5.4

Pulmonary function Results for Rats in Phase III, Parts 1 and 2 (After 4-Week Recovery Period) (Values are Mean \pm SE; N = 16) Table 1-14

				Aerosol Co Phase III	Aerosol Concentration of Powdered Cu-Zn Alloy, mg/m ³ Phase III. Part 1	tion of	Powdered (Cu-Zn Al	loy. mg/m ³ Phase III	Part	2
Parameter	Units		0.	3	2.		10	0	O (Sham)	3	2
Total Lung Capacity (TLC)	겉	12.5	± 0.5	13.1	± 0.7	12.7	± 0.5	11.2	± 0.4	11.7	± 0.5
Vital Capacity/TLC	percent	88.9	* 0.9	88.9	₹ 0.9	98.6	* 0.7	93.1	\$ 0.8	92.0	₹ 0.8
Functional Residual Capacity	ī	2.7	* 0.1	2.7	± 0.1	2.7	± 0.1	2.1	± 0.1	2.3	± 0.1
Dynamic Lung Compliance	mt/cm H ₂ 0	0.43	± 0.04	0.45	★ 0.05	0.40	± 0.04	0.39	* 0.03	0.43	± 0.03
Quasistatic Chord Compliance	mL/cm H20	0.75	± 0.03	0.77	± 0.04	0.78	₹ 0.03	0.68	* 0.02	0.70	* 0.02
CO Diffusing Capacity (DLCO)	at/min/mm Hg	0.26	± 0.02	0.26	★ 0.02	0.25	* 0.02	0.24	* 0.05	0.24	± 0.01
OLCO/Lung Volume	DLCO/mL	0.021	0.021 \$ 0.001	0.019	0.019 ± 0.001	0.020	0.020 \$ 0.001	0.019	0.019 ± 0.001	0.019	0.019 ± 0.001
DLCO/kg Body Weight	DLCO/kg	0.88	0.88 ± 0.06	0.74	0.74 \$ 0.06	0.84	0.84 * 0.05	0.88	0.88 \$ 0.03	0.91	± 0.03
Forced Vital Capacity Exhaled in O.1 Second	percent	67.9	± 1.7	65.4	± 2.4	70.8	± 1.8	8.79	± 2.5	65.5	± 2.8
Mean Midexpiratory Flow (MMEF)	mL/sec	11.1	± 2.7	17.2	\$ 5.8	84.7	± 2.5	65.8	± 4.7	64.8	₹ 6.0
HMEF/Forced Vital Capacity	ml/sec/ml	6.4	± 0.3	6.1	± 0.5	7.0	± 0.3	6.5	± 0.5	9.0	≠ 0.5
Slope of Phase III of Single-Breath M ₂ Washout	percent N2/mL	63.2	± 5.4	9.09	± 6.8	57.0	4.4	65.0	± 4.5	8.99	± 3.6

Table I-15

Summary of Respiratory Tract Lesions in F344/N Rats
After 13-Week Exposure to Aerosols of Cu-Zn Alloy Powder
(End of Exposure)

	Phas	e III. Pa	rt l	Pha	se III. P	art 2
Lesion	1.0a	3.2	_10_	Sham	0.32	3.2
Nasal Epithelium	3/22b	3/22	15/22	0	0	3/22
Atrophy	(1) ^c	(1)	(1.2)			(1)
Alveolar Macrophage	0	14/22	18/22	1/22	0	10/22
Hyperplasia		(1)	(1.4)	(1)		(1)
Type II Pneumocyte	0	7/22	17/22	0	0	5/22
Hyperplasia		(1)	(1.2)			(1)
Alveolitis	0	7/22	18/22	0	0	4/22
		(1)	(1.4)			(1)

aConcentration of exposure atmosphere of Cu-Zn alloy powder, mg/m³.

bFraction of rats with lesion.

CAverage severity score for animals with induced lesions: 0 = no changes relative to normal, lesion not present; l = slight degree of changes, or small amount present, mild response; 2 = moderate, median, or middle severity or amount; 3 = marked severity or degree of changes, large amount present.

Table I-16

Summary of Respiratory Tract Lesions in F344/N Rats
After 4-Week Recovery Period Following Exposure to
Aerosols of Cu-Zn Alloy Powder (After Recovery)

	Pha	se III. Pa	rt 1	Phas	e III. Par	t 2
Lesion	1.0 ^a	3.2	10	<u>Sham</u>	0.32	3.2
Nasal Epithelium	Op	1/21	7/22	0	0	0
Atrophy		(1) ^C	(1.4)			
Alveolar Macrophage	0	5/21	22/22	3/22	1/22	5/22
Hyperplasia		(1)	(1)	(1)	(1)	(1)
Type II Pneumocyte	1/22	4/21	22/22	0	1/22	4/22
Hyperplasia	(1)	(1)	(1)		(1)	(1)
Alveolitis	0	0	0	0	1/22	1/22
					(1)	(1)

³aConcentration of exposure atmosphere of Cu-Zn alloy powder, mg/m³.

bFraction of rats with lesions.

 $^{^{\}text{C}}\text{Average}$ severity score for animals with induced lesions: defined in Table I-15.

Table I-17

Summary Results for Statistical^a Comparisons for Endpoint Evaluations at the End of Exposure and After a 4-Meek Recovery Period for F344/M Rats Exposed to 3.2 mg Cu- $2n/m^3$ in Phase III, Parts 1 and 2

				End of	of Exposure	9				1	Afte	er Recovery			
Evaluation	싵	Part			Part 2	Ħ	2	519	Part	t		Pal	1 2		Sig
B-Glucuronidase in BALF, mIU	12	1.84	#	0.23	1.39	#	0.22	SE	1.79	#	0.26	1.1	#	0.13	S.
Alkaline Phosphatase in BALF, mIU	12	469	#	39	387	#	38	SN	293	#1	18	215	#	7	SE
Lactate Dehydrogenase in BALF, mIU	12	1658	#	165	175	#	63	0.01	827	#	144	406	#	2	0.0
Total Protein in BALF, mg	12	1.87	*	0.10	1.54	#	0.12	SN	1.04	#1	0.14	1.34	#	0.11	S.
Total Cells in BALF x 10-6	12	1.44	#1	0.16	1.26	#	0.10	SN	1.26	#	0.14	0.89	44	0.05	S
Weutrophils in BALF, Percent	12	4.48	#	0.70	2.03	#	0.56	SN	0.59	#	0.24	0.33	#1	0.11	SE
Neutrophils in BALF, Total x 10-6	12	₹ 090.0	#	0.00	0.027	#	0.008	SN	0.007	4 /	0.005	0.003	#	0.001	SE
Lymphocytes in BALF, Percent	12	9.5	#	1.3	10.5	#	6.0	NS	12.0	#	1.4	8.5	#	9.0	S.
Lymphocytes in BALF, Total x 10-6	12	0.13	#	0.05	0.14	#	0.05	NS	0.15	#	0.03	0.0	#	0.01	SE.
Macrophages in BALF, Percent	12	85.8	#	6.0	87.3	#	1.0	N.	87.2	#	1.4	91.5	#	9.0	S
Macrophages in BALF, Total x 10-6	12	1.25	#1	0.15	1.10	#	0.08	SH.	1.1	#	0.12	0.82	#	0.05	SE.
Collagen in BALF, µg/g Control Lung	T	59.8	#	4.2	55.1	#	4.6	RS	64.1	#	3.6	44.9	#1	2.2	0.0
Collagen in BALF, µg/kg Body Weight	•	288.3	#	23.7	264.4	#	6.92	NS	281.4	#	17.9	188.7	**	4.1	0.0
Total Lung Collagen, mg/g Control Lung	0	18.1	#	9.0	19.3	#	1.0	SE SE							
Total Lung Collagen, mg/kg Body Height	01	88	#1	٣	16	#	ស	SE							
Total Lymphoid Cells, x 10 ⁻⁶	15	15.9	#	5.6	15.3	#	1.5	SN	7.5	#1	0.7	8.5	#	1.3	₹
Antibody-Forming Cells per Million Lymphocytes	15	887	#	133	346	#	83	0.01	394	#	144 ×	493	#	131	SE
Total Antibody-Forming Cells	15	14650	#	17.21	5569	#	1340	0.01	2980	#1	365	5288	¥ 18	2	N
RBC Phagocytized per 100 Macrophages	12	331	41	12	467	#	56	0.01	289	#1	39	417	#1	=	SE
Percent of Macrophages that Phagocytized RBC	12	67.3	+	2.5	76.6	#	2.1	SE	72.9	4	8.8	85.6	•	2.2	¥

Table I-17 (Cont.)

Summary Results for Statistical^a Comparisons for Endpoint Evaluations at the End of Exposure and After a 4-Week Recovery Period for F344/N Rats Exposed to $3.2~{\rm mg~Cu-2n/m}^3$ in Phase III, Parts 1 and 2

	•		Endo	End of Exposure				Afte	After Recovery	
Evaluation	2	Part	_	Part 2	t 2	Sig	Part 1		Part 2	519
Total Lung Capacity (TLC), m.L.	91	12.0 ±	9.0	11.3	± 0.4	Ş	13.1 ±		11.7 ± 0.5	
Vital Capacity/TLC (VC/TLC), Percent	16	94.6 ±		95.6	£ 0.8	NS	₩ 0.68		92.0 ± 0.8	
Functional Residual Capacity (FRC), mL	16	2.1 ±	0.1	2.1 ± (١.0 ء	NS	2.7 ±	0.1	2.3 ± 0.1	SM
Dynamic Lung Compliance (CDYN), mL/cm H ₂ D	16	0.47 ±		0.39	€ 0.03	NS	0.45 ±		0.43 ± 0.0	
Quasistatic Chord Compliance (CCORD), mL/cm H20	16	0.77 ±		0.68	₹ 0.02	NS	0.77 ±		0.70 ± 0.0	
CO Diffusing Capacity (DLCO), mL/min/mm Hg	16	0.25 ±		0.24	€ 0.01	MS	0.19 ±		0.24 ± 0.0	
OLCO/Lung Volume, DLCO/mL	16	0.020 ±		0.022 ±	€ 0.001	NS	0.015 ±		0.021 ± 0.0	_
DLCO/kg Body Weight, DLCO/kg	16	0.97 ±		0.95	± 0.03	WS	0.74 ±		0.9 ± 16.0	
Forced Vital Capacity Exhaled in O.1 Second (FEVI), Percent	16	64.6 ±	1.5		± 2.2	M.	65.4 ±			
Mean Hidexpiratory Flow (MMEF), mL/Second	16	€7.0 ±	0.4	9.69	± 4.6	NS	11.2 ±	5.8	64.8 ± 6.0	MS
MMEE/Forced Vital Capacity, mL/Second/mL	16	5.7 ±	0.3	6.1	t 0.4	NS	6.1	0.5	6.0 ± 0.5	
Slope of Phase III of Single-Breath N2 Washout, Percent N2/mL	91	69.4	8.3	9.69	£ 5.4	SI S	₹ 9.09	8.	66.8 ± 3.6	
Nasal Epithelium Atrophy, Severity Score	21 or 22	0.14 ±	0.08	0.14	t 0.08	NS	0.05	0.02	0	NS
Alveolar Macrophage Hyperplasia, Severity Score	21 or 22	0.64 ±	0.11		± 0.11	NS	0.24 ±	0.10	0.23 ± 0.09	
Type II Pneumocyte Hyperplasia, Severity Score	2) or 22	0.32	0.10	0.23	€ 0.09	NS	0.19 ±	0.0	0.18 ± 0.0	
Alveolitis, Severity Score	21 or 22	0.32 ±	0.10	0.18	€ 0.08	NS	0		#	

^aThe groups exposed to 3.2 mg Cu-2n/m³ in Parts 1 and 2 were compared using Student's t-test for unequal variances when Levene's test indicated the variances, Student's t-test for equal variances, Student's t-test for equal variances was used. Probability values were adjusted for multiple comparisons using Bonferroni's inequality.

bw = The same for Phase III, Parts 1 and 2.

CThe values for lactate dehydrogenase (LDH) were higher for all groups in Phase III, Part 1 than they were for groups in Phase III, Part 2. The values for LDH in the sham-exposed rats in Phase III, Part 2 were in agreement with historical control values. Therefore, the LDH values for Phase III, Part 1 were considered invalid and were ignored in evaluating the combined results from Phase III, Parts 1 and 2.

 $d_{M} = 11$ at end of exposure; M = 12 after the recovery period.

Continental Grain Co.

CERTIFICATE	OF FEED	ANALYSIS
PLANT NO 010 / 738		
FEED NO. 8728.00	CATEGOR	RY NO. BL-1
	" ECIAL STOD	- MON-MODITIVE
DATE MFG. 7/23/86	RUN OR BATO	CH NO. PU7236-1
ANALYSIS:		LAB NO. 5665
GUAR. CALC.	ASSAY	$\overline{\mathcal{L}}$
PROT.	25.3	Plane gund
MOIST.	9.55	1-513
ASH	6.90] ' -3
FAT	4.51	
FIBER	4.09	
C•	1.19	
Р	.92	
SALT	. 76	-
N.P.N		
VITA		REMARKS
THIAMINE		REM
•	DA RFI	TE 7-24.86
2		,
ANALYST	cô	TE MPLETED
©ud 2 · ·		RES-19C

RECEIPT

ASSAY DONE APPROVED BY RED LAB MGR: 129__ DISTRIBUTE TO ROB BEVERLY

27-061-8c

- ASSAY = R5665

DATE

AS FED

TYPE MFG-DATE BATCH NO COMMENT-----COMMENT FEED PLANT 010 872800 SPECIAL 860723 P07236-1

		RESUL	_TS		
TEST	UNITS	FED	•	C-VAL	GUAR-VAL
VITAMIN A THIAMINE	IU/L MG/L	8998.000 4.430	0.000		

178

SPECIMEN	SP	PECIMEN I.D. NUMBER	ACCESSION NO
R-5665		0390775	39 0775
•	DATE COLLECT		
REFERRING CLIENT	07/24/86		RECEIVED
	U//E4/50	CLIENT LAB NO.	07/25/BE REPORTED
CONTINENTAL GRAIN CO.	0775	00000	QB/04/88
TEST	RESULT	REFERENCE LIMITS	UNITS
TOTAL FEED SCREEN			
ARSENIC	Q. 55		PPM
CADMIUM	0. 35		PPM
LEAD	0. 20		PPM
MERCURY	<0.01		PPM
SELENIUM	0. 25		PPM
AFLATOXIN #1	<0.01		PPM
AFLATOXIN B2	<0.01		PPM
AFLATOXIN G1	<0.01		PPM
AFLATOXIN G2	< 0. 01		PPM
ALDRIN	<0.01		PPM
DIELDRIN	<0.01		PPM
ENDRIN	<0.01		PPM
HEPTACHLOR	<0.01		PPM
HEPTACHLOREPOXIDE	<0.01		PPM
LINDANE	< 0. 01		PPM
CHLORDANE	<0.01		PPM
DDT RELATED SUBS.	<0.01		
TOXAPHENE	<0.10		PPM
PCBS	<0.10		PPM
DIAZINON	<0.10		PPM
DISULFATON	< 0. 10		PPM
ETHION	< 0. 10		PPM
MALATHION	0. 33		PPM
METHYL PARATHION	<0.10		PPM
PARATHION	< 0. 10		PPM
THIMET	<0.10		PPM
THIODAN	< 0. 10		PPM
TRITHION	<0.10		PPM
CAROTENE	5. 91		PPM
NITROGEN, NITRATE	74		PPM
NITROGEN, NITRITE	<1		PPM
STANDARD PLATE COUNT	. 34000		
COLIFORMS, FECAL	· 0		COL/DL
E. COLI	0	•	MPN
BHA	<1		PPM
BHT	<1		PPM
NITROSAMINES	<1		MCG/L
ALPHA BHC	<0. 01	<u> </u>	PPM

SPECIMEN	SPI	ECIMEN I.D. NUMBER	₹	ACCESSION N
R-5665		0390775		390775
. REFERRING CLIENT	DATE COLLECT	ED TIME	COLLECTED	RECEIVED
	07/24/86	CLIENT LAB NO.	0 0: 0 0	07/25/80 REPORTED
CONTINENTAL GRAIN CO.	0775	00000		08/04/8
TEST	RESULT	REFEREN	CE LIMITS	UNITS
BETA BHC	<0. 01			PPM
DELTA BHC	<0.01			PPM
4,4'DDE .	<0.01			PPM
4,4'DDD .	<0. 01			PPM
HCB	<0.01			PPM
MIREX	<0.10			PPM
METHOXYCHLOR	<0.10			PPM
TELODRIN	<0.10			PPM
RONNEL	<0.10			PPM
ETHYL PARATHION	<0.10			PPM
ALPHA ENDOSULFAN	<0.10			PPM
BETA ENDOSULFAN	<0.10			PPM
ENDOSULFAN SULFATE	<0.10			PPM

XIII. LIST OF PUBLICATIONS
None

Name	Duty
Snipes, M. B., Ph.D.	Principal investigator responsible for coordination of activities in the project.
Bice, D. E., Ph.D.	Immunology and phagocytosis evaluations.
Burt, D. G., D.V.M.	Small animal care operations.
Damon, E. G., Ph.D.	Data management in Path/Tox Data Base System.
Eidson, A. F., Ph.D.	Coordinator for activities associated with analytical techniques used in this project.
Hahn, F. F., D.V.M., Ph.D.	Pathology evaluations.
Harkema, J. R., D.V.M., Ph.D.	Pathology evaluations.
Harris, D. L., M.S.	Quality Assurance
Henderson, R. F., Ph.D.	Biochemistry evaluations
Hobbs, C. H., D.V.M.	Veterinarian for project and member of the ITRI Directorate in charge of this research.
Mauderly, J. L., D.V.M., Ph.D.	Respiratory function evaluations.
Pickrell, J. A., D.V.M., Ph.D.	Blood chemistry evaluations.
Seiler, F. A., Ph.D.	Statistician for project.
Yeh, H. C., Ph.D.	Responsible for aerosol science activities.

XV. DISTRIBUTION LIST

Number of Copies	Address
6	Project Manager for Smoke/Obscurants Bldg. 324 ATTN: AMCPEO-CNS (!1r. Smalley) Aberdeen Proving Ground, MD 21005-5001
1	Commander/Director Chemical Research, Development and Engineering Center ATTN: SMCCR-MUS-P (Mr. Young) Aberdeen Proving Ground, MD 21010-5423
1	Commander/Director Chemical Research, Development and Engineering Center ATTN: SMCCR-RST-E (Mr. Weimer) Aberdeen Proving Ground, MD 21010-5423
1	Officer-in-Charge Naval Medical Research Institute Toxicology Detachment Building 433 Wright Patterson AFB, OH 45433
1	HQDA (DASG-PSP-O) 5111 Leesburg Pike Falls Church, VA 22041-3258
1	Commander U.S. Air Force Aerospace Medical Research Laboratory ATTN: Toxic Hazards Division Bldg. 79, Area B Wright Patterson AFB, OH 45433
1	Commander U.S. Army Medical Research and Development Command ATTN: SGRD-PLC Fort Detrick Frederick, MD 21701-5012
1	Commander U.S. Army Health Services Command Fort Sam Houston, TX 78234-6000

1	Commander U.S. Army Armament Munitions and Chemical Command ATTN: AMSMC-SG Rock Island, IL 61299-6000
1	Commander U.S. Army Environmental Hygiene Agency ATTN: HSHB-AD-L Aberdeen Proving Ground, MD 21020-5422
1	Commander USACACDA ATTN: ATZL-CAM Fort Leavenworth, KS 66027
1	Commander U.S. Army Environmental Hygiene Agency ATTN: HSHB-OA Aberdeen Proving Ground, MD 21010-5422
1	Commander U.S. Army Training and Doctrine Command ATTN: ATMD Fort Monroe, VA 23651-5000
1	Commander U.S. Army Forces Command ATTN: AFMD Fort McPherson, GA 30330
	Commanding Officer Naval Weapons Support Center ATTN: Code 5601 (D. Haas) Crane, IN 47522
1	HQ U.S. Army Material Command ATTN: AMCSG-S 5001 Eisenhower Ave. Alexandria, VA 22333-5001
1	Commanding Officer Naval Heapons Support Center ATTN: Code 5063 (Dr. Kennedy) Crane, IN 47522
8	Commander U.S. Army Biomedical Research and Development Laboratory ATTN: SGRD-UBZ-C Fort Detrick Frederick, MD 21701-5010

1	U.S. Army Medical Research and Development Command ATTN: SGRD-RMI-S Fort Detrick Frederick, MD 21701-5012
1	Defense Technical Information Center ATTN: DTIC-DDA Cameron Station Alexandria, VA 22314
1	Dean, School of Medicine Uniformed Services University of the Health Sciences 4301 Jones Bridge Road Bethesda, MD 20014